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ABSTRACT 
  
 Studies during the last decades have shown the cellular epigenetic 
machinery to be of major importance in the control of gene expression in living 
organisms. Misregulation of these mechanisms has been described in a variety of 
cancers, and small molecule inhibitors of enzymes involved in epigenetic gene 
regulation have emerged as promising agents for the development of new 
anticancer therapies.  
 Naturally isolated products continue to play a significant role in anticancer 
drug discovery. We are interested in the structural and biological properties of the 
natural product Psammaplin A. Recent studies highlighted its extreme potency 
against both Histone Deacetylases (HDACs) and DNA Methyltransferase 1 
(DNMT1) enzymes, which both play a central role in the regulation of gene 
expression and tumour development.
 
In enzyme-based assays, Psammaplin A 
displayed potent activity (IC50s) against an HDAC extract (4.2 nM) and Dnmt1 
(18.6 nM). Subsequent studies have shown Psammaplin A to exhibit significant 
cytotoxicity against a number of cancer cell lines.
 
In vivo,
 
studies showed 
inhibition of tumour growth in the A549 lung xenograph mouse model while 
maintaining low toxicity. 
 The goal of our project is to establish a structure-activity relationship 
(SAR) of Psammaplin A, in order to understand the structural features responsible 
for such HDAC and DNMT inhibition and help us in the design of new 
generations of drug-like molecules for epigenetic anticancer therapies. An 
important number of Psammaplin A analogues could be obtained in few steps 
from versatile reagents.  We will present our synthetic routes towards libraries of 
Psammaplin A analogues, results on their biological activity, and recent 
developments towards novel epigenetic modulators. 
 
 Based on our high interest in HDACs, results of a number of other novel 
and early stage projects aimed at dissecting the chemical biology of HDACs will 
be presented. 
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ABBREVIATIONS 
 
°C   Degree Celsius 
Å   Angström 
δ   Chemical shift 
Ac   Acetyl 
AcOEt   Ethyl acetate 
AcOH   Acetic acid 
Anal.   Analysis 
app   Apparent 
aq.   Aqueous 
Ar   Aryl 
Bn   Benzyl 
Boc   tert-Butoxycarbonyl 
BOP   Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium  
   hexafluorophosphate 
br   Broad 
brsm   Based on the recovery of starting material 
Bu   Butyl 
Bz   Benzoyl 
C   Concentration 
ca.   Circa 
Calc.   Calculated 
Cat.   Catalytic 
CDI   Carbonyldiimidazole 
CI   Chemical ionisation 
Cy   Cyclohexyl 
d   Doublet 
d   Deuterated 
DBU   1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC   1,3-Dicyclohexylcarbodiimide 
dd   Doublet of doublets 
DIAD   Diisopropyl azodicarboxylate 
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DIPEA  Diisopropylethylamine 
DMF   Dimethylformamide 
DMAP   4-(Dimethylamino)pyridine 
DMSO   Dimethylsulfoxide 
DNA   Deoxyribonucleic acid 
DNMT  DNA methyltransferase 
EDCI   1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide 
e.g.    Exempli gratia 
EI   Electron ionisation 
Enz   Enzyme 
eq.   Equivalent 
ESI   Electron spray ionisation 
Et   Ethyl 
FDA   Food and Drug Administration 
g   Gram 
h   Hour 
HAT   Histone acetyl transferase 
HDAC   Histone deacetylase 
HDAH   Histone deacetylase-like amidohydrolase 
HOBt   1-Hydroxybenzotriazole 
HRMS   High resolution mass spectrometry 
Hz   Hertz 
i   Iso 
i.e.   Id est 
IR   Infrared 
J   Coupling constant 
K   Kelvin 
Lit.   Literature  
m   Multiplet 
μ   Micro (10-6) 
M   Molar or mega (10
6
) 
MD   Molecular dynamics 
Me   Methyl 
min   Minute 
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MOM   Methoxymethyl 
mp   Melting point 
MS   Mass spectrometry or molecular sieves 
m/z   Mass to charge ratio 
NBS   N-Bromosuccinimide 
NHS   N-Hydroxysuccinimide 
nm   Nanometer 
nM   Nanomolar 
NMO   4-Methylmorpholine N-oxide 
NMR   Nuclear Magnetic Resonnance 
NOE   Nuclear Overhauser effect 
NOHP   N-hydroxyphthalimide 
pdb   Protein data bank 
PDT   Photodynamic therapy 
PE   Petroleum ether 
Ph   Phenyl 
pm   Part per million 
Pr   Propyl 
PS   Photosensitiser 
PTM   Post translational modification 
Py   Pyridine 
q   Quartet 
Rf   Retention factor 
RNA   Ribonucleic acid 
rt   Room temperature 
s   Singlet 
SAH   S-adenosyl homocysteine 
SAHA   Suberoylanilide hydroxamic acid 
SAM   S-adenosyl methionine 
SAR   Structure-activity relationship 
t   Triplet 
T   Temperature 
TBS   tert-Butyldimethylsilyl 
TCEP   Tris(2-carboxyethyl)phosphine hydrochloride 
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TFA   Trifluoroacetic acid 
THF   Tetrahydrofuran 
THP   Tetrahydropyran 
TLC   Thin layer chromatography 
TMS   Trimethylsilyl 
Ts   Toluene sulfonyl 
TSA   Trichostatin A 
TSG   Tumour suppressor gene 
UV   Ultra violet 
VDW   van der Waals 
ZBG   Zinc binding group  
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 The scientist does not study nature because it is useful; he studies it 
because he delights in it, and he delights in it because it is beautiful. If nature 
were not beautiful, it would not be worth knowing, and if nature were not worth 
knowing, life would not be worth living.  
     Jules Henri Poincaré (1854-1912) 
 
 
 
 
 Every honest researcher I know admits he's just a professional amateur. 
He's doing whatever he's doing for the first time. That makes him an amateur. He 
has sense enough to know that he's going to have a lot of trouble, so that makes 
him a professional.  
       
    Charles Franklin Kettering (1876-1958) 
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INTRODUCTION 
 
1. The genetic basis of cancer 
 
 Nowadays, cancer represents one of the most important causes of 
mortality worldwide. Significant progress was made during the 20
th
 century 
towards a better understanding of its origin and development. A number of 
important studies, including Peyton Rous‟ pioneering works1,2 (1910) on the Rous 
Sarcoma Virus (RSV) and studies of cellular tumour inducing genes by Bishop 
and Varmus in the 1970s,
3
 led to the discovery of the now called “proto-
oncogenes” in the genome of a variety of living organisms. Upon specific 
modifications at the molecular level, the so-called genes can be converted to 
“oncogenes”, which are genes able to transform normal cells and induce tumours. 
 The concept of proto-oncogenes marked a great advance, implying that the 
genome of normal vertebrate cells, including human, carry genes that have the 
potential, under certain conditions, to induce cell transformation and thus cancer. 
These discoveries, and the following studies, brought strong support to the idea of 
misregulation of the host genome as a major cause of cancer. Since the discovery 
of proto-oncogenes in 1974 by Varmus and Bishop, a variety of proto-oncogenes 
have been discovered in the human genome, such as myc and Ras. Following 
these discoveries, cellular proto-oncogenes and the mechanisms leading to 
oncogenic activation were intensively studied. Activation of oncogenes was 
shown to arise through different pathways, notably through misregulation of the 
level of expression of proto-oncogenes and/or alteration of the structure of their 
encoded proteins via point mutation. Misregulation of the level of expression of a 
proto-oncogene could itself be the result of different factors, such as gene 
amplification or chromosomal translocation.
4 
For example, the widely studied H-
Ras was the first oncogene to be discovered to have a point mutation in its reading 
frame. Within a decade, a large number of tumours were found that carried point 
mutations in one of the three Ras (H-Ras, K-Ras, N-Ras) genes present in 
mammalian genomes, these point mutations were always observed in specific 
codons. More than 20% of human tumours, from varying tissues, were found to 
carry these specific point mutations in their ras genes.
5
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 While the discovery and study of (proto-)oncogenes provided a powerful 
tool to explain, at least partially, mechanisms leading to cancer, a number of 
important discoveries in the 1970s and early 1980s were difficult to reconcile with 
the known tumour inducing character of oncogenes at the time. Importantly, 
studies by Harris and co-workers from 1965 to 1969 demonstrated the recessivity 
of the malignant versus wild type phenotype.
6-8
 These observations, emerging 
from cell fusion (Figure 1) between mutant and wild-type cells, suggested the 
existence of a second class of genes involved in the regulation of cell growth and 
division, which were apparently acting as negative regulators (in opposition to 
positive regulation by proto-oncogenes). Further studies led to the identification 
of such genes,
9,10
 later called “Tumour Suppressor Genes” (TSGs), which marked 
a new important step forward in the understanding of the mechanisms regulating 
normal cell proliferation, and the consequences of their alteration on cancer 
pathogenesis. Their discovery provided a new model to explain tumour 
development: normal cells carry genes able to constrain or suppress their 
proliferation. During the development of a tumour, the evolving cancer 
deactivates these genes in addition to oncogenic activation. The loss or 
deactivation of these growth-suppressing genes then allows rapid progression of 
cancer. As long as the cancerous cells lack these genes, the proliferation can 
continue in a malignant fashion. However, as soon as the wild-type, intact 
versions of these genes operate again in the cell (such as after introduction by cell 
fusion experiment), cancer progression is shut down and finally stops.  
 
 
 
Figure 1 - Illustration of the experimental fusion of cells used to test the 
dominance or recessiveness of the cancer cell phenotype
 
+ 
OR 
Fusogenic agent 
normal cell              cancerous cell 
Hybrid cell is tumourigenic 
 Cancer alleles are dominant 
Hybrid cell is non-tumourigenic 
 Cancer alleles are recessive 
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 An important number of TSGs have been discovered so far, including for 
example RB1 (cell cycle) and TP53 (DNA repair, cell cycle, apoptosis) and their 
deactivation seems to be required in order to induce cell transformation and 
malignant behaviour. TSGs are grouped into two main classes, under the generic 
name of “gatekeepers” and “caretakers”. “Gatekeepers” are genes that operate on 
cell multiplication, but also cell differentiation and cell death (e.g. TP53). 
“Caretakers” are genes that encode proteins responsible for maintaining the 
integrity of the genome, such as ATM and BRCA1/2 which are involved in DNA 
repair. Importantly, deactivation of both wild-type alleles of a given TSG is 
required in order to fully abolish its effect. While genetic mutations were already 
known as a factor able to alter gene expression, the elimination of both copies of a 
TSG by successive genetic mutations is statistically unlikely. In particular, 
alternative mechanisms such as loss of heterozygosity
11,12
 and epigenetic 
modifications have been shown to be implicated in the silencing of TSGs.
13
 
Epigenetic gene regulation will be the subject of the next section of this thesis. 
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2. EPIGENETICS 
 
2.1. Overview 
 
 The human genome is packaged into chromatin, a macromolecular 
assembly of deoxyribonucleic acid (DNA), histones and non histone proteins (e.g. 
DNA polymerase, Heterochromatin Protein 1, Polycomb-group proteins). The 
nucleosomes, forming the repeating unit of chromatin, are composed of 
approximately 146 base pairs of DNA wrapped around a histone octamer. The 
latter is composed of an H3/H4 tetramer and two H2A/H2B dimers. In 
nucleosomes, the N-terminal regions of histones, or histone tails, project outward 
of the assembly. The succession of nucleosomes forms a higher order structure 
(Figure 2) whose three dimensional characteristics are partly responsible for the 
expression of genes, making these genes accessible (or not) to the transcriptional 
machinery.
14-16
 In particular, chromatin can be found in an open form 
(euchromatin), associated with active transcription, or  in a condensed form 
(heterochromatin), associated with transcriptional repression (Figure 3).  
 While the genetic information is contained in the DNA, regulation of 
phenomena such as transcription, replication, recombination or DNA repair is 
controlled by the “epigenome” (from the greek epi: upon/in addition to). 
“Epigenetic” is a term used to describe heritable and reversible changes in gene 
expression that do not involve changes in the DNA sequence.  
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Figure 2 - Model illustrating the different level of organisation in chromatin. 
Yellow cylinders: histone octamers. Non histone proteins are omitted for clarity. 
Reproduced and adapted from Bruce Alberts et al, Molecular Biology of The Cell. 
5th ed.; Garland Science: 2008
17
 
 
 
   
Figure 3 - Top: DNA (red wire) is wrapped around a histone octamer (yellow 
cylinder). Bottom: Post-translational modifications of histone tails dynamically 
affects the three dimensional structure of chromatin, and consequently gene 
expression. In particular, heterochromatin (left) and euchromatin (right) are 
associated with low and high transcriptional activity respectively. Reproduced and 
adapted from Bruce Alberts et al, Molecular Biology of The Cell. 5th ed.; Garland 
Science: 2008
17
 
PTMs 
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 A number of biological processes are regulated by epigenetic gene 
regulation, such as apoptosis or X-chromosome inactivation.
18
 The epigenetic 
regulation of gene expression notably plays a major role in cell differentiation 
during embryogenesis. In some ways, epigenetics can be seen as a link between 
genotype and phenotype (Figure 4). 
 
            
Figure 4 - The caterpillar and the butterfly are classical examples of how 
epigenetic modifications affect the phenotype of an organism. While sharing the 
same genome, major phenotypic characteristics differentiate them. These 
phenotypic differences are due to differences in their gene expression patterns,
19
 
controlled by epigenetic modifications 
 
 Epigenetic gene regulation can be achieved via a myriad of mechanisms, 
such as covalent modifications of DNA and terminal amino groups of histone tails 
pointing out of the nucleosomes (Figure 5), and via silencing RNA.
20-22 
In 
particular, covalent modifications of DNA and histones have a direct effect on the 
higher order chromatin structure, and subsequently on the ability of DNA to 
interact with the transcriptional machinery. Numerous modifications of chromatin 
affecting the epigenetic regulation of gene expression are known,
20-23
 including 
for example DNA methylation, histone acetylation/deacetylation, 
methylation/demethylation, phosphorylation, ADP-ribosylation, citrullination, 
ubiquitination, sumoylation, prolyl isomerisation, biotinylation.
 
The function of 
the recently discovered DNA hydroxymethylation, originating from the oxidation 
of methylated DNA, is poorly understood.
24-27
 
 
 
 
 
Towards novel small molecule epigenetic inhibitors Introduction 
7 
 
 
Figure 5 - Examples of dynamic epigenetic modifications of chromatin occurring 
on DNA (black) and histone tails (blue line). Lysine residues (K) can be 
acetylated (pink), methylated (yellow), sumoylated (purple) or ubiquitinilated 
(orange); arginine residues (R) can be methylated (green), while serine (S) and 
threonine (T) residues can be phosphorylated (cyan); DNA can be methylated 
(grey) on cytosine residues (black). Blue cylinder: histone octamer. Reproduced 
and adapted from Cherblanc et al.
28
 
 
 These modifications come within the framework of a large model called 
the “histone code hypothesis”, specifying the local status of the chromatin with 
respect to three dimensional characteristics and transcriptional activity. This 
model suggests that a unique combination of epigenetic states in chromatin can be 
related to a particular biological outcome.
29
 
 Epigenetics represent a relatively new area of research, arousing an 
increasing interest in the scientific community in term of its importance in the 
regulation of gene expression, and its omnipresence in the mechanisms leading to 
the development of tumours. In particular, the phenomena of DNA methylation 
and histone acetylation/deacetylation have been shown to be at the centre of the 
epigenetic network, and will be the subject of the next section. 
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2.2. DNA methylation and histone acetylation/deacetylation 
 
 DNA methylation 
 
 DNA methylation plays a central role in the epigenetic regulation of gene 
expression. This phenomenon, occuring on the C5-position of cytosine residues 
(Scheme 1), is mediated by enzymes called DNA methyltransferases (DNMTs) 
which use S-adenosyl methionine (SAM or AdoMet) as a cofactor. It generally 
takes place in particular regions of the DNA called CpG islands, which are rich in 
cytosine residues and generally located in the proximity of gene promoters.
15,30
 
CpG islands are found in more than half of genes in the genome. 
Hypermethylation of these regions has been found to be associated with 
transcriptional silencing.
31-34
 While the study of the implication of DNA 
methylation in the regulation of gene expression became a particularly hot topic 
during the last few decades, first reports mentioning the characteristics, synthesis 
and natural occurrence of the 5-methylcytosine motif can be traced back to the 
beginning of the 20
th
 century.
35-38
  
N
1
2 N
3
4
5
6
NH2
O
R
N
1
2 N
3
4
5
6
NH2
O
R
SAM SAH
DNMT
 
Scheme 1 - Methylation of the C5-position of cytosine (left) by DNMTs, using 
SAM as a cofactor, affords the product C5-methylcytosine (right) 
  
 DNA methylation is involved in a myriad of biological processes, and the 
DNA methylation pattern of CpG dinucleotides in a given organism is tissue 
specific, and varies from one cell type to another, with largest divergences 
observed for embryonic stem cells.
39,40
 DNA methylation is notably involved in 
gene regulation, DNA-protein interactions, cellular differentiation, 
embryogenesis, genomic imprinting, stabilisation of X-chromosome inactivation, 
protection against endogeneous retroviruses and transposons, development of the 
immune system, brain function and behaviour.
41
 In terms of gene regulation, DNA 
methylation can induce downregulation of gene expression through different 
mechanisms. First, it can prevent the binding of transcription factors to target 
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DNA sequences by decreasing binding affinity, which consequently inhibits 
transcriptional activity.
31,32
 Second, methylated DNA sequences can also be 
recognised and bound by methyl-CpG binding proteins (MBPs). Binding of MBPs 
can directly prevent interaction with transcription factors, but can also promote 
the recruitment of transcriptional repressor multiprotein complexes, for example 
involving HDACs.
42,43
  
 To date, three active DNMTs -called DNMT1, DNMT3a and DNMT3b- 
and a related protein lacking the catalytic domain -called DNMT3L- have been 
identified in mammals. The function of a fifth postulated DNMT, called DNMT2 
and lacking DNA methyltransferase activity, is still enigmatic.
44
 
 DNMT1 was the first mammalian DNA methyltranferase cloned
45
 and 
characterised. It preferentially methylates hemimethylated DNA over 
unmethylated DNA
46,47
 and has been implicated in the maintenance of the DNA 
methylation pattern during cellular division (Figure 6). For this reason, DNMT1 is 
sometimes called maintenance methylase. DNMT1 is present in the nucleus of 
most somatic cells, however its subnuclear distribution varies dynamically during 
the cell cycle. Two tissue specific DNMT1s isoforms have been identified. 
DNMT1o (DNMT1 oocyte) and DNMT1p (DNMT1 pachytene) have been 
described in oocytes and spermatocytes respectively.
48
 While DNMT1 is a 
maintenance methylase, its presence has been shown to be required for de novo 
methylation by DNMT3a and DNMT3b.
49,50
 
 DNMT1 is at the centre of a complex epigenetic network and interacts 
with a multitude of proteins. It has notably been shown to interact with histone 
deacetylase 1 (HDAC1), HDAC2, DNMT3a, DNMT3b, Rb and E2F1 
transcription factors, the histone lysine methyltransferases Suv39H1, SET7/9, G9a 
and EZH2, the silencing effectors HP1 and MeCP2, the chromatin factor UHFR1, 
PCNA and DMAP1.
41
 
 
 
 
 
 
Towards novel small molecule epigenetic inhibitors Introduction 
10 
 
 
 
 
 
 
 
 
 
 
Figure 6 - Maintenance of DNA methylation patterns by DNMT1 during 
replication 
 
 The mammalian DNMT3 family contains three members: DNMT3a, 
DNMT3b and DNMT3L. DNMT3a and DNMT3b are catalytically active and 
known as de novo methylases, able to methylate previously unmethylated 
DNA.
51,52
 They play a vital role in the establishment of DNA methylation patterns 
during embryogenesis.
53
 Although they are primarily involved in de novo DNA 
methylation, they have been shown to be involved in the maintenance of DNA 
methylation in heterochromatic regions. The molecular mechanisms underlying 
the establishment of the de novo methylation pattern in mammal is still under 
intensive investigation. In particular, the dynamic and sequence specific 
methylation of DNA by DNMTs is poorly understood. A recent review by Jeltsch 
and co-workers
41
 provides a good overview of current models proposed to explain 
such selectivity. DNMT3L is catalytically inactive but has a regulatory role in 
germ cells.
54-56
 Whereas devoid of a catalytic domain, DNMT3L has been found 
to interact with de novo DNMTs.
55,57-61
 
DNMT3a and DNMT3b are present at high level in embryonic tissues and 
undifferentiated embryonic stem (ES) cells. In contrast, their expression is down-
regulated in differentiated cells. DNMT3a is expressed in most tissues. Variants 
of DNMT3a and DNMT3b have also been reported. DNMT3a2
62
 is cell type 
specific and generally present in ES cells, germ cells, embryonal carcinoma cells, 
spleen and thymus. However, it is not expressed in adult tissues.
 
Similarly, the 
expression level and localisation of DNMT3b isoforms varies during 
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development, potentially illustrating differences in their function and target 
sequences.
63
 The catalytically inactive DNMT3L is expressed in germ cells during 
gametogenesis and embryogenesis.
54,55
  
DNMT3a and DNMT3b are associated with chromatin containing methylated 
DNA
64
 and localise in pericentromeric heterochromatin.
65-67
 The localisation of 
DNMT3L is dependent on its interaction with DNMT3a and DNMT3b. In the 
absence of the two de novo methylases, DNMT3L is distributed in both the 
nucleus and the cytoplasm. However, the concentration of DNMT3L in chromatin 
was shown to increase upon binding to DNMT3a or DNMT3b.
68
 
 
 A mechanism for the catalytic mechanism of DNA methylation by 
DNMTs has been previously proposed (Scheme 2).
69-71
 This model involves the 
nucleophilic attack of position 6 of the cytosine residue by a cysteine in the active 
site of the DNMT. This results in a covalent complex which is nucleophilic in 
position C-5. The reactive intermediate, stabilised by a glutamic acid from the 
protein, can then accept a methyl group from SAM, resulting in a 5-methyl 
covalent adduct and S-adenosyl homocysteine (SAH). Abstraction of the proton in 
the C5-position, followed by elimination of the thiol finally liberates the 5-
methylcytosine residue. Importantly, while the reversibility of DNA methylation 
in vivo is known, enzymes exhibiting DNA demethylating activity have not been 
discovered so far. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2 - Proposed catalytic cycle for the methylation of cytosine (black) by 
DNMTs (red), using SAM (blue) as a cofactor 
N
NO
R
N
H
HH
5
4
O
O
enzyme
Enzcytosine
S
H
N
NO
R
N
H
HH
5
4
O
O
enzyme
cytosine
N
N
N
N
NH2
O
OH
OH
S
NH3
COO
S Enz
H
N
NO
R
NH2
H
S Enz
cytosine
SAM
N
NO
R
NH2
5
4
5
4
5-methylcytosine
(Glu)
(Cys)
SAM
Towards novel small molecule epigenetic inhibitors Introduction 
12 
 
 Histone acetylation/deacetylation 
 
 Another highly studied key process in the epigenetic regulation of gene 
expression is the dynamic phenomenon of acetylation/deacetylation of histones. 
The dynamic regulation of the acetylation pattern of lysine residues of histone 
tails is controlled by enzymes called histone acetyl transferases (HATs) and 
histone deacetylases (HDACs) respectively. In particular, HDACs are able to 
remove acetyl groups from the lysine residues of these histone tails (Figure 5), 
and are associated with transcriptional repression via chromatin condensation. At 
the molecular level, the dynamic modification of the histone acetylation pattern by 
HDACs is thought to control the interactions between positively charged lysine 
histone tails with the negatively charged DNA. Modulation of these interactions 
has a direct impact on the three dimensional chromatin structure, and 
subsequently on transcriptional activity. So far, 18 human genes encoding HDACs 
have been identified.
20
 HDACs
20,21
 can be divided into two groups: zinc-
dependent HDACs, and NAD+ dependent HDACs also called Sirtuins (silent 
information regulator 2-related proteins) or SIRTs. Zinc dependent HDACs 
possess a catalytic Zn(II) cation in their active site, whereas SIRTs use the 
oxidised form of nicotinamide adenine dinucleotide (NAD+) as a cofactor in the 
deacetylation process. 
 Zinc dependent HDACs can be subdivided into different classes, 
according to their sequence homology and structural characteristics (Figure 7). 
Class I HDACs are expressed in the nucleus of most cell lines and include 
HDAC1, 2, 3 and 8. Class II HDACs are larger than class I enzymes and are 
tissue specific, shuttling between the cytoplasm and nucleus.
14,72,73
 While called 
“histone deacetylases”, certain HDACs have been shown to be able to deacetylate 
non-histone proteins, such as hormone receptors, chaperone proteins, transcription 
factors and cytoskeletal proteins.
73,74
 While the term “lysine deacetylase” (KDAC) 
would be more appropriate as a name for these enzymes owing to their lack of 
specificity for histones, the term HDAC is still used extensively. Class II is further 
subdivided into class IIa (HDAC4, 5, 7 and 9) and class IIb (HDAC6 and 10) 
according to their sequence homology, structural characteristics and number of 
catalytic domains. The recently identified HDAC11 constitutes its own class, IV.  
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Figure 7 - Zinc dependent HDACs can be subdivided into different classes. 
HDAC11 constitutes its own class IV 
 
 The cleavage of acetyl groups of acetylated lysine histone tails by class I, 
class II and class IV HDACs proceeds through a zinc(II)-activated water molecule 
in the active site. Class III HDACs share a common active site of 275 amino acids  
and use nicotinamide adenine dinucleotide (NAD+) dependent as a cofactor. The 
function of the recently discovered HDAC11 is still under investigation.  
 In class I, II and IV HDACs, the active site containing the Zn(II) catalytic 
centre is connected to the surface of the protein via a narrow 11Å long 
hydrophobic channel (Figure 8).  
 
Figure 8 - Crystal structure (pdb 3MAX) of HDAC2 in complex with a 
benzamide derivative.
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 In the active site, the zinc cation is generally found in a tetrahedral 
environment in its native state, and is complexed by two aspartates, one histidine 
and a water molecule. A model for Zn(II) dependent HDACs catalytic activity 
was proposed
76
 in 1999  (Scheme 3) based on crystallographic studies of a HDAC 
homologue from the hyperthermophilic bacterium Aquifex aeolicus (sharing 
35.2% identity with human HDAC1 over 375 residues). This model involves the 
coordination of the carbonyl oxygen of the acetylated lysine substrate to the zinc 
cation, positioning the acetate group in ideal position for nucleophilic attack by a 
zinc-activated water molecule. The tetrahedral oxyanion intermediate is stabilised 
by both electrostatic interactions with Zn(II), and hydrogen bonding with the 
neighbouring tyrosine hydroxyl group. Decomposition of the tetrahedral 
intermediate and proton transfer affords the deacetylated lysine and the acetate 
moiety. Class IIa HDACs display a highly reduced activity, in part due to the 
replacement of the catalytic tyrosine by a histidine residue. Indeed, mutagenesis 
experiments have shown class IIa HDACs to display a highly increased activity 
when this histidine was mutated by a tyrosine.
77
  
 However, recent DFT studies by Vanommeslaeghe
78
 and co-workers 
suggested a slightly different mechanism for the deacetylation process. This 
model mainly differs in the initial protonation state in the active site, in particular 
the two histidines forming the charge relay system and the zinc activated water 
molecule. In this model (Scheme 4) the carbonyl of the substrate undergoes 
nucleophilic attack of a hydroxide ion bound to Tyr303 (HDLP numbering) and 
the zinc cation. The negative charge of the resulting tetrahedral oxyanion 
intermediate is stabilised by the protonated His131 and the zinc cation. 
Subsequent proton transfer from His131 to neutral His132 occurs through a low 
potential channel, followed by decomposition of the intermediate and new proton 
transfer from His132 to the amino group of the deacetylated lysine. 
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 Scheme 3 - Deacetylation mechanism by Zn(II) dependent HDACs of acetylated lysine residues, proposed by Finnin. HDLP active-site residues and 
their proposed human HDAC1 counterparts (in parenthesis) are labelled 
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Scheme 4 - Alternative deacetylation mechanism by Zn(II) dependent HDACs of acetylated lysine residues, proposed by 
Vanommeslaeghe. HDLP active-site residues and their proposed human HDAC1 counterparts (in parenthesis) are labelled 
 
Towards novel small molecule epigenetic inhibitors Introduction 
17 
 
 Class III HDACs are homologous of the yeast enzyme Sir2.  To date, 7 
sirtuins isoforms have been discovered in human (SIRT1-7), with SIRT1
79
 and 
SIRT2
80
 having received the most attention. They are structurally and 
mechanistically different from zinc dependent HDACs,  and use NAD+ as a 
cofactor in the deacetylation process.
81,82
 SIRTs target a wide range of proteins 
playing important roles in biological processes such as differentiation,  apoptosis, 
inflammation, energy metabolism, glucose and lipid metabolism, DNA repair and 
transcriptional silencing.
83
 Like zinc dependent HDACs, SIRTs are not 
exclusively restricted to histone deacetylation but are able to deacetylate non 
histone proteins, such as Ac-CoA, α-tubulin and p-53. Importantly, disregulation 
of SIRTs activity has been shown to be involved in cancer and aging related 
diseases, making the search of novel SIRT inhibitors an intensive area of research. 
As the results presented in this thesis will be mainly focused on Zn(II) dependent 
HDACs, SIRTs will not be discussed in depth here. 
 
2.3. Aberrant DNA methylation and histone deacetylation in cancer 
 
 It is now recognised that both genetic and epigenetic modifications are 
critical to every stage of cancer and epigenetic silencing has been shown to play 
an important role in the misregulation of genes involved in all the hallmarks of 
cancer.
84,85
 In this context, DNA methylation and histone (de)acetylation are at the 
center of a complex regulatory network controlling gene expression via 
interrelated epigenetic modifications of chromatin. Aberrant DNA methylation 
and histone acetylation patterns have been observed in many tumours, often 
involving aberrant TSGs silencing through hypermethylation of TSG promoters, 
in addition to hypoacetylation of histones associated with TSG promoters. While 
hypermethylation of gene promoters is usually associated with transcriptional 
silencing, global hypomethylation has been shown to lead to chromosomal 
instability.
86
 An important number of TSG promoters have been found abnormally 
hypermethylated in various cancer types, leading to their silencing.
87
 Genes 
involved in DNA repair (e.g. BRCA1, MLH1, MGMT), signal transduction (e.g. 
RASSF1), cell cycle (e.g. p16
INK4a
, p15
INK4b
), metabolism of mutagens (e.g. 
GSTP1), cell adhesion (e.g. CDH1, CDH13), apoptosis (e.g. DAPK, TMS1, p73), 
angiogenesis (e.g. THBS1) are examples. As an illustration, the promoter 
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hypermethylation frequency of a selected set of known or postulated TSGs in 
various tumour types is shown in Figure 9.
87
 In contrast, promoters of these genes 
were found unmethylated (or methylated to an insignificant extent) in normal 
tissues. 
 
Figure 9 - Methylation of multiple tumour suppressor gene promoters within 
tumour cells genome, adapted from Esteller et al.
87
 
 
 The downstream cascade linking promoter hypermethylation to final gene 
silencing is not completely understood, however it is now generally accepted that 
DNA methylation and histone modifications are intricately interrelated, acting in 
concert to determine cell fate.
88
 As previously mentioned, DNA methylation can 
induce downregulation/silencing of genes by directly or indirectly (MBPs) 
preventing the binding of transcription factors,
31,32
 but can also promote the 
recruitment of HDAC containing transcriptional repressor complexes.
42,43
 
 As stated earlier, epigenetic modifications of chromatin are reversible (in 
opposition to genetic mutations), and it is nowadays well accepted that the 
potential reversibility of the DNA methylation and histone acetylation patterns are 
viable targets for the treatment of cancer. While a number of approaches for 
therapy in the past involved the inhibition of proteins acting in an oncogenic way, 
such as kinases, glycosidases and telomerase, the goal of “epigenetic therapies”89 
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lies in the modulation of the activity of enzymes involved in epigenetic gene 
regulation. The goal of such a modulation is to restore a regular epigenetic 
landscape in cancer cells and stop cancer progression. In particular, reversing the 
aberrant epigenetic patterns in cancer cells is expected to reactivate aberrantly 
silenced TSGs, and subsequently induce cell growth down regulation. In this 
context, the development of new inhibitors aimed at correcting the unregulated 
activity of DNMTs and HDACs has arisen as one of the most promising 
approaches to cancer therapy. 
 
2.4. HDAC inhibitors 
 
 In recent years, there have been significant efforts made towards the 
discovery of new inhibitors of enzymes involved in the epigenetic regulation of 
gene expression. In particular, HDACs and DNMTs have been intensely studied 
for their potential application as potential therapeutic agents but also as potential 
probes for deeper investigation into epigenetic phenomena at the molecular level. 
HDAC inhibitors have received a lot of attention, partially due to the success of 
suberoylanilide hydroxamic acid
90,91
 1 (SAHA, also known as Vorinostat or 
Zolinza) and Romidepsin 2
92
 in clinical trials, and their recent FDA approval 
(Figure 10). In particular, SAHA was the first HDAC inhibitor approved by the 
FDA in 2006 (marketed as Zolinza), and is used for the treatment of cutaneous T-
cell lymphomas (CTCL). 
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Figure 10 - FDA approved HDAC inhibitors 
 
 To date a large number of HDAC inhibitors (HDACis) have been reported, 
with inhibitors of class I and class II HDACs having received most attention. The 
majority of these inhibitors possess a zinc binding group (ZBG) coordinating to 
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the zinc cation in the HDAC active site, a “cap” unit interacting with amino acids 
at the entrance of the channel leading to the active site, and a linker lying in the 
connecting hydrophobic channel, positioning the ZBG and the “cap” at an 
adequate distance (Figure 11). 
cap linker ZBG
 
Figure 11 - Pharmacophore of the majority of HDAC inhibitors, the cap-linker-
ZBG model 
   
 The majority of class I and class II HDAC inhibitors fall in one of the 
following categories: short chain fatty acids, hydroxamic acids, cyclic peptides 
and benzamides. Short-chain fatty acids such as butyrate 3, phenylbutyrate 4 and 
valproic acid 5 were the first HDAC inhibitors identified (Figure 12). These 
compounds are structurally very simple, however exhibit only moderate 
inhibition, usually in the millimolar range, and lack isoform specificity and 
bioavailability. 
COONa
COONa
COOH
3 4 5  
Figure 12 - Examples of short-chain fatty acid HDAC inhibitors 
 
 Hydroxamic acids represent the largest and most studied class of HDAC 
inhibitors. Examples of hydroxamic acid HDACis are shown in Figure 13. 
Trichostatin A (6, TSA), isolated from Streptomyces Hygroscopicus, was the first 
hydroxamic acid inhibitor reported.
93,94 
TSA and SAHA are two of the most 
studied HDAC inhibitors and display low nanomolar activity in vitro. While 
highly potent, both TSA and SAHA display low isoform selectivity. Crystal 
structures
76
 of an HDAC1 homologue complexed with TSA
94,95
 6 and
 
SAHA
96,97
 1
 
provided important structural information regarding their binding mode. In these 
crystal structures, the two inhibitors complex the zinc cation in the active site and 
engage in a number of H-bonds via their hydroxamic acid moiety. The 
hydroxamic acid is connected to an aromatic capping unit by the intermediate of a 
hydrophobic linker participating in van der Waals interactions throughout a 
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hydrophobic tubular channel connecting the active site to the surface of the 
protein.
76
 The capping group is involved in hydrophobic interactions at the 
entrance of the tubular pocket. Hydroxamic acids are potent HDACis in vitro, and 
usually exhibit IC50s in the low μM to low nM range. However, they generally 
exhibit low isoform selectivity. PCI-34051
98
 7 and tubacin
99
 8 are two of the rare 
examples of potent and isoform selective hydroxamic acid based HDACis in vitro, 
inhibiting HDAC8 and HDAC6 respectively.  
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Figure 13 - Examples of hydroxamic acid HDAC inhibitors 
 
 A number of cyclic tetrapeptide based natural products have been reported 
to be highly potent HDACis. Examples include the recently FDA approved 
Romidepsin (2, Figure 10) epoxyketone Trapoxin B
100,101
 (9) ethylketone 
Apicidin
102
 10 and thioester Largazole
103,104
 11 (Figure 14). Cyclic peptides 
HDACis efficiently inhibit HDACs at low nanomolar concentration in vitro. 
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Figure 14 - Examples of naturally occurring cyclic peptide based HDACis 
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 Ortho-aminoanilide derivatives constitute a fourth class of inhibitors. This 
category includes the class I selective inhibitor MS-275
105-107
 (12, Figure 15). This 
class of compounds has received significant attention due to their ability to 
selectively inhibit class I HDACs while being weakly active against class II.
15
 
Other examples of HDAC inhibitors, mainly varying in the nature of their ZBG, 
include electrophilic ketones (e.g. 13), N-formylhydroxylamine derivatives (e.g. 
14) and thiols (e.g. 15).
20
 Thiols are a good ZBG, as exemplified by Romidepsin 2 
or Largazole 11 which are both low nanomolar HDAC inhibitors and thought to 
exhibit a thiol as the active species against HDAC activity. Other examples 
include the thiol analogue of SAHA 15, which was found to be as potent as 
SAHA itself.
108
 A number of sulfur based inhibitors was synthesized and tested by 
Suzuki, Miyata and co-workers,
108-112
 involving notably thiol, thioacetate, 
alkylsulfone, methylthioether as zinc binding groups. 
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Figure 15 - Examples of non hydroxamate HDAC inhibitors 
 
 Despite the success of SAHA and Romidepsin in clinical trials, the 
majority of HDAC inhibitors suffer from a number of drawbacks. In particular, 
the correlation between specific epigenetic signalling pathway alteration and their 
cytotoxicity still needs to be established. This is mainly due to their lack of 
isoform selectivity, inducing modifications of a variety of downstream HDAC 
mediated signalling pathways. Despite the discovery of the isoform selective PCI-
34051 and Tubacin (Figure 13), novel isoform selective HDACis are still needed. 
Clearly, not only would such compounds be useful for the development of probes 
aimed at studying the biological role of individual isoforms, but also for the 
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development of new anticancer drug candidates able to target specific pathways 
and therefore potentially display less side effects during therapy. Interestingly, 
recent preliminary studies have shed light on molecular features exploitable for 
the development of isoform selective probes. These studies notably demonstrated 
that structural alteration of the ZBG and capping units of HDACis could lead to 
class and/or isoform selective compounds.
99,113,114
 In particular the o-aminoanilide 
motif, while being less potent than the hydroxamic acid moiety for zinc binding, 
was found to selectively target class I HDACs. Other functional groups, such as 
thiol, have also been reported to exhibit class selectivity.
115
 Concerning the 
capping group, a number of studies demonstrated its importance for both potency 
and selectivity. For example, it was found that alteration of the capping unit of the 
unselective compound SAHA (1) could be exploited for the development of the 
HDAC6 selective compound Tubacin 8, demonstrating the importance of the 
interactions at the surface of the protein for both binding and selectivity. 
  
2.5. DNMT inhibitors 
 
 The list of DNMT inhibitors is much smaller compared to the cohort of 
HDAC inhibitors reported.
15,20,21
 They fall into two classes: nucleoside and non-
nucleoside analogues. Among nucleoside analogues are several cytidine mimics 
such as 5-azacytidine 16,
116
 5-aza-2‟-deoxycytidine 17 (also known as 
decitabine),
117
 5-fluoro-2‟-deoxycytidine 18,118 5,6-dihydro-5-azacytidine 19119 
and zebularine 20
120,121
 (Figure 16). In particular, 16 and 17 have received FDA 
approval for the treatment of myelodysplastic syndromes. These analogues act as 
prodrugs since they require incorporation into DNA to exhibit DNMT inhibition. 
The inhibition of DNMT activity is mechanism-based. During the methylation 
process, proton elimination in position 5 is made impossible, inducing trapping of 
the DNMT in an irreversible covalent adduct (Figure 17).
 
However, it is still 
unclear whether the effect of these molecules can be attributed to induction of 
DNA hypomethylation or DNMT depletion.
122
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Figure 16 - Cytidine analogues inhibitors of DNA methylation 
 
 However, cytidine analogues suffer from a number of drawbacks, such as 
significant toxicity and poor stability in aqueous media. While zebularine 20 
possesses an improved stability in aqueous solution, it still suffers from poor 
bioavailability.
121
 With the limitations encountered with nucleoside DNMT 
inhibitors, such as poor stability, lack of sequence specificity and incorporation 
into DNA, efforts have been focused towards the development of non-nucleoside 
analogues with improved properties.  
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Figure 17 - Irreversible covalent adduct formed during methylation of cytidine 
analogues by DNMTs (examples of 16 and 18) 
 
Several non nucleoside inhibitors have been reported. Procaine (21), an anesthetic 
drug, was able to reduce DNA methylation in MCF7 cells. However, it failed to 
inhibit DNMT in vitro. Procainamide
123-125
 (22) (Figure 18) was also shown to be 
a demethylating agent with antiproliferative activity, its action is thought to be 
mediated by its binding to CpG rich sequences in DNA. Lyko and co-workers 
No proton available 
for elimination 
F instead of H, 
does not eliminate 
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discovered the phthaloyl tryptophan derivative RG108
126
 (23) via virtual 
screening. RG108 is able to inhibit methyltransferase activity and has been shown 
to induce DNA hypomethylation in vitro. However its ability to induce significant 
DNA hypomethylation in cells is limited. Hydrazaline (24) is a vasodilating drug, 
and has been reported to inhibit DNA methylation
127
 and to reactivate TSGs in 
cervical cancer patients.
128
 Several polyphenols were also reported as inhibitors of 
DNMT activity; among them are EGCG
129
 (25), Caffeic acid (26) and 
Chlorogenic acid
130
 (27).  
 Despite their increased stability, non nucleoside analogues have so far 
shown only reduced potency compared to nucleoside analogues.
131
 Intensive 
research is still ongoing towards potent non nucleoside DNMT inhibitors.
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Figure 18 - Examples of non-nucleoside inhibitors of DNA methylation 
 
 Nowadays, epigenetic chemotherapies using HDAC and DNMT inhibitors 
are considered amongst the most promising approach in cancer therapies, notably 
through the reactivation of TSGs. However in most instances, it has been shown 
that epigenetically silenced genes cannot be reactivated by HDACis alone, but 
require the synergistic functions of other agents. In particular, HDACis with 
DNMT inhibitors (DNMTis) has been recently shown to have synergistic effects 
against cancer cells when used in combination.
132-134
 This synergy between 
HDACis and DNMTis is considered as a new promising approach for therapy.
Towards novel small molecule epigenetic inhibitors Results and discussion 
26 
 
RESULTS AND DISCUSSION 
 
1. Design and synthesis of Psammaplin A analogue libraries 
 
1.1. Introduction 
 
 Naturally isolated products continue to play a significant role in anticancer 
drug discovery. Of relevance, a number of HDAC inhibitors isolated from natural 
sources have been reported,
15,20,21,108,109,112
 including for example Trichostatin A 
(6), sodium butyrate (3), Trapoxin B (9), and Largazole (11) (Figure 19). 
Naturally occurring DNMT inhibitors have also been reported, such as 
polyphenols EGCG (25)
129
, caffeic acid (26) and chlorogenic acid (27).
130
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Figure 19 - Examples of naturally occurring HDAC and DNMT inhibitors 
 
In this project, we were particularly interested in the natural product Psammaplin 
A (28, Figure 20), which has been reported to exhibit a range of interesting 
biological activities.  
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Figure 20 - Structure of the natural product Psammaplin A 
 
Psammaplin A is a member of the psammaplin family of natural products (Figure 
21).
135
 All the family members have in common a bromotyrosine scaffold, and 
differ in the nature of their pendant terminal end group (Y, Figure 21, top). 
Psammaplins belong to the larger bromotyrosine based metabolite family. 
Numerous bromotyrosine metabolites were isolated from marine sponges,
135a-g, 135j
 
notably from marine sponges of the order Verongida, known to be a rich source of 
such metabolites.
136
 Psammaplin A was isolated from several marine sponges 
including Pseudoceratina purpurea.
135g
 It is a symmetrical, dimeric natural 
product, and was characterised and reported in several publications in 1987,
135a-c
 
representing the first example of disulfide and oxime containing metabolite 
isolated from a marine sponge. The presence of the very unusual α-hydroxyimino 
amide motif, in addition to the bromophenol functionality, confers Psammaplin A 
a very unusual structure. 
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Figure 21 - The psammaplin family of natural products. A number of other 
derivatives have also been reported, such as psammaplin sulfates
135j
 or 
psammaplin trisulfides (not shown) 
 
 The geometry of the two oximes of Psammaplin A was assigned as (E) by 
Arabshahi and Schmitz, based on extensive NMR studies.
135c
 Indeed it is known 
that the 
1
H and 
13
C chemical shifts for a methylene group in the α position to an 
oxime are dependent on the oxime geometry.
137
 In 1987 Arabshahi and Schmitz 
isolated several new brominated metabolites from an unidentified sponge.
135c
 
Interestingly two of these compounds exhibited very similar NMR spectra. One 
was found to be the natural product now called Psammaplin A (Figure 20), having 
an (E,E) oxime geometry and the second was found to be the product with an 
(E,Z) geometry, one oxime being isomerized. They later observed that the (E,Z) 
product completely isomerized to the (E,E) one after a few weeks, demonstrating 
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the increased stability of the (E) geometry. Notably, it was shown that in the (Z) 
geometry the methylene carbon (α to the oxime) shifted downfield (δ = 35.7 ppm) 
compared to the (E) geometry (δ = 27.7 ppm) (Figure 22). The benzylic protons 
were found to be upfield (δ = 3.68 ppm) in the (Z) geometry compared to the (E) 
geometry (δ = 3.87 ppm) in Psammaplin A, which was in accordance with 
previous oxime studies made by Karabatsos.
138
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Figure 22 
 
The (E) geometry proposed by Arabshahi and Schmitz
135c
 for Psammaplin A was 
later confirmed by X-ray analysis of the bromotyrosine derived metabolites 
Bastadin 5 (43) and Bastadin 4 (44),
139
 and a synthetic Psammaplin A analogue 
(45) (Figure 23).
140 
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 Interestingly, Psammaplin A has been shown to exhibit a wide range of 
biological activities. While it has been implicated as an inhibitor of numerous 
targets such as Topoisomerase II,
141
 DNA gyrase,
142
 Leucine aminopeptidase,
135e
 
Farnesyl protein transferase,
135e
 Chitinase B,
135f
 Mycothiol-S-conjugate 
amidase,
143
 Aminopeptidase N
144
 and DNA polymerase α-primase,145 screening of 
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numerous psammaplins by Crews and co-workers showed Psammaplin A to be an 
extremely potent inhibitor of both HDAC and DNMT enzymes.
135g 
In particular, 
Psammaplin A was found to be the most effective inhibitor among all 
psammaplins tested. In enzymatic assays, Psammaplin A displayed potent activity 
(IC50) against an HDAC cell extract (4.2 nM) and semi purified DNMT1 (18.6 
nM). Subsequently, studies on the antiproliferative properties of Psammaplin A in 
vitro have shown it to have significant cytotoxicity (ED50, μg/mL) against human 
lung (A549, 0.57), ovarian (SK-OV-3, 0.14), skin (SK-MEL-2, 0.13), CNS 
(XF498, 0.57), and colon (HCT15, 0.68) cancer cell lines.
146 
In vivo,
 
it inhibited 
tumour growth in the A549 lung xenograph mouse model while maintaining low 
toxicity.
135g
  
 
 Based on our ongoing interest in epigenetics and potential exciting 
applications in anticancer therapies, we thought Psammaplin A to be a highly 
valuable starting point for our project. We decided to elucidate the reasons for the 
observed HDAC and DNMT inhibition by this natural product, by establishing 
structure-activity relationships (SAR) against both enzymes. We envisaged that 
such studies would not only allow dissection of the epigenetic activity of 
psammaplin A, but would inspire new leads in cancer drug discovery. Indeed, 
non-nucleoside DNMT inhibitors and isoform selective HDAC inhibitors are 
severely underdeveloped, vindicating the need for new small molecule leads. 
Furthermore, epigenetic pathways such as histone deacetylation and DNA 
methylation are intimately interrelated, with the efficacy of HDAC inhibitors 
potentiated by co-administration of DNMT inhibitors.
14,132
 Clearly, inhibitory 
molecules with dual activity against several classes of epigenetic enzymes may 
provide novel approaches to therapy. 
 
 As previously mentioned, epigenetically silenced genes cannot be 
reactivated by HDAC inhibitors alone, and require the synergistic functions of 
demethylating agents, such as DNMT inhibitors.
14,132
 The discovery of the highly 
potent inhibitory effect of Psammaplin A against both HDAC and DNMT activity 
represents a very valuable starting point for our anticancer drug discovery project. 
Whereas the highly potent HDAC inhibitory properties of several members of the 
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psammaplins have been reported,
135g
 the molecular mechanisms underlying this 
inhibitory effect are not completely understood. In 2007, studies performed by 
Kwon and co-workers
115
 were consistent with the cap-linker-ZBG model for 
HDAC inhibitors (Figure 11), as discussed in section 2.4. Their work strongly 
suggested that Psammaplin A could be a natural prodrug, with the species 
responsible for HDAC inhibition, a thiol, revealed via reduction of the disulfide 
moiety. Indeed there were precedents, several thiol containing HDAC inhibitors 
had already been reported previously,
108,109,112,147,148
 such as the thiol analogue of 
SAHA (15, Figure 24), the cyclic peptide based natural products FK228 
(Romidepsin, 2),
148
 Spiruchostatin A (46) and Spiruchostatin B (47). In an 
enzymatic assay, 15 was found to be as potent as SAHA.
108
 In 2002, studies by 
Furumai and co-workers showed that the HDAC inhibitory potency of 
Romidepsin (2), containing an internal disulfide moiety, was significantly 
enhanced when in its reduced form.
147
 On the contrary, incubation with 1% H2O2 
led to a drop in potency. Reduction of 2, followed by methylation of the resulting 
thiols led to a completely inactive compound against HDACs. Taken together, 
these observations were in agreement with 2 being a natural prodrug. The potency 
of 2 was also considerably reduced in glutathione deficient cells, bringing 
additional support to the prodrug hypothesis. 
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 In 2007, Kwon and co-workers showed in a similar manner the HDAC 
inhibitory potency of Psammaplin A to be dependent on the oxidation state around 
the sulfur atom (Scheme 5).
115
 Enzymatic assays performed with Psammaplin A 
in the presence of 1% H2O2 led to very low HDAC inhibition compared to non 
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treated Psammaplin A. The same experiment performed in the presence of 
dithiothreitol (DTT) instead of H2O2 led to results similar to those obtained with 
the non pre-treated Psammaplin A. This latter result could be explained by the 
usual presence of cellular reducing agents in the extracts used for the enzymatic 
assay, potentially reducing Psammaplin A in situ; further addition of H2O2 
permitted recover of enzymatic activity. During the same study, it was shown that 
Psammaplin A exhibited greatly decreased HDAC inhibitory potency in 
glutathione deficient cells, an observation which parallels previous results 
obtained with other disulfide containing HDAC inhibitors, such as Romidepsin 
(2). Taken together, all these observations strongly suggested Psammaplin A to be 
a natural prodrug for HDAC inhibition (Figure 25). Other cell based assays by 
Kwon and co-workers showed that Psammaplin A, in its reduced form, was a 
selective class I HDAC inhibitor, efficiently inducing histone hyperacylation but 
failing to significantly affect the level of acetylated tubulin. This class selectivity 
has already been observed with other non hydroxamic acid HDAC inhibitors.
21,113
 
Although Psammaplin A induced an upregulation of acetylated histones (substrate 
for class I HDACs) while leaving the level of acetylated tubulin (substrate for the 
class II HDAC6) unaffected, subclass isoform specificity was not thoroughly 
studied.  
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Scheme 5 - HDAC inhibition by Psammaplin A is affected by the presence 
of oxidants and reducing agents 
 
Whereas the presence of a thiol as a ZBG seems to be important for HDAC 
inhibition by Psammaplin A, the importance of the amide, the oxime 
functionality, and the aromatic “cap” for HDAC inhibition is still unclear. 
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Figure 25 - Proposed cap-linker-ZBG model for Psammaplin A 
 
 The mechanism underlying the reported DNMT1 inhibition by 
Psammaplin A is poorly understood. There is no evidence as to whether the 
species responsible for DNMT inhibition is a thiol or a disulfide. An initial 
hypothesis we formulated was that inhibition could proceed via crosslinkage 
between the disulfide bond of Psammaplin A and the thiol residue in the active 
site of DNMT1 (Scheme 6).
69,70,149
 However this hypothesis is difficult to 
reconcile with the usual presence of reducing agents (such as DTT) in 
methyltransferase enzyme based assays, used to stabilize the enzyme and its 
substrate. Indeed, as previously mentioned Psammaplin A is chemically sensitive 
to reducing agents, the latter potentially converting it to the corresponding thiol. 
Alternatively, inhibition via an allosteric mechanism cannot be neglected. 
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Scheme 6 - Hypothesis for the inhibition of DNMT1 by Psammaplin A 
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1.2. Results and discussion 
 
1.21. Library design 
 
 Initial work was therefore undertaken with the aim of establishing a 
structure-activity relationship (SAR) of Psammaplin A against HDAC and DNMT 
enzymes, in order to shed light on the required structural features of Psammaplin 
A for HDAC and DNMT inhibition. In order to establish the SAR for Psammaplin 
A around our targets of interest, we designed and synthesised a library of 
compounds (Figure 26), in order to probe the nature of the sulfur end group 
(disulfide, thioether, thiol, etc), the oxime functionality (AB, Figure 26) and to 
fully explore variation in the substituents of the aromatic “capping” group. 
 
A
B
H
N
O
SR
X
Y
Z
Phenyl substitution
sulfur environment
heteroatom substitution
A = N, O
B = OH, OMe, NH2
R = S(dimer), H, Me
 
Figure 26: Library design, variation of aromatic substitution,  
oxime unit and oxidation state of the sulfur 
 
 In terms of HDAC inhibition, variation of the disulfide moiety should give 
a definitive answer to the question of whether the active species is the thiol or the 
disulfide. In addition to the original disulfide, preparation of the corresponding 
thiols and methylthioethers was planned. Based on our hypothesis of the thiol as 
active species against HDACs, we initially expected greatly decreased HDAC 
inhibitory properties for methiolthioether containing compounds. 
 
 The role of the oxime unit for HDAC inhibition is undocumented. 
Variation around it should provide useful information about its role in binding. 
 
 Finally, variations at the level of the phenol (OH vs OMe) should provide 
clues about the possible implication of this O-H group in H-bond interactions. 
Further variation of aromatic substitution should allow the study of the 
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importance of aromatic substitution on potency and selectivity. For example, 
electron-withdrawing functionalities should enhance arene-arene (π-π) 
interactions,
150
 whereas electron-donating groups, in combination with halogen 
substituents should enhance a potential sulfur-halogen bond.
151,152
 Likewise, 
should a sulfur-halogen bond be important, replacement of the bromide moiety in 
the psammaplin structure with an iodine atom, will increase the halogen atom‟s 
polarisibility, and subsequently enhance the sulfur-halogen bond. 
 
1.22. Previous syntheses of Psammaplin A and other bromotyrosine 
metabolites 
 
 Previously reported synthetic routes towards Psammaplin A, and in 
general, hydroxyimino bromotyrosine based natural products usually suffer from 
drawbacks when it comes to the synthesis of libraries of analogues. Several total 
syntheses of Psammaplin A have been reported previously. The first synthesis was 
reported by Hoshino in 1992 and involved tyrosine 48 as starting material 
(scheme 7).
153
 Bromination afforded bromotyrosine 49 in high yield. Refluxing of 
49 in trifluoroacetic anhydride afforded trifluorooxazolone 50, which was then 
hydrolyzed in aqueous acidic conditions to afford the arylpyruvic acid precursor 
51 in good yield. Further condensation with hydroxylamine, followed by direct 
DCC/N-hydroxyphthalimide (NOHP) coupling with cystamine 53 afforded 
Psammaplin A in 18% overall yield. Nicolaou‟s approach154 was similar, except 
that O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (O-THP protected 
hydroxylamine, 54)
155
 was employed as a precursor for the final oxime units, 
generated at the final step by acidic deprotection.  
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Reagents and conditions:
(i) KBr, KBrO3, 0.25N HCl, 23 °C, 12h, 81%
(ii) TFAA, 80-120°C, 1h, 61%
(iii) 70% aq. TFA, rt, 24h, 97%
(iv) HONH2.HCl, AcONa, EtOH, rt, 57%
(v) 53, DCC, NOHP, Et3N, dioxane, rt, 12h, 67%
(vi) 54, EtOH, rt, 12h
(vii) EDC, NHS, dioxane, rt
(viii) 53 (dihydrochloride salt), Et3N, dioxane/MeOH, rt
(ix) HCl, CH2Cl2, Et2O, MeOH, reflux, 2h, 36% from 3
54
53
(v)
(vi)
(vii-ix)
 
Scheme 7 - Total synthesis of Psammaplin A, Hoshino‟s and Nicolaou‟s routes 
 
 While both Hoshino and Nicolaou used tyrosine as a starting material, 
Sufrin based her synthesis on the commercially available 4-hydroxyphenylpyruvic 
acid 56 (Scheme 8).
156
 Condensation with hydroxylamine, followed by 
bromination and final DCC/NOHP mediated coupling with cystamine 53 afforded 
Psammaplin A in 43% overall yield, representing a substantial yield improvement 
compared to previous syntheses.  
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Reagents and conditions:
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(ii) KBr, KBrO3, 0.25N HCl, rt, 40 min, 81%
(iii) DCC, NHS, DMF, rt, 8h
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Scheme 8 - Total synthesis of Psammaplin A, Sufrin‟s route 
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 As an alternative for the introduction of the arylpyruvate motif, 
Wasserman and co-workers used a cyano ylide coupling strategy, allowing for the 
synthesis of the natural product Verongamine (58) from a phenylacetic acid 
derived starting material (scheme 9).
157
 The applicability of this methodology for 
the synthesis of Psammaplin A analogues is relatively limited. Indeed, in addition 
to the fact that only a limited number of phenylacetic acid derivatives are 
commercially available, the strong oxidative conditions necessary to generate the 
phenylpyruvoyl cyanide intermediate 61 limit the scope of aromatic substituents 
compatible with this chemistry (i.e. amines, thioether), not to mention the high 
toxicity of the formed cyanides. 
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Reagents and conditions:
(i) 62, EDC, CH2Cl2, rt, 4h, 82%
(ii) O3, CH2Cl2, -78°C, 5 min
(iii) histamine 63, t-BuOH/CH2Cl2, -78°C, 5 min; rt, 1h
(iv) HONH2.HCl, NaOAc, EtOH/THF, rt, 16h, 52% from 60
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N
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N
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N
Histamine (63)
CNPh3P
62  
Scheme 9 - Wasserman‟s total synthesis of Verongamine via a cyano ylide 
coupling 
 
 Using a different approach, De Lera synthesised Psammaplin A from 
tyrosine methyl ester 64, employing conditions previously reported by Spiling and 
co-workers for the synthesis of the natural product Verongamine 57 (Scheme 
10).
158
 Direct oxidation of the amino group
158-160
 using Na2WO4 afforded oxime 
65 in moderate yield. Further bromination afforded bromophenol 66 in good 
yield. Hydrolysis of ester 66 and DCC/NOHP mediated coupling with cystamine 
53 using conditions similar to those employed by Hoshino afforded Psammaplin 
A in 29% overall yield.  
 
 Despite the fact that the previously described synthetic routes afforded 
several Psammaplin A analogues,
140,154,156,161a-c
 they suffer from a number of 
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drawbacks. While they allow diversity introduction for the AB system (Figure 26) 
and the amine nucleophile [and therefore R (Figure 26)], diversity introduction in 
the aromatic substitution mainly depends on the relatively limited number of 
commercially available phenylalanine, tyrosine and arylpyruvic acid derivatives. 
This considerably limits variation of aromatic substitution patterns of Psammaplin 
A analogues. Early stage aromatic functionalisation of these building blocks is a 
potential solution to overcome this problem, however it increases the number of 
steps of the whole sequence. Another general approach was therefore required, 
allowing cheap and easy access to a wide range of substituted arylpyruvic acid 
derivatives. 
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(i) Na2WO4, H2O2, rt, 3h, 65%
(ii) NBS, MeCN, rt, 2h, 82%
(iii) LiOH, THF/H2O, rt, 12h, 99%
(iv) DCC, NOHP, Et3N, 53, dioxane/MeOH, rt, 12h, 60%
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Scheme 10 - Total synthesis of Psammaplin A, de Lera‟s route 
 
 The use of Nakamura‟s α-OTBS-functionalised dimethylphosphonate 
67
162
 by Spiling and co-workers, in a Horner-Wadsworth-Emmons (HWE) 
reaction with aromatic aldehyde 68 afforded the protected and functionalised 
methyl arylpyruvate 69 in high yield (scheme 11). The silylenol ether of 69 could 
be then converted into the corresponding oxime derivative 70 in high yield. Final 
amidation and MOM deprotection gave access to the natural product Purealidin A 
(71) in good overall yield.
162
 The use of an aromatic aldehyde as starting building 
block represents an important advantage. Indeed a wide range of structurally 
diverse aromatic aldehydes are available from commercial sources and usually 
cheap, which is ideal for the construction of a library of analogues. However, 
conditions used in the initial HWE reaction are incompatible with the presence of 
deprotonable and/or base sensitive aromatic substituents (i.e. hydroxyl) and 
therefore involves the use of protecting groups. 
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Scheme 11 - Spilling‟s total synthesis of Purealidin A using Nakamura‟s α-
OTBS-functionalized dimethylphosphonate
162
 
 
 While starting the synthesis of our libraries from aromatic aldehydes 
would represent a valuable synthetic advantage for diversity introduction on the 
aromatic ring, milder conditions had to be found in order to convert them to the 
corresponding arylpyruvic acid derivatives. It was thought that the well known 
Erlenmeyer-Plöchl azlactone synthesis
163
/hydrolysis sequence
164
 was the method 
of choice to achieve this goal (Scheme 12). 
 
O
R
72
(ii)(i)
Reagents and conditions:
(i) N-acyl-Gly, NaOAc, Ac2O
(ii) HCl/H2O
R
73
N
O
O
R
74
O
OH
O
 
Scheme 12 - Erlenmeyer-Plöchl azlactone synthesis/hydrolysis for the expedient 
access to a wide range of substituted arylpyruvic acids 
 
 The retrosynthetic analysis of target compounds 75 is shown in Scheme 
13. Psammaplin A analogues with general structure 75 should be accessible from 
the corresponding acids 76 using conditions reported previously by others for 
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amide bond formation.
153,154,156
 Acids 76 should be obtained easily after 
condensation of arylpyruvic acids 74 with a hydroxylamine derivative (in the case 
AB = oxime or O-methyloxime). Finally Erlenmeyer azlactone synthesis followed 
by acidic hydrolysis should provide acids 74 from aldehydes 72.  
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Scheme 13 - Retrosynthetic analysis of Psammaplin A analogues 
 
1.23. Synthesis of oxime and O-methyloxime containing analogues 
 
 Our synthetic route to the various arylpyruvic acids is described in Scheme 
14 (+ see Table 1 for structures). Upon exposure to N-acetyl glycine and acetic 
anhydride in the presence of sodium acetate, aromatic aldehydes 72a-n were 
converted to the corresponding azlactones 73a-n in moderate (i.e. 73g) to high 
(i.e. 73h) yield. Simple filtration, trituration in cold water, and a second filtration 
afforded the crude azlactones. Importantly, these were pure enough to be used for 
the next step. Further reflux in 10% aqueous HCl afforded arylpyruvic acids 51, 
56, 74a-n in moderate (i.e. 74f) to excellent (i.e. 74n) yield. Once again, simple 
isolation by filtration afforded arylpyruvic acids 74a-p as crude products which 
were used for the next step without further purification. Indeed, attempted 
purification by normal phase column chromatography proved unsuccessful owing 
to the high polarity and poor stability of these compounds on silica. Other 
purification methods were not investigated. Characterisation by NMR showed that 
these compounds are present exclusively in the enol form in solution (CD3OD).  
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Reagents and conditions:
(i) N-Ac-Gly, NaOAc, Ac2O, reflux, 3h, 37-90%
(ii) 10% aq. HCl, reflux, 48-98%
O
R1
72a-n
R1
73a-n
(i)
O
OH
O
R1
51, 56, 74a-n
(ii)
N
O
O
 
Scheme 14 - Synthesis of substituted arylpyruvic acids 
 
 The structurally diverse arylpyruvic acids generated were used as 
precursors to Psammaplin A analogues following procedures inspired by the 
previously reported routes (Scheme 15).
151,152,158b
 Condensation of arylpyruvic 
acids 51, 56, 74a-n with O-THP protected hydroxylamine afforded oximes 55, 
76a-o, which were used as a crude product for the next step after a simple acidic 
aqueous work-up. EDC mediated amide bond formation with 53 or 77 afforded 
protected precursors 78a-r, which were purified via a short silica column. Final 
THP deprotection in anhydrous acidic conditions afforded Psammaplin A (28) and 
analogues 75a-q in moderate (i.e. 75o) to high (i.e. 75c) yield after purification by 
flash column chromatography. The synthesis of O-methyloxime containing 
analogues was achieved in a similar manner, except methoxylamine was used 
instead of the O-THP protected hydroxylamine. A summary of the structures of 
azlactones, arylpyruvic acids and analogues 75a-u, in addition to the yields for the 
different synthetic steps, can be found in Table 1. Phenylpyruvic acid 74b and 4-
hydroxyphenylpyruvic acid 56 were obtained from commercial sources.  
 
 Initially, a comparative study using selected substrates was undertaken 
(data not shown) in order to determine the best conditions to be used for amide 
bond formation among those reported by Hoshino, Nicolaou and Godert.
153,154,156
 
While the DCC/NOHP mediated amide bond formation used by Hoshino afforded 
Psammaplin A in only two steps from arylpyruvic 51 (Scheme 7), we found the 
yield of the coupling between hydroxyimino acids (e.g. 52) and cystamine 53 to 
be relatively capricious and substrate-dependent. It therefore decided to switch 
towards more robust and general coupling conditions. While Godert and Nicolaou 
both reported efficient coupling procedures using DCC/NHS and EDC/NHS 
respectively, the latter conditions were found to proceed in a much cleaner 
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fashion. First, it is well known that dicyclohexylurea, the byproduct of DCC 
mediated couplings, can be difficult to remove completely by standard 
purification techniques. The use of the water-soluble EDC represents a 
considerable advantage, as its corresponding urea is also water-soluble and 
usually completely removed during standard aqueous work-up. Efficient and 
general purification methods are particularly important when synthesising large 
libraries of analogues. Moreover, the low boiling point solvents and the simple 
intermediate aqueous work-up involved in Nicolaou‟s synthesis were found to 
greatly facilitate the purification of the final products. An O-THP protected 
hydroxylamine was preferred as a precursor of the final oxime, as described by 
Nicolaou,
154
 once again for ease of purification of the final product. 
 
Reagents and conditions:
(i) 54, pyridine, rt, 12h
(ii) EDC, NHS,  dioxane, rt, 3h
(iii) nucleophile, Et3N, dioxane/MeOH, rt
(iv) HCl, CH2Cl2/Et2O/MeOH, sealed tubed, reflux, 11-45% from acid
(v) MeONH2.HCl, pyridine, rt, 12h, 30-67% from acid
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Scheme 15 - Synthesis of oxime and O-methyloxime containing analogues 
 
 In summary, this synthetic route involved clean and high-yielding 
transformations, allowing the access to oxime and O-methyloxime containing 
compounds after minimum purification by flash column chromatography 
throughout the whole synthetic sequence. 
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Entry aldehyde 
Azlactone 
yield 
acid 
yield 
AB 
Amine 
nucleophile 
Product, 
yield from 
pyruvic acid  
72a 
Br
HO
O  
73a, 71% 51, 88% 
NOH 80 75a, 40% 
NOH 53 28, 35% 
NOMe 80 75r, 43% 
NOMe 53 75s, 30% 
       
72b 
Br
O
O
 
73b, 75% 74a, 83% 
NOH 80 75b, 38% 
NOH 53 75c, 49% 
NOMe 80 75t, 67% 
NOMe 53 75u, 41% 
       
   
74b, R1 = H 
Commercial 
NOH 53 75d, 24% 
    
56, R1 = 4-OH 
Commercial 
NOH 53 75e, 20% 
72c 
F
O  
73c, 54% 74c, 72% NOH 53 75f, 29% 
72d 
S
O  
73d, 66% 74d, 71% NOH 53 75g, 20% 
72e 
O
I
O  
73e, 69% 74e, 94% NOH 53 75h, 36% 
72f 
Br
F
O
 
73f, 66% 74f, 48% NOH 53 75i, 30% 
72g 
S
Br
O  
73g, 37% 74g, 92% NOH 53 75j, 25% 
72h 
O
I
O
O  
73h, 90% 74h, 86% NOH 53 75k, 23% 
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72i 
O
Br
O
O  
73i, 70% 74i, 93% NOH 53 75l, 45% 
72j 
O
O
O  
73j, 69% 74j, 62% NOH 53 75m, 13% 
72k 
O2N
O  
73k, 57% 74k, 72% NOH 53 75n, 30% 
72l 
O2N
Br
O  
73l, 60% 74l, 95% NOH 53 75o, 11% 
72m 
Br
Br
HO
O  
73m, 56% 74m, 82% NOH 53 75p, 22% 
72n 
O
S
O  
73n, 63% 74n, 98% NOH 53 75q, 36% 
 
Table 1 - Structure of oxime and O-methyloxime containing analogues, and 
yields for the different synthetic steps 
 
  
 The oxime geometry of final compounds was assigned as (E) in each case, 
based on the NMR chemical shifts (Table 2) of the benzylic protons and carbon 
(see section 3.1). Indeed, as previously mentioned NMR studies performed on 
Psammaplin A by Arabshahi and Schmitz
135c
 have shown that in the (Z) geometry 
the methylene carbon (α to the oxime) shifted downfield (δ = 35.7 ppm) compared 
to the (E) geometry (δ = 27.7 ppm) (Figure 22). In their study, the benzylic 
protons were found to be upfield (δ = 3.68 ppm) in the (Z) geometry compared to 
the (E) geometry δ = (3.87 ppm) in Psammaplin A. Structures can be found in 
Table 1 above. NMR data reported in Table 2 were in full agreement with an (E) 
geometry in each case. 
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N
R3O
H
N
O
SR2
R1
H H
 
Entry 
Benzylic protons  
δ (ppm) 
Benzylic carbon 
δ (ppm) 
75a 3.79 28.7
 
28 3.79 28.7
 
 
75r 3.81
a
 28.5
a
 
75s 3.81
a
 28.5
a
 
75b 3.90
a
 28.0
a
 
75c 3.87
a
 28.0
a
 
75t 3.83
a
 28.5
a
 
75d 3.91 30.0 
75e 3.80 29.1 
75f 3.88 29.2
 
 
75g 3.76
b
 28.3
b
 
75h 3.81 28.6 
75i 3.87 29.0 
75j 3.85 29.1 
75k 3.83 29.2 
75l 3.85 29.5 
75m 3.85 29.5
 
75n 4.03 29.8 
75o 4.02 29.8
c
 
75p 3.79 28.5 
75q 3.88 29.9 
 a
 CDCl3; 
b 
d
6
-DMSO; 
c
 CD3OD/d
6
-DMSO 
 
Table 2 - chemical shifts (ppm) of the benzylic protons and carbons for oxime 
and O-methyloxime containing analogues confirmed the (E) geometry in each 
case 
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 While the synthetic route described in Scheme 15 allowed us to access an 
important number of analogues, we faced several synthetic issues however when 
starting with electron-rich benzaldehydes, such as p-dimethylaminobenzaldehyde. 
While the Erlenmeyer azlactone synthesis is sufficient in the case of electron-poor 
aromatic aldehydes, low yields were generally obtained for electron rich 
substrates. Moreover, adjustment of the pH and isolation of the subsequent 
arylpyruvic acids was difficult when the aromatic ring contained basic 
functionalities. To overcome these problems and allow access to electron-rich 
aromatic Psammaplin A analogues, we developed alternative routes to 
Psammaplin A and analogues not accessible via the previously employed route. 
 
1.24. New synthetic route towards Psammaplin A analogues bearing electron 
rich aromatics 
 
 The retrosynthetic analysis of 79 is given in Scheme 16. The product 79 
was considered to be accessible through condensation of ester 80 with 
hydroxylamine and subsequent double amidation with cystamine 53. The key step 
in this synthesis was initially thought to be the introduction of the pyruvate motif. 
Alternatively, we considered accessing it via dihydroxylation of alkene 82 
followed by regioselective dehydration of the diol under acidic conditions.  
R1
N
HO
H
N
O
S
2
R1
O
OR2
O
R1
OR2
O
R1
O
X
R1
80, R2 = alkyl
82, R2 = alkyl
Path A
Knoevenagel-Doebner
79, R1 = electron donating
72 84
HO2C CO2Et CO2Me
83 85
Path B
Heck
R1
OR2
O81, R2 = alkyl OH
OH
OR
H2N
S
S
NH2
53
 
Scheme 16 - Retrosynthetic analysis of Psammaplin A analogues 
bearing electron rich aromatics (EDG = electron donating group) 
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 This process is likely to occur via an E1 mechanism and should be 
facilitated by the electron donating ability of the aromatic substituent, stabilising 
the positively charged benzylic position during dehydration (Scheme 17). Finally, 
the unsaturated ester should be easily accessible from a Knoevenagel-Doebner 
condensation between 3-ethoxy-3-oxopropanoic acid 83 and aromatic aldehyde 
72, or a Heck reaction between aryl halide 84 and methyl acrylate 85. Again, this 
synthetic route would employ commercially available, diverse and cheap starting 
materials. 
OR2
OOH
OH
OR2
O
OHH+ or LA
-H2O
EDG EDG
OR2
O
OH
EDG
OR2
O
OH
EDG
OR2
O
O
EDG
-H+
81
80  
Scheme 17 - Expected regioselective dehydration of diol 81, facilitated by the 
presence of electron donating groups on the aromatic ring 
 
 In order to test the applicability of this synthetic route for the synthesis of 
Psammaplin A analogues, we first decided to attempt the synthesis of Psammaplin 
A itself. Knoevenagel-Doebner condensation between aromatic aldehyde 72a and 
3-ethoxy-3-oxopropanoic acid 83 afforded unsaturated ester 86 in excellent yield 
(Scheme 18). The latter was converted in high yield to diol 87 using osmium 
tetroxide in a water/acetonitrile mixture. We were pleased to observe 
regioselective dehydration of diol 87 with catalytic amounts (0.1 eq.) of p-TsOH 
in refluxing benzene. Further condensation with hydroxylamine afforded α-
hydroxyimino ester 88 in 71% yield after 2 steps, as a single isomer (NMR). 
Compound 88 has been previously reported in the literature as an intermediate for 
the synthesis of the natural product Verongamine (58, Scheme 9) by Spilling et 
al.,
15
 and its structure confirmed by X-ray crystallography.
16
 Comparison of our 
data with that reported matched perfectly. This protecting group free sequence 
employed mild reaction conditions, and represents a considerable advantage 
compared to the use of Nakamura‟s α-OTBS-protected dimethylphosphonate in a 
Horner-Wadsworth-Emmons reaction with aromatic aldehydes.
14,17,18  
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 Direct double amidation of 88 with cystamine was preferred to a two step 
hydrolysis-coupling sequence. Heating ester 88 in the presence of 0.5 equivalents 
of cystamine (53) in MeOH led to no reaction after extended periods of time, 
despite the successful application of these conditions to the synthesis of the 
natural product Verongamine (58) using histamine (63, Scheme 9) as 
nucleophile.
15
 The direct conversion of esters to amides in neutral conditions is 
known to be relatively substrate dependent, and usually operates at very high 
temperatures/pressures and reaction times. High temperatures, pressures or the use 
of strong alkali metal catalysts however are often incompatible with delicate 
substrates. In our case, the presence of the oxime, the phenol and the disulfide was 
a concern and therefore milder reagents had to be found. A number of aluminium-
based reagents
165
 have been reported for this purpose, trimethylaluminium being 
the most popular.
165a
 Ammonia, primary, and secondary amines readily react with 
AlMe3 to form the corresponding aluminium amide, with evolution of methane 
gas. In the presence of esters, aluminium amides react smoothly to afford amides. 
 
HO HO
CO2Et
HO
CO2Et
OH
OH
HO
CO2Et
N
O
Br Br
Br
72a 86 87
88
28
HO
(i) (ii)
(iii) (iv)
Reagents and conditions:
(i) 83, pyridine, piperidine, 75°C, 5h, 90%
(ii) OsO4, NMO, MeCN/H2O/t-BuOH, 0°C to rt, 13h, 90%
(iii) p-TsOH.H2O, benzene, reflux, 3h
(iv) HONH2.HCl, NaOAc, MeOH,  0°C to rt, 6.5h, 71% 2 steps
(v) 53, AlMe3, CH2Cl2/MeCN, 60°C, 12h, 49% (82% brsm)
H2N
S
S
NH2
53
HO2C CO2Et
83
Br
 
Scheme 18 - Alternative total synthesis of Psammaplin A and analogues bearing 
electron rich aromatic groups 
 
 We were pleased to observe the formation of Psammaplin A when 
submitting ester 88 and cystamine (53) to these coupling conditions. However, the 
choice of solvent, reaction time and quantity of aluminium reagent were found to 
be crucial. Indeed, relatively apolar organic solvents, such as CH2Cl2 and CHCl3, 
led to no reaction or very low yields respectively. This was principally attributed 
to low substrate solubility. Solvent polarity was therefore screened and the use of 
a CH2Cl2/MeCN mixture facilitated the formation of Psammaplin A (28) in 
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moderate yield, with partial recovery of the starting material. Since yields for the 
amidation of esters using AlMe3 are known to be capricious, partially owing to the 
moisture sensitivity of the aluminium reagent, more than one equivalent of amine 
and AlMe3 is generally used in order to obtain high conversion (usually 1.5 eq.). 
While the yield of the reaction could be increased with additional equivalents of 
AlMe3, the quantity of cystamine 53 had to remain constant (0.5 eq.) in order to 
avoid the formation of the monoamidated intermediate as the major product. 
While an improved yield would be potentially achievable using other coupling 
reagents, such transformation was not investigated further. For example, the 
DABAL-Me3 reagent (Bis(trimethylaluminum)-1,4-diazabicyclo[2.2.2]octane) 
developed by Woodward
165f
 has been shown to be an improved reagent for the 
conversion of esters to amides. In particular, it overcomes a number of drawbacks 
generally encountered with AlMe3, such as moisture sensitivity, handling, lifetime 
and substrate scope.  
 With this new synthesis of Psammaplin A established, we decided to 
attempt the synthesis of new analogues, bearing strong electron donating aromatic 
substituents. Analogues 89 and 90 (Figure 27) were thought to be good 
candidates. 
 
N
N
X
HO
H
N
O
S
S
N
H
O
N
OH OH
Br
89, X = H
90, X = Br
 
Figure 27 
 
The synthesis is described in Scheme 19. Unsaturated ester 92 was prepared via a 
Heck reaction between 4-bromo-N,N-dimethylaniline 91 and methyl acrylate 85. 
Dihydroxylation afforded diol 93 in good yield. We were pleased to observe 
quantitative formation of ester 94 in 2 steps. Notably, dehydration proceeded 
smoothly using only 0.05 eq. p-TsOH. Again, only one isomer could be observed 
by NMR for oxime 94. Amidation as before afforded 89 in moderate yield. 
Bromination of diol 93 using NBS afforded brominated compound 95 in 90% 
yield. Under the same conditions, the dehydration/condensation sequence afforded 
hydroxyimino ester 96 in only 54% yield (75% brsm), even by using 0.2 eq. p-
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TsOH. The presence of the bromine was believed to have an important influence 
on the reaction rate. Despite extensive effort, double amidation as before afforded 
final product 90 in only 39% yield. 
N
Br
N
CO2Et
N
CO2Et
OH
OH
HO
CO2Et
N
X
X
91 92
HO
(i) (ii)
(iv),(v) (vi)
Reagents and conditions:
(i) 85, Pd(OAc)2, P(o-tol)3, Et3N, DMF, 140°C, 20h, 86%
(ii) OsO4, NMO, MeCN/H2O/t-BuOH, 0°C to rt, 36h, 73%
(iii) NBS, DMF, rt, 2h, 90%
(iv) p-TsOH.H2O, benzene, reflux, 3.5h (94) or 36h (96)
(v) HONH2.HCl, NaOAc, MeOH, rt, 2h
(vi) 53, AlMe3, CH2Cl2/MeCN, reflux, 8h
H2N
S
S
NH2
53
CO2Me
85
93, X = H
95, X = Br
89, 53% (72% brsm)
90, 39% (50% brsm)
94, 98% 2 steps
96, 54% 2 steps (75% brsm)
(iii)
 
Scheme 19 - Synthesis of analogues 89 and 90 using our newly developed 
synthetic route 
 
 In summary, we have developed two new routes towards new Psammaplin 
A analogues bearing an oxime or an O-methyloxime functionality. The azlactone 
route (Schemes 14 and 15) was proven particularly efficient for the synthesis of 
analogues bearing electron poor aromatics, while the diol route (Schemes 18 and 
19) was efficient for the synthesis of analogues bearing electon donating aromatic 
substituents. These routes employed aromatic aldehydes or aryl halides as starting 
material, which are generally commercially available, diverse and inexpensive. 
 
1.25. Synthesis of ketoamide derivatives 
 
Disappointingly, amide coupling between arylpyruvic acids 51 and 74a, and 
amine nucleophiles 53 and 77 was unsuccessful (Scheme 20) using EDC and NHS 
as described earlier (Scheme 15).  
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O
OH
O
O
H
N
O
(i), (ii)
SR2
Reagents and conditions:
(i) EDC, NHS,  dioxane, rt, 3h
(ii) nucleophile, Et3N, dioxane/MeOH, rt
H2N
S
H2N
S
S
NH2
5377
R1O
Br
R1O
Br
51, R1 = H
74a, R1 = Me
97a, R1 = H, R2 = Me
98a, R1 = Me, R2 = Me
 
Scheme 20 
 
The best results were obtained using Py-BOP as the coupling reagent, affording 
the title analogues 97a-b and 98a-b in low to moderate yields. The yields were 
particularly poor for the coupling of 51 with diamine 53 (Scheme 21). 
 
O
OH
O51 or 74a
O
H
N
O
(i), (ii)
SR2
Reagents and conditions:
(i) nucleophile, DIPEA, THF, rt, 5min
(ii) Py-BOP
H2N
S
H2N
S
S
NH2
5377
R1O
Br
R1O
Br
97a, R1 = H,    R2 = Me              40%
97b, R1 = H,    R2 = SR(dimer)  24%
98a, R1 = Me,  R2 = Me             63%
98b, R1 = Me,  R2 = SR(dimer)  42%
 
Scheme 21 - Synthesis of ketoamide containing analogues using Py-BOP 
 
 In parallel, a number of other conditions was employed in order to 
improve the yield of this coupling. Acid 74a, bearing a methylated phenol, and 
monoamine 77 were used as a model system for investigation. A set of 
representative attempted conditions are reported in Table 3. All conditions 
involving carbodiimides led to low and non reproducible yields or complete 
degradation of the starting material. Carbonyl diimidazole (CDI) or POCl3 also 
led to complete degradation. Changing the order of addition of reagents did not 
lead to any improvement. 
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Substrate Entry conditions product 
O
OH
O
O
Br
74a  
1 
i) EDC, HOBt dioxane, rt, 3h 
ii) 77, Et3N, rt 
Degradation 
2 
i) EDC, NHS dioxane, rt, 0.5h 
ii) 77, Et3N, rt 
Degradation 
3 
i) DCC, NHS, dioxane, rt, 1h 
ii) 77, Et3N, rt 
Low and non 
reproducible yield 
4 
i) DCC, NHS, DMF, rt, 1h 
ii) 77, Et3N, rt 
Degradation 
5 
DCC, DMAP, 77, CH2Cl2, 
0°C to rt 
Low and non 
reproducible yield 
6 
i) CDI, CH2Cl2, rt 
ii) 77 
Degradation 
7 
i) POCl3, pyridine, -20°C 
ii) 77 
degradation 
 
Table 3 - Attempted alternative synthesis of ketoamide containing analogues,  
conditions attempted for amide bond formation 
 
 The problematic nature of the coupling was thought to be attributable to 
the enol form of acid 74a, which is the only species visible by NMR (CD3OD). 
This can be exemplified by conditions 3 and 4. In these conditions, compound 99 
(Scheme 22) was obtained as the major product. Dehydration by DCC, followed 
by activation of the acid is thought to be responsible for the formation of 99. 
 
Br
O
O
O
N
H
N
dehydration
activation
99
Br
O
COOH
OH
DCC
74a
 
Scheme 22 - Main product of the reaction of acid 74a with DCC 
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A mechanism for the formation of 99 is shown in Scheme 23. In this mechanism, 
dehydration is thought to occur faster than the activation of the carboxylic acid. 
Varying the temperature (-20°C to rt) did not have any significant influence on the 
outcome of the reaction. 
 
Br
O
OH
O
Br
O
OH
OH
O
Br
O
O
O
N
NH
Cy
Br
O
OH
O
O
NH
N
Cy
Cy
Cy
D
C
C
 (-urea)
fast
D
C
C
 (-
ur
ea
)
sl
ow
D
C
C
 (-
ur
ea
)
sl
ow
D
C
C
 (-urea)
fast
NHS      slow
Br
O
OH
O
O
N
O
O
Br
O
O
O
N
O
O
NHS           unreactive
Nu
product
DCC (-urea)
74a
99
100
101
103
102
 
Scheme 23 - Proposed mechanism for the formation of 99 
 
 The low yields obtained for the formation of 97a-b and 98a-b lead us to 
investigate new routes towards these compounds: 
 
 The chloroformate route: The increased reactivity of the enol functionality 
of 74a led us to consider new synthetic routes, involving protection of the enol. 
The first way we envisaged involved the use of a chloroformate reagent, allowing 
protection of the enol as a carbonate and subsequent activation of the carboxylic 
acid as a mixed anhydride (Scheme 24). The reaction proceeded smoothly upon 
exposure of 74a to 2.1 equivalents of isobutyl chloromormate at low temperature, 
affording mixed anhydride 104 in high yield. Interestingly, 104 was stable enough 
to be purified by flash column chromatography and characterized by 
1
H NMR, 
13
C NMR and mass spectrometry. Using only 1 equivalent of isobutyl 
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chloroformate did not allow selective formation of the mixed anhydride. 
Treatment of 104 with amine 77 afforded amide 105 in good yield. Amide 105 
could also be obtained in one step (75%) from acid 74a without intermediate 
purification of the mixed anhydride, however necessitating a larger quantity of the 
expensive nucleophile 77 to drive the reaction to completion. Despite extensive 
efforts, carbonate deprotection could only be achieved in moderate yield under 
basic conditions. A representative set of conditions can be found in Table 4. 
 
Br
O
OH
OH
O
Br
O
O
O
O O
Oi-Bu
Br
O
O
H
N
O
S
O
Oi-Bu
O
Oi-Bu
104
105
74a
Br
O
O
H
N
O
S
98a
(i)
Reagents and conditions:
(i) isobutyl chloroformate (2.2 eq.), NMM, THF, -25ºC, 2h, 87%
(ii) 77, THF, 0ºC then rt, 45min, 77%
(iii) 1:1 0.8N aq. NaOH/dioxane, 54%
(ii)
(iii)
H2N
S
77  
Scheme 24 
 
 
 
Conditions product 
BF3.OEt2, 4Å MS, CH2Cl2, -10°C to rt
166
 No reaction 
1% K2CO3, 25:75 MeOH/H2O, rt Degradation 
LiOH, aq. H2O2, THF, rt Degradation 
8:2 AcOH/H2O, reflux 
oxazolidine-2,4-dione 106, 
quantitative 
1:1 0.8N aq. NaOH/dioxane 54% 
 
Table 4 - conditions attempted for the carbonate deprotection 
 
 This sequence afforded 98a in 36% overall yield, therefore not 
representing a particular improvement to the one step Py-BOP route (Scheme 21). 
The applicability of this route was also found to be relatively limited when 
106
Br
O
O
N
O
S
O
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applied to other substrates (Scheme 25). Indeed, attempted double carbonate 
deprotection of 108 under the same conditions led to a complex mixture. Only 
traces of the product 97a could be observed by 
1
H NMR and mass spectrometry. 
The use of milder conditions such as DIPEA in MeOH, aqueous NH3 in THF, 7M 
NH3 in MeOH, did not give rise to any improvement, usually affording complex 
mixtures or recovery of the starting material. This route was therefore judged 
unsuitable and not investigated further. 
 
Br
HO
OH
OH
O
Br
O
O
O
O O
Oi-Bu
Br
O
O
H
N
O
S
O
Oi-Bu
O
Oi-Bu
107
108
51
Br
HO
O
H
N
O
S
97a
(i)
Reagents and conditions:
(i) isobutyl chloroformate (3.2 eq.), NMM, THF, -25ºC, 5h, 84%
(ii) 77, THF, 0ºC then rt, 45min, 72%
(iii) 1:1 0.8N aq. NaOH/dioxane
(ii)
(iii)
H2N
S
i-BuO
O
i-BuO
O
77  
Scheme 25 
 
 
 The silyl ester route: It is well known that silyl esters can be converted to 
the corresponding acyl halides upon exposure to halogenating agents. Double 
TBS protection of acid 74a afforded diprotected compound 109 in nearly 
quantitative yield after purification by column chromatography (Scheme 26). 
Exposure to oxalyl chloride
167
 in CH2Cl2 or CHCl3 only allowed poor conversion 
(TLC) to the corresponding acyl chloride, even after extended reaction time (up to 
1 day) and increased temperature (reflux). The use of thionyl chloride led to a 
slightly higher conversion, but a significant amount of starting material was still 
observed. Triphenylphosphine tribromide, known to be an excellent reagent for 
the conversion of bulky silyl esters to the corresponding acyl bromides,
168
 did not 
lead to significant improvement. In each case, addition of the nucleophile before 
complete conversion to the acyl halide afforded complex mixtures with no trace 
(NMR, MS) of the product 98a. Based on these unconvincing results, this route 
was not investigated further. The reason for this lack of reactivity is unclear, but 
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can possibly be attributed to the presence of the second TBS group, locally 
increasing steric hindrance and therefore slowing conversion. Although less 
robust, the use of the smaller TMS instead of TBS was not investigated but 
represents a possible alternative. 
Br
O
OH
OH
O
Br
O
OTBS
OTBS
O
Br
O
OH
X
O
109
110
74a
Br
O
O
H
N
O
S
98a
(i)
Reagents and conditions:
(i) TBSOTf, 2,6-lutidine, CH2Cl2, 0ºC then rt, 2.5h, 97%
conditions: a. Oxalyl chloride, CH2Cl2, cat.DMF, 0ºC-rt-reflux
                  b. SOCl2, 0ºC-rt-reflux
                  c. triphenylphosphine dibromide, CH2Cl2, rt then reflux
H2N
S
77
conditions
 
Scheme 26 
 
 
 Hydrolysis of oximes: In the final alternative synthetic route explored, it 
was envisaged that we could obtain ketoamide compounds 97a-b and 98a-b by 
deprotection of their O-methyloxime or oxime containing analogues. 75b and 75t 
were chosen as a model system for investigation. Surprisingly, few examples in 
the literature report the deprotection of the O-methyloxime functionality, owing to 
its high stability.
169,170
 Indeed all reductive conditions employed, inspired by 
literature examples,
171,172 
led to no reaction (Table 5, entries 1-3). Strong aqueous 
acids did not lead to a significant improvement (entry 4). After several 
unsuccessful attempts, following literature procedures involving either 
reductive
173 
(entry 5)
 
or oxidative conditions with the Dess-Martin periodinane 
(entry 6),
174 
encouraging results were obtained for the hydrolysis of oxime 75b, 
using 1.2 M HCl in an acetonitrile-water mixture. These conditions afforded 98a 
in 34% yield. Despite intensive effort, this yield could not be improved. 
Moreover, when the same conditions were applied to Psammaplin A (28), mostly 
degradation and only traces of the doubly deprotected product were observed 
(HRMS). Once again, this synthetic route did not present any particular advantage 
compared to the Py-BOP route in term of yields, and was therefore abandoned.  
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Br
O
N
O
H
N
S
Br
O
O
O
H
N
S
conditions
RO
75b, R = H
75t, R = Me
98a
 
Entry Substrate R conditions product 
1 
75t Me 
Zn, AcOH, rt, 1h, 24h, 48h Starting material 
2 Zn, AcOH, 60°C, 24h Starting material 
3 
Amberlyst 15, paraformaldehyde, 
acetone/H2O, rt to 80°C, 12h 
Starting material 
4 
1M HCl, MeCN/H2O, acetaldehyde, 
50°C, 12h 
Starting material 
5   TiCl4, NaI, MeCN, rt, 0.25h Starting material 
6 75b H 
Dess-Martin periodinane, CH2Cl2, 
rt, 0.75h 
degradation 
7   
1.2M HCl, MeCN/H2O, 
acetaldehyde, 50°C, 12h 
34% 
 
Table 5 - Conditions attempted for the hydrolysis of oximes 
 
 
1.26. Synthesis of hydrazonoamide derivatives 
 
 The synthesis of the title analogues was achieved as described in Scheme 
27. Reflux of the keto derivatives 97a-b, 98a-b with hydrazine monohydrate in 
MeOH afforded the corresponding hydrazones in moderate to high yield after 
purification by flash column chromatography. The formation of only one product 
could be observed in each case by 
1
H NMR of the crude mixtures.  
O
H
N
O97a-b, 98a-b
(i)
SR2
R1O
Br
N
H
N
O
SR2
R1O
Br
H2N
Reagents and conditions:
(i) hydrazine hydrate, MeOH, reflux, 2.5h
111a, R1 = H,    R2 = Me              58%
111b, R1 = H,    R2 = SR(dimer)  69%
112a, R1 = Me,  R2 = Me             74%
112b, R1 = Me,  R2 = SR(dimer)  59%  
Scheme 27 
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 The geometry of the hydrazone could be assigned as (E) based on NOE 
studies performed with analogue 111b (Figure 28). Indeed, correlation could be 
observed between the hydrazone hydrogen (NNH2) and H
A
 (weak), H
B
 (weak) 
and H
C
 (benzylic H, strong). However, no correlation could be observed between 
the hydrazone protons (NNH2) and H
D
 (NH amide), H
E
 (N-CH2-) and H
F
 (-CH2-
S). 
R1O
Br
HB
HA
NNH2 HD
N
O
SR2
HC HC HE HE
HF HF
 
Figure 28 - Correlation between the hydrazone hydrogens and H
A
, H
B
, H
C
 (111b) 
 
 The (E) geometry was finally confirmed by Dr. Andrew J. P. White 
(service of crystallography, Imperial College London) with the X-ray crystal 
structure of analogue 111a (Figure 29). Of interest, the geometry adopted by the 
molecule in the solid state suggests the presence of an intramolecular H-bond 
between the hydrazone and the amide hydrogen. 
 
 
 
Figure 29 - Crystal structure of 111a  
 
 
1.27. Synthesis of the a Psammaplin A analogue lacking the oxime units 
 
 In order to further study the importance of the oxime unit of Psammaplin 
A for potency against HDACs and DNMTs, an analogue of Psammaplin A 
completely lacking the oxime unit was prepared (Scheme 28) for biological 
(E) 
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evaluation. Bromination of 3-(4-hydroxyphenyl)propanoic acid 113 afforded 114, 
and subsequent coupling with cystamine 53 using EDC and HOBt as coupling 
reagents afforded simple analogue 115. The latter has been recently reported by de 
Lera.
161a
 The bromination step afforded a 1:0.3 mixture of monobrominated 
compound 114 and its dibrominated analogue. The reported yield was calculated 
from the ratios observed by 
1
H NMR. Flash column chromatography afforded 
pure samples of 114 to be used for the final coupling step. The relatively low yield 
for the coupling step was principally due to the presence of the free phenolic 
functionality, reacting as a competitive nucleophile. Reaction conditions for both 
bromination and coupling were not optimised, suggesting higher yields are 
potentially achievable. In particular, coupling via a more robust activated ester, 
such as a succinic ester, could potentially avoid side reaction with the phenol 
functionality. 
Reagents and conditions:
(i) Br2, AcOH, rt, 2h, 79% (NMR)
(ii) EDC, HOBt, CH2Cl2, rt, 20 min
(iii) 53, Et3N, rt, 48% 2 steps
HO
OH
O
HO
OH
O
Br
H
N
O
S
115 2
Br
HO
114113
(i)
(ii),(iii)
H2N
S
S
NH2
53
 
Scheme 28 
 
 
1.28. Synthesis of hydroxamic acid analogues of Psammaplin A 
 
 Since in terms of HDAC inhibition it is likely that the sulfur end group of 
Psammaplin A functions as a zinc binding group, we also decided to prepare a 
hydroxamic acid analogue  of Psammaplin A 116 and its one carbon homologue 
117 (Figure 30). Hydroxamic acids are well known to be strong zinc-binding 
groups for HDACs, and therefore we envisaged 116 and 117 would offer useful 
additional information regarding the Psammaplin A HDAC pharmacophore. 
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H
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HO
N
H
O
OH
117
N
HO
N
HO
 
Figure 30 
 
 The synthesis of these two analogues is described in Scheme 29. Heating 
3-aminopropanoic acid 118 or 4-aminobutanoic acid 119 in the presence of 
phthalic anhydride 120 under solvent free conditions afforded the phthalimide 
protected intermediates 121 and 122 in nearly quantitative yield.
175
 Further EDC 
mediated coupling with O-THP hydroxylamine 54 afforded intermediates 123 and 
124 in high yield. Classical phthalimide deprotection then allowed access to 
primary amines 125 and 126 in moderate yield after purification by flash column 
chromatography. Analogues 116 and 117 were obtained in moderate yield after 
condensation of 51 with O-THP hydroxylamine 54, further amide coupling with 
125 or 126 and final THP double deprotection under acidic conditions. 
 
O
O
O
H2N OH
O
+ N
O
O
O
OH
N
O
O
O
HN O
O
H2N N
H
O
O O
118, n = 1
119, n = 2
120 121, n = 1, quant.
122, n = 2, quant.
123, n = 1, 80%
124, n = 2, 94%
125, n = 1, 42%
126, n = 2, 50%
n
n
n
n
HO
Br
O
OH
O
51
H
N
O
Br
HO
H
N
O
OHn
116, n = 1, 13% from 51
117, n = 2, 15% from 51
N
HO
Reagents and conditions:
(i) 170-180°C, neat, 2h
(ii) 54, EDC, DMAP, CHCl3, rt, 12h
(iii) hydrazine monohydrate, MeOH, reflux, 3h
(iv) 54, pyridine, rt, 12h
(v) EDC, NHS, dioxane, 3h
(vi) 125 or 126, Et3N, dioxane/MeOH, rt, 12h
(vii) 0.5N HCl, 9:1 dioxane/i-PrOH, rt, 20h
(i) (ii)
(iii)
(iv)-(vii)
H2N
O O
54
 
Scheme 29 
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1.29. Synthesis of acetate-protected thiol analogues of Psammaplin A 
 
 In line with our design for the first library, a number of thioacetate 
containing analogues were prepared (Scheme 30). We envisaged that these 
compounds may generate the corresponding thiols in situ in cell-based assays 
following cleavage of the acetyl group in vivo by non-selective esterases. 
Moreover, protection as a thioester is likely to improve cell permeability during 
cell based assays. Condensation between acid 74a and O-methylhydroxylamine, 
and subsequent EDC coupling with S-2-aminoethyl ethanethioate 127
176
 afforded 
thioacetate analogue 128. Condensation of acid 74a with hydroxylamine, 
followed by coupling with 127 using DCC and N-hydroxyphthalimide
153
 as 
coupling reagents afforded thioacetate 129 in poor yield. The latter conditions 
were applied to 98a and afforded thioacetate analogue 130, in relatively low yield. 
 
Reagents and conditions:
(i) HCl.H2NOMe, pyridine, rt, 12h
(ii) EDC, NHS, dioxane, rt, 3h
(iii) 127, Et3N, dioxane/MeOH, rt
(iv) HCl.H2NOH, pyridine, rt, 12h
(v) DCC, NOHP, 127, Et3N, dioxane, rt, 24h
Br
O
COOH
O
Br
O
A
H
N
O
S
B
O
128, AB = NOMe, conditions: (i), (ii), (iii), 30%
129, AB = NOH, conditions: (iv), (v), 19%
130, A = O, conditions: (v), 23%
+H3N
SAc 127Cl-
 
Scheme 30 
 
1.3. Conclusions 
 
In this section are reported the new synthetic routes we developed towards 
libraries of Psammaplin A analogues. In particular, two new routes were 
developed, allowing access to Psammaplin A analogues inaccessible via currently 
reported routes, notably bearing electron-rich aromatics. Both routes allow 
expedient access to the target analogues and employ commercially available, 
diverse and inexpensive starting materials. 
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2. Biological evaluation 
 
2.1. Introduction 
 
 Our libraries of analogues were then assayed against HDACs and DNMT1 
in order to establish the SARs of Psammaplin A against these enzymes. In 
addition, cytotoxicity data for selected analogues were obtained against A549 
(human lung carcinoma), MCF7 (human breast carcinoma) and WI38 (human 
lung fibroblast) cell lines. Finally, cellular studies were performed in order to 
propose a mode of action for Psammaplin A and analogues in cells. All HDAC 
assays were performed in collaboration with Pr. Franz-Josef Meyer-Almes‟ group 
in Darmstadt (Germany). DNMT1 assays were performed in collaboration with 
Dr. Fabrice Turlais‟ group at Cancer Research Technology in London. Finally, 
cellular studies were performed in collaboration with Pr. Stephen Neidle‟s group 
at School of Pharmacy in London. 
 
2.2. Results and discussion 
 
2.21. HDAC inhibition 
 
 HDAC assays were performed as described by Wegener et al.
177
 with 
minor modifications. Briefly, The fluorogenic HDAC assay consists of two steps: 
In the first step the Boc-Lys(Ac)-AMC  substrate is deacetylated by the 
corresponding HDAC. The deacetylated substrate, therefore containing a basic 
amino acid residue serves as substrate for trypsin in the subsequent second step. 
The second step generates the signal due to the release of fluorescent AMC, 
whose fluorescence serves as an indirect measure of HDAC enzyme activity 
(Scheme 31). 
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Scheme 31 - HDAC assay principle. Fluorescence of the AMC is used as a 
measurement of HDAC activity 
 
 
 Our synthetic analogues were assayed against recombinant human 
HDAC1 (rHDAC1, class I), recombinant human HDAC6 (rHDAC6, class II), and 
purified bacterial histone deacetylase like amidohydrolase (HDAH)
178,179
 which 
exhibits 35% sequence identity with the second domain of the human HDAC6. 
The results are shown in Table 6.  
 As previously mentioned, Psammaplin A has been reported by Crews to be 
a potent inhibitor of HDAC activity (4.2 nM on a cell extract). Indeed, in our 
hands, Psammaplin A was found to be a potent HDAC1 inhibitor (28, 45 nM), 
however less potent than previously reported albeit using a recombinant enzyme 
rather than cell extract.
135g
 Reference compound SAHA (1) displayed an IC50 of 
30 nM, correlating nicely with previously reported values (27 nM).
180
 
Importantly, Psammaplin A was found 96 fold more potent against HDAC1 (45 
nM) compared to the class II HDAC6 (4.3 μM). There is a pressing need for 
isoform selective HDAC inhibitors to further validate these important targets, 
with most of the known inhibitors being non- or class-selective. Previously, 
psammaplin A was defined as a Class I selective inhibitor by Kwon and co-
workers, through its selective effects of histone acetylation (versus tubulin 
acetylation) in HeLa cells. To the best of our knowledge, our data provides the 
first isoform selectivity profile of psammaplin A and analogues in cell-free assays. 
In Table 6, IC50
6/1
 is defined by the ratio IC50
HDAC6
/IC50
HDAC1
 and was used as an 
indicator of isoform selectivity. The SAR around our library can be described as 
follows: 
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Nature of the sulfur end group. Since previous studies have postulated 
psammaplin A to be a natural prodrug, whereby the disulfide functionality is 
reduced in cells to give a free thiol that functions as a zinc binding group,
115,161a
 
we felt it was important to assay the corresponding thiol directly. Indeed, direct 
assay of reduced psammaplin A analogues in cell-free assays have not been 
previously reported. Thus all monomeric compounds (R2 = SH) were prepared 
immediately prior to assay from the corresponding disulfide analogues (R2 = SR 
dimer), using tris(2-carboxyethyl)phosphine hydrochloride (TCEP) as the 
reducing agent, in a 9:1 DMSO/water solution (see experimental section). 
Importantly, control experiments have shown TCEP to have no influence in our 
assay conditions at concentrations up to 25 μM. When the sulfur end group was 
present as a free thiol (R2 = SH, 28’, 75c’, 75s’, 75u’, 97b’, 98b’, 111b’, 112b’, 
115’), highly potent compounds were observed in each case, efficiently inhibiting 
HDAC1 in the nanomolar range, while still showing important isoform selectivity. 
The impressive selectivity of these compounds was found to be particularly 
accentuated in the case of oxime (AB = NOH) and hydrazone (AB = NNH2) 
containing compounds 28’/75c’ and 97b’/98b’ respectively, which were found to 
be highly selective for HDAC1 over HDAC6. The reduced natural product 28’ 
was found to be the most potent HDAC1 inhibitor of this series (IC50 of 0.9 nM), 
50 fold more potent than its dimeric parent Psammaplin A (28, 45 nM). Overall 
the disulfide analogues 28, 75c, 75s, 75u, 97b, 98b, 111b, 112b, and 115 were 
found to be less potent than their reduced counterparts in every case. “Protection” 
of the free thiol as either a thioether or a thioacetate had vastly different effects on 
potency. Analogues containing a thioether end group (R2 = SMe, 75a, 75b, 75r, 
75t, 97a, 98a, 111a, 112a) displayed low to no inhibition of both HDAC1 and 
HDAC6. In contrast, potencies of acetate protected analogues (R2 = SAc) 128-130 
were approaching those of their corresponding thiols 75u’, 75c’ and 98b’ 
respectively. Notably, 129 was found to be highly potent against HDAC1, 
displaying an IC50 of 5 nM. With the exception of 130, acetyl protected 
compounds were found 2.8 (129) to 8 times (128) less potent than the 
corresponding free thiol analogues against HDAC1. Curiously, acetyl protected 
compounds 128-130 were found to be moderately active to completely inactive 
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against HDAC6 in each case, highlighting the important isoform selectivity of 
these compounds. Very recently, de Lera and coworkers reported compound 134, 
where the disulfide functionality of Psammaplin A has been replaced by two 
methylene groups.
161a
 In their assay, 134 did not have any significant influence 
against HDAC activity. Finally, hydroxamic analogue 116 was found to be highly 
potent against HDAC1 (2 nM), and HDAC6 (190 nM) with a similar potency to 
the thiol 28’ derived from Psammaplin A. Hydroxamic acid 117 was found to be 
less potent than 116, demonstrating the importance of the alkyl chain length for 
high potency. 
 
Requirement of the oxime functionality (A-B). Among the different AB systems 
tested (Table 6), the hydrazone compounds 111b’ (5 nM) and 112b’ (6 nM) were 
found to retain high potency against HDAC1, with values approaching those of 
their respective oxime analogues 28’ (0.9 nM) and 75c’ (1.8 nM). Compounds 
75s’ (27 nM) and 75u’ (15 nM), bearing an O-methyloxime moiety (AB = 
NOMe), were found to be 8-30 fold less active against HDAC1 compared to their 
respective oxime containing analogues 28’ (0.9 nM) and 75c’ (1.8 nM), 
suggesting the requirement of a free oxime for potent HDAC1 inhibition. Indeed, 
ketone analogues (AB = O) 97b’ (0.40 μM) and 98b’ (1.1 μM) were found to be 
448 and 622 times less potent against HDAC1 respectively than their 
corresponding oxime containing analogues 28’ (0.9 nM) and 75c’ (1.8 nM). 
Moreover, 97b’ and 98b’ were found to be in the same range of potency than 115’ 
(0.42 μM), for which the A-B functionality had been removed completely. 
Interestingly, variation of the AB system had little effect on the potency against 
HDAC6, despite its impact on potency against HDAC1. This possibly suggests a 
design criterion for isoform selectivity. Indeed, while analogue 115’ (AB = H2) 
and the α-ketoamide containing compounds (AB = O, 97b’ and 98b’) did not 
significantly discriminate between HDAC1 and HDAC6, introduction of the O-
methyloxime functionality induced a 15-75 increase in potency against HDAC1, 
while maintaining a similar potency against HDAC6. This effect is even more 
accentuated in the case of oxime containing analogues 28’ and 75c’ (AB = NOH) 
and hydrazone analogues 111b’ and 112b’ (AB = NNH2), which were 448-622 
and 81-187 fold more potent respectively than 97b’, 98b’ and 115’ against 
HDAC1, while being similarly potent against HDAC6. 
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Phenol methylation status. Compounds bearing a methylated phenol (R1 = Me, 
Table 6) led to similar potencies against HDAC1 compared to the corresponding 
free phenol (R1 = H) in each case. Methylation of 28’ and 75s’ led to compounds 
75c’ and 75u’ which were 9 and 12 times less active respectively against HDAC6, 
whereas this pattern was found reversed for 97b’ and 111b’ which were found to 
be 4 and 3 times less potent respectively than their corresponding methylated 
analogues.  
 While these data are limited to HDAC1 and HDAC6, several 
representative compounds were also assayed against HDAH.
178,179
 Surprisingly, 
all our synthetic analogues were found completely inactive under the assay 
conditions, even at concentrations of up to 100 μM. The exception to this rule 
were the hydroxamic analogues 116 and 117 however. For example, compound 
116 was found to be significantly potent against HDAH (310 nM). 
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A
B
H
N
O
R2
Br
R1O
 
Cpd R1 AB R2
a
 
rHDAC1 
IC50 [μM] 
rHDAC6 
IC50 [μM] 
IC50
6/1
 
75a H NOH SMe 7.7 > 50  
75b Me NOH SMe 23 > 50  
28 H NOH S2R (dimer) 0.045 2.8 62 
75c Me NOH S2R (dimer) 0.043 2.0 46 
28’ H NOH SH 0.0009 0.36
 
 360 
75c’ Me NOH SH 0.0018
 
 3.2
 
 1772 
75r H NOMe SMe 11 
0.377 
0.027 
 
> 50  
75t Me NOMe SMe > 50 > 50  
75s H NOMe S2R (dimer) 0.38 9.5 25 
75u Me NOMe S2R (dimer) 0.22 > 50 > 230 
75s’ H NOMe SH 0.027
 
 0.22
 
 8 
75u’ Me NOMe SH 0.015
 
 2.7
 
 180 
97a H O SMe 7.3 ca 30  
98a Me O SMe > 50 > 50  
97b H O S2R (dimer) 5 9 1.8 
98b Me O S2R (dimer) 9 8 0.9 
97b’ H O SH 0.40
 
 1.0 2.6 
98b’ Me O SH 1.1
 
 0.25 0.22 
111a H NNH2 SMe ca 50 > 50  
112a Me NNH2 SMe 13 > 50  
111b H NNH2 S2R (dimer) 6.1 5 0.8 
112b Me NNH2 S2R (dimer) 3 >50 > 16 
111b’ H NNH2 SH 0.005
 
 1.0
 
 204 
112b’ Me NNH2 SH 0.006
 
 0.32
 
 53 
115 H H2 S2R (dimer) > 50 20 < 0.4 
115’ H H2 SH 0.42
 
 1.1
 
 2.6 
116 H NOH C(O)NHOH 0.002 0.19 95 
117 H NOH CH2C(O)NHOH 0.31 1.7 5 
129 Me NOH SAc 0.005 23 4560 
128 Me NOMe SAc 0.12 >50 > 417 
130 Me O SAc 0.48 9.5 > 20 
SAHA    0.030 0.21 7 
TCEP    > 25 > 25  
 
Table 6 - HDAC inhibition data. IC50s for Psammaplin A and synthetic analogues 
against HDAC1 and HDAC6. 
a
Thiols were prepared by in situ reduction of the 
respective disulfides using tris(2-carboxyethyl)phosphine hydrochloride, and used 
immediately. Details about the procedure used for reduction can be found in the 
Experimental section 
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 We then further explored the effects of aromatic substitution patterns on 
HDAC potency and selectivity. Data for disulfides and thiols are given in Table 7 
and Table 8 respectively. Once again derivatives containing a free thiol 
functionality (Table 8) were found to be more potent than their dimeric 
counterparts. The unsubstituted compound 75d’ was found to be the least active 
against both HDAC1 and HDAC6. Despite this, compound 75d’ (IC50 of 12 nM) 
was still more potent than the reference compound SAHA (30 nM, lit. 27 nM).
180
 
Importantly, several compounds exhibited subnanomolar IC50 values against 
HDAC1: 75q’ (0.6 nM), 75j’ (0.48 nM) and the extremely potent compound 75p’ 
(0.2 nM). To the best of our knowledge, compound 75p’ represents the most 
potent HDAC1 inhibitor not containing a cyclic tetrapeptide core. This compound 
also exhibited the highest selectivity with an IC50
6/1
 value of 3950. Analogue 75p’ 
was found to be 60 times more active than unsubstituted analogue 75d’ and 
demonstrates that aromatic substitution plays a role for potency against HDAC1, 
however its influence on potency is minor compared to the presence of the free 
thiol, or the free oxime. 
 
 Several important trends emerged from the HDAC6 assays. Compounds 
75k’ (0.27 μM), 75h’ (0.24 μM) and 75j’ (0.19 μM) were found to be more potent 
than the reduced form of Psammaplin A (28’, 0.36 μM). The most potent 
compounds were found to involve a halogen in the meta position. This can be 
clearly seen by comparing the IC50 values (μM) for 75f’ (2.9) vs 75i’ (0.64), 75m’ 
(2.7) vs 75l’ (0.51) and75k’ (0.27), 89’ (2.3) vs 90’ (0.70), 75e’ (1.7) vs 28’ 
(0.36), 75g’ (1.3) vs 75j’ (0.19) and 75n’ (1.2) vs 75o’ (0.74). In each case the 
presence of a halogen was found to enhance potency against HDAC6. Moreover, 
iodinated compounds 75k’ (0.27) and 75h’ (0.24) were found to be more potent 
than their respective brominated analogues 75l’ (0.51) and 75c’ (3.2). Comparison 
of the IC50 values (μM) for 75c’ (3.2), 90’ (0.70), 75i’ (0.64), 28’ (0.36), and 75j’ 
(0.19) allowed a preliminary ranking of functional groups in the para position: 
OMe < NMe2 < F < OH < SMe. Indeed, comparison of IC50s (μM) for the 
corresponding para monosubstituted compounds 75f’ (2.9), 89’ (2.3), 75e’ (1.7) 
and 75g’ (1.3) confirms this trend, indicating that the hydroxyl and 
thiomethylether substituents are most favourable in the para position for potency 
against HDAC6. 
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4
5
6
1
2
3
R
N
HO
H
N
O
S
2  
 
cpd R 
rHDAC1 
IC50 [μM] 
rHDAC6 
IC50 [μM] 
IC50
6/1
 
28 3-Br-4-OH 0.045 2.8 62 
75c 3-Br-4-OMe 0.043 2.0 46 
75d / 6.0 35 6 
75e 4-OH  0.18 3.7 21 
75f 4-F  0.42 > 50 > 118 
75g 4-SMe 0.20 20 99 
75h 3-I-4-OMe  0.0050 3.5 704 
75i 3-Br-4-F  0.051 15 298 
75j 3-Br-4-SMe  0.34 > 50 > 146 
75k 3-I-4,5-OMe  0.040 3.9 96 
75l 3-Br-4,5-OMe  0.053 10 194 
75m 3,4-OMe  3.9 13 3 
75n 3-NO2 ca 0.50 7.8 16 
75o 3-Br-5-NO2 0.12 > 50 > 420 
75p 3,5-Br-4-OH nd 5.0 nd 
75q 3-OMe-4-SMe 1.7 > 50 > 30 
89 4-NMe2 3.6 > 50 > 14 
90 3-Br-4-NMe2 0.18 ca 50 278 
 
Table 7 - HDAC inhibition data, variation of aromatic substitution. IC50s for 
synthetic Psammaplin A analogues (dimers) against HDAC1 and HDAC6 
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4
5
6
1
2
3
R
N
HO
H
N
O
SH
 
cpd R1 
rHDAC1 
IC50 [μM] 
rHDAC6 
IC50 [μM] 
IC50
6/1
 
28’ 3-Br-4-OH 0.0010 0.36 360 
75c’ 3-Br-4-OMe 0.0018 3.2 1772 
75d’ / 0.012 3.3 271 
75e’ 4-OH 0.0040 1.7 418 
75f’ 4-F 0.0070 2.9 420 
75g’ 4-SMe 0.0020 1.3 630 
75h’ 3-I-4-OMe 0.0010 0.24 240 
75i’ 3-Br-4-F 0.0010 0.64 640 
75j’ 3-Br-4-SMe 0.00048 0.19 388 
75k’ 3-I-4,5-OMe 0.0010 0.27 270 
75l’ 3-Br-4,5-OMe 0.0010 0.51 510 
75m’ 3,4-OMe 0.0030 2.7 900 
75n’ 3-NO2 0.0010 1.2 1210 
75o’ 3-Br-5-NO2 0.0050 0.74 148 
75p’ 3,5-Br-4-OH 0.00020 0.79 3950 
75q’ 3-OMe-4-SMe 0.00060 1.4 2372 
89’ 4-NMe2 0.0010 2.3 2262 
90’ 3-Br-4-NMe2 0.0040 0.70 164 
 
 
Table 8 - HDAC inhibition data, variation of aromatic substitution. IC50s for 
synthetic Psammaplin A analogues (thiols) against HDAC1 and HDAC6. Thiols 
were prepared by in situ reduction of the respective disulfides using Tris(2-
carboxyethyl)phosphine hydrochloride, and used immediately. Details of the 
procedure used for reduction can be found in the Experimental section 
 
 
 In light of the exciting isoform selectivity of some of our library 
compounds, we decided to further investigate this effect. The reduced form of 
Psammaplin A (28’) and its hydrazone containing analogue 111b’ were chosen as 
representative compounds. 28’ and 111b’ were assayed against rHDAC1 and 
rHDAC8 as Class I representatives, rHDAC6 as representative of class IIb and 
rHDAC7 as representative of class IIa. The results are shown in Table 9. Both 
compounds displayed similar selectivity profiles. As previously mentioned, 28’ 
and 111b’ were found extremely potent against HDAC1. Interestingly, 28’ and 
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111b’ displayed important isoform selectivity within the Class I HDACs. Indeed, 
they were 1340 and 1663 times less potent against the other representative 
member of class I, HDAC8. While having previously been shown to be less 
potent against the Class IIb HDAC6, 28’ and 111b’ were also found to have only 
weak activity against HDAC7. 
 
 
cpd
a
 AB 
rHDAC1 
IC50 [μM] 
rHDAC6 
IC50 [μM] 
rHDAC7 
IC50 [μM] 
rHDAC8 
IC50 [μM] 
28’ NOH 0.0010 0.36 17 1.3 
111b
’ 
NNH2 0.0050 1.0 45 13 
 
Table 9 - Isoform selectivity profile of 28’ and 111b’. aThiols were prepared by in 
situ reduction of the respective disulfides using Tris(2-carboxyethyl)phosphine 
hydrochloride, and used immediately. Details about the procedure used for 
reduction can be found in the Experimental section 
 
Docking and Molecular Dynamics simulations for HDAC inhibition. Since 
our data were consistent with the postulate that psammaplin A is a natural 
prodrug, with the free thiol functioning as a zinc binding group, we initiated 
computational studies to study its interactions with HDAC1. Recently, de Lera 
and co-workers performed preliminary computational studies on the binding of 
Psammaplin A to HDACs, using the crystal structure of HDAC8.
161a
 It would 
seem that in light of our isoform selectivity data (Table 9) that HDAC8 is not a 
particularly good model to study the binding of Psammaplin A. Recently, the X-
Ray structure of HDAC2 in complex with a small ligand was solved
75
 (PDB-entry 
3MAX), and since HDAC1 and HDAC2 are 93.7% identical in a 318 amino acid 
overlap, homology modelling of HDAC1 based on the 3D-structure of HDAC2 
should provide a realistic structural model of HDAC1. The homology model of 
HDAC1 was calculated by Pr. Franz-Josef Meyer-Almes using SWISS-
MODEL.
181
 A set of 120 conformers of deprotonated 28’ was generated using 
MarvinSketch 5.1.5 (ChemAxon Ltd.). Atomic charges were applied using 
ANTECHAMBER.
182
 The conformers were extensively docked into the active 
site pocket of HDAC1 using DOCK6.4 with a maximum of 5000 orientations and 
10000 simplex iterations per conformer.
183
 The ten conformers with best scores 
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were refined in a subsequent docking using AMBER score.
184
 The best AMBER 
docking pose was used as a starting point for subsequent molecular dynamics 
calculations using GROMACS
185
 and AMBER99
186
 as an implemented forcefield. 
After in vacuo minimization using steepest descent and conjugate gradient 
algorithms, the complex consisting of HDAC1 and 28’ was solvated in a box 
containing 15526 TIP4 water molecules and 250 mM NaCl. A position-restrained 
dynamics simulation was run to equilibrate the water around the protein and to 
position water molecules and ligand within the active site of the enzyme. Then the 
temperature of the system was raised stepwise from 100K to 300K. In the last step 
at 300K a period of 2 ns was simulated.  
 The trajectory traces were analyzed using VMD 1.8.7 (University of 
Illinois). The psammaplin A monomer 28’ was found to form three hydrogen 
brigdes to Y303 (64%), D99 (77%) and the protonated H141 (26%) (see Figure 
31). The percentages in brackets denote the fractional period of simulation where 
the hydrogen bonds are formed. In addition, there appeared to be a structural 
water molecule with extraordinary restrained position during the simulation. This 
water molecule brigdes the amide-oxygen of 28’ and H178. The hydrogen bond 
between the ligand and this water molecule is formed through 96% of the 
simulation run whereas the hydrogen bond between the ligand and H178 is 
formed about 50 % of the run period. Moreover a strong interaction between the 
thiolate and the catalytic Zn
2+ 
ion could be observed, with a very sharp radial pair 
distribution between Zn
2+
 and the sulfur atom of the ligand with a mean distance 
of (0.20±0.01) nm. 
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Figure 31 - Snapshot of MD simulation of 28’ in complex with HDAC1 
(homology model). 28’ forms hydrogen bonds (dotted yellow lines) with Y303, 
H141 and D99. A structural water molecule forms brigded hydrogen bonds with 
inhibitor and H178 
 
 
2.22. DNMT inhibition 
 
 Since small molecule, non-nucleoside DMNT inhibitors are severely 
underdeveloped in the literature, we were particularly interested to assess the 
DNMT activity of our libraries. Despite the initial report by Crews and co-
workers that Psammaplin A is highly potent against semi purified DNMT1 (18.6 
nM),
135g
 recent studies by de Lera and co-workers observed no inhibition of 
DNMT1 immunoprecipated from K562 cells or recombinant DMNT3A.
161a
 We 
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therefore felt we could further study the potential for DNMT1 inhibition using a 
high-throughput fluorescence intensity assay. Purified full length N-terminal His6-
tagged human DNMT1 was used in the assay, under conditions similar to those 
described by Roach and co-workers.
187
 In this assay, a hemimethylated break light 
oligonucleotide is used as a substrate for DNMT1. A break light is a single-
stranded self complementary oligonucleotide able spontaneously to form a hairpin 
structure, and bearing a fluorophore and a quencher at the 5’ and 3’ termini 
respectively.
188
 The formation of the hairpin structure places the fluorophore and 
the quencher in close proximity, therefore inducing efficient quenching of the 
fluorescence. Following methylation by DNMT1, the fully methylated oligo is 
preferentially cleaved
189
 over the hemi-methylated substrate by a restriction 
endonuclease, Gla I.
190
 Further melting of the short cleaved sequence induces the 
separation of the fluorophore from the quencher, and therefore an increase in 
fluorescence which is used as an indicator of enzymatic activity (Scheme 32). 
Further experimental details can be found in the Experimental section of this 
thesis. 
 
 
 
 
 
 
 
 
 
 
Scheme 32 - “break-light” cytosine-C5 methyltransferase activity assay. 
Drawing adapted from Roach et al.
187
 
 
 Psammaplin A and our synthetic analogues were therefore assayed against 
DNMT1 using the assay described above. A counterscreen assay against Gla I 
was also performed in order to detect any potential Gla I inhibition by our 
compounds. 
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 Disappointingly, none of our synthetic analogues assessed showed 
significant inhibition of DNMT1 at 30 μM. The dimeric analogues were also 
assayed as free thiols, but no significant inhibition could be observed, even at 120 
μM. S-Adenosyl homocysteine (SAH) was used as a positive control in the assay 
(Figure 32), and gave an IC50 of 0.9 μM (160 replicates, lit. 2-4 μM
191,192
). 
 
 
 
 
 
 
 
 
 
Figure 32 - DNMT1 assay, dose response curve for SAH 
 
 One potential concern was the reductive assay conditions required (5mM 
DTT), which would result in the reduction of any disulfide analogues assessed. 
Should it be the parent, dimeric structure that was active, it is likely this would not 
be present under the assay conditions. Analogues 134
161a
 and 135 (obtained from 
diamines 136 and 137 respectively, Figure 33), were prepared to replace the 
native disulfide functionality of Psammaplin A with 2 methylene groups and a 
thioether respectively (Scheme 33). Such analogues should be chemically stable 
under the reaction conditions.  
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 Unfortunately, 134 and 135 were also found inactive against DNMT1 
under our assay conditions. As an alternative assay, we decided to study the 
effects of Psammaplin A (28) on the bacterial methyltransferase MSssI. MSssI is 
a widely used model to study the effects of DNA methylation on mammalian 
genomes, since this bacterial enzyme is structurally related to mammalian DNA 
methyltransferases and recognizes the same sequence (CpG).
193
 Indeed, it has 
been previously used as the basis of an in vitro model to study the activities of 
inhibitors of mammalian methyltransferases.
130,194
  Furthermore, Sufrin and co-
workers have previously reported Psammaplin A to inhibit bacterial 
methyltransferases.
129,156
 Following incubation of the enzyme with its DNA 
substrate, examination of the degree of DNA digestion with the restriction enzyme 
BstU1 (CGCG), which cannot cut if the site is cytosine methylated, can 
conveniently be used to assess the degree of MSssI activity in the presence of 
inhbitors. As can be seen in Figure 34, Psammaplin A (28) was found to potently 
inhibit MSssI at 50 μM. The assay was repeated four times, including positive and 
negative controls, and in each case Psammaplin Awas seen to inhibit MSssI  
activity equivalently down to 5 μM . 
 
 
 
Figure 34 - MSssI assays. Psammaplin  A inhibits the bacterial methyltransferase 
MSssI
129
 in vitro 
 
 
 
28 
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2.23. Cell studies 
 
 A large selection of compounds from our library were assessed for 
cytotoxicity. Our synthetic analogues were assayed against A549 (human lung 
carcinoma), MCF7 (human breast carcinoma) and WI38 (normal human lung 
fibroblast) cell lines. The results are given in Tables 10 and 11. Methylthioether 
containing analogues 75a, 75b, 75r, 75t, 97a, 98a, 111a and 112a were found 
almost inactive against the three cell lines tested. Most of disulfides and thiols 
exhibited micromolar activities. Compound 75c’ was found particularly active 
(0.16 μM against A549, 0.61 μM against MCF7). Interestingly, thiol 111b’ was 
found particularly selective against MCF7 (3.42 μM) with a 10-fold increase in 
potency compared to the other cell lines.  
 In order to shed light on the mode of action of Psammaplin A and our 
synthetic analogues in cells, western blot analysis was performed in MCF7 cells 
with compounds 28’ and Trichostatin A which was used as a positive control. 
Untreated cells were used as a reference. Variations in the level of expression of 
acetylated histone H3 (Ace-H3), histone H3 (H3), Ace-tubulin, tubulin and p21 
were studied. The results are shown in Figure 35. 28’ and Trichostatin A were all 
found to induce a significant upregulation of Ace-H3, what is in accordance with 
their HDAC inhibitory potency. p21, which is known to be upregulated by HDAC 
inhibitors, was indeed observed. While important upregulation of p21 by 
Trichostatin A was observed below 1 μM, a concentration of 5 μM  was necessary 
in order to observe a similar result with 28’. Compound 28’ was however found to 
have only marginal influence on the level of Ace-tubulin compared to the 
upregulation of Ace-H3, whereas significant upregulation of Ace-tubulin was 
observed in the case of Trichostatin A. This is consistent with the HDAC isoform 
selectivity observed in vitro for 28’ and other Psammaplin A analogues. As 
control experiments, the total level of histone H3, tubulin and actin (not shown) 
were found unchanged in each case. 
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4
5
6
1
2
3
R1
A
B
H
N
O
R2
 
 
compound R1 AB R2
a
 
A549 
IC50 [μM] 
MCF7 
IC50 [μM] 
WI38 
IC50 [μM] 
75a H NOH SMe > 50 > 50 > 50 
75b Me NOH SMe 22.8 46.7 > 50 
28 H NOH S2R (dimer) 7.5 1.27 3.44 
75c Me NOH S2R (dimer) 4.09 0.63 2.2 
28’ H NOH SH 2.53 2.35 3.4 
75c’ Me NOH SH 0.16 0.61 1.13 
75r H NOMe SMe > 50 > 50 > 50 
75t Me NOMe SMe > 50 49.5 > 50 
75s H NOMe S2R (dimer) 49.5 nd > 50 
75u Me NOMe S2R (dimer) 45.9 12.8 nd 
75s’ H NOMe SH 10.6 19.3 24.2 
75u’ Me NOMe SH 5.11 12.4 10 
97a H O SMe > 50 18.3 nd 
98a Me O SMe > 50 > 50 > 50 
97b H O S2R (dimer) 15.2 13.1 33.1 
98b Me O S2R (dimer) 10.3 3.86 4.12 
97b’ H O SH 43 35.4 42.6 
98b’ Me O SH 11.4 3.42 14.1 
111a H NNH2 SMe > 50 > 50 > 50 
112a Me NNH2 SMe > 50 > 50 > 50 
111b H NNH2 S2R (dimer) 18.8 3.81 nd 
112b Me NNH2 S2R (dimer) 10.1 >50 nd 
111b’ H NNH2 SH 33.4 3.42 37.2 
112b’ Me NNH2 SH 17.5 10.8 34.0 
129 Me NOH SAc 8.33 3.23 5.2 
128 Me NOMe SAc 44.6 12.2 16.6 
130 Me O SAc > 50 21.1 > 50 
       
 
 
Table 10 - Psammaplin A and synthetic analogues display micromolar 
cytotoxicity against A549, MCF7 and WI38 cell lines. 
a
Thiols were prepared by in 
situ reduction of the respective disulfides using Tris(2-carboxyethyl)phosphine 
hydrochloride, and used immediately. Details about the procedure used for 
reduction can be found in the Experimental section 
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compound R1 R2
a
 
A549 
IC50 [μM] 
MCF7 
IC50 [μM] 
WI38 
IC50 [μM] 
11c 3-Br-4-OH S2R dimer 7.5 1.27 3.44 
11c’  SH 2.53 2.35 3.4 
11d’ 3-Br-4-OMe S2R dimer 4.09 0.63 2.2 
11d’  SH 0.16 0.61 1.13 
11i / S2R dimer 16.3 11.1 > 50 
(52.84) 
11i’  SH 15.2 9.38 10.9 
11j 4-OH  S2R dimer 19.5 5.55 nd 
11j’  SH 19.6 15.5 31.8 
11k 4-F  S2R dimer 12.8 2.96 nd 
11k’  SH 16.6 11.9 12.8 
11m 3-I-4-OMe  S2R dimer 1.08 0.52 nd 
11m’  SH 2.6 1.14 1.03 
11n 3-Br-4-F  S2R dimer 2.73 1 1.8 
11n’  SH 6.24 2.87 7.72 
11q 3-Br-3’,4-OMe  S2R dimer 2.51 0.72 2.14 
11q’  SH 4.4 2.25 4.31 
11r 3,4-OMe  S2R dimer 8.11 2.92 8.67 
11r’  SH nd nd nd 
11t 3-Br-3’-NO2 S2R dimer 2.53 0.94 2.23 
11t’  SH 2.4 nd 4.84 
 
 
Table 11 - Psammaplin A and synthetic analogues (variation of aromatic 
substitution) display micromolar cytotoxicity against A549, MCF7 and WI38 cell 
lines. 
a
Thiols were prepared by in situ reduction of the respective disulfides using 
tris(2-carboxyethyl)phosphine hydrochloride, and used immediately. Details about 
the procedure used for reduction can be found in the Experimental section 
 
 
 
 
 
 
 
 
 
 
C
o
n
tr
o
l 
T
S
A
 (
0
.5
 μ
M
) 
T
S
A
 (
1
 μ
M
) 
2
8
’ 
(5
 μ
M
) 
Figure 35 - Western blot analysis 
of 28’ in MCF7. Untreted cells and 
Trichostatin A (TSA) were used as 
negative and positive control 
respectively 
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2.24. Discussion 
 
HDAC inhibitory activity and selectivity of Psammaplin A and analogues. It has 
been previously reported by Kwon and co-workers that in terms of its HDAC 
activity, psammaplin A functions as a natural prodrug; the active free thiol being 
revealed following disulfide reduction in vivo.
115
 The evidence presented for this 
proposal was the fact that pre-treatment of both psammaplin A and HDAC1 with 
H2O2 as an oxidant led to low inhibition of HDAC activity,
115
 coupled with the 
decreased potency of Psammaplin A against glutathione deficient cells. Recently, 
an analogous proposal was presented by de Lera and co-workers based on the fact 
that a psammaplin A analogue lacking the disulfide bound (134) was inactive, as 
were analogues where the disulfide unit was replaced by methyl ether, methyl 
thioether and alcohol functionalities.
161a
 Similar conclusions have been drawn for 
other disulfide bearing cyclic peptidic natural products, such as the HDAC 
inhibitor Romidepsin (2).
147
 Since the common pharmacophore of most HDAC 
inhibitors requires a zinc-binding end group (ZBG), and the fact that thiols are 
known to be excellent ligands for zinc,
195
 we felt the prospect of a free thiol as the 
active species is highly plausible. Indeed, synthetic HDAC inhibitors utilizing 
thiol zinc binding groups (protected as thioesters) have been previously 
reported.
108-112
 The SAR described for our psammaplin A derived libraries is in 
line with the hypothesis that psammaplin A is first reduced to the monomeric 
thiol, and this corresponding monomer is the active HDAC inhibitor. Indeed, by 
directly assaying the free thiol species, we observed the inhibitory activity of 
these compounds to be highly potent. In contrast, the corresponding methyl 
thioethers were not active at all. A parallel observation was previously made by 
Horinouchi and co-workers during their study of Romidepsin.
147
 To validate this 
hypothesis further, computational studies of the active site of HDAC enzymes 
such as HDLP (pdb code 1C3P, 1C3R, 1C3S), HDAC2 (pdb code 3MAX), 
HDAC8 (pdb code 1T64, 3F0R, 1T69), HDAC4 (pdb code 2VQJ, 2VQM), 
HDAC7 (pdb code 3C10, 3C0Z) or HDAH (pdb code 1ZZ1, 1ZZ3, 1ZZ0, 2VCG) 
were carried out and revealed the parent psammaplin A to be too “large” in its 
dimeric form to fit into the active site of the HDACs (Figure 36, example of 
HDAC2). Our model for compound binding to HDAC1 (vide supra, Figure 31) is 
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also consistent for a thiol being the active species. What  is unclear however, is 
why the parent disulfide analogues retain any potency in cell free assays. While 
this may be related to their ability to generate the corresponding thiols in situ 
under the assay conditions, the mechanism for this is still unclear. It is plausible 
that traces of reducing agents could be present in commercial kits (rHDAC1, 
rHDAC6), and could therefore be responsible for their observed potency. To 
check whether contamination of the dimeric disulfides with their thiol 
counterparts was giving rise to inhibitory effects, we incubated 28 and 75c in the 
presence of hydrogen peroxide prior to the assay (5 mM disulfide, 1% H2O2, 90 
minutes in the dark, then dilution to 5 μM and further dilutions for assay). The 
resultant IC50 values for 28 (45 nM, HDAC1) and 75c (43 nM, HDAC1) showed a 
loss in potency. The enzyme activity was found unaffected by the presence of 
H2O2. This result confirms the preliminary results obtained by Kwon and 
coworkers,
115
 and strongly suggests the thiol as the active species. Regardless of 
mechanism, the initial incubation time of the disulfide species under the assay 
conditions is thought to play a role in the final recorded potency, suggesting that 
the active free thiol is generated in situ. 
 
 
 
Figure 36 - Top: crystal structure of HDAC2 (pdb 3MAX) in complex with a N-
(2-aminophenyl)benzamide derivative.
75
 Bottom left: pharmacophore for common 
HDAC inhibitors. Bottom right: reduced Psammaplin A, proposed active species 
for HDAC inhibition 
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 As final confirmation of the monomeric thiol species being the active 
compound, we found hydroxamic acid analogue 116 to be highly potent against 
HDAC1, HDAC6 and HDAH.  Not only does this illustrate the compatibility of 
the hydroxamic acid group with the hydroxiimino bromotyrosine based scaffold 
of Psammaplin A, but also supports the hypothesis that the thiol end group is 
functioning as a zinc-binding group. One caveat is that in contrast with 
hydroxamic acids 116 and 117, all thiols tested were found very weakly active 
against HDAH (IC50 of 116: 0.31 μM; IC50 of 117: 5.25 μM). Indeed, in our assay, 
28’ and 111b’ displayed IC50s of 30.2 μM and 32.0 μM respectively against 
HDAH. The reason for the lack of activity of thiols against HDAH is still unclear 
and is under further investigation. 
 While the use of the disulfide functionality is one strategy for a thiol 
prodrug, we also envisaged that our acetate-protected thiols 128-130 may generate 
the corresponding thiol in situ after cleavage of the acetyl group in vivo. Indeed, 
during their research of SAHA-based non hydroxamate inhibitors of HDACs, 
Miyata and co-workers synthesized a number of thioesters analogues which 
exhibited moderate to high potency in enzymatic and cell based assays.
109,112
 The 
potency of their compounds was interestingly higher than the potency of their 
corresponding dimeric analogues, and was thought to reflect a rate of thioester 
hydrolysis versus the rate of disulfide reduction. 
 We were surprised therefore to observe HDAC inhibition in vitro by 
acetate protected compounds 128-130. Previously observed during assays against 
rat liver extracts (RLE), we hypothesized this to be due to the potential presence 
of non specific esterases in the extract. However, the same pattern was observed 
with purified rHDAC1 and purified rHDAC6. Recently, Williams reported the 
high potency of the natural product largazole, bearing an octanoyl protected thiol, 
against HDACs.
103
 While the deprotected analogue displayed nanomolar to 
subnanomolar potency in vitro against purified HDACs, it was observed that the 
native thioester was still highly potent. While reasonably hypothesizing that the 
octanoyl group was cleaved in situ to liberate the active thiol, no rigorous studies 
were reported to explain these observations.  
 We began preliminary studies in order to shed some light on the 
mechanisms leading to acetate deprotection of our compounds in situ. While using 
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purified HDACs, we envisaged our buffered conditions to be potentially 
responsible for thioester deprotection. We prepared and used synthetic probe 137 
(Scheme 34) in order to test this hypothesis.
196
 Coumarin based probe 137 is 
known to react very fast with thiols through a Michael addition reaction. 
Fluorescence of the coumarin moiety of 137 is efficiently quenched by the 
intramolecular double bond. However, reaction between a thiol and 137 affords a 
highly fluorescent conjugate 138. This system has been found to be particularly 
efficient to quantify thiol concentration in biological systems. We thought this 
probe to be a valuable tool to detect any formation of the free thiol from our 
thioacetates in our buffer. 137 was prepared as previously described.
196
 
 
 
O O
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Scheme 34 - Probe 137 reacts very fast with thiols to form the highly fluorescent 
conjugate 138 
 
 
Control experiments were performed using 2-mercaptoethanol as the source of 
thiol.
196
 Fluorescence spectra of 137 (10
-6
 M in buffer FB-188
178
) were recorded 
in the presence of 0, 0.2, 0.4, 0.6, 0.8, 1.0 and 1.5 eq. 2-mercaptoethanol 139 
(Figure 37, top). 
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Figure 37 - Top: Fluorescence spectra (a. u.) of 137 (1 μM) in buffer FB188178 in 
the presence of 0, 0.2, 0.4, 0.6, 0.8, 1.0 and 1.5 eq. 2-mercaptoethanol. Excitation: 
400 nm, emission: 420-600 nm. 137 and different quantities of 2-mercaptoethanol 
were initially incubated at 1 mM (137) for 5h, and further /1000 dilution in buffer 
was performed before recording the fluorescence spectra.. Bottom: fluorescence 
intensity (a. u.) at 465 nm as a function of the number of equivalent of 2-
mercaptoethanol  
 
 
As expected, a linear relationship between fluorescence intensity and the 
concentration of thiol could be observed between 0 and 1.0 eq., confirming the 
sensitivity and reliability of this system (Figure 37, bottom). 
 
0 
20 
40 
60 
80 
100 
120 
420 470 520 570 
0 eq. 
0.2 eq. 
0.4 eq. 
0.6 eq. 
0.8eq. 
1.0 eq. 
1.5 eq. 
0 
20 
40 
60 
80 
100 
120 
0 0.5 1 1.5 2 
Towards novel small molecule epigenetic inhibitors Results and discussion 
85 
 
 However, no significant variation of the fluorescence intensity could be 
observed when 2-mercaptoethanol was replaced by thioester 129 in our 
experiment (Figure 38). While the classical incubation time of thioesters are about 
20-30 minutes in HDAC assays, the incubation time for this fluorescence 
experiment (100 minutes) was chosen to be about 3 times higher in order to 
ensure the observation of any potential variation, and to exclude the incubation 
time as a possible systematic error in the final results. Two explanations can be 
envisaged to explain this last result. 1) The thioester is stable in these conditions 
and therefore the buffer does not contribute to the in situ generation of the free 
thiol. 2) The quantity of free thiol generated in situ is lower than the limit of 
detection of the experiment, and therefore can’t be quantified by this technique. 
Simplistic calculations suggested that the presence of only 2-3% of active thiol 
among the thioester (or disulfide) samples should theoretically be enough to result 
in an IC50 in the low nanomolar range. 
 
 
Figure 38 - Time (minutes, X-axis) dependent fluorescence intensity (465 nm, a. 
u., Y-axis) of 137 (1μM) in buffer FB188178 in the presence of 2.0 eq. thioester 
129. 137 and 129 were incubated at 1 mM (137) in buffer FB188
178
 (3% DMSO), 
and further /1000 dilution in buffer was performed before recording the 
fluorescence spectra. 
 
 Another study was later undertaken by our collaborator Pr. Franz Meyer-
Almes and his group (Hochschule Darmstadt, University of Applied Sciences, 
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hydrolysis of the thioesters. Indeed, HDACs are enzyme able to remove acetyl 
groups from their substrates and are therefore obvious candidates for 
investigation. In particular, the initial incubation time of the thioester substrate 
with HDAC1 was thought to play a role in the final recorded potency. In this 
experiment (data not shown), inhibition of HDAC1 was measured (single 
concentration) as a function of the initial incubation time (1-60 minutes) with 
different thioesters. o variation of enzymatic inhibition could be observed in each 
case, which seems to exclude HDAC1 as the source of hydrolysis. 
 In conclusion, the reasons for the observed potency of our thioesters 
against HDAC1 are still elusive. While inhibition by the thioester itself cannot be 
excluded, it seems relatively unlikely. Investigations are still in progress in order 
to shed light on the mechanisms underlying these observations. 
 
 
 One striking aspect of our data is the high selectivity of Psammaplin A and 
many of our analogues for HDAC1. As described, the oxime functionality in 
Psammaplin A seems to play an important role, not only for potency against 
HDAC1, but also HDAC1 selectivity. Indeed, while ketone analogues 97b’ and 
98b’ and compound 115’ bearing no functionality in this position displayed 
similar potencies against both HDAC1 and HDAC6, introduction of the oxime 
(and to a lower extent, the hydrazone) resulted in an increase in potency against 
HDAC1, while keeping potency against HDAC6 relatively unaffected. These 
result thus suggest a possible design criterion for HDAC1 selective inhibitors. At 
the molecular level, we suspect the selectivity may be due to structural differences 
between the active sites of class I and class II HDACs. The structural basis for the 
observed pronounced selectivity of the reduced psammaplin analogues for 
HDAC1 versus HDAC8,6,7 is still under discussion. We hypothesize that among 
other structural features hydrogen bonding to Y303 contributes to selectivity 
because it is substituted by histidine in class IIa HDACs. This tyrosine is assumed 
to stabilize the oxyanion during the catalytic deacetylation process.
197
 Crystal 
structures of enzyme-inhibitor complexes involving  HDAC2 (3MAX), HDAC8 
(1T64) and HDAH (1ZZ1) show hydrogen bonds between the hydroxyl group of 
the catalytic tyrosine and the corresponding inhibitors. In contrast, in the crystal 
structures of enzyme-inhibitor complexes of HDAC4 (e.g. 2VQJ, 2VQM) and 
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HDAC7 (3COZ,3C10) the histidine residues corresponding to the catalytic 
tyrosine are rotated outward from the active site.  
 L271 (HDAC1) is conserved through class II and class I HDACs unless 
HDAC8, where leucine is replaced by methionine. This difference might 
contribute to the observed differences in substrate and inhibitor selectivities 
within class I  between HDACs 1, 2 , 3 and HDAC8. 
 D99 (HDAC1) is conserved through all members of zinc dependent 
HDACs, but is substituted by an isoleucine in HDAH which might be a possible 
explanation for the low potencies of the reduced psammaplin analogues against 
the bacterial HDAC homologue. 
 
 In terms of the substitution pattern of the aromatic “capping” unit, we 
found this feature to have less of an effect on potency and selectivity than the thiol 
or the oxime functionality. This is agreement with the SAR observed by de Lera 
and co-workers.
161a
 Our model (see Figure 31) suggests that the aromatic ring is 
positioned at the entrance of the channel leading to the active site, potentially 
interacting with one or both of the conserved phenylalanines at the channel 
entrance. It is therefore clear that a number of our analogues could make 
interactions with surface residues, resulting in the observed changes in potency 
and selectivity.  
 
Methyltransferase inhibitory activity of Psammaplin A and analogues 
 
 Psammaplin A and other members of the Psammaplin family have been 
previously reported to be potent inhibitors of the human DNMT1 in vitro (IC50 = 
18.6 nM for Psammaplin A against semi-purified DNMT1).
135g
 In our DNMT1 
assay,  Psammaplin A and all synthetic analogues were found inactive at 
concentrations of up to 30 μM and 120 μM (free thiols). These data are in 
agreement with the recent data reported by de Lera and coworkers, who reported 
the lack of potency of several Psammaplin A analogues against 
immunopreciptated DNMT1 in an alternative methyltransferase assay.
161a
 The 
origin of the discrepancy between our data and the values reported by Crews and 
co-workers
135g
 is still unclear, but several differences in protein purity and the 
assay conditions are apparent. Crews and coworkers used semi-purified DNMT1, 
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whereas highly purified enzyme was used in our assay. The methylation substrate 
(and its concentration) was also different in each case, with biotinylated poly(dl-
dC) used by Crews and a hairpin DNA mimic oligomer being used in our assay. 
This difference is likely to be important and could account for the inactivity 
observed in our assay. It is germane to mention however that the de Lera study 
also used a poly(dl-dC) substrate.
161a
 Since most DNMT assays involve 
substantial quantities of reducing agents (usually DTT) in order to avoid 
degradation of the DNA substrate by external oxidative agents (such as O2), it is 
important to highlight the chemical instability of our dimeric compounds under 
these conditions. Our results on the non reducible analogues 134
161a
 and 135 (vide 
supra), which were also found to be inactive, suggest however that chemical 
reduction of psammaplin A analogues may not responsible for the lack of potency 
against DNMT1. Taken together, the lack of activity observed in our in vitro 
assays, coupled with the lack of activity observed by de Lera and co-workers, lead 
us to question the activity of Psammaplin A (and analogues) against DNMT1. 
While such a supposition is based on data from cell-free assays, it is important to 
highlight that Sufrin and co-workers have reported a lack of DNA 
hypomethylation as a result of exposure of HCT116 human colon carcinoma cells 
to Psammaplin A. Psammaplin A also failed to induce the hypomethylation or 
reactivation of methylation silenced genes.
156,198
 Since psammaplin A has been 
reported to have low physiological stability,
143,144,199 
it is plausible the lack of an 
effect on DNA methylation in cells is due to transport and stability issues. An 
alternative explanation is that psammaplin A is largely inactive against  human 
DNMTases. 
 Interestingly, Psammaplin A was found to inhibit the bacterial 
methyltransferase MSssI potently at low μM concentrations (Figure 34). This 
result is in accordance with preliminary data reported by Sufrin, who also reported 
activity aginst bacterial methyltransferases.
156
 Importantly, we observed that both 
Psammaplin A and its reduced form were active against the bacterial 
methyltransferase, DTT contained in the buffer likely generated substantial 
amounts of reduced Psammaplin A in situ regardless of how the compound was 
dosed. It is difficult to draw a firm conclusion from the fact that our data show 
lack of activity against DNMT, but activity against MSssI, however it is important 
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to note that our MSssI assay used bacteriophage λ DNA as the substrate at it 
therefore remains possible that psammaplin A is instead affecting the analysis 
through interaction with the DNA substrate (for example by intercalation), rather 
than a direct interaction with the methyltransferase. Further studies are needed to 
elucidate this possibility. 
 
Cellular studies. Our synthetic analogues showed significant toxicity against 
A549 (human lung carcinoma), MCF7 (human breast carcinoma) and WI38 
(normal human lung fibroblast) cell lines (see Tables 10 and 11). For example 
several compounds were found to inhibit cell growth at sub-micromolar 
concentrations, including 75c’ (A549: 0.16 μM MCF7: 0.61 μM) and 11q (MCF7: 
0.72 μM). This data is in agreement with previous studies that have reported 
Psammaplin A to have significant cytotoxicity (ED50, μg/mL) against human lung 
(A549, 0.57), ovarian (SK-OV-3, 0.14), skin (SK-MEL-2, 0.13), CNS (XF498, 
0.57), and colon (HCT15, 0.68) cancer cell lines.
146 
Furthermore, it
 
has been 
reported to cause G1 arrest in human endometrial Ishikawa cancer cells
200
 and 
U937 leukaemia cells,
161a
 which correlates to the effect of known HDAC 
inhibitors. We found that methylthioether-containing analogues 75a, 75b, 75r, 
75t, 97a, 98a, 111a and 112a (Table 10) were largely inactive against all cell lines 
tested, correlating with our SAR against HDAC inhibition. Additionally, 
compounds bearing an oxime motive (AB = NOH, Table 10) were found more 
potent than their respective analogues bearing an O-methyloxime (AB = NOMe, 
Table 10), ketone (AB = O, Table 10) or hydrazone (AB = NNH2, Table 10) unit, 
once again correlating with SAR data previously obtained in HDAC assays. 
Taken together this suggests that Psammaplin A mediates its cellular effects 
through HDAC inhibition.  
HDAC1 knockdown in MCF-7 cells has been previously reported to result 
in cell cycle arrest in G1 and G2.
201
 In light of the fact that our studies indicated 
psammaplin A to have significant potency and selectivity against HDAC1, and 
that HDAC inhibitors are being clinically evaluated for breast cancer treatment,
202
 
we decided to investigate further the mode of action of our inhibitors in MCF7 
cells, through study of reported HDAC biomarkers. Western blot analysis 
revealed 28’ to induce an important upregulation of Ace-H3, nicely correlating 
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with its HDAC inhibitory potency. Interestingly the inability of 28’ to 
significantly upregulate Ace-tubulin, a substrate for HDAC6, nicely correlates 
with the low inhibitory potency of this compound against HDAC6 in vitro. 
Finally, 28’ was able to upregulate the level of p21, known to be affected by 
HDAC inhibitors. This result is again suggestive that HDAC inhibition could 
account for 28’ (and related analogues) cytotoxicity. Interestingly, preliminary 
studies have shown that similar results could be observed with hydrazone 
analogue 111b’ and the hydroxamic acid analogue of Psammaplin A 116 (data not 
shown). Additional studies are still in progress in order to establish a more 
accurate picture of the mode of action of 28’ and related synthesic analogues. The 
results of this study will be reported in future manuscripts 
 
2.3. Conclusions 
 
 In this study, we demonstrated that Psammaplin A was a prodrug for 
HDAC inhibition, requiring reduction of the disulfide unit in order to generate the 
active species, a thiol. Assaying our libraries of analogues allowed us to draw a 
robust SAR of Psammaplin A against HDACs, and to propose a binding mode to 
HDACs. The important isoform selectivity exhibited by our coumpounds in vitro 
against HDACs allowed us to highlight important structural features potentially 
exploitable for the development of novel and selective lead compounds. We were 
however disappointed by the lack of potency of our libraries against DNMT1, 
which is inconsistent with results previously reported by Crews.
135g
 While 
differences between our assay conditions and those reported by Crews, notably 
the nature of the DNMT substrate and enzyme purity, could be invoked in order to 
explain such differences, this led us seriously to doubt of the DNMT1 inhibitory 
activity reported by Crews. Finally, cytotoxicity assays and Western blot analysis 
allowed us to characterise HDAC inhibition by 28’ in MCF7 cells. Interestingly, 
the ability of 28’ to upregulate histone acetylation while having only a marginal 
effect on the level of acetylated tubulin was consistent with its HDAC selectivity 
in vitro. Further studies are underway in order to obtain a more accurate picture of 
the mode of action of 28’ and related synthetic analogues.  
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3. Further investigation of the role of the oxime unit in 
Psammaplin A and design of novel lead compounds  
 
3.1. Introduction 
 
 As seen earlier in section 3, the synthesis and biological evaluation of the 
libraries of Psammaplin A analogues allowed us to develop a robust SAR against 
HDAC inhibition. The work described in section 3 allowed us to dissect the 
HDAC activity of Psammaplin A and to understand the structural features 
necessary for potency and selectivity. The impressive selectivity of our 
compounds for HDAC1 inhibition in vitro, mediated by the presence of either the 
oxime or hydrazone functionality, has not been documented previously. This 
selectivity represents a highly valuable asset for the design of new generations of 
novel, potent and selective HDAC inhibitors for anticancer therapies. Indeed, 
class I HDACs, comprising HDAC1, have been shown to play an important role 
in the silencing of tumour suppressor genes (TSGs) in cancer and to be amongst 
the most promising HDAC targets.
203
 While Psammaplin A and analogues have 
been shown to be highly potent and selective HDAC inhibitors in vitro, their low 
stability in vivo prevents their potential use in anticancer therapy. Their first 
drawback lies in the presence of the oxime functionality, potentially source of 
cytotoxicity in vivo. A number of oximes, and the parent compound 
hydroxylamine, have been shown to exhibit a wide range of cytotoxic effects.
204
 
These effects are mainly of haematological nature,
204a,204d,e
 and are usually related 
to oxidative stress. Also, Cytochrome P450 mediated metabolic degradation of 
oximes has been shown to produce reactive species, such as nitriles
204c
 or 
nitronates.
204b
 The second and probably most important drawback lies in the 
presence of the pendant terminal thiol. While being necessary for high potency, 
the low stability of thiols in vivo generally prevent them from being incorporated 
into drug candidates. Although a number of thiols, such as cysteine or glutathione 
(GSH), play an essential role in various biochemical processes,
205
 they are in 
general well known for their ability to produce highly reactive and harmful 
species in vivo during redox reactions in human cells.
206
 Finally, metalloproteins, 
such as zinc-dependent proteins,
207-210
 represent approximately one third of the 
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human proteome. The presence of a thiol is therefore likely to induce off-target 
effects, as thiols are well known to be particularly good ligands for a variety of 
metals in biological systems. 
 While a binding mode of Psammaplin A (reduced form) to HDAC1 has 
been proposed in section 3 based on extensive docking and MD studies, this 
binding mode is still under discussion in our laboratory. In particular, the role of 
the oxime and the coordination mode of the zinc cation are still subject to 
discussion. The results of additional computational studies will be presented in the 
next sections, with the aim to improve our understanding of the binding mode of 
Psammaplin A analogues to HDAC1. We hoped these studies to help us in the 
design of novel drug-like lead structures with the aim of overcoming the in vivo 
instability of Psammaplin A analogues. The design, synthesis and biological 
evaluation of novel inhibitors will be discussed. 
 
3.2. Results and discussion 
 
3.21. Computational studies 
 
 As seen previously in section 3, the oxime present in Psammaplin A and 
analogues (thiols) is proposed to hydrogen bond with Asp99 (HDAC1 homology 
model), which is thought to participate to their isoform selectivity. It is therefore 
surprising that methylated oxime derivatives 75s’ and 75u’, which are unable to 
form this hydrogen bond, are still highly potent (IC50) and selective for HDAC1 
(75s’: 27 nM, 75u’: 15 nM). This led us to question the importance of the oxime 
hydrogen for binding, and investigate the possible involvement of the oxime 
oxygen or nitrogen. Indeed, while the SAR data previously collected did not 
exclude the implication of the oxime hydrogen in H-bonding interactions with the 
protein, they strongly suggest that this hypothetical H-bond may not be the 
causative factor for the observed potency and selectivity observed with oxime 
containing analogues. For example, the potency (IC50) of O-methyloxime 
containing analogues 75s’ (27 nM) and 75u’ (15 nM) should likely be comparable 
to the potencies of keto analogues 97b’ (0.40 μM) and 98b’ (1.1 μM) and 
analogue 115’ lacking the oxime unit (0.42 μM). 
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 We therefore performed additional docking (Schrodinger) and MD 
(Gromacs) studies, and proposed other plausible binding modes. In particular, 
there is still the question of whether Psammaplin A and thiol analogues bind to 
HDACs in a monodentate or bidentate fashion. Indeed, due to its particular 
electronic properties, Zn(II) has been shown  to tolerate different coordination 
numbers in biological systems.
210
 Its “borderline” character confers Zn(II) the 
ability to form stable complexes with oxygen and/or nitrogen and/or sulfur 
containing ligands. In biological systems, Zn(II) is generally tetracoordinated by a 
combination of His, Asp, Glu, Cys and water. While often found in a 
tetracoordinated environment, it is not rare to find Zn(II) pentacoordinated, 
notably in the presence of bidentate ligands. This is, for example, the case for 
hydroxamic acids (Figure 39).
76
 
 
 
Figure 39 – Crystal structure (1C3S) of SAHA (dark grey, stick representation) 
bound in the active site of a histone deacetylase like protein (HDLP, green, ribbon 
representation); Zn(II) (grey sphere) is visible; the bidentate coordination of 
Zn(II) by SAHA is clearly visible (red dots) 
 
 Docking studies performed with analogue 75d’ and the recently published 
crystal structure of human HDAC2 (pdb code 3MAX)
75
 revealed orientations in 
which the ligand coordinates to the zinc in a bidentate fashion, with the thiol and 
the amide oxygen interacting with the metal centre (Figure 40). Although van der 
Waals radii for the ligand and/or the protein had to be artificially decreased (x 0.7) 
1.8 Å 
2.7 Å 
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during docking in order to allow the ligand to adopt such a conformation, this may 
be acceptable considering that the conformation of a protein in its crystal structure 
and its conformation in solution may differ. A bidentate complexation mode was 
already proposed by Anandan and coworkers
211
 for the N-(2-mercaptoethyl)amide 
motif during their study of mercaptoamide based inhibitors, however this result 
has not been experimentally validated. 
 In our new docking experiments, His145 (HDAC2 numbering) was 
protonated and the thiol docked as a thiolate anion. The choice of the protonation 
state of the two His residues forming the charge relay system was particularly 
important and had a crucial influence on the outcome of docking and MD 
experiments. In this model (Figure 41, left), the thiol is deprotonated by His145 
and interacts strongly with Zn(II). The amide interacts with Tyr308 (H-bond) and 
Zn(II) (O-Zn) via the oxygen, and with Gly154 (H-bond) via the hydrogen. 
Interestingly, a similar binding mode can be observed in the crystal structure of 
HDAC2 with a cocrystalized benzamide derivative (pdb code 3MAX, Figure 41 
(right)),
75
 in support of our model. A MD simulation using our HDAC1 homology 
model has shown this bidentate coordination for 75d’ to remain unchanged for at 
least 2.5 ns. 
 
Figure 40 - Left: 75d’ (dark grey, sticks representation) docked in the active site 
of HDAC2 (green, ribbon representation). Zn(II) (grey sphere) is visible;right: 
75d’ (stick representation) docked in the active site of HDAC2 (surface 
representation) 
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Figure 41 - Left: bidentate binding mode proposed for the N-(2-
mercaptoethyl)acetamide motif of 75d’ (dark grey: carbon, white: hydrogen, red: 
oxygen, blue: nitrogen, yellow: sulfur; stick representation). Hydrogen bonds of 
interest with the protein (green: carbon, white: hydrogen, red: oxygen, blue: 
nitrogen; stick representation) are highlighted in orange; right: crystal structure 
(pdb 3MAX) of an o-aminobenzamide derivative (pink: carbon, white: hydrogen, 
red: oxygen, blue: nitrogen; stick representation) in the active site of HDAC2. 
Hydrogen bonds of interest are highlighted in orange 
 
 However, the model shown in Figure 41 (left) fails to reveal the role of the 
oxime in binding, since no H-bond donor or acceptor can be observed in its direct 
vicinity. Several hypotheses were proposed in order to explain this observation: 
 
Alternative model 1: It is possible that one or several structural water molecules 
are involved in oxime binding. The position of these hypothetical water molecules 
is still unknown and subject to investigation. A plausible candidate for interacting 
with the ligand via a structural water molecule was identified. This candidate is 
His146 (HDAC2 numbering), which appears to be at approximately 3.6 Å from 
the oxime nitrogen (Figure 42). However, MD experiments have so far not been 
able to provide evidence for the presence of such a water molecule. Interaction 
between the oxime nitrogen and His146 via a structural water molecule would 
allow the oxime to occupy a position that avoids an internal steric clash with the 
aromatic ring. In the meatime, this would potentially allow the aromatic ring of 
the ligand to be involved in hydrophobic interactions at the entrance of the active 
site, possibly via π-stacking interactions with the phenyl rings of Phe155 and 
Phe210. In this conformation, the oxime hydrogen atom could plausibly interact 
Phe155 
Phe210 
Gly154 
Tyr308 
Asp269 Asp181 
His145 
His146 
Leu276 
His183 
Zn 
Asp269 
Asp181 
His145 
His146 
Phe210 
Gly154 
Phe155 
Leu276 
Tyr308 
Zn 
His183 
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with Phe210 via an O-H-π bond. In this model the meta and para positions of the 
aromatic ring are solvent-exposed and therefore potency should not be drastically 
affected by the introduction of substituents, which correlates to SAR data 
described in section 3. Then, the slightly reduced potency of O-methyloxime 
analogues could be explained by the steric clash appearing between the methyl 
group and the rest of the ligand-enzyme complex at the entrance of the active site 
(Figure 42), notably Phe155 and Phe210. The drop in potency for ketone 
analogues could be partially explained by the reduced length of the C=O double 
bond (therefore the position of the oxygen with respect to His146) and the 
reduced H-bond acceptor character of the carbonyl compared to the nitrogen atom 
of an oxime or an hydrazone. 
 The model proposed here alone does give insight to the isoform selectivity 
profile observed for Psammaplin A analogues, as the two histidine residues 
involved in the charge relay system are conserved in all members of class I and 
class IIb. It can be hypothesized that this selectivity, mediated by the oxime or the 
hydrazone, comes from variation in the orientation and basicity of the two 
histidine residues among the different isoforms. To date, study of the flexibility 
and basicity of this system is limited to few examples.
78
 A full study, extended to 
all isoforms, would be of considerable use for this study. 
 
Figure 42 - Ligand 75d’ (dark grey, stick representation) docked in the active site 
of HDAC2). A structural water molecule bridges the oxime nitrogen and His146. 
The water molecule was introduced manually (by the user) after docking, and 
subsequent steric clashes were reduced manually by rotation around the 
appropriate bonds. Hydrogen bonds of interest are highlighted in orange 
Phe155 
Phe210 
Tyr308 
His145 
His146 
Leu276 
His183 
Zn 
Distance NHis146-Noxime ~ 3.6 Å 
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Alternative model 2: MD simulations (Gromacs) were performed on HDAC2 (pdb 
3MAX)
75
 in which the native ligand has been removed, and trajectories of the 
residues in the active site were analysed (Figure 43). While Asp181, Asp269, 
His183 and a water molecule together form a relatively stable tetracoordinated 
environment for the catalytic zinc (Figure 43, Figure 44 (top)), the position of 
His183 was found to be altered during the 0.5 ns simulation. The imidazole ring 
was notably found to deviate significantly from the starting position during 5-6% 
of the simulation, in particular it was found to be able to achieve a ~ 90° flip from 
its original position (Figure 44 (bottom) and Figure 45 (top)). Interestingly, in this 
conformation His183 is located at an acceptable distance (ca. 2Å) to interact with 
the oxime of 75d‟ (Figure 45, bottom), potentially H-bonding with the sp2 
nitrogen. While this flipped conformation for His183 is not favoured due to the 
important disturbance of the Zn(II) coordination sphere, addition of the ligand 
could account for its stabilisation. 
 
 While isoform selectivity of our Psammaplin A analogues could 
potentially be related to the relative flexibility of the zinc coordination sphere 
among the different HDAC isoforms, this flexibility is poorly documented. Recent 
ab initio QM/MM molecular dynamics studies by Zhang allowed a theoretical 
assessment of the stability of the zinc coordination sphere in HDAC8,
212
 however 
no experimental validation has been reported. Moreover, no study has been 
thoroughly performed on other isoforms, making an accurate comparison 
impossible at this time. 
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Figure 43 – Superimposed snapshots of MD simulations with HDAC2 (green, 
ribbon representation) were superimposed. Zn(II) (grey sphere) is visible) 
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Figure 44 – top: Asp181, Asp 269, His183 (stick representation) and a water 
molecule (not shown) efficiently coordinate the Zn(II) cation (grey sphere) in the 
active site of HDAC2 (green, ribbon representation); bottom: His183 was able to 
flip from its initial/stable position, therefore perturbing the tetracoordinated 
environment of Zn(II) 
 
 
 
Asp269 
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His183 
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Towards novel small molecule epigenetic inhibitors Results and discussion 
100 
 
 
 
 
 
 
Figure 45 - Top: ~ 90° flip of His183 from its initial/stable position. Bottom: 
ligand 75d’ (dark grey, stick representation) docked in the active site of HDAC2. 
The oxime nitrogen of 75d’ forms a hydrogen bond (orange) with flipped His183. 
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Alternative model 3: An alternative binding mode could involve an isomerised 
oxime. Indeed, in the (Z) geometry the oxime hydrogen is positioned at 
approximately 2.2 Å from His146, therefore potentially able to form a H-bond 
(Figure 46). Isomerisation of the oxime of Psammaplin A has already been 
experimentally observed,
135c
 demonstrating the (Z) geometry to be stable under 
certain conditions. Indeed, in 1987 Arabshahi and Schmitz isolated several new 
brominated metabolites from an unidentified sponge.
135c
 Interestingly two of these 
compounds exhibited very similar NMR spectra. One was found to be the natural 
product now called Psammaplin A, having an (E,E) oxime geometry and the 
second was found to be the product with an (E,Z) geometry, one oxime being 
isomerized. They later observed that the (E,Z) product completely isomerized to 
the (E,E) one after a few weeks, demonstrating the increased stability of the (E) 
geometry. We therefore hypothesised that in situ isomerisation of the oxime upon 
binding could induce stabilisation of the HDAC2-ligand complex via hydrogen 
bonding with His146. However, this binding mode is still difficult to reconcile 
with the observed potency of methylated oxime derivatives. 
 
Figure 46 - Isomerized 75d’ (dark grey, stick representation) docked in the active 
site of HDAC2 (green, stick representation). A hydrogen bond (orange) between 
the oxime hydrogen and His146 is visible 
 
 In summary, while a binding mode for Psammaplin A and analogues to 
HDAC1 has been proposed in previous sections, difficulties to rely it to the 
potency observed for methylated oxime derivatives led us to question this model 
and to hypothesise three alternative binding modes. In those, the zinc(II) cation is 
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pentacoordinated, by Asp181, Asp269, His183, the thiol and the amide oxygen of 
the ligand. The aromatic ring is involved in hydrophobic interactions at the 
entrance of the active site, possibly π-stacking with Phe210 and Phe155. In this 
model, several possible interaction partners were identified to interact with the 
oxime: 
 
a) His146 via a structural water molecule (C=N - - - HOH - - - His, 
Figure 42) 
 Phe210, π-H interaction 
b) flipped His183 (C=N - - - HHis, Figure 45) 
c) His146 via an isomerised oxime (C=N-OH - - - His, Figure 46) 
 
 In order to bring additional support to one of these three proposed binding 
modes, and in particular the type of interactions underlying their impressive 
isoform selectivity, a library of new and structurally simplified compounds was 
designed. These new compounds combine an (hetero)aromatic unit linked to the 
native N-(2-mercaptoethyl)acetamide motif present in Psammaplin A (Scheme 
35). 
 
H
N
O
SH
(het)Ar
H
N
O
S
(het)Ar
2
in situ
 
Scheme 35 
 
We felt the use of functionalised aromatics and heteroaromatics to be an obvious 
choice in order to mimic the oxime or hydrazone of Psammaplin A and analogues. 
For example, the oxime sp
2
 nitrogen can potentially be mimicked by another 
strong ζ-donor atom, such as a pyridine nitrogen. The hydrogen bond donor 
character of a hydrazone could potentially be reproduced using heterocycles such 
as pyrrole or pyrazole. 
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3.22. Synthesis of (hetero)aromatic amides as potential oxime mimics 
 
 The synthesis of the different library members was relatively 
straightforward and was usually achieved through amide bond formation between 
an aromatic or heteroaromatic carboxylic acid derivative and cystamine 53. A 
summary of structures, conditions and yields can be found in Table 12. Yields 
were generally good, except for compounds 146, 148, 152, 158 and 162. The low 
yields obtained for 148, 152 and 162 were mostly attributed to poor solubility of 
both the starting materials and products. AlMe3-mediated amide bond formation 
between esters and cystamine were capricious, and afforded 146 and 158 in low 
yields. Carboxylic acids and benzoyl chloride were all obtained from commercial 
sources. Ethyl 1H-pyrrole-3-carboxylate 145 and methyl pyrimidine-2-
carboxylate 157 were prepared according literature procedures.
213,214
 
 
H
N
O
S
(het)ArX
O
(het)Ar
2
X = OH, OAlkyl, Cl
H2N
S
S
NH2
4
 
Entry Starting material Conditions 
product 
yield 
Mimic 
139 Cl
O  
(i) 140, 95% reference 
141 OH
O
NO
 
(ii), (iii) 142, 62% 
N
O
R
O
H
N
 
143 OH
O
NHN
 
(ii), (iii) 144, 81% 
N
H
N
R
H
N
O  
145 OEt
O
HN
 
(iv) 
146, 27% 
(69% brsm) 
N
H
N
R
H
N
O  
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147 OH
O
HN
 
(ii), (iii) 148, 9% 
149 
N
OH
O  
(ii), (iii) 150, 64% 
N
O
R
H
N
O  
151 OH
O
O
 
(ii), (iii) 152, 20% 
153 OH
O
S
 
(ii), (iii) 154, 78% 
155 
N
OH
O  
(ii), (iii) 156, 80% 
N
O
R
H
N
O  
N
H
N
R
H
N
O  
157 N
N
O
O  
(iv) 158, 31% 
159 OH
O
OH
 
(ii), (iii) 160, 59% 
N
OH
H
N
O  
161 OH
O
OH
OH  
(ii), (iii) 162, 16% 
163 
N
OH
O
OH
 
(ii), (iii) 164, 53% 
 
N
OH
H
N
O
N
O
R
H
N
O
and
 
 
Table 12 - R = H, alkyl 
Conditions: (i) PhC(O)Cl, cystamine 53, Et3N, CH2Cl2, 0°C to rt, 20h; (ii) 
ArCOOH, EDC, HOBt, CH2Cl2, rt, 20 minutes; (iii) cystamine 53, Et3N, rt, 14-
40h; (iv) ArCOOR, cystamine 53, AlMe3, CH2Cl2, reflux, 24h 
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3.23. HDAC inhibition 
 
 Dimeric compounds were reduced with TCEP as described previously and 
the corresponding thiols were assayed against HDAC1 and HDAC6. The results 
are given in Table 13. Important trends emerged during our search for 
oxime/hydrazone mimics.  
 
HDAC1: Analogues bearing an H-bond acceptor in a 1,3 relationship with the 
amide were found to be only moderately potent (IC50s), as exemplified with furan 
152’ (12 μM) which was in the same range of potency as the reference compound 
140’ (3.7 μM), bearing a simple phenyl ring. Varying the polarisability of the 
acceptor, for example with a thiophene 154’ (6.0 μM) did not have a significant 
effect on potency. Introduction of the strong ζ-donor pyridine 150’ again did not 
lead to any improvement. Replacing the H-bond acceptor by a H-bond donor did 
not have any significant influence. Indeed, pyrrole 146’ (7.2 μM) and indole 148’ 
(2.1 μM) still displayed potencies comparable to reference compound 140’ (3.7 
μM).  
 In contrast, analogues bearing a hydrogen bond acceptor, typically a 
nitrogen, in a 1,2 relationship with the amide were found to be more potent than 
the corresponding analogues lacking this nitrogen in each case. This is clear when 
comparing potencies of analogues 152’ (11.8 μM) vs. 142’ (0.51 μM), 146’ (7.2 
μM) vs. 144’ (0.48 μM), 140’ (3.8 μM) vs. 156’ (0.15 μM) and 160’ (2.0 μM) vs. 
164’ (0.24 μM). In particular, 156’ (0.15 μM) was the best HDAC1 inhibitor and 
was 25 times more potent than reference compound 140’ (3.8 μM). 6-Membered 
ring systems were found to give increased potency compared to 5-membered 
ones. Indeed, both pyridine 156’ (0.15 μM) and pyrimidine 158’ (0.22 μM) were 
slightly more potent than isoxazole 142’ (0.51 μM) and pyrazole 144’ (0.48 μM). 
In addition to the differences in electronic properties, this could be related to the 
value of the C-C=N angle and therefore the spatial position of the nitrogen respect 
to other functional groups on the molecule. 
 The o-hydroxy substituent of 160’, designed to imitate an isomerized ((Z) 
geometry) was not found to be significantly more potent than reference compound 
140’. However, functionalisation of both ortho positions led to a slight increase in 
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potency, compound 162’ (0.61 μM) being 3 and 6 times more potent than 160’ 
(2.0 μM) and 140’ (3.7 μM) respectively.  
 
 As seen previously, analogues bearing an sp
2
 nitrogen adjacent to the 
amide were found to be very potent and selective against HDAC1. Although the 
steric and electronic properties of an oxime/hydrazone and the heterocycles 
analysed are different, we hypothesise these compounds to bind to HDAC1 in a 
similar way to Psammaplin A. Thus, this study strongly suggests the potency and 
selectivity of the oxime unit of Psammaplin A to be mostly related to the effect of 
its nitrogen atom, rather than the H-bond donor character of its hydroxyl 
functionality. Indeed, every (hetero)aromatic unit employed to imitate the H-bond 
donor ability of an oxime, in both the (E) or (Z) geometry,  were found not to be 
significantly more active than the reference compound 140’. Taken together, these 
observations disfavour the model previously proposed in section 3, involving a 
monodentate Zn(II) coordination and a hydrogen bond between the oxime and 
Asp99 (HDAC1 numbering) at the entrance of the active site. The important 
difference in potency between 142’, 144’, 156’, 158’, 164’ and reference 
compound 140’ is likely to reflect the involvement of the nitrogen in specific 
interactions with HDAC1. 
 Interestingly, preliminary results suggest hit compounds, bearing a 
nitrogen atom in ortho position, to be highly selective for HDAC1 compared to 
HDAC6. This is clearly exemplified by 158’ and 164’, both displaying IC50s > 35 
μM against HDAC6, while being submicromolar inhibitors of HDAC1. 
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HDAC1 IC50s 
(μM) 
HDAC6 IC50s 
(μM) 
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3.8  Reference 
142’ 
NO
 
0.51  
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156’ 
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0.15  
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2.0  
 
N
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OH
OH  
0.61  
164’ 
N
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0.24 > 35 
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O
R
H
N
O
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Table 13 - HDAC inhibition data for (hetero)aromatic amide containing 
analogues 
 
 
3.24. Further SAR around N-(2-mercaptoethyl)picolinamide 156’ 
 
 Based on the SAR data around this new series, we decided to consider the 
potent and structurally simple inhibitor 156’ as a starting point for further 
investigation. New docking studies were performed using the crystal structure of 
HDAC2 (pdb 3MAX)
75
 and the best pose is presented in Figure 47 and Figure 48. 
In this model, the N-(2-mercaptoethyl)amide motif coordinates the Zn(II) cation 
in a bidentate way, as previously proposed for analogue 75d’ (Figure 41). 
Interestingly, VDW radii did not have to be decreased in order to allow the ligand 
to adopt this conformation. This can potentially be explained by the difference in 
size between the pyridine ring and the hydroxyiminophenylalanine motif of 75d’, 
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allowing easier access of ligand 156’ to the active site via the narrow entrance 
channel. As expected, no specific interaction between the pyridine nitrogen and 
the protein could be realised by docking, as the software is unable to predict the 
existence and position of potential structural water molecules or enzyme 
dynamics. According to this model, substituents in positions 2, 3 and 4 should be 
tolerated, and substituents in position 5 would be expected to induce a steric clash 
with the enzyme and therefore a drop in potency. 
 
 
 
Figure 47 - Left: ligand 156’ (dark grey, stick representation) docked in the active 
site of HDAC2 (green, ribbon representation). Zn(II) (grey sphere) is visible; 
right: ligand 156’ (sticks representation) docked in the active site of HDAC2 
(surface representation) 
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Figure 48 - Left: bidentate binding mode proposed for the N-(2-
mercaptoethyl)acetamide motif of 156’ (dark grey: carbon, white: hydrogen, red: 
oxygen, blue: nitrogen, yellow: sulfur; stick representation). Hydrogen bonds of 
interest with the protein (green: carbon, white: hydrogen, red: oxygen, blue: 
nitrogen; stick representation) are highlighted in orange; right: backview of ligand 
156’ in the active site of HDAC2. Hydrogen bonds of interest are highlighted in 
orange 
 
 
 Based on this new model, we hypothesized that careful introduction of 
aromatic substituents may have an influence on the potency against HDAC1 
(Figure 49). In addition to steric considerations, the introduction of electron 
withdrawing groups (EWG) would be expected to induce a decrease of the 
electronic density of the ring and notably the pyridine nitrogen. Conversely, 
introduction of electron donating groups (EDG) may counterbalance the 
deactivating effect of the electron-withdrawing amide and increase the electronic 
density of the ring, which should potentially strengthen any proposed H-bonding 
with the pyridine nitrogen. 
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 For a preliminary study, a chlorine or amine as substituent was chosen. 
Indeed, the electronegative chlorine was thought to be a particularly good 
deactivating group, moreover a number of chloropyridine carboxylic acids are 
commercially available and inexpensive. On the contrary, the strong +M effect of 
amine substituents should be particularly efficient for increasing the electronic 
density of the ring. Simple methylamine and dimethylamine were therefore 
chosen as model substituents. Variation of the amine substitution pattern should 
not only inform on the electronic influence on potency, but also the effect of 
substituents size in relation to its location. 
 
 The synthesis of target compounds is described in Scheme 36. EDC-
mediated coupling of chloropyridine carboxylic acids 165-167 with cystamine 53 
afforded analogues 168-179 in moderate to good yields. Subsequent SNAr 
afforded the corresponding amino derivatives 171-176. In each case, substitution 
on position 4 was found to be more efficient, due to the increased stabilisation by 
the pyridine nitrogen. Substitution at positions 2 and 4 with methylamine afforded 
174 and 176 in low yields, owing to the lower reactivity of methylamine, but also 
possibly due to oligomerisation. Substitution with either methylamine or 
dimethylamine led to degradation when attempted on position 3. 
 
168, 2-Cl, 66%
169, 3-Cl, 69%
170, 4-Cl, 42%
3
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Cl
(i), (ii)
Reagents and conditions:
(i) EDC, HOBt, CH2Cl2, rt, 20 minutes
(ii) cystamine 53, Et3N, rt, 24h
(iii) H2NMe or HNMe2 (40% w/w in water), THF, microwave, 160°C
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172, 3-NMe2, degradation
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167, 4-Cl
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S
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Scheme 36 
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Since introduction of amine substituents in position 3 was unsuccessful by SNAr, 
other conditions were attempted. An Eschweiler-Clarke reaction between 5-
aminopicolinic acid 177, formic acid and formaldehyde as previously described
215
 
afforded 5-(dimethylamino)picolinic acid 178, which was then coupled with 
cystamine and afforded analogue 179 in 13% yield after 3 steps.  
 
N
OH
O
(i)
Reagents and conditions:
i) HCOOH, HCHO, reflux, 2.5h
(ii) EDC, HOBt, CH2Cl2, rt, 20 minutes
(iii) cystamine 53, Et3N, rt, 24h, 13% 3 steps
(ii), (iii)N
OH
O
N
H
N
O
S
2
H2N
S
S
NH2
53
H2N N N
177 178 179
 
Scheme 37 
 
 In order to study the influence of substitution in position 5 (Figure 49), 
two analogues were synthesised (Scheme 38). EDC mediated coupling between 3-
methylpicolinic acid 180 and cystamine 53 afforded 5-methyl substituted 
analogue 181 in high yield. Double methylation of 3-hydroxypicolinic acid 182 
using methyl iodide and silver oxide afforded methyl 3-methoxypicolinate 183 in 
31% yield. Hydrolysis under basic conditions, followed by EDC-mediated amide 
bond formation with cystamine 53 afforded 5-methoxy substituted analogue 184 
in 31% yield over 2 steps. 
 
N
OH
O
(iii),(iv)
Reagents and conditions:
(i) EDC, HOBt, CH2Cl2, rt, 20 minutes
(ii) cystamine 53, Et3N, rt, 24h, 31% 2 steps
(iii) MeI, Ag2O, 1:1 CH2Cl2/DMSO, rt, 48h, 31%
(iv) 1N aq. KOH, MeOH, rt, 12h
(i),(ii)N
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O
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Scheme 38 
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3.25. HDAC inhibition 
 Dimeric compounds were reduced with TCEP as described previously and 
the corresponding thiols were assayed against HDAC1 and HDAC6. The results 
are given in Table 14.  
 
HDAC1: Chlorinated pyridines 168’-170’ were found highly potent (IC50) against 
HDAC1. In particular, analogue 168’ (0.021 μM) was found 7 times more active 
than the reference pyridine compound 156’ (0.15 μM). In contrast, introduction of 
amines in positions 2, 3 or 4 did not lead to any improvement in potency, as 
exemplified by analogues 171’, 179’, 173’ and 176’ being similarly potent or 
slightly less potent (0.17-0.54 μM) than 156’. Finally, substitution of position 5 
with a methyl or a methoxy group did not have a dramatic influence on potency. 
 
 While introduction of the electronegative chlorine led to a 7-fold increase 
in potency, introduction of the electron-donating amines did not lead to any 
improvement, suggesting the electronic properties of the pyridine ring to be of 
importance. Moreover, it seems the position of the chlorine (2, 3 or 4) does not 
have a dramatic influence, and affords a highly potent compound in each case. At 
this time, the reasons for these observations are still unclear and subject to further 
investigation. 
 
Ar
H
N
O
SH
 
 
Compound Ar 
HDAC1 IC50s 
(μM) 
HDAC6 IC50s 
(μM) 
156’ 
(reference) 
N
 
0.15  
168’ 
N
Cl
 
0.021  
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169’ 
N
Cl
 
0.087  
170’ 
N
Cl
 
0.052  
171’ N
N
 
0.54  
179’ 
N
N
 
0.42  
173’ 
N
N
 
0.29  
174’ N
NH
 
  
176’ 
N
HN
 
0.17  
181’ 
N
 
0.45  
184’ 
N
O
 
0.22  
Table 14 - HDAC inhibition data for substituted pyridine containing analogues 
 
 In conclusion, our search for oxime mimics led us to the discovery of 
structurally simple and highly potent pyridine containing compounds against 
HDAC1 (Figure 50). New computational studies, in addition to biological 
assessment of these compounds against HDACs led us to propose several 
alternative binding modes for Psammaplin A and analogues. Interestingly, the 
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isoform selectivity (HDAC1 and 6) previously observed for Psammaplin A was 
retained with our new inhibitors, which represent a highly valuable advantage for 
the further development of isoform selective probes for in vivo investigation. The 
establishment of a more accurate isoform selectivity profile for these inhibitors is 
in progress. In particular, assessment of selected analogues (156’ and 168’) 
against other HDAC isoforms, notably HDAC7 and HDAC8, will be reported in 
future manuscripts. 
H
N
O
SH
H
N
O
SH
N
140' 168'
Cl
 
 
 
Figure 50 - progress achieved in our search of novel isoform selective inhibitors 
 
 
3.3. Current/future work and conclusions 
 
 Current work (Figure 51, general structure 185’) is involving further 
variation of the aromatic substitution pattern and its influence on potency. In 
particular, other halogens (Cl vs F, Br, I), deactivating groups (e.g. NO2, CO2R) 
and electron donating groups (e.g. NR2, OR, alkyl) will be probed in order to draw 
a robust SAR around this pyridine series and improve the potency of our 
compounds. 
H
N
O
SH
N
156'
H
N
O
SH
N
185'
R
H
N
O
ZBG
N
186
R = EDG, EWG, small, bulky
 
Figure 51 - current work 
 
 In parallel, a number of more drug like chemical functionalities will be 
probed with a view to replacing the thiol moiety of our compounds, while 
IC50 = 3.8 μM (HDAC1) 
MW = 181.3 g/mol 
IC50 = 0.021-0.087 μM (HDAC1) 
MW = 216.7 g/mol 
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retaining potency (Figure 51, general structure 186). For this purpose, the simple 
pyridine derivative 156’ will be used as a starting point. The presence of the thiol 
in our pyridine based analogues is very important for potency, as similarly 
observed previously in section 3 for Psammaplin A derivatives. Indeed, whereas 
the reduced form of Psammaplin A (28’) was highly potent (IC50) against HDAC1 
(0.0009 μM), its methylthioether analogue 75a was 8500 times less active (7.7 
μM). Interestingly, while the potency of 75a was low, it proved that low 
micromolar potency is potentially achievable using a ZBG as weak as a 
methylthioether. The discovery of potent HDAC inhibitors not primarily relying 
on their ability to strongly bind to the active site zinc would represent a major 
advance in the field of HDACis. Indeed, the potency of most HDACis reported in 
the literature relies on the presence of a strong ZBG (e.g. hydroxamic acid, thiol, 
electrophilic ketone...), which possibly contributes to their usual toxicity and 
possible off-target effects. 
 
 We envisage the current study has the potential to lead to the discovery of 
new small molecule HDAC inhibitors whose potency does not involve zinc 
coordination as the principal factor for binding. In particular, we hope that 
optimisation of the pyridine substitution pattern in combination with a weak zinc 
binding group will lead us to the discovery of submicromolar selective HDAC1 
inhibitors. This would be unprecedented and would represent a highly valuable 
tool not only for the development of selective probes for in vivo studies, but also 
for the discovery of potential drug candidates for clinical trials. Results of this 
study will be reported in further manuscripts.  
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4. Towards photoswitchable HDAC inhibitors 
 
4.1.  Introduction 
 
 Cellular processes are mediated by a myriad of complex and intricate 
biochemical pathways, involving thousands of biomolecules interacting with each 
other in a temporal and spatial manner. As such, probing the spatiotemporal roles 
of a biomolecule in its native environment is highly challenging. The use of light 
as a means to control biomolecules is of particular interest, since irradiation of 
samples can be controlled with high spatial and temporal precision. Moreover, 
technological advances during the last decades allowed for routine access to a 
variety of light sources with accurately adjusted wavelength, power and delivery 
mode. 
 In this context, the development of systems which allow the control of 
biological processes using light has become an increasingly attractive area of 
research during the last decades.
216
 A number of chemical functionalities have 
been reported to allow a variety of effects to be produced in vivo as a result of 
light irradiation. Well-known examples of photoresponsive systems include 
porphyrin-based metal complexes and azobenzene derivatives
217
 (Figure 52). 
Upon irradiation, porphyrin complexes are able to catalyse oxidoreduction 
reactions and are notably able to convert triplet oxygen (
3
O2) into cytotoxic singlet 
oxygen (
1
O2). Irradiation of azobenzene induces a cis/trans isomerisation, which 
can be exploited to modify the conformation of biological systems and therefore 
influence their behaviour. Another example of light-sensitive systems which have 
found applications in biology are caged organic molecules, whose effect is 
revealed after cleavage of a photo-labile group with light.
218
 
 In particular, a number of studies aimed at controlling biological systems 
using photoswitchable azobenzene containing small molecules have shown 
significant success. The photocontrol of biological processes using azobenzene 
functionalities is usually achieved via either covalent introduction of the 
photoswitch into the biological system (e.g. protein) itself, or via the development 
of azobenzene containing small molecules able to interact with this biological 
system.  Recent examples include notably the development of photochromic ion 
channel ligands,
219
 photoswitchable oligonucleotides, lipids and carbohydrates.
217
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Figure 52 - Examples of photoresponsive systems; Left: photoinduced generation 
of singlet oxygen using porphyrin derivatives. Grey: carbon; blue: nitrogen; 
white: hydrogen; orange: metal; Right: cis/trans azobenzene photoisomerisation. 
Grey: carbon; blue: nitrogen; white: hydrogen 
 
 
 While controlling biological systems with light represents a powerful tool 
for probing the role of biomolecules in vivo, important downstream applications 
are possible in therapy. One of the most famous applications of photoresponsive 
systems in the clinic is the development of the concept of “photodynamic 
therapy”. 
 
Photodynamic therapy: 
 
 “Photodynamic therapy” (PDT) refers to the use of a ligh-sensitive drug 
(photosensitiser, PS) in combination with light in order to destroy a particular 
subset of target cells (e.g. cancerous cells).
220
 PDT can be used as a primary 
treatment or in conjunction with others such as chemotherapy, radiotherapy or 
surgery. PDT has been used in the treatment of various invasive and non-invasive 
tumours, age-related macular degeneration, cardiovascular disease, psoriasis, acne 
vulgaris and viral warts.
221
 In particular, an important number of studies have 
been focusing on the development of porphyrins inspired PS for PDT.
216,222
 Upon 
irradiation in cells, these compounds are able to generate 
1
O2 and other highly 
reactive and cytotoxic oxygenated species (e.g. H2O2).
223
  
 
PDT involves several steps (Figure 53): i) administration of the PS into the 
organism, ii) accumulation of the PS into the target cell population, iii) irradiation 
3
O
2 
1
O
2 
λ1 
 λ2 
 
 
λ 
 
 
Towards novel small molecule epigenetic inhibitors Results and discussion 
119 
 
of the tumour with a regulated dose of light, and at an adequate wavelength, iv) 
activation of the drug upon irradiation and subsequent induction of the cytotoxic 
effect. Wavelengths between 600 and 1200 nm are particularly efficient for 
penetrating living tissues. Highly energetic (e.g. UV, X-ray, γ-ray) wavelengths 
should be avoided in order to prevent damaging of neighbouring tissues. 
 
Figure 53 - Principle of PDT 
 
 One particular advantage of using PDT lies in the possibility to achieve 
high regioselectivity for tissue targeting. Indeed, provided the PS is not 
intrinsically cytotoxic, only the irradiated areas (e.g. tumour) will be affected.  
 PDT is considered to be a new and promising strategy for cancer 
treatment. While a number of PSs have already been evaluated in clinical trials, 
the full potential of the PDT approach is still to be shown, alone or in combination 
with other therapies. As previously mentioned, the vast majority of currently 
developed PSs are porphyrin derivatives.
216
 In this study, we were particularly 
interested in the design and synthesis of novel light-responsive small molecules 
with the view in the long term to develop new agents for PDT. We were 
particularly interested in developing new molecules which cytotoxicity upon 
irradiation in cell does not rely on 
1
O2 formation. Indeed, while hundreds of these 
compounds (e.g. porphyrin based) have been reported, the use of non-porphyrin-
based PSs in PDT is severely undocumented. The development of such molecules 
could therefore open the door to a number of new agents for PDT, with novel 
modes of action. 
 
PS administration 
PS distribution 
PS accumulation in 
target cells 
PDT 
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4.2.  Results and discussion 
 
4.21. Design of photochromic HDAC inhibitors 
 
 Based on our high interest in HDACs, we decided to undertake a 
preliminary investigation in order to study the possibility of controlling HDAC 
activity in vitro with light. In the long term, the major goal of such a study is to 
develop novel azobenzene containing small molecules which would enable us to 
control HDAC activity in cells using light, and possibly reprogramme gene 
expression as a downstream consequence of irradiation. Ultimately, optimisation 
of such a system would be of interest for the development of the concept of 
“epigenetic photodynamic chemotherapy” (EPDCT) against cancer. In particular, 
photocontrolled reactivation of important genes, such as TSGs, could be of 
particular interest for inducing cell cytotoxicity in cancer cells. While an 
important number of small molecule PSs are based on the generation of singlet 
oxygen, the development of epigenetic modulator PSs and applications in PDT 
have never been reported. 
 We therefore decided to conduct a proof of concept study in vitro, through 
the derivatisation of simple ligand 187 (Figure 54). 187 has been previously 
reported to inhibit HDAC activity.
224
 It contains a hydroxamic acid, which is 
thought to bind the Zn(II) cation in the active site of HDACs.  
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Figure 54 
 
 
 Docking studies using the crystal structures of HDAC2 (pdb 3MAX),
75
 
revealed the molecular features of 187 responsible for inhibiting its HDAC targets 
(Figure 55). The hydroxamic acid moiety complexes the zinc as previously 
reported.
76
 The two carbon linker positions itself in the hydrophobic channel and 
the aromatic ring is flanked between the two phenylalanine residues lying at the 
entrance of the active site. 
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Figure 55 - Left: 187 (dark grey, stick representation) docked in the active site of 
HDAC2 (green, stick representation, pdb 3MAX). The Zn(II) cation is shown as a 
grey sphere. Right: ligand 187 docked in HDAC2. The aromatic ring of 187 
positions at the entrance of the channel 
 
 For the photoswitch we chose an azobenzene moiety. The rationale behind 
this choice lies in the narrow channel within the HDAC active site. Indeed, the 
tubular pocket leading to the active site of HDACs is only 3-5Å wide and only 
ligands exhibiting a cross-section smaller than the diameter of the entrance 
channel are therefore able to bind. Introduction of an azobenzene at the level of 
the aromatic ring of 187 would ideally position it at the entrance of the tubular 
channel. In an ideal case, while the trans isomer of the inhibitor would be able to 
inhibit the HDAC, the cis isomer would induce a steric clash with amino acids 
lining the channel (Figure 56) and decrease the stability of the whole complex. 
Rigorously, the two different isomers should exhibit different affinities, and we 
hoped this difference in affinity to be important enough to observe a significant 
alteration of the enzyme activity/inhibition upon switching. 
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Figure 56 - Left: trans-201 (dark grey, stick representation) and cis-201 
(magenta) docked in the active site of HDAC2 (blue, surface representation). Left: 
trans-202 (dark grey, stick representation) and cis-202 (magenta) docked in the 
active site of HDAC2 (blue, surface representation) 
 
 The docking poses generated with HDAC2 (Figure 56) suggested the 
functionalisation of positions 1 and 2 to be particularly appropriate for a model 
study. Functionalisation of position 3 was thought not to be suitable, potentially 
sterically destabilising the enzyme-ligand complex for both isomers (Figure 56). 
 
4.22. Synthesis of azobenzene-hydroxamic acid conjugates 
 
 We therefore undertook the preparation of two derivatives of 187, 
derivatised with an azobenzene moiety in positions 1 and 2 respectively. The 
structures of the two derivatives 188 and 189 are given in Figure 57. A simple, 
unfunctionalised azobenzene moiety was chosen for this preliminary study, both 
for proof of concept and ease of synthesis. 
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 The retrosynthesis of compounds 188 and 189 is shown is Scheme 39. It 
was that thought 188 and 189 could be obtained via a cross coupling between an 
O-protected N-hydroxyacrylamide derivative 190 and a halogenated azobenzene 
derivative. Halogenated azobenzenes 191 should finally be accessed via the 
condensation of nitrosobenzene 192 with haloaniline 193 as previously 
reported.
219d
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Scheme 39 
 
 The synthesis of both compounds is shown in Scheme 40. Condensation of 
nitrosobenzene 192 with 3-iodoaniline 194 and 4-iodoaniline 195 afforded 
iodinated azobenzene compounds 196 and 197 respectively, in nearly quantitative 
yield. Coupling of 196 and 197 with N-(tetrahydro-2H-pyran-2-yloxy)acrylamide 
198 could be achieved in one step and in high yield via a Heck reaction, afforded 
intermediates 199 and 200. Heck reactions between aryl halides and N-
hydroxyacrylamide derivatives have already been reported.
225-227
 In particular, a 
similar Heck coupling between aryl bromides and 198 has already been reported 
by Bressi and co-workers during their research on new HDAC inhibitors.
227
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(i)
Reagents and conditions:
(i) AcOH, 50°C, 12h
(ii) 198, Pd(OAc)2, P(o-tol)3, Et3N, DMF, 100°C, 24h
(iii) cat. PPTS, 1:1 THF/i-PrOH, 50°C, 8h
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O O
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H
N
O
OH
(iii)
3-amino, 194
4-amino, 195
position 3, 196, quant.
position 4, 197, 94%
position 3, 199, 82%
position 4, 200, 79%
position 3, 201, 79%
position 4, 202, 76%
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O O
198  
Scheme 40 
 
 Final THP deprotection was achieved by using 0.1 eq. pyridinium p-
toluenesulfonate (PPTS) at 50°C in a 1:1 THF/i-PrOH mixture. These mild 
conditions afforded 3-diazo and 4-diazo substituted analogues in 79% and 76% 
yield respectively. This three step sequence allowed for the synthesis of 201 and 
202 in 65% and 56% overall yield respectively. Interestingly, this synthetic route 
was found to be particularly robust and easily scalable. The two first steps could 
be achieved on a multigram scale (196, 197: ~ 5.6 g; 199, 200: ~ 1.7 g). Starting 
from 500 mg of 199 and 200, 302 mg of 201 and 288 mg of 202 could be obtained 
as amorphous orange solids. Attempted recrystalisation, using a number of solvent 
systems, yielded an amorphous solid in each case. 
 The synthesis of the THP protected N-hydroxyacrylamide fragment 198 
was straightforward (Scheme 41). Acylation of O-(tetrahydro-2H-pyran-2-
yl)hydroxylamine 54
155
 with acryloyl chloride 203 afforded 198 in 60% yield. 
 
H
N
O
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O
H2N
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(i)
Reagents and conditions:
(i) Et3N, CH2Cl2, 0°C to rt, 24h, 60%
203 54
 
Scheme 41 
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4.23. HDAC inhibition 
 
 As a starting point for our study, the in vitro potency (IC50) of trans 
azobenzene containing analogues 201 and 202 against HDAC1 was determined. 
The results were obtained in collaboration with Pr. Franz-Josef Meyer-Almes 
(University of Applied Sciences, Darmstadt, Germany) and are given in Table 15. 
Trans isomers 201 and 202 exhibited submicromolar IC50s against HDAC1. 
 
Compound Structure 
HDAC1 IC50s 
(μM) 
201 
H
N
O
OHN
N
 
0.186 
202 H
N
O
OH
N
N
 
0.478 
 
Table 15 
 
 
4.24. Photophysical study of 201 and 202 
 
 The photophysical properties of 201 and 202 in solution (DMSO) were 
then studied in collaboration with Dr. Marina Kuimova (Department of 
Chemistry, Imperial College London). All data were obtained in collaboration 
with Dr. Marina Kuimova (Imperial College London). The UV-Vis spectra of 
pure trans-201 and trans-202 are shown in Figure 58. All samples were prepared 
in the dark prior to irradiation. Absorption maxima around 350 nm could be 
observed for both compounds (Table 16). λmax and εmax for 201 and 202 are given 
in Table 16. 
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Figure 58 - UV spectra in of 201 and 202 in their pure trans state (DMSO, C = 5 
x 10
-5
 M, 293K). X-axis: wavelength (nm), Y-axis: absorbance 
 
 
 λmax (nm) εmax (L.mol
-1
.cm
-1
) 
201 324 20800 
202 353 28800 
 
Table 16 
 
 We then studied the photophysical properties of 201 and 202 upon 
irradiation. As previously mentioned, irradiation of azobenzene derivatives at a 
given wavelength rarely induces a quantitative trans→cis photoisomerisation, but 
generally affords a mixture of both isomers at the photostationary state (PhS). 
Both compounds were irradiated at 355 nm, close to their maximum absorption, 
and UV spectra were recorded at regular intervals (Figures 59 and 60). In these 
conditions, the photostationary state was reached after only a few minutes in both 
cases. In particular, it was nearly reached after 2 minutes in the case of 202. A 
clear isobestic point could be observed at approximately 320 nm in the spectrum 
of 202. A significant decrease in the absorption in the 350 nm region could be 
observed in each case, illustrating the photoconversion of the trans compounds. 
Notably, a new absorption maximum at 302 nm could be observed for 202. 
0 
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Figure 59 - UV spectrum of 201 as a function of irradiation time at 355 nm 
(DMSO, C = 5 x 10
-5
 M, 293K, 20 mW). X-axis: wavelength (nm), Y-axis: 
absorbance. 
 
Figure 60 - UV spectrum of 202 as a function of irradiation time at 355 nm 
(DMSO, C = 5 x 10
-5
 M, 293K, 20 mW). X-axis: wavelength (nm), Y-axis: 
absorbance. 
 
 The reversibility of this system was then studied. Following irradiation at 
355 nm (Figures 59 and 60), it was found that irradiation of the same cuvettes at 
430 nm displaced the photostationnary state back towards the trans isomer 
(Figures 61 and 62). The new photostationary states were rapidly reached in both 
cases. It was notably nearly reached in 2 minutes in the case of 202 (Figure 62). 
While the absorption of 201 and 202 at 430 nm is low and does not change 
significantly as a function of irradiation (Figures 59 and 60), the photochemical 
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isomerisation under irradiation at this wavelength is likely to reflect a higher 
quantum yield for the cis→trans transition. Interestingly, reversibility of this 
system could be illustrated by performing two successive isomerisation cycles 
(trans→cis→trans→cis, data not shown) without significant degradation of the 
system observed by UV. 
  
Figure 61 - UV spectrum of 201 as a function of irradiation time at 430 nm, 
starting from the photostationary state reached under irradiation at 355 nm (PhS 
355 nm, t0), see Figure 59 for comparison. (DMSO, C = 5 x 10
-5
 M, 293K, 20 
mW). X-axis: wavelength (nm), Y-axis: absorbance. The spectrum of pure trans-
201 is given as a reference 
 
Figure 62 - UV spectrum of 202 as a function of irradiation time at 430 nm, 
starting from the photostationary state reached under irradiation at 355 nm (PhS 
355 nm, t0), see Figure 60 for comparison. (DMSO, C = 5 x 10
-5
 M, 293K, 20 
mW). X-axis: wavelength (nm), Y-axis: absorbance. The spectrum of pure trans-
202 is given as a reference 
0 
0.5 
1 
1.5 
2 
2.5 
3 
250 350 450 550 
pure trans 
PhS 355 nm 
30s 
60s 
90s 
150s 
480s 
570s 
0 
0.5 
1 
1.5 
2 
2.5 
3 
250 350 450 550 
pure trans 
PhS 355 nm 
30s 
60s 
90s 
180s 
390s 
570s 
Towards novel small molecule epigenetic inhibitors Results and discussion 
129 
 
 Following irradiation at 355 nm (Figures 59 and 60), laser promoted 
cis→trans isomerisation could also be achieved using a different, higher 
wavelength. Indeed, while the absorption of 201 and 202 at 532 nm is low and 
does not change significantly as a function of irradiation (Figures 59 and 60), 
cis→trans isomerisation could be observed (Figures 63 and 64).  
 
Figure 63 - UV spectrum of 201 as a function of irradiation time at 532 nm, 
starting from the photostationary state reached under irradiation at 355 nm (PhS 
355 nm, t0), see Figure 59 for comparison. (DMSO, C = 5 x 10
-5
 M, 293K, 20 
mW). X-axis: wavelength (nm), Y-axis: absorbance. The spectrum of pure trans-
201 is given as a reference 
 
Figure 64 - UV spectrum of 202 as a function of irradiation time at 532 nm, 
starting from the photostationary state reached under irradiation at 355 nm (PhS 
355 nm, t0), see Figure 60 for comparison. (DMSO, C = 5 x 10
-5
 M, 293K, 20 
mW). X-axis: wavelength (nm), Y-axis: absorbance. The spectrum of pure trans-
202 is given as a reference 
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 While irradiation at 532 nm allowed for the photoreversion of both 
systems after reaching the first photostationary state at 355 nm, it was found less 
efficient than irradiation at 430 nm (Table 17). Indeed, the absorbance at 324 nm 
(maximum absorbance of pure trans 201) under 532 nm irradiation was lower 
(0.80) than under irradiation at 430 nm (0.92), directly reflecting a lower 
proportion of trans 201. In a similar way, the absorbance at 353 nm (maximum 
absorbance of pure trans 202) under 532 nm irradiation was lower (1.19) than 
under irradiation at 430 nm (1.25). Taken together, these data showed the slightly 
higher efficiency of the 430 nm wavelength for the cis→trans process in each 
case. 
 A324 (PhS 430 nm) A324 (PhS 532 nm) A353 (PhS 430 nm) A353 (PhS 532 nm) 
201 0.92 0.80   
202   1.25 1.19 
 
Table 17 
 
 
4.25. Current and future work 
  
Determination of cis/trans ratios at photostationary states 
 
 We are currently performing studies in order to determine the proportions 
of cis-201 and cis-202 formed at the different photostationnary states, and 
extrapolate their UV-vis spectra using the method developed by Fischer.
228
 This 
method allows the determination of the proportions of two related species at a 
given photostionary state when only the UV-vis spectrum for the pure starting 
material and the spectra of the mixture of the two species at two different 
photostationary states are known. This method has already been successfully 
applied in the context of diazobenzenes.
219d
 Preliminary data (not shown) suggest 
a conversion higher than 80% for the trans to cis photoisomerisation at 355 nm, 
demonstrating the efficiency of the process. Results of the full study will be 
reported in future manuscripts. 
 
Towards novel small molecule epigenetic inhibitors Results and discussion 
131 
 
Half-life of thermal relaxation 
 
While we demonstrated the efficient reversibility of our systems by using the 
appropriate wavelength for irradiation, their cis→trans thermal relaxation has not 
been thoroughly studied. Preliminary NMR experiments suggested the cis state to 
exhibit a relatively long half-life of thermal relaxation. A solution of 202 (~ 15 x 
10
-3
 M) in d
6
-DMSO was irradiated at 350 nm for 6 hours using a custom set up. 
The photostationary state could not be reached in these conditions, likely due to 
the high concentration of the sample and reduced power of the UV source 
compared to the laser source used for previous studies. However, a new set of 
signals corresponding to the cis isomer was unambiguously observed. Recording 
NMR spectra at different time intervals after irradiation and integrating the NMR 
signals of cis and trans 202 as a function of time (Figure 66) allowed us to obtain 
a first approximation of the thermal stability of cis-202 in DMSO. The spectrum 
of pure trans-202 is shown in Figure 65. 
 
 
Figure 65 - NMR spectrum of 202 in the pure trans state (before irradiation) 
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t0 (before irradiation) 
 
 
 
t0 (after 6h irradiation) 
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Figure 66 - Time dependent NMR spectrum of a mixture of trans and cis 202 
obtained after 6 hours irradiation. Signals corresponding to HA and HA‟ (top) were 
integrated and normalised to 1 in respect to trans-202 
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 Integration of HA and HA’ signals (Figure 66) gave the proportions 
(%) of cis and trans isomers in solution (Table 18). However, it is of note that 
complete thermal relaxation could not be achieved at rt after more than 40 h. 
 
 
t (h) 
Integration 
(Trans) 
Integration 
(Cis) 
%trans %cis 
0 (before irradiation) 1 0 100 0 
0 (after irradiation) 1 0.49 67 33 
0.033 1 0.49 67 33 
0.066 1 0.49 67 33 
3.5 1 0.38 72 28 
15.2 1 0.25 80 20 
23.7 1 0.21 83 17 
34.2 1 0.15 87 13 
40.3 1 0.14 88 12 
 
Table 18 - Integration of NMR signals for HA and HA’ (Figure 66) and 
determination of the proportion (%) of cis-202 in solution as a function of time (h) 
 
 
A simple plot of the concentration of cis-202 versus time allowed us to fit the data 
to a single exponential (Figure 67) with an equation of type: 
 
Ccis (t) = Ccis0 . e
-t/η
      (1) 
 
This gave an approximate τ ≈ 42 h.  
 
t1/2 = τ . ln(2)              (2) 
 
The value determined for τ was then introduced in equation (2), affording a half-
life of thermal relaxation for cis-202      t1/2 ≈ 29 hours (Figure 69). 
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Figure 67 - Thermal relaxation of cis-202 at room temperature (20°C). The 
relative concentrations of cis-202 in solution, obtained from NMR (Figure 66) 
were plotted versus time. X-axis: time (h), Y-axis: concentration of cis-202 (a.u.) 
 
 
 While these data allowed for an approximate determination of the half-
life of cis-202, more accurate UV studies are underway in order to confirm this 
value, in addition to determining the half-life of cis-201. 
 
 
In vitro and in vivo potency of cis-201 and cis-202 against HDAC1 
 
 The first step following completion of the photophysical study of 201 and 
202 in solution (DMSO, H2O, buffer) will consist of the evaluation of the potency 
of cis-201 and cis-202 against HDAC1 in vitro. In a second step, the cytotoxicity 
of 201 and 202 as a function of irradiation will be studied (Figure 68). We hope to 
observe a differential potency between cis and trans isomers in vitro that could be 
exploited to modulate the cytotoxicity of 201 and 202 with light. Results on these 
preliminary studies will be presented in future reports. 
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Figure 68 
 
 
4.3.Conclusions 
 
 In conclusion, we have developed two new photoswitchable HDAC 
inhibitors which combine a hydroxamic acid as a ZBG and an azobenzene unit in 
the cap region. UV-vis studies demonstrated these inhibitors to be light-
responsive, efficiently isomerising from trans to cis (and vice versa) under light 
irradiation. Studies are in progress in order to determine the cis/trans ratios at the 
different photostationnary states, in addition to the half times of thermal relaxation 
of the cis isomers. Further studies are in progress in order to evaluate the HDAC 
inhibitory potency of the cis compounds in vitro, possibly using the corresponding 
alkenes as model systems. Finally, the cytotoxicity of 201 and 202 as a function of 
irradiation will be evaluated in the near future. It is hoped that a significant 
difference in cytoxicity will be observed upon irradiation of these compounds at 
different wavelengths. Such a study would be unprecedented in the field of 
HDACis. This would potentially open the way towards novel photoswitchable 
HDACis as candidates for photodynamic chemotherapy. 
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5. Development of new probes for a Fluorescence Resonance 
Energy Transfer (FRET) based inhibitor assay for histone 
deacetylases 
 
5.1. Introduction 
 
 Elucidation of the molecular mechanisms leading to HDAC inhibition by 
HDACis is of crucial importance not only for the development of new probes for 
the understanding of the role of individual HDAC isoforms but also to improve 
our knowledge for the rational design of novel, potent and selective inhibitors for 
anticancer therapy. Progress in this field is mainly dependent on the efficiency of 
the methods available for inhibitor screening and access to information regarding 
the molecular mechanisms of binding of these inhibitors to HDACs. In particular, 
access to thermodynamic parameters for inhibitor binding is complementary of 
conventional functional assays. Indeed, while commonly used functional assays 
provide information regarding the structural features responsible for the activity of 
an inhibitor, they do not provide informations regarding the binding energy (ΔG) 
and its components (ΔH and ΔS). Access to these parameters is crucial for a 
deeper understanding of the nature of the interactions involved in the enzyme-
ligand complex. In particular, access to thermodynamic data is important for the 
optimization of the thermodynamic signature of an inhibitor. Indeed, inhibitors 
should exhibit more enthalpic (ΔH) than entropic (ΔS) characteristics, reflective 
of specific (such as H-bonds) rather than non-specific (hydrophobic) interactions. 
In addition to thermodynamic data, a binding assay can give access to crucial data 
not accessible via conventional functional assays, such as binding kinetics and 
residence time of inhibitors in a binding pocket. Such tools are of high interest for 
the rational optimisation of lead compounds. 
 
 In 2007, Pr. F-J. Meyer-Almes reported a new binding assay for HDACs 
presenting a number of advantages over previously reported assays. This assay is 
particularly well suited for the study of the binding and dissociation kinetics of 
HDACis, in addition to the screening of compound libraries.
229
 Initially developed 
using histone deacetylase like amidohydrolase (HDAH),
178,179
 this nonisotopic 
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assay is based on FRET between the intrinsically fluorescent tryptophan residues 
of the enzyme and the fluorescent ligand 2-furylacryloylhydroxamate (FAHA) 
(204, Figure 69). Binding of FAHA to HDAH causes a FRET signal (Figure 69) 
leading to a decrease of the tryptophan fluorescence of HDAH (λem = 350 nm) and 
an increase of FAHA fluorescence.  
 
 The intensity of the FRET is dependent on the amount of FAHA bound to 
the enzyme, therefore the ratio of the fluorescence intensities (FIs) FIFAHA/FI350 
can be directly related to the binding degree (BD) of FAHA to HDAH. As a 
consequence, it becomes possible to determine the corresponding dissociation 
constant Kd and its temperature dependency by performing titration experiments 
under isothermal conditions at different temperatures. This gives access to the 
value of ΔG at different temperatures (eq. 1). 
 
ΔG (T) = - R . T . ln(1/Kd (T)) (1) 
 
 This temperature dependent study of Kd and ΔG allows a Van‟t Hoff plot 
of ΔG versus temperature, giving a straight line which intercepts the Y-axis at ΔH 
and whose slope is –ΔS (eq. 2) 
 
ΔG (T) = ΔH - TΔS  (2) 
 
 Determination of the thermodynamic parameters of FAHA further allows 
the determination of these parameters for a non fluorescent ligand, by engaging 
FAHA and the non fluorescent ligand in competition experiments. 
 
 In order to determine the Kd of a non-fluorescent ligand and its 
temperature dependency, a number of titration experiments must be performed. In 
such experiments, a complex of FAHA and HDAH is preformed. When the 
system reaches equilibrium, a titration is performed in which the concentration of 
the non-fluorescent ligand (e.g. SAHA) is increased. Increasing the concentration 
of the non fluorescent ligand leads to a decrease of the FRET signal due to the 
displacement of the bound FAHA. Assuming that the displacement of FAHA 
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occurs competitively, it is possible to calculate the Kd of the non-fluorescent 
ligand from the EC50 of the titration curve. ΔG can subsequently be obtained from 
Kd (eq. 1). Performing titration experiments under isotherm conditions at different 
temperatures further allows a Van‟t Hoff plot of ΔG versus temperature, giving 
the parameters ΔH and ΔS (eq. 2). 
 
 While FAHA has been very useful tool for a proof of concept during the 
development of this assay, it suffers from a number of limitations. In the 
following section, the synthesis of new ligands expected to overcome these 
limitations, and preliminary results obtained with these ligands when introduced 
in the FRET assay will be given. 
 
Figure 69 - Overlay of the HDAH-SAHA structure (1ZZ1)
179
 and FAHA. FAHA 
and SAHA are shown as stick models colored by element (grey: carbon; red: 
oxygen; blue: nitrogen). The five intrinsic tryptophan residues (violet) and active 
site  Zn
2+
 (green) are highlighted. FAHA is superimposed with SAHA in the 
active site of the HDAH-SAHA complex. Distances (Angstroms) between the 
chromophores of the tryptophan residues and FAHA are shown. Reproduced and 
adapted from Sykora and Meyer-Almes.
230
 Upon binding, a FRET appears 
between the HDAH tryptophan and FAHA
229,230 
 
 
H
N
O
OH
O
FAHA (204)
Towards novel small molecule epigenetic inhibitors Results and discussion 
139 
 
5.2.  Results and discussion 
 
5.21. Design of the fluorescent conjugates 
  
 The general structure of the target compounds is shown in Figure 70 
(general structure 205). They combine a dansyl moiety expected to participate in 
FRET through interactions with tryptophan residues of the enzyme, and a 
hydroxamic acid moiety able to bind the zinc cation in the active site. In each 
case, the dansyl moiety and the ZBG are connected by simple, linear amino acids 
of various length. Dansyl derivatives are well known for their strong absorption 
maxima between 300 and 350 nm, which coincide with the emission wavelength 
of HDAC tryptophans, and therefore the dansyl group appeared to be optimal for 
our study. The use of a dansyl group is particularly advantageous in comparison to 
FAHA, because it allows the variation of the distance between the fluorescent 
moiety and the ZBG. Indeed, the distance between the ZBG and the fluorophore 
and consequently between the fluorophore and tryptophan residues of the enzyme 
is likely to have a significant influence on the FRET efficiency. Since FAHA has 
been shown to induce the expected FRET (Figure 69), variation of the distance 
between the acryloyl part and the furan ring (e.g. with an alkyl chain) is not 
possible, as it would abolish the fluorescence and therefore the FRET (Figure 70). 
This potentially limits the applicability of this assay to other HDAC isoforms, as 
the position of tryptophan residues is likely to differ according to the HDAC 
isoform considered (Figure 71). Consequently, introduction of alkyl chains of 
different length between the dansyl group and the ZBG was thought to present a 
particular advantage for the optimisation of the assay. Firstly, it should improve 
the FRET efficiency with HDAH and secondly it should broaden the versatility 
and applicability of this assay to other HDAC isoforms. 
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Figure 70 - general structure of target ligands (left). While variation of the chain 
length between the fluorophore (red) and the ZBG (blue) is easily achievable in 
the case of the new conjugates (left), it is difficult to achieve in the case of FAHA, 
as the fluorophore is directly connected to the ZBG 
 
 
Figure 71 - Crystal structures of HDAH (1ZZ1), HDLP (1C3S), HDAC2 
(3MAX) and HDAC8 (1T69) were aligned using Pymol. The relative positions of 
tryptophan residues in HDAH (yellow), HDLP (pink), HDAC2 (orange) and 
HDAC8 (red) are highlighted. For clarity, the cocrystalised ligands have been 
removed and only the structure of HDAH (1ZZ1, green, ribbon representation) is 
displayed. The Zn(II) cation is displayed as a grey sphere 
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5.22.  Synthesis of target compounds 
 
 The synthesis of the dansyl-hydroxamic acid conjugates was 
straightforward (Scheme 42). Condensation between commercially available 
dansyl chloride 206 and aminoacids 207-212 afforded sulphonamides 213-218 in 
58-85% yields. Further EDC mediated coupling with O-benzylhydroxylamine 
afforded hydroxamic acid precursors 219-224 in 48-92% yields. Final 
hydrogenolysis of the benzyl protecting group afforded the target conjugates 225-
230 in 57-85% yields. 
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(i) amino acid 207-212, NaOH, THF/H2O, rt, 1.5h
(ii) EDC, HOBt, CH2Cl2, rt, 30 minutes
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(iv) H2, Pd/C, MeOH, rt, 3h
N
S
O
O
NH
COOH
n
(ii), (iii)
N
S
O
O
NH
n
O
HN O
(iii)
N
S
O
O
NH
n
O
HN OH
213, n = 2, 59%
214, n = 3, 63%
215, n = 4, 67%
216, n = 5, 58%
217, n = 6, 81%
218, n = 7, 85%
219, n = 2, 85%
220, n = 3, 48%
221, n = 4, 72%
222, n = 5, 92%
223, n = 6, 82%
224, n = 7, 78%
225, n = 2, 83%
226, n = 3, 67%
227, n = 4, 69%
228, n = 5, 60%
229, n = 6, 85%
230, n = 7, 57%
H2N
COOH
n
206
207, n = 2
208, n = 3
209, n = 4
210, n = 5
212, n = 6
212, n = 7
 
Scheme 42 
 
 
5.3.  Preliminary results and conclusions 
 
 Preliminary experiments led by our collaborator F-J. Meyer-Almes and his 
group (University of Applied Sciences, Darmstadt, Germany) have successfully 
shown the appearance of a FRET signal between HDAH and our synthetic probes 
225-230. An example is shown in Figure 72. Upon addition of ligand 228, a new 
fluorescence signal could be clearly observed at 525 nm, confirming the 
efficiency of the FRET between HDAH and 228.  
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Figure 72 - Example: fluorescence emission spectra of HDAH and a HDAH-228 
complex. The solid line shows the fluorescence emission spectrum of 200 nM 
HDAH in FB188-buffer
178
 at 30° C. The dashed line shows the fluorescence 
emission spectrum of a mixture of 6.34 µM 228 and 200 nM HDAH in FB188-
buffer
178
 pH 8.0 at 30° C. Both samples were excited at 285 nm using the same 
instrument settings 
 
 Optimisation of the assay parameters is underway, and Kds, ΔGs, ΔH and 
ΔS for each probe are currently being determined against HDAH. Preliminary 
experiments allowed for the determination of thermodynamic data for common 
HDACis such as SAHA (data not shown) and will be extended to a number of 
other inhibitors in the near future. Interestingly, preliminary studies using SAHA 
(data not shown) revealed the binding of this well known inhibitor to HDAH to be 
mostly due to entropic factors, rather than enthalpic, highlighting possible reasons 
for its lack of selectivity among HDAC isoforms. Once the assay is fully 
established and operational on HDAH, it will be extended to other human HDAC 
isoforms. In particular, we expect this assay to provide information regarding the 
thermodynamic signature of Psammaplin A and other synthetic analogues 
described in previous chapters. Such information would not only enable us to shed 
light on their binding mode, but also help us in the discovery and design of novel 
inhibitors displaying high enthalpic contribution to binding as starting points for 
lead optimisation. All results regarding this study will be reported in future 
publications. 
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6. Chemoproteomics of HDAC8 
 
6.1.  Introduction 
 
 While epigenetics is a very active area of scientific research, there is still 
much progress to be made in understanding the complex and inter-related 
signalling pathways mediated by epigenetic enzymes, including HDACs. 
Specifically, a deeper understanding of the role of individual HDAC isoforms is 
crucial for establishing an accurate picture of HDAC mediated cellular signalling. 
To date, a number of isoform-selective HDAC inhibitors have been reported in 
vitro,
231
 representing important starting points for further in cell investigation. 
While in vitro HDAC assays using recombinant enzymes or protein fragments are 
a valuable starting point for the evaluation of small molecule inhibitors, they are 
generally unable to reproduce the native cellular environment of HDAC proteins. 
The enzymes are therefore unlikely to display accurately a number of their native 
characteristics, including conformation, post-translational modifications and the 
presence of regulatory subunits. In particular, it is known that HDACs interact 
with a number of proteins in cells and usually fulfil their regulatory role as part of 
multiprotein complexes.
232
 A number of HDAC-containing regulatory complexes 
have been identified. For example, CoREST, NuRD and Sin3 comprise an 
HDAC1-HDAC2 dimer core, and NCoR is built around an HDAC3 core. The 
roles of these complexes are multiple and cell-type dependent. For example, 
CoREST connects histone deacetylation and demethylation, and functions as a 
neuronal corepressor complex.
233
 NuRD couples histone deacetylation to a 
chromatin-remodeling ATPase to promote gene silencing,
234
 and displays a 
noticeable DNA-methylation-dependent gene silencing ability.
32,235
 owing to the 
issues associated with standard HDAC in vitro assays, new techniques aimed at 
studying the proteomics of HDACs to enable the targeting of HDAC complexes 
directly in cells have been developed.
236-239
  
 
 Recently, Bantscheff and co-workers developed a new approach 
combining affinity capture and quantitative mass spectrometry to study the 
proteomics of zinc-dependent HDACs using small molecule inhibitors.
239
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Typically, known non-selective HDAC inhibitors were derivatised and coupled 
with an activated polymer (Figure 73). Competition experiments were performed 
between a panel of HDACis and the bead bound unselective probes in the 
presence of cell extracts. This allowed the potency of HDACis to be quantified 
against cellular HDAC complexes, and enabled the discovery of previously 
undocumented cellular HDAC containing complexes, in addition to new non-
histone targets. Interestingly, the in vitro class and isoform selectivity profile of a 
number of well known HDACis was found to significantly differ in cells, 
highlighting the necessity to consider full HDAC complexes in their native 
environment when attempting to assess the selectivity of HDACis. 
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Figure 73 
 
 In the present study, we were particularly interested in applying a modified 
approach to study the proteomics of the fourth class I human deacetylase, 
HDAC8, in collaboration with F-J. Meyer-Almes and his group. While a number 
of HDAC-containing repressor complexes containing HDAC1, HDAC2 or 
HDAC3, HDAC8-containing complexes thus far remain uncharacterised. It was 
therefore decided to undertake a number of preliminary studies in order to shed 
light on the still unknown proteomics of HDAC8. The first step of this early stage 
study is to identify potential HDAC8 interaction partners in cell by affinity 
capture using a polymer supported HDAC8 selective inhibitor. It was thought the 
previously reported, HDAC8 selective (in vitro) HDACi PCI-34051
98
 (7, Table 
19) to be a good starting point for investigation. Indeed, previous studies by 
Balasubramanian and co-workers have shown this compound would be highly 
selective against HDAC8 in vitro (Table 19). This selectivity for HDAC8 was 
Towards novel small molecule epigenetic inhibitors Results and discussion 
145 
 
therefore thought to be a particular advantage to preferentially bind HDAC8 in 
cells. 
X
O
N
O
N
H
OH
 
 HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 HDAC10 
IC50 
(μM) 
4 >50 >50 2.9 0.01 13 
 
Table 19 - HDAC isoform selectivity profile of 7
98
 
 
 
6.2. Synthesis of a polymer supported PCI-34051 derivative 
 
 We designed compound 232 (Figure 74, right), a new derivative of PCI-
34051 7 bearing a pendant primary amine to be coupled with an activated 
polymer. The amine was introduced so as to maximise the distance with the 
hydroxamic acid moiety and therefore minimise potential perturbation of the 
binding to the protein. 
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Figure 74 - derivatisation of 7 
 
 The synthesis of this modified HDAC8-selective inhibitor was 
straightforward and is described in Scheme 43. The Mitsunobu reaction between 
Coupling with an 
activated polymer 
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methyl 4-hydroxybenzoate 233 and Boc-protected ethanolamine 234 was 
performed as previously reported
240
 and afforded compound 235 in excellent 
yield. Selective reduction of the ester to the alcohol was achieved in nearly 
quantitative yield using LiAlH4 at low temperature and afforded 236. The 
subsequent Appel reaction afforded the benzyl bromide derivative 237 in high 
yield. Slight degradation of 237 on silica was observed by TLCs, purification by 
flash column chromatography was therefore performed as rapidly as possible 
using minimal amounts of silica gel. N-Alkylation of indole 238 with the benzyl 
bromide derivative 237 afforded 239 in good yield using NaH in DMF. 
Subsequent treatment with aqueous hydroxylamine in a THF/MeOH mixture, and 
a final acidic Boc deprotection afforded 232 in moderate yield after 2 steps. The 
moderate yield for 232 was mainly due to loss of a substantial amount of material 
during the final purification by preparative reverse phase LC/MS (low pH, 
HCOOH). This synthetic route proved to be very robust, and most steps could be 
performed in multigram quantities. 
 
(ii)
236
(i)
Reagents and conditions:
(i) PPh3, DIAD, THF, rt, 24h, 92%
(ii) LiAlH4, THF, -20°C, 2h, 95%
(iii) PPh3, CBr4, CH2Cl2, rt, 2h, 83%
(iv) 238, NaH, DMF, 0°C, rt, 5.5h, 80%
(v) H2NOH, NaOH, THF/MeOH, rt, 8h, 67%
(vi) 4N HCl/dioxane, rt, 5h
HO
O
O
BocHN
OH
O
O
O
BocHN
O
OH
BocHN
(iv)
239
(iii) O
Br
BocHN
O
N
BocHN
O
O
(v), (vi)
232
O
N
+H3N
O
N
H
OH
HCOO-
233
235
234
237
N
H
O
O
238
 
Scheme 43 - synthesis of the modified PCI-34051 inhibitor 
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 232 was then coupled with NHS-activated Sepharose
TM
 4 Fast Flow (GE 
Healthcare) using a customised procedure (Scheme 44). This NHS-activated 
polymer is particularly efficient for the immobilisation of ligands bearing primary 
or secondary amines, and has been shown particularly adapted in previously 
reported chemoproteomics studies.
239
 The resin, supplied in pure isopropanol (16 
mL, 256-368 μmol NHS), was filtered and washed with 0.001M HCl (2 x 16 mL, 
0-4°C), distilled water (2 x 16 mL, 0-4°C) and anhydrous DMF (3 x 16 mL, 0-
4°C). The washed resin was then incubated with 232 (20.0 mg, 53.9 μmol, 0.15-
0.21 eq. respect to NHS) and freshly distilled Et3N (173.0 μL, 3.2 eq. with respect 
to 232) dissolved in anhydrous DMF (16 mL, [232] ~ 3 x 10-3 M) for 4 hours at rt. 
The progress of the reaction was followed by UV-Vis (285 nm). After completion 
of the reaction (80% conversion), the resin was filtered, washed with anhydrous 
DMF (2 x 16 mL, rt), incubated with aqueous ethanolamine (0.5M ethanolamine, 
0.5M NaCl, pH 8.3, 16 mL, rt) for 3 hours and filtered, washed with distilled 
water (3 x 16 mL, rt) and stored in 20% aqueous EtOH at 0-4°C, in the dark (final 
volume: 20 mL). 
 
Final loading of 232 ≈ 2.2 μmol/mL drained medium 
 
 
O
OH
H
N
O
O
N
O
O
5
R-NH2
O
OH
H
N
N
H
O
R
5
10 carbon linker
 
 
Scheme 44 - coupling of amines with NHS-activated Sepharose
TM
 4 Fast 
Flow (GE Healthcare). Grey sphere: spherical, highly cross-linked 4% 
agarose; mean particle size: 90 μm; particle size range: 45-165 μm; NHS 
density: 16-23 μmol NHS/mL drained medium; green: epichlorohydrin based 
anchor; blue: 6-aminohexanoic acid based linker; red: NHS activation; black: 
ligand bearing an amine (e.g. 232) 
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  This system, shown in Scheme 44, is expected to selectively immobilise 
HDAC8 containing complexes on the polymer beads upon exposure to cell 
extracts (Figure 75). Further custom analytical techniques and comparison with 
protein databases is hoped to provide crucial information regarding the proteomics 
of HDAC8 in a number of cell lines. While the selectivity of this compound has 
been demonstrated in vitro only, we expect 232 to exhibit sufficient isoform 
selectivity in cells in order to preferentially target HDAC8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 75 – Study of the proteomics of HDAC8. 1) coupling of HDAC8 
selective ligand 232 (red sphere) with NHS-activated Sepharose
TM
 4 Fast 
Flow (GE Healthcare); 2) capture of HDAC8 and interaction partners at the 
surface of the beads upon exposure to cell extracts; purple: HDAC8; green, 
orange, black: potential HDAC8 interaction partners in cell 
 
 
 Preliminary experiments by Meyer-Almes and his group have shown 232 
(unbound) to remain potent against HDAC8 in vitro, displaying an IC50 of 
approximately 90 nM. The isolation and characterisation of HDAC8 containing 
complexes in Hek293 (Human Embryonic Kidney) and K562 (Myelogenous 
Leukaemia) cell lines, both displaying HDAC8 activity,
241
 is currently attempted 
and will be reported in future manuscripts. 
1) 
2) 
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EXPERIMENTAL 
 
General experimental  procedures 
 
 All reagents and solvents were supplied from commercial sources, and 
used as supplied unless otherwise indicated. Reactions requiring anhydrous 
conditions were conducted in heated glassware (heat gun), under an inert 
atmosphere (argon), and using anhydrous solvents. CH2Cl2 and MeOH were 
distilled over CaH2. THF and Et2O were distilled on Na/benzophenone. Toluene 
was distilled over Na. All reactions were monitored by analytical thin-layer 
chromatography (TLC) using indicated solvent systems on E. Merck silica gel 60 
F254 plates (0.25mm). TLC plates were visualized using UV light (254nm) and/or 
by staining in potassium permanganate followed by heating. Solvents were 
removed by rotary evaporator below 40˚C and the compounds further dried using 
high vacuum pumps. Purification of the different compounds was achieved by 
column chromatography using Merck Flash Silica Gel 60 (230 – 400 mesh) and 
reagent/GPR grade solvents.  
 Melting points were obtained on a Reichert-Thermovar melting point 
apparatus and are uncorrected. Infrared spectra were recorded on a Perkin Elmer 
Spectrum BX II FT-IR System. Reported absorptions are strong or medium 
strength unless stated otherwise and given in wavenumbers (cm
-1
).
 1
H and 
13
C 
NMR were recorded on a Bruker Advance 400 spectrophotometer at 400 MHz 
and 100 MHz respectively. Chemical shifts (δ H) are quoted in ppm (parts per 
million) and referenced to residual solvent signals: 
1H δ = 7.26 (CDCl3), 2.50 (d
6
-
DMSO), 3.31 (CD3OD), 
13C δ = 77.0 (CDCl3), 39.43 (d
6
-DMSO), 49.05 
(CD3OD). Coupling constants (J) are given in Hz. Low and high resolution mass 
spectra (EI, CI, ESI) were recorded by the Imperial College London Department 
of Chemistry Mass Spectroscopy Service using a Micromass Platform II and 
Micromass AutoSpec-Q spectrometer. For compounds containing bromine, 
calculated and experimental masses are reported based on the 
79
Br isotope. 
Elemental analyses were determined by the University of North London 
Analytical Service. X-ray crystallographic studies were performed at Imperial 
College.  
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1. Design and synthesis of Psammaplin A analogue libraries 
 
Parallel synthesis, general procedure for oxazolone synthesis:  
A mixture of the appropriate aromatic aldehyde (1.0 eq.), N-acetylglycine (1.3 
eq.) and sodium acetate (1.3 eq.) in acetic anhydride (0.45 ml/mmol) was stirred 
at reflux for 3h, then cooled to room temperature. After complete precipitation the 
solid was filtered, poured into ice cold water and stirred for 30 minutes. The 
mixture was then filtered and the remaining solid was dried under vacuum. The 
crude oxazolone was used for the next step without further purification. 
 
2-Bromo-4-((2-methyl-5-oxooxazol-4(5H)-ylidene)methyl)phenyl acetate 
(73a) 
1
2
3
4
5
6
O
Br
N
O
O
O
 
Oxazolone 73a (yellow solid, 11,6 g, 71%) was prepared from 3-bromo-4-
hydroxybenzaldehyde 72a following the general procedure above. 
1
H NMR (400 
MHz, CDCl3) δ 2.38 (s, 3H, CH3C(O)O), 2.42 (s, 3H, CH3C(N)O), 7.03 (s, 1H, 4-
CH), 7.20 (d, J = 8.5 Hz, 1H, 2-H), 8.00 (dd, J = 8.5, 2.0 Hz, 1H, 3-H), 8.43 (d, J 
= 2.0 Hz, 1H, 5-H); 
13
C NMR (100 MHz, CDCl3) δ 15.7, 20.8, 116.8, 124.0, 
128.3, 132.2, 132.5, 133.5, 136.5, 149.9, 167.0, 167.3, 168.1; HRMS (ESI+) m/z 
calc. for C13H11BrNO4 [M+H]
+ 
323.9866, found: 323.9860. 
 
4-(3-Bromo-4-methoxybenzylidene)-2-methyl-4H-oxazol-5-one (73b) 
1
2
3
4
5
6
O
Br
N
O
O
 
Oxazolone 73b (yellow solid, 10.3 g, 75%) was prepared from 3-bromo-4-
methoxybenzaldehyde 72b following the general procedure above. 
1
H NMR (400 
MHz, CDCl3) δ 2.41 (s, 3H, CH3O), 3.96 (s, 3H, CH3C), 6.95 (d, J = 8.6 Hz, 1H, 
2-H), 7.02 (s, 1H, 4-CH), 7.95 (dd, J = 8.6, 2.0 Hz, 1H, 3-H), 8.42 (d, J = 2.0 Hz, 
1H, 5-H); 
13
C NMR (100 MHz, CDCl3) 15.7, 56.5, 111.7, 112.3, 127.4, 129.6, 
131.5, 133.3, 136.8, 158.0, 165.7, 167.8; HRMS (ESI+) m/z calc. for 
C12H11BrNO3 [M+H]
+
 295.9917, found: 295.9919. 
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4-(4-Fluorobenzylidene)-2-methyloxazol-5(4H)-one (73c) 
1
2
3
4
5
6
N
O
OF
 
Oxazolone 73c (yellow solid, 2.30 g, 54%) was prepared from 4-
fluorobenzaldehyde 72b following the general procedure above. 
1
H NMR (400 
MHz, CDCl3) δ 2.41 (s, 3H, CH3), 7.08 - 7.17 (m, 3H, 4-CH + 3-H + 5-H), 8.07 - 
8.14 (m, 2H, 2-H + 6-H); 
13
C NMR (100 MHz, CDCl3) δ 15.7, 116.1 (d, JCF = 
22.3 Hz), 129.5 (d, JCF = 2.4 Hz), 130.0, 132.2, 134.3 (d, JCF = 8.7 Hz), 164.2 (d, 
JCF = 254.5 Hz), 166.2, 167.7; HRMS (ESI+) m/z calc. for C11H9FNO2 [M+H]
+ 
206.0612, found: 206.0612. 
 
2-Methyl-4-(4-(methylthio)benzylidene)oxazol-5(4H)-one (73d) 
1
2
3
4
5
6
N
O
OS
 
Oxazolone 73d (orange solid, 3.20 g, 66%) was prepared from 4-
methylthiobenzaldehyde 72d following the general procedure above. 
1
H NMR 
(400 MHz, CDCl3) δ 2.39 (s, 3H, CH3C), 2.52 (s, 3H, CH3S), 7.09 (s, 1H, 4-CH), 
7.24 - 7.28 (m, 2H, 2-H + 6-H), 7.96 - 8.02 (m, 2H, 3-H + 5-H); 
13
C NMR (100 
MHz, CDCl3) δ 14.8, 15.6, 125.5, 129.6, 131.0, 131.6, 132.4, 143.7, 165.4, 167.9; 
HRMS (ESI+) m/z calc. for C12H12NO2S [M+H]
+
 234.0583, found: 234.0587.  
 
4-(3-Iodo-4-methoxybenzylidene)-2-methyloxazol-5(4H)-one (73e) 
1
2
3
4
5
6
N
O
OO
I
 
Oxazolone 73e (orange solid, 3.70 g, 69%) was prepared from 3-iodo-4-
methoxybenzaldehyde 72e following the general procedure above. 
1
H NMR (400 
MHz, CDCl3) δ 2.41 (s, 3H, CH3C), 3.95 (s, 3H, CH3O), 6.87 (d, J = 8.6 Hz, 1H, 
2-H), 7.00 (s, 1H, 4-CH), 8.04 (dd, J = 8.6, 2.1 Hz, 1H, 3-H), 8.59 (d, J = 2.1 Hz, 
1H, 5-H); 
13
C NMR (100 MHz, CDCl3) δ 15.6, 56.5, 86.4, 110.6, 128.0, 129.4, 
131.3, 134.1, 143.1, 160.1, 165.6, 167.7; HRMS (ESI+) m/z calc. for C12H11INO3 
[M+H]
+
 343.9778, found: 343.9791. 
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4-(3-Bromo-4-fluorobenzylidene)-2-methyloxazol-5(4H)-one (73f) 
1
2
3
4
5
6
N
O
OF
Br
 
Oxazolone 73f (yellow solid, 4.00 g, 66%) was prepared from 3-bromo-4-
fluorobenzaldehyde 72f following the general procedure above. 
1
H NMR (400 
MHz, CDCl3) δ 2.42 (s, 3H, CH3), 7.01 (s, 1H, 4-CH), 7.18 (app-t, J = 8.4 Hz, 
1H, 2-H), 7.98 (m, 1H, 3-H), 8.39 (app-d, J = 5.5 Hz, 1H, 5-H); 
13
C NMR (100 
MHz, CDCl3) δ 15.7, 109.8 (d, JCF = 22.3 Hz), 116.9 (d, JCF = 22.7 Hz), 128.2, 
130.9 (d, JCF = 3.4 Hz), 133.0 (d, JCF = 7.6 Hz), 133.2 (d, JCF = 2.4 Hz), 137.0, 
160.3 (d, JCF = 255.0 Hz), 167.0, 167.3; HRMS (ESI+) m/z calc. for 
C11H8BrFNO2 [M+H]
+ 
283.9717, found: 283.9727. 
 
4-(3-Bromo-4-(methylthio)benzylidene)-2-methyloxazol-5(4H)-one (73g) 
1
2
3
4
5
6
Br
N
O
OS
 
Oxazolone 73g (yellow solid, 2.47 g, 37%) was prepared from 3-bromo-4-
(methylthio)benzaldehyde 72g following the general procedure above. 
1
H NMR 
(400 MHz, CDCl3) δ 2.41 (s, 3H, CH3C), 2.52 (s, 3H, CH3S), 7.01 (s, 1H, 4-CH), 
7.14 (d, J = 8.4 Hz, 1H, 2-H), 7.95 (dd, J = 8.4, 1.8 Hz, 1H, 3-H), 8.33 (d, J = 1.8 
Hz, 1H, 5-H); 
13
C NMR (100 MHz, CDCl3) δ 15.5, 15.7, 121.3, 124.4, 129.2, 
130.5, 131.2, 132.5, 135.2, 144.3, 166.1, 167.5; HRMS (ESI+) m/z calc. for 
C12H11BrNO2S [M+H]
+ 
311.9688, found: 311.9689. 
 
4-(3-Iodo-4,5-dimethoxybenzylidene)-2-methyloxazol-5(4H)-one (73h) 
1
2
3
4
5
6
N
O
O
I
O
O
 
Oxazolone 73h (orange solid, 2.70 g, 90%) was prepared from 3-iodo-4,5-
dimethoxybenzaldehyde 72h following the general procedure above. 
1
H NMR 
(400 MHz, CDCl3) δ 2.41 (s, 3H, CH3C), 3.90 (s, 3H, CH3O), 3.92 (s, 3H, CH3O), 
6.97 (s, 1H, 4-CH), 7.84 (d, J = 1.8 Hz, 1H, 3-H), 7.96 (d, J = 1.8 Hz, 1H, 5-H); 
Towards novel small molecule epigenetic inhibitors  Experimental 
153 
 
13
C NMR (100 MHz, CDCl3) δ 15.7, 56.0, 60.6, 92.3, 115.7, 129.3, 131.1, 132.4, 
135.2, 151.3, 152.4, 166.2, 167.5; HRMS (ESI+) m/z calc. for C13H13INO4 
[M+H]
+ 
373.9884, found: 373.9886. 
 
4-(3-Bromo-4,5-dimethoxybenzylidene)-2-methyloxazol-5(4H)-one (73i) 
1
2
3
4
5
6
N
O
OO
O
Br
 
Oxazolone 73i (orange solid, 3.20 g, 70%) was prepared from 3-bromo-4,5-
dimethoxybenzaldehyde 72i following the general procedure above. 
1
H NMR 
(400 MHz, CDCl3) δ 2.41 (s, 3H, CH3C), 3.92 (s, 3H, CH3O), 3.93 (s, 3H, CH3O), 
6.98 (s, 1H, 4-CH), 7.77 (d, J = 1.8 Hz, 1H, 3-H), 7.80 (d, J = 1.8 Hz, 1H, 5-H); 
13
C NMR (100 MHz, CDCl3) δ 15.7, 56.1, 60.8, 114.7, 117.7, 129.3, 129.4, 130.1, 
132.6, 148.8, 153.5, 166.3, 167.5; HRMS (ESI+) m/z calc. for C13H13BrNO4 
[M+H]
+ 
326.0022, found: 326.0019. 
 
4-(3,4-Dimethoxybenzylidene)-2-methyloxazol-5(4H)-one (73j) 
1
2
3
4
5
6
N
O
OO
O
 
Oxazolone 73j (brown solid, 3.60 g, 69%) was prepared from 3,4-
dimethoxybenzaldehyde 72j following the general procedure above. 
1
H NMR 
(400 MHz, CDCl3) δ 2.38 (s, 3H, CH3C), 3.94 (s, 3H, CH3O), 3.95 (s, 3H, CH3O), 
6.90 (d, J = 8.4 Hz, 1H, 2-H), 7.08 (s, 1H, 4-CH), 7.50 (dd, J = 8.4, 1.9 Hz, 1H, 3-
H), 7.93 (d, J = 1.9 Hz, 1H, 5-H); 
13
C NMR (100 MHz, CDCl3) δ 15.6, 55.9 (2C), 
110.8, 113.8, 126.4, 127.3, 130.5, 131.6, 149.1, 151.9, 164.9, 168.1; HRMS 
(ESI+) m/z calc. for C13H14NO4 [M+H]
+
 248.0917, found: 248.0916. 
 
2-Methyl-4-(3-nitrobenzylidene)oxazol-5(4H)-one (73k) 
1
2
3
4
5
6
N
O
O
O2N  
Oxazolone 73k (yellow solid, 2.12 g, 57%) was prepared from 3-
nitrobenzaldehyde 72k following the general procedure above. 
1
H NMR (400 
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MHz, CDCl3) δ 2.45 (s, 3H, CH3C), 7.13 (s, 1H, 4-CH), 7.62 (app-t, J = 8.0 Hz, 
1H, 6-H), 8.24 (d, J = 7.9 Hz, 1H, 5-H), 8.32 (d, J = 7.7 Hz, 1H, 1-H), 8.99 (s, 1H, 
3-H); 
13
C NMR (100 MHz, CDCl3) δ 15.8, 125.0, 126.3, 127.6, 129.8, 134.6, 
134.9, 137.3, 148.6, 166.9, 168.0; HRMS (ESI+) m/z calc. for C11H9N2O4 
233.0557, found: 233.0559. 
 
4-(3-Bromo-5-nitrobenzylidene)-2-methyloxazol-5(4H)-one (73l) 
1
2
3
4
5
6
N
O
O
Br
O2N  
Oxazolone 73l (brown solid, 1.91 g, 60%) was prepared from 3-bromo-5-
nitrobenzaldehyde 72l following the general procedure above. 
1
H NMR (400 
MHz, CDCl3) δ 2.48 (s, 3H, CH3C), 7.05 (s, 1H, 4-CH), 8.39 (app-t, J = 1.9 Hz, 
1H, 5-H), 8.53 (app-t, J = 1.5 Hz, 1H, 3-H), 8.89 (app-t, J = 1.6 Hz, 1H, 1-H); 
13
C 
NMR (100 MHz, CDCl3) δ 15.9, 123.2, 124.9, 125.8, 127.8, 135.9, 136.1, 139.7, 
149.0, 166.5, 168.9; HRMS (EI+) m/z calc. for C11H7BrN2O4 [M
.
]
+ 
309.9589, 
found: 309.9595. 
 
2,6-Dibromo-4-((2-methyl-5-oxooxazol-4(5H)-ylidene)methyl)phenyl acetate 
(73m) 
1
2
3
4
5
6
AcO
Br
N
O
O
Br
 
Oxazolone 73m (yellow solid, 4.04 g, 56%) was prepared from 3,5-dibromo-4-
hydroxybenzaldehyde 72m following the general procedure above. 
1
H NMR (400 
MHz, CDCl3) δ 2.42 (s, 3H, CH3), 2.44 (s, 3H, CH3), 6.94 (s, 1H, 4-CH), 8.30 (s, 
2H, 3-H + 5-H); 
13
C NMR (100 MHz, CDCl3) δ 15.4, 20.1, 117.5, 125.1, 134.0, 
134.6, 134.9, 146.6, 166.6, 167.0, 168.4; HRMS (ESI+) m/z calc. for 
C13H10Br2NO4 [M+H]
+ 
401.8971, found: 401.8990. 
 
4-(3-Methoxy-4-(methylthio)benzylidene)-2-methyloxazol-5(4H)-one (73n) 
1
2
3
4
5
6
O
N
O
OS
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Oxazolone 73n (orange solid, 4.54 g, 63%) was prepared from 3-methoxy-4-
(methylthio)benzaldehyde 72n following the general procedure above. 
1
H NMR 
(400 MHz, CDCl3) δ 2.40 (s, 3H, CH3C), 2.48 (s, 3H, CH3S), 3.97 (s, 3H, CH3O), 
7.10 (s, 1H, 4-CH), 7.13 (d, J = 8.1 Hz, 1H, 2-H), 7.53 (dd, J = 8.1, 1.5 Hz, 1H, 3-
H), 7.80 (d, J = 1.5 Hz, 1H, 5-H); 
13
C NMR (100 MHz, CDCl3) δ 13.9, 15.7, 55.9, 
111.8, 124.1, 126.2, 130.4, 131.3, 131.5, 133.1, 155.6, 165.2, 167.9; HRMS 
(ESI+) m/z calc. for C13H14NO3S [M+H]
+ 
264.0689, found: 264.0685. 
 
Parallel Synthesis, general procedure for the conversion of azlactones to 
arylpyruvic acids:  
A mixture of the appropriate azlactone in 10% aqueous HCl was heated overnight 
at reflux. After complete precipitation upon cooling the remaining solid was 
filtered, washed with a small amount of cold water, and dried under vaccum. The 
crude product was used for the next step without further purification. Further 
extraction of the aqueous phase with AcOEt could be achieved in the case of low 
precipitation of the product. 
 
 
3-(3-Bromo-4-hydroxyphenyl)-2-hydroxyacrylic acid (51) 
1
2
3
4
5
6
HO
Br
OH
COOH
 
Acid 51 (orange solid, 8.15 g, 88%) was obtained from oxazolone 73a following 
the general procedure above. 
1
H NMR (400 MHz, CD3OD) 6.38 (s, 1H, 4-CH), 
6.85 (d, J = 8.5 Hz, 1H, 2-H), 7.51 (dd, J = 8.5, 2.1 Hz, 1H, 3-H), 8.01 (d, J = 2.1 
Hz, 1H, 5-H); 
13
C NMR (100 MHz, CD3OD) 110.5, 110.8, 116.9, 129.6, 131.4, 
135.2, 141.1, 154.7, 168.3; HRMS (ESI-) m/z calc. for C9H6BrO4 [M-H]
-
 
256.9455, found: 256.9447. 
 
 
3-(3-Bromo-4-methoxyphenyl)-2-hydroxyacrylic acid (74a) 
1
2
3
4
5
6
O
Br
OH
COOH
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Acid 74a (yellow solid, 7.71 g, 83%) was obtained from oxazolone 73b following 
the general procedure above. 
1
H NMR (400 MHz, CD3OD) 3.89 (s, 3H, CH3O), 
6.40 (s, 1H, 4-CH), 7.01 (d, J = 8.6 Hz, 1H, 2-H), 7.65 (dd, J = 8.6, 2.1 Hz, 1H, 3-
H), 8.09 (d, J = 2.1 Hz, 1H, 5-H); 
13
C NMR (100 MHz, CD3OD) 56.7, 110.0, 
112.4, 112.8, 130.6, 131.4, 135.2, 141.8, 156.5, 168.2; HRMS (ESI-) m/z calc. for 
C10H8BrO4 [M-H]
-
 270.9611, found: 270.9596. 
 
2-Hydroxy-3-phenylacrylic acid (74b) 
COOH
OH
 
Acid 74b was purchased from Sigma-Aldrich. 
 
2-Hydroxy-3-(4-hydroxyphenyl)acrylic acid (56) 
COOH
OH
HO
 
Acid 56 was purchased from Sigma-Aldrich. 
 
 3-(4-Fluorophenyl)-2-hydroxyacrylic acid (74c) 
1
2
3
4
5
6
COOH
OH
F
 
Acid 74c (orange solid, 1.48 g, 72%) was obtained from oxazolone 73c following 
the general procedure above. 
1
H NMR (400 MHz, CD3OD) 6.47 (s, 1H, 4-CH), 
7.02 - 7.09 (m, 2H, 3-H + 5-H), 7.77 - 7.84 (m, 2H, 2-H + 6-H); 
13
C NMR (100 
MHz, CD3OD) 110.4, 116.0 (d, 
2
JC-F = 22.2 Hz), 132.6 (d, 
3
JC-F = 8.2 Hz), 132.9, 
142.1, 163.3 (d, 
1
JC-F = 246.3 Hz), 168.3; HRMS (ESI-) m/z calc. for C9H6FO3 
[M-H]
-
 181.0306, found: 181.0296. 
 
 2-Hydroxy-3-(4-(methylthio)phenyl)acrylic acid (74d) 
1
2
3
4
5
6
COOH
OH
S
 
Acid 74d (brown solid, 2.05 g, 71%) was obtained from oxazolone 73d following 
the general procedure above. 
1
H NMR (400 MHz, CD3OD) 2.48 (s, 3H, CH3S), 
6.45 (s, 1H, 4-CH), 7.19 - 7.25 (m, 2H, 3-H + 5-H), 7.68 - 7.74 (m, 2H, 2-H + 6-
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H); 
13
C NMR (100 MHz, CD3OD) 15.5, 111.2, 127.1, 131.2, 133.2, 139.4, 142.0, 
168.3; HRMS (ESI-) m/z calc. for C10H9O3S [M-H]
-
 209.0278, found: 209.0269. 
 
2-Hydroxy-3-(3-iodo-4-methoxyphenyl)acrylic acid (74e) 
1
2
3
4
5
6
COOH
OH
O
I
 
Acid 74e (orange solid, 3.25 g, 94%) was obtained from oxazolone 73e following 
the general procedure above. 
1
H NMR (400 MHz, CD3OD) 3.87 (s, 3H, CH3O),  
6.38 (s, 1H, 4-CH), 6.91 (d, J = 8.6 Hz, 1H, 2-H), 7.70 (dd, J = 8.6, 2.0 Hz, 1H, 3-
H), 8.29 (d, J = 2.0 Hz, 1H, 5-H); 
13
C NMR (100 MHz, DMSO-d
6
) 56.3, 86.0, 
108.0, 111.2, 129.6, 130.9, 139.3, 140.8, 156.6, 166.2. ; HRMS (ESI-) m/z calc. 
for C10H8IO4 [M-H]
-
 318.9473, found: 318.9472. 
 
3-(3-Bromo-4-fluorophenyl)-2-hydroxyacrylic acid (74f) 
1
2
3
4
5
6
COOH
OH
F
Br
 
Acid 74f (white solid, 1.76 g, 48%) was obtained from oxazolone 73f following 
the general procedure above. 
1
H NMR (400 MHz, CD3OD) 6.42 (s, 1H, 4-CH), 
7.16 (app-t, J = 8.7 Hz, 1H, 2-H), 7.66 - 7.72 (m, 1H, 3-H), 8.14 (dd, J = 7.0, 2.1 
Hz, 1H, 5-H); 
13
C NMR (100 MHz, CD3OD) 108.7, 109.5 (d, 
2
JC-F = 21.5 Hz), 
117.2 (d, 
2
JC-F = 22.6 Hz), 131.7 (d, 
3
JC-F = 6.9 Hz), 134.6, 135.3, 143.3, 159.2 (d, 
1
JC-F = 247 Hz), 167.8; HRMS (ESI-) m/z calc. for C9H5BrFO3 [M-H]
-
 258.9412, 
found: 258.9418. 
 
3-(3-Bromo-4-(methylthio)phenyl)-2-hydroxyacrylic acid (74g) 
1
2
3
4
5
6
Br
S
COOH
OH
 
Acid 74g (brown solid, 1.88g, 92%) was obtained from oxazolone 73g following 
the general procedure above.
 1
H NMR (400 MHz, CD3OD) 2.48 (s, 3H, CH3S), 
6.40 (s, 1H, 4-CH), 7.18 (d, J = 8.4 Hz, 1H, 2-H), 7.66 (dd, J = 8.4, 1.8 Hz, 3-H), 
8.06 (d, J = 1.8 Hz, 1H, 5-H); 
13
C NMR (100 MHz, CD3OD/d
6
-DMSO) 15.6, 
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109.5, 121.9, 126.1, 130.4, 134.1, 134.4, 140.2, 143.1, 167.7; HRMS (ESI-) m/z 
calc. for C10H8BrO3S [M-H]
-
 286.9383, found: 286.9379. 
 
2-Hydroxy-3-(3-iodo-4,5-dimethoxyphenyl)acrylic acid (74h) 
1
2
3
4
5
6
COOH
OH
O
O
I
 
Acid 74h (brown solid, 2.19 g, 86%) was obtained from oxazolone 73h following 
the general procedure above. 
1
H NMR (400 MHz, CD3OD) 3.78 (s, 3H, CH3O), 
3.85 (s, 3H, CH3O),  6.37 (s, 1H, 4-CH), 7.48 (d, J = 1.7 Hz, 1H, 3-H), 7.76 (d, J 
= 1.7 Hz, 1H, 5-H); 
13
C NMR (100 MHz, CD3OD) 56.4, 60.8, 92.6, 109.7, 115.3, 
132.9, 134.8, 142.6, 149.3, 153.5, 168.0; HRMS (ESI-) m/z calc. for C11H10IO5 
[M-H]
-
 348.9578, found: 348.9586. 
 
3-(3-Bromo-4,5-dimethoxyphenyl)-2-hydroxyacrylic acid (74i) 
1
2
3
4
5
6
COOH
OH
O
Br
O
 
Acid 74i (orange solid, 2.76 g, 93%) was obtained from oxazolone 73i following 
the general procedure above. 
1
H NMR (400 MHz, CD3OD) 3.81 (s, 3H, CH3O), 
3.87 (s, 3H, CH3O),  6.40 (s, 1H, 4-CH), 7.45 (d, J = 1.8 Hz, 1H, 3-H), 7.59 (d, J 
= 1.8 Hz, 1H, 5-H); 
13
C NMR (100 MHz, CD3OD) 56.5, 61.0, 109.8, 114.3, 
118.1, 127.0, 134.1, 142.9, 146.7, 154.7, 168.0; HRMS (ESI-) m/z calc. for 
C11H10BrO5 [M-H]
-
 300.9717, found: 300.9707. 
 
 3-(3,4-Dimethoxyphenyl)-2-hydroxyacrylic acid (74j) 
1
2
3
4
5
6
COOH
OH
O
O
 
Acid 74j (brown solid, 2.11 g, 62%) was obtained from oxazolone 73j following 
the general procedure above. 
1
H NMR (400 MHz, CD3OD) 3.84 (s, 6H, CH3O),  
6.46 (s, 1H, 4-CH), 6.93 (d, J = 8.4 Hz, 1H, 6-H), 7.27 (d, J = 8.4 Hz, 1H, 5-H), 
7.57 (s, 1H, 3-H); 
13
C NMR (100 MHz, CD3OD) 56.4 (2C), 112.0, 112.6, 114.4, 
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124.5, 129.8, 140.9, 150.1, 150.2, 168.6; HRMS (ESI-) m/z calc. for C11H11O5 
[M-H]
-
 223.0612, found: 223.0616. 
 
 2-Hydroxy-3-(3-nitrophenyl)acrylic acid (74k) 
1
2
3
4
5
6
COOH
OH
O2N  
Acid 74k (brown solid, 1.82 g, 72%) was obtained from oxazolone 73k following 
the general procedure above. 
1
H NMR (400 MHz, CD3OD) 6.56 (s, 1H, 4-CH), 
7.56 (app-t., J = 8.0 Hz, 1H, 6-H), 8.04 (app-d., J = 7.9 Hz, 1H, 1-H), 8.08 (ddd, J 
=  8.3, 2.4, 0.9 Hz, 1H, 5-H), 8.77 (app-t., J = 1.9 Hz, 1H, 3-H); 
13
C NMR (100 
MHz, CD3OD) 108.6, 122.6, 124.7, 130.4, 136.4, 138.4, 144.8, 149.8, 167.5; 
HRMS (ESI-) m/z calc. for C9H6NO5 [M-H]
-
 208.0251, found: 208.0251. 
 
 3-(3-Bromo-5-nitrophenyl)-2-hydroxyacrylic acid (74l) 
1
2
3
4
5
6
COOH
OH
Br
O2N  
Acid 74l (grey solid, 1.68 g, 95%) was obtained from oxazolone 73l following the 
general procedure above. 
1
H NMR (400 MHz, CD3OD) 6.49 (s, 1H, 4-CH), 8.19 
(app-t., J = 1.9 Hz, 1H, 5-H), 8.28 (app-t., J = 1.4 Hz, 1H, 3-H), 8.63 (app-t., J = 
1.6 Hz, 1H, 1-H); 
13
C NMR (100 MHz, CD3OD) 15.5, 111.2, 127.1, 127.4, 131.2, 
132.1, 133.2, 139.4, 142.0, 168.3; HRMS (ESI-) m/z calc. for C9H5BrNO5 [M-H]
-
 
285.9357, found: 285.9353. 
 
3-(3,5-Dibromo-4-hydroxyphenyl)-2-hydroxyacrylic acid (74m) 
1
2
3
4
5
6
Br
HO
COOH
OH
Br
 
Acid 74m (brown solid, 2.60g, 82%) was obtained from oxazolone 73m following 
the general procedure above.
 1
H NMR (400 MHz, CD3OD) 6.32 (s, 1H, 4-CH), 
7.92 (s, 2H, 3-H + 5-H); 
13
C NMR (100 MHz, CD3OD) 108.7, 111.9, 131.1, 
134.3, 142.5, 151.3, 167.9; HRMS (ESI-) m/z calc. for C9H5Br2O4 [M-H]
-
 
334.8560, found: 334.8560. 
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2-Hydroxy-3-(3-methoxy-4-(methylthio)phenyl)acrylic acid (74n) 
1
2
3
4
5
6
O
S
COOH
OH
 
Acid 74n (off-white solid, 3.75g, 98%) was obtained from oxazolone 73n 
following the general procedure above.
 1
H NMR (400 MHz, CD3OD) 2.40 (s, 3H, 
CH3S), 3.87 (s, 3H, CH3O), 6.48 (s, 1H, 4-CH), 7.11 (d, J = 8.1 Hz, 1H, 2-H), 
7.30 (dd, J = 8.1, 1.5 Hz, 1H, 3-H), 7.49 (d, J = 1.5 Hz, 1H, 5-H); 
13
C NMR (100 
MHz, CD3OD) 14.4, 56.2, 111.6, 112.2, 124.2, 126.2, 128.3, 134.2, 141.9, 157.3, 
168.3; HRMS (ESI-) m/z calc. for C11H11O4S [M-H]
-
 239.0384, found: 239.0370. 
 
 
Synthesis of Psammaplin A analogues from arylpyruvic acids, general 
procedures: 
Procedure A, synthesis of oxime derivatives: To a solution of the appropriate 
crude acid (1 eq.) in freshly distilled pyridine (2 mL/mmol), under an argon 
atmosphere, was added O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (1.5 eq.). 
The resulting mixture was stirred overnight at room temperature. Pyridine was 
then removed in vacuo, the residue was dissolved in 1N HCl (5.5 mL/mmol) and 
extracted three times with AcOEt (5.5 mL/mmol). The combined organic layers 
were dried (Na2SO4), filtrated and concentrated to afford the crude O-THP 
protected oxime intermediate, used for the next step without further purification. 
To a solution of the crude O-THP protected oxime intermediate (1 eq.) in dry 
dioxane (2.7 mL/mmol) under an argon atmosphere were added EDCI (1.7 equiv.) 
and N-hydroxysuccinimide (NHS) (1.9 equiv.). The resulting mixture was stirred 
at room temperature for 3 hours. The solvent was then evaporated in vacuo. The 
residue was dissolved in AcOEt (12 mL/mmol), washed with saturated aqueous 
NaHCO3 (2 x 12 mL/mmol), 1N aqueous HCl (2 x 12 mL/mmol) and brine (1 x 
12 mL/mmol). The organic phase was then dried (Na2SO4) and the solvent 
evaporated in vacuo. The residue was dissolved in dry dioxane (2.7 mL/mmol) 
under an argon atmosphere and a second solution of the appropriate amine (1 eq. 
2-(methylthio)ethanamine or 0.5 eq. cystamine dihydrochloride) and NEt3 (1.1 eq. 
for 2-(methylthio)ethanamine or 2.1 eq. for cystamine dihydrochloride) in freshly 
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distilled MeOH (2.7 mL/mmol) was added. The resulting mixture was then stirred 
overnight at rt. The solvent was then evaporated in vacuo and the product was 
purified by flash collumn chromatography (AcOEt/PE40-60 or AcOEt/CH2Cl2 
mixtures). The O-THP protected precursor was then dissolved in a anhydrous 20 : 
1 CH2Cl2 : MeOH mixture (6.7 mL / mmol for monomers, 13.4 mL / mmol for 
disulfides) and 1M HCl in anhydrous Et2O (6.7 mL / mmol for monomers, 13.4 
mL / mmol for disulfides) was added. The resulting mixture was stirred for 3 
hours at 60   C. The solvent was then evaporated in vacuo and the product purified 
by flash column chromatography. 
 
Procedure B, synthesis of O-methyloxime derivatives: To a solution of the 
appropriate crude acid (1 eq.) in freshly distilled pyridine (2 mL/mmol), under an 
argon atmosphere, was added methoxylamine hydrochloride (1.5 eq.). The 
resulting mixture was stirred overnight at room temperature. Pyridine was then 
removed in vacuo, the residue was dissolved in 1N HCl (5.5 mL/mmol) and 
extracted three times with AcOEt (5.5 mL/mmol). The combined organic layers 
were dried (Na2SO4), filtered and concentrated to afford the crude O-methylated 
oxime intermediate, used for the next step without further purification. To a 
solution of the crude O-methylated oxime intermediate (1 eq.) in dry dioxane (2.7 
mL/mmol) under an argon atmosphere was added EDCI (1.7 eq.) and NHS (1.9 
eq.). The resulting mixture was stirred at room temperature for 3 hours. The 
solvent was then evaporated in vacuo. The residue was dissolved in AcOEt (12 
mL/mmol), washed with saturated aqueous NaHCO3 (2 x 12 mL/mmol), 1N 
aqueous HCl (2 x 12 mL/mmol) and brine (1 x 12 mL/mmol). The organic phase 
was then dried (Na2SO4) and the solvent evaporated in vacuo. The residue was 
dissolved in dry dioxane (2.7 mL/mmol) under an argon atmosphere and a second 
solution of the appropriate amine (1 eq. 2-(methylthio)ethanamine or 0.5 eq. 
cystamine dihydrochloride) and NEt3 (1.1 eq. for 2-(methylthio)ethanamine or 2.1 
eq. for cystamine dihydrochloride) in freshly distilled MeOH (2.7 mL/mmol) is 
added. The resulting mixture was then stirred overnight at rt. The solvent was then 
evaporated in vacuo and the product was purified by flash column 
chromatography. 
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(E)-3-(3-Bromo-4-hydroxyphenyl)-2-(hydroxyimino)-N-(2-(methylthio)ethyl) 
propanamide (75a) 
1
2
3
4
5
6
Br
HO
N
O
H
N
S
HO
 
75a (184 mg, 40% from acid 51) was prepared according to general procedure A 
above, and obtained as a white solid after purification by flash column 
chromatography (MeOH : CH2Cl2, 4 : 96) and recrystallization from Et2O: m.p. 
102-104 °C. Rf 0.35 (MeOH : CH2Cl2, 5 : 95); IR 3225, 1618, 1548, 1509, 1419, 
1013 cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 2.09 (s, 3H, CH3S), 2.60 (t, J = 6.9 
Hz, 2H, CH2S), 3.44 (t, J = 6.9 Hz, 2H, CH2N), 3.79 (s, 2H, 4-CH2), 6.76 (d, J = 
8.3 Hz, 1H, 2-H), 7.07 (dd, J = 8.3, 2.1 Hz, 1H, 3-H), 7.37 (d, J = 2.1 Hz, 1H, 5-
H). 
13
C NMR (100 MHz, CD3OD) δ 15.2, 28.7, 34.2, 39.6, 110.5, 117.0, 130.4, 
130.7, 134.5, 153.2, 153.8, 165.8; HRMS (ESI+) m/z calc. for C12H16BrN2O3S 
[M+H]
+ 
347.0060, found: 347.0067; Anal. Calc. for C12H15BrN2O3S: C, 41.51; H, 
4.35; N, 8.07. Found: C, 41.45; H, 4.27; N, 7.96. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
hydroxyphenyl)-2-(hydroxyimino)propanamide) (natural product 
PSAMMAPLIN A) (28) 
1
2
3
4
5
6
Br
HO
N
H
N
O
S
Br
OH
N
N
H
O
S
HO
OH
 
28 (249 mg, 35% from acid 51) was prepared according to general procedure A 
above, and obtained as an amorphous light yellow solid after purification by flash 
column chromatography (gradient AcOEt/PE40-60, 1 : 1 then 100% AcOEt). The 
full characterisation of psammaplin A has been reported in the 
literature;
153,154,156,135a-c
 NMR data obtained matched perfectly those reported. 
 1
H 
NMR (400 MHz, CD3OD) δ 2.81 (t, J = 6.7 Hz, 4H, CH2S), 3.52 (t, J = 6.7 Hz, 
4H, CH2N), 3.79 (s, 4H, 4-CH2), 6.76 (d, J = 8.3 Hz, 2H, 2-H), 7.07 (dd, J = 8.3, 
2.1 Hz, 2H, 3-H), 7.36 (d, J = 2.1 Hz, 2H, 5-H); 
13
C NMR (100 MHz, CD3OD) δ 
28.7, 38.6, 39.6, 110.5, 117.1, 130.5, 130.7, 134.5, 153.2, 153.8, 165.9; HRMS 
(ESI+) m/z calc. for C22H25Br2N4O6S2 [M+H]
+ 
662.9577, found: 662.9590. 
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(E)-3-(3-Bromo-4-hydroxyphenyl)-2-(methoxyimino)-N-(2-(methylthio)ethyl) 
propanamide (75r) 
1
2
3
4
5
6
Br
HO
N
H
N
O
S
O
 
75r (98 mg, 43% from acid 51) was prepared according to general procedure B 
above, and obtained as a yellow oil after flash purification by flash column 
chromatography (AcOEt : PE40-60°C, 1 : 1). Rf 0.55 (AcOEt : PE40-60°C, 1 : 1); IR 
3327, 1657, 1530, 1509, 1493, 1422, 1045 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 
2.12 (s, 3H, CH3S), 2.66 (t, J = 6.5 Hz, 2H, CH2S), 3.52 (m, 2H, CH2N), 3.81 (s, 
2H, 4-CH2), 4.01 (s, 3H, CH3O), 5.46 (br. s, 1H, OH), 6.89 (d, J = 8.3 Hz, 1H, 2-
H), 7.06 (br. t., 1H, NH), 7.15 (dd, J = 8.3, 2.0 Hz, 1H, 3-H), 7.40 (d, J = 2.0 Hz, 
1H, 5-H). 
13
C NMR (100 MHz, CDCl3) δ 15.2, 28.5, 33.7, 38.0, 63.1, 109.9, 
115.9, 129.7, 130.1, 132.5, 150.9, 151.5, 162.5; HRMS (ESI+) m/z calc. for 
C13H18BrN2O3S [M+H]
+ 
361.0216, found: 361.0222; Anal. Calc. for 
C13H17BrN2O3S: C, 43.22; H, 4.74; N, 7.75. Found: C, 43.13; H, 4.72; N, 7.65.  
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
hydroxyphenyl)-2-(methoxyimino)propanamide) (75s) 
1
2
3
4
5
6
Br
HO
N
H
N
O
S
Br
OH
N
N
H
O
S
O
O
 
75s (135mg, 30% from acid 51) was prepared according to general procedure B 
above, and obtained as an amorphous yellow solid after purification by flash 
column chromatography (AcOEt : PE40-60°C : MeOH, 5.8 : 4 : 0.2). Rf 0.6 (AcOEt 
: PE40-60°C, 7 : 3); IR 3356, 1657, 1528, 1508, 1492, 1422, 1045 cm
-1
; 
1
H NMR 
(400 MHz, CDCl3) δ 2.81 (t, J = 6.4 Hz, 4H, CH2S), 3.61 (m, 4H, CH2N), 3.81 (s, 
4H, 4-CH2), 4.00 (s, 6H, CH3O), 5.56 (br. s, 2H, OH), 6.88 (d, J = 8.3 Hz, 2H, 2-
H), 7.06 (br. t., 2H, NH), 7.14 (dd, J = 8.3, 2.0 Hz, 2H, 3-H), 7.39 (d, J = 2.0 Hz, 
2H, 5-H). 
13
C NMR (100 MHz, CDCl3) δ 28.5, 37.6, 38.3, 63.1, 110.0, 115.9, 
129.7, 130.2, 132.5, 150.9, 151.5, 162.6; HRMS (ESI+) m/z calc. for 
C24H29Br2N4O6S2 [M+H]
+ 
690.9890, found: 690.9893; Anal. Calc. for 
C24H28Br2N4O6S2: C, 41.63; H, 4.08; N, 8.09. Found: C, 41.56; H, 3.97; N, 8.15. 
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 (E)-3-(3-Bromo-4-methoxyphenyl)-2-(hydroxyimino)-N-(2-(methylthio)ethyl) 
propanamide (75b) 
1
2
3
4
5
6
Br
O
N
H
N
O
S
HO
 
75b (102 mg, 38% from acid 74a) was prepared according to general procedure A 
above, and obtained as a yellowish oil after purification by flash column 
chromatography (AcOEt : PE40-60, 1 : 1). Rf 0.35 (AcOEt : PE40-60, 1 : 1); IR 1658, 
1528, 1495, 1257, 1283, 1055 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 2.10 (s, 3H, 
CH3S), 2.65 (t, J = 6.4 Hz, 2H, CH2S), 3.52 (m, 2H, CH2N), 3.85 (s, 3H, CH3O), 
3.90 (s, 2H, 4-CH2), 6.79 (d, J = 8.5 Hz, 1H, 2-H), 7.05 (br. t., 1H, NH), 7.27 (dd, 
J = 8.5, 2.1 Hz, 1H, 3-H), 7.53 (d, J = 2.1 Hz, 1H, 5-H), 7.69 (br. s, 1H, OH). 
13
C 
NMR (100 MHz, CDCl3) δ 15.1, 28.0, 33.6, 37.8, 56.2, 111.4, 111.8, 129.5, 
129.7, 134.0, 153.2, 154.5, 162.8; HRMS (ESI+) m/z calc. for C13H18BrN2O3S 
[M+H]
+
 361.0216, found: 361.0222; Anal. Calc. for C13H17BrN2O3S: C, 43.22; H, 
4.74; N, 7.75. Found: C, 43.18; H, 4.63; N, 7.78. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
methoxyphenyl)-2-(hydroxyimino)propanamide) (75c) 
1
2
3
4
5
6
Br
O
N
H
N
O
S
Br
O
N
N
H
O
S
HO
OH
 
75c (185 mg, 49% from acid 74a) was prepared according to general procedure A 
above, and obtained as a yellow amorphous solid after purification by flash 
column chromatography (AcOEt : PE40-60, 6 :4). Rf 0.45 (AcOEt : PE40-60, 7 : 3); 
IR 1659, 1530, 1495, 1281, 1256, 1055 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 2.77 
(t, J = 6.2 Hz, 4H, CH2S), 3.59 (m, 4H, CH2N), 3.81 (s, 6H, CH3O), 3.87 (s, 4H, 
4-CH2), 6.74 (d, J = 8.5 Hz, 2H, 2-H), 7.15 (br. t, 2H, NH), 7.24 (dd, J = 8.4, 2.1 
Hz, 2H, 3-H), 7.51 (d, J = 2.1 Hz, 2H, 5-H). 
13
C NMR (100 MHz, CDCl3) δ 28.0, 
38.0, 38.3, 56.2, 111.4, 111.8, 129.6, 129.7, 133.9, 152.6, 154.5, 163.5; HRMS 
(ESI+) m/z calc. for C24H29Br2N4O6S2 [M+H]
+ 
690.9890, found: 690.9882; Anal. 
Calc. for C24H28Br2N4O6S2: C, 41.63; H, 4.08; N, 8.09. Found: C, 41.55; H, 4.01; 
N, 8.15. 
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(E)-3-(3-Bromo-4-methoxyphenyl)-2-(methoxyimino)-N-(2-(methylthio)ethyl) 
propanamide (75t) 
1
2
3
4
5
6
Br
O
N
H
N
O
S
O
 
75t (75 mg, 67% from acid 74a) was prepared according to general procedure B 
above, and obtained as colourless needles after flash purification by flash column 
chromatography (AcOEt/PE40-60°C, 1 : 2), and recrystallization (Bu2O): m.p. 63-
65°C (Bu2O); Rf 0.65 (AcOEt/PE40-60°C, 1 : 1); IR 1671, 1519, 1494, 1284, 1255, 
1045 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 2.12 (s, 3H, CH3S), 2.66 (t, J = 6.6 Hz, 
2H, CH2S), 3.52 (m, 2H, CH2N), 3.83 (s, 2H, 4-CH2), 3.85 (s, 3H, CH3O-1), 4.02 
(s, 3H, CH3O-N), 6.78 (d, J = 8.4 Hz, 1H, 2-H), 7.06 (br. t., 1H, NH), 7.22 (dd, J 
= 8.4, 2.1 Hz, 1H, 3-H), 7.47 (d, J = 2.1 Hz, 1H, 5-H); 
13
C NMR (100 MHz, 
CDCl3) δ 15.2, 28.5, 33.7, 37.9, 56.2, 63.1, 111.3, 111.7, 129.4, 129.8, 133.9, 
151.5, 154.4, 162.4; HRMS (ESI+) m/z calc. for C14H20BrN2O3S [M+H]
+
 
375.0373, found: 375.0378; Anal. Calc. for C14H19BrN2O3S: C, 44.81; H, 5.10; N, 
7.46. Found: C, 44.86; H, 5.03; N, 7.41. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
methoxyphenyl)-2-(methoxyimino)propanamide) (75u) 
1
2
3
4
5
6
Br
O
N
H
N
O
S
Br
O
N
N
H
O
S
O
O
 
75u (161mg, 41% from acid 74a) was prepared according to general procedure B 
above, and obtained as a white solid after purification by flash column 
chromatography (AcOEt : PE40-60°C, 1 : 1) and recrystallisation (AcOEt/hexane): 
m.p. 81-83 °C (AcOEt/hexane); Rf 0.5 (AcOEt : PE40-60°C, 1 : 1); 75u has been 
reported previously,
135a-c
 
1
H NMR (400 MHz, CDCl3) δ 2.82 (t, J = 6.4 Hz, 4H, 
CH2S), 3.62 (m, 4H, CH2N), 3.82 (s, 4H, 4-CH2), 3.84 (s, 6H, CH3O-1), 4.00 (s, 
6H, CH3O-N), 6.78 (d, J = 8.4 Hz, 2H, 2-H), 7.06 (br. t., 2H, NH), 7.20 (dd, J = 
8.4, 2.2 Hz, 2H 3-H), 7.46 (d, J = 2.2 Hz, 2H, 5-H); HRMS (ESI+) m/z calc. for 
C26H33Br2N4O6S2 [M+H]
+
 719.0203, found: 719.0209. 
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(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(2-(hydroxyimino)-3-
phenylpropanamide) (75d) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH  
75d (225 mg, 24% from acid 74b) was prepared according to general procedure A 
above, and obtained as an amorphous white solid after purification by flash 
column chromatography (gradient acetone : PE40-60, 3 : 7 to 4 : 6) and 
precipitation from CH2Cl2. Rf 0.3 (acetone : PE40-60, 3 : 7); IR (neat) 1654, 1625, 
1522, 1493, 1426, 1000 cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 2.79 (t, J = 6.7 Hz, 
4H, CH2S), 3.50 (t, J = 6.7 Hz, 4H, CH2N), 3.91 (s, 4H, 4-CH2), 7.10-7.16 (m, 
2H, 1-H), 7.17-7.30 (m, 8H, 2-H + 3-H + 5-H + 6-H). 
13
C NMR (100 MHz, 
CD3OD) δ 30.0, 38.5, 39.6, 127.3, 129.4, 130.1, 138.2, 153.3, 166.0; HRMS 
(ESI+) m/z calc. for C22H27N4O4S2 [M+H]
+ 
475.1468, found: 475.1470; Anal. 
Calc. for C22H26N4O4S2: C, 55.68; H, 5.52; N, 11.81. Found: C, 55.75; H, 5.44; N, 
11.89. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(2-(hydroxyimino)-3-
(4-hydroxyphenyl)propanamide) (75e) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH
HO
OH  
75e (175 mg, 20% from acid 56) was prepared according to general procedure A 
above, and obtained as an amorphous white solid after purification by flash 
column chromatography (gradient acetone : PE40-60, 4 : 6 to 1 : 1). Important 
degradation was observed during the final deprotection step for reaction times 
superior to 2h. Only partial conversion to the product (and recovery of the starting 
material) was achieved during the deprotection step, avoiding degradation and 
allowing efficient purification of the product. Rf 0.3 (acetone : PE40-60, 1 : 1); IR 
(neat) 1655, 1613, 1531, 1511, 1437, 1214, 1011, 980 cm
-1
; 
1
H NMR (400 MHz, 
CD3OD) δ 2.79 (t, J = 6.8 Hz, 4H, CH2S), 3.51 (t, J = 6.8 Hz, 4H, CH2N), 3.80 (s, 
4H, 4-CH2), 6.62-6.67 (m, 4H, 2-H + 6-H), 7.05-7.11 (m, 4H, 3-H + 5-H). 
13
C 
NMR (100 MHz, CD3OD) δ 29.1, 38.5, 39.6, 116.1, 128.9, 131.2, 153.8, 156.9, 
166.2; HRMS (ESI+) m/z calc. for C22H27N4O6S2 [M+H]
+ 
507.1367, found: 
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507.1371; Anal. Calc. for C22H26N4O6S2: C, 52.16; H, 5.17; N, 11.06. Found: C, 
52.10; H, 5.11; N, 10.97. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(4-fluorophenyl)-
2-(hydroxyimino)propanamide) (75f) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH
F
F  
75f (225 mg, 29% from acid 74c) was prepared according to general procedure A 
above, and obtained as an amorphous white solid after purification by flash 
column chromatography (gradient acetone : PE40-60, 3 : 7 to 4 : 6). Rf 0.25 
(acetone : PE40-60, 3 : 7); IR (neat) 1654, 1625, 1528, 1508, 1427, 1235, 1221, 
1023, 1001 cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 2.81 (t, J = 6.6 Hz, 4H, CH2S), 
3.52 (t, J = 6.6 Hz, 4H, CH2N), 3.88 (s, 4H, 4-CH2), 6.89-7.00 (m, 4H, 2-H + 6-
H), 7.23-7.33 (m, 4H, 3-H + 5-H). 
13
C NMR (100 MHz, CD3OD) δ 29.2, 38.6, 
39.6, 115.9 (d, JCF = 21.4 Hz), 131.8 (d, JCF = 7.5 Hz), 134.1, 153.1, 162.9 (d, JCF 
= 243 Hz), 165.9; HRMS (ESI+) m/z calc. for C22H25F2N4O4S2 [M+H]
+ 
511.1280, 
found: 511.1269; Anal. Calc. for C22H24F2N4O4S2: C, 51.75; H, 4.74; N, 10.97. 
Found: C, 51.73; H, 4.64; N, 10.92. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(2-(hydroxyimino)-3-
(4-(methylthio)phenyl)propanamide) (75g) 
N
H
N
O
S
N
N
H
O
S
HO
OH
S
S  
75g (114 mg, 20% from acid 74d) was prepared according to general procedure A 
above, and obtained as an amorphous light yellow solid after purification by flash 
column chromatography (acetone : PE40-60, 3 : 7 then MeOH : CH2Cl2 1 : 9). Rf 
0.4 (acetone : PE40-60, 4 : 6); IR (neat) 1653, 1625, 1523, 1492, 1424, 1000 cm
-1
; 
1
H NMR (400 MHz, d
6
-DMSO) δ 2.42 (s, 6H, CH3S), 2.81 (t, J = 6.7 Hz, 4H, 
CH2S), 3.41 (m, 4H, CH2N), 3.76 (s, 4H, 4-CH2), 7.15 (m, 8H, Ar-H), 8.06 (br. t, 
J = 5.4, 2H, NH), 11.85 (s, 2H, OH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 14.9, 
28.3, 36.9, 38.1, 126.1, 129.3, 133.5, 135.4, 151.6, 163.2; HRMS (ESI+) m/z calc. 
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for C24H31N4O4S4 [M+H]
+ 
567.1223, found: 567.1230; Anal. Calc. for 
C24H30N4O4S4: C, 50.86; H, 5.34; N, 9.89. Found: C, 50.91; H, 5.30; N, 9.81. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(2-(hydroxyimino)-3-
(3-iodo-4-methoxyphenyl)propanamide) (75h) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH
O
O
I
I  
75h (428 mg, 36% from acid 74e) was prepared according to general procedure A 
above,  and obtained as an amorphous light yellow solid after purification by flash 
column chromatography (gradient acetone : PE40-60, 3 : 7 to 4 : 6). Rf 0.45 
(acetone : PE40-60, 4 : 6); IR (neat) 1657, 1624, 1527, 1487, 1437, 1279, 1251, 
1047, 1014, 981 cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 2.80 (t, J = 6.7 Hz, 4H, 
CH2S), 3.50 (t, J = 6.7 Hz, 4H, CH2N), 3.79 (s, 6H, CH3O), 3.81 (s, 4H, 4-CH2), 
6.79 (d, J = 8.5 Hz, 2H, 2-H), 7.24 (dd, J = 8.5, 2.2 Hz, 2H, 3-H), 7.67 (d, J = 2.2 
Hz, 2H, 5-H). 
13
C NMR (100 MHz, CD3OD) δ 28.6, 38.7, 39.6, 56.9, 86.2, 112.0, 
131.5, 132.3, 141.0, 153.1, 158.3, 165.9; HRMS (ESI+) m/z calc. for 
C24H29I2N4O6S2 [M+H]
+ 
786.9612, found: 786.9631; Anal. Calc. for 
C24H28I2N4O6S2: C, 36.65; H, 3.59; N, 7.12. Found: C, 36.73; H, 3.48; N, 7.07. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
fluorophenyl)-2-(hydroxyimino)propanamide) (75i) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH
Br
F
Br
F
 
75i (201 mg, 30% from acid 74f) was prepared according to general procedure A 
above, and obtained as an amorphous white solid after purification by flash 
column chromatography (gradient acetone : PE40-60, 3 : 7 to 4 : 6). Rf 0.55 
(acetone : PE40-60, 4 : 6); IR (neat) 1655, 1623, 1528, 1491, 1427, 1404, 1242, 
1358, 1013, 984 cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 2.82 (t, J = 6.7 Hz, 4H, 
CH2S), 3.53 (t, J = 6.7 Hz, 4H, CH2N), 3.87 (s, 4H, 4-CH2), 7.06 (app-t, J = 8.5 
Hz, 2H, 2-H), 7.27 (ddd, J = 8.5, 4.7, 2.2 Hz, 2H, 3-H), 7.51 (dd, J = 6.7, 2.2 Hz, 
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2H, 5-H). 
13
C NMR (100 MHz, CD3OD) δ 29.0, 38.6, 39.6, 109.2 (d, JCF = 21.1 
Hz), 117.2 (d, JCF = 22.5 Hz), 131.2 (d, JCF = 6.9 Hz), 135.1, 136.1 (d, JCF = 3.5 
Hz), 152.5, 159.1 (d, JCF = 245 Hz), 165.7; HRMS (ESI+) m/z calc. for 
C22H23Br2F2N4O4S2 [M+H]
+ 
666.9490, found: 666.9500; Anal. Calc. for 
C22H22Br2F2N4O4S2: C, 39.53; H, 3.32; N, 8.38. Found: C, 39.58; H, 3.30; N, 
8.28. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
(methylthio)phenyl)-2-(hydroxyimino)propanamide) (75j) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH
S
Br
S
Br  
75j (270 mg, 25% from acid 74g) was prepared according to general procedure A 
above, and obtained as an amorphous light yellow solid after purification by flash 
column chromatography (gradient acetone : PE40-60, 3 : 7 to 1 : 1). Rf 0.25 
(acetone : PE40-60, 3 : 7); IR (neat) 1655, 1623, 1526, 1462, 1432, 1026 cm
-1
; 
1
H 
NMR (400 MHz, CD3OD) δ 2.41 (s, 6H, CH3S), 2.80 (t, J = 6.7 Hz, 4H, CH2S), 
3.51 (t, J = 6.7 Hz, 4H, CH2N), 3.85 (s, 4H, 4-CH2), 7.09 (d, J = 8.2 Hz, 2H, 2-H), 
7.25 (dd, J = 8.2, 1.8 Hz, 2H, 3-H), 7.45 (d, J = 1.8 Hz, 2H, 5-H). 
13
C NMR (100 
MHz, CD3OD) δ 15.8, 29.1, 38.7, 39.6, 122.4, 126.8, 130.1, 134.2, 136.3, 138.9, 
152.7, 165.8; HRMS (ESI+) m/z calc. for C24H29Br2N4O4S4 [M+H]
+ 
722.9433, 
found: 722.9441; Anal. Calc. for C24H28Br2N4O4S4: C, 39.78; H, 3.90; N, 7.73. 
Found: C, 39.73; H, 3.85; N, 7.67. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(2-(hydroxyimino)-3-
(3-iodo-4,5-dimethoxyphenyl)propanamide) (75k) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH
I
O
O
I
O
O
 
75k (295 mg, 23% from acid 74h) was prepared according to general procedure A 
above, and obtained as an amorphous light yellow solid after purification by flash 
column chromatography (gradient acetone : PE40-60, 3 : 7 to 4 : 6). Rf 0.15 
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(acetone : PE40-60, 3 : 7); IR (neat) 1657, 1528, 1480, 1413, 1268, 1137, 1041, 993 
cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 2.82 (t, J = 6.7 Hz, 4H, CH2S), 3.51 (t, J = 
6.7 Hz, 4H, CH2N), 3.71 (s, 6H, CH3O), 3.80 (s, 6H, CH3O), 3.83 (s, 4H, 4-CH2), 
6.95 (d, J = 1.7 Hz, 2H, 3-H), 7.23 (d, J = 1.7 Hz, 2H, 5-H). 
13
C NMR (100 MHz, 
CD3OD) δ 29.2, 38.7, 39.6, 56.4, 60.8, 92.5, 115.3, 131.9, 136.5, 148.7, 152.8, 
153.7, 165.8; HRMS (ESI+) m/z calc. for C26H33I2N4O8S2 [M+H]
+ 
846.9824, 
found: 846.9858; Anal. Calc. for C26H32I2N4O8S2: C, 36.89; H, 3.81; N, 6.62. 
Found: C, 36.92; H, 3.79; N, 6.57. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4,5-
dimethoxyphenyl)-2-(hydroxyimino)propanamide) (75l) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH
Br
O
O
Br
O
O
 
75l (339 mg, 45% from acid 74i) was prepared according to general procedure A 
above, and obtained as an amorphous white solid after purification by flash 
column chromatography (gradient acetone : PE40-60, 3 : 7 to 4 : 6). Rf 0.35 
(acetone : PE40-60, 4 : 6); IR (neat) 1656, 1625, 1528, 1487, 1413, 1271, 1138, 
1044, 998 cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 2.82 (t, J = 6.7 Hz, 4H, CH2S), 
3.52 (t, J = 6.7 Hz, 4H, CH2N), 3.74 (s, 6H, CH3O), 3.81 (s, 6H, CH3O), 3.85 (s, 
4H, 4-CH2), 6.93 (d, J = 1.8 Hz, 2H, 3-H), 7.03 (d, J = 1.8 Hz, 2H, 5-H). 
13
C 
NMR (100 MHz, CD3OD) δ 29.5, 38.7, 39.6, 56.6, 60.9, 114.3, 118.0, 126.1, 
135.7, 146.1, 152.7, 154.8, 165.8; HRMS (ESI+) m/z calc. for C26H33Br2N4O8S2 
[M+H]
+ 
751.0101, found: 751.0117; Anal. Calc. for C26H32Br2N4O8S2: C, 41.50; 
H, 4.29; N, 7.45. Found: C, 41.45; H, 4.21; N, 7.48. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3,4-
dimethoxyphenyl)-2-(hydroxyimino)propanamide) (75m) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH
O
O
O
O  
75m (115 mg, 13% from acid 74j) was prepared according to general procedure A 
above, and obtained as an amorphous light yellow solid after purification by flash 
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column chromatography (gradient acetone : PE40-60, 3 : 7 to 4 : 6). Important 
degradation was observed during the final deprotection step for reaction times 
superior to 2h. Only partial conversion to the product (and recovery of the starting 
material) was achieved during the deprotection step, avoiding degradation and 
allowing efficient purification of the product; Rf 0.25 (acetone : PE40-60, 4 : 6); IR 
(neat) 1658, 1628, 1511, 1419, 1259, 1233, 1141, 1022 cm
-1
; 
1
H NMR (400 MHz, 
CD3OD) δ 2.79 (t, J = 6.7 Hz, 4H, CH2S), 3.50 (t, J = 6.7 Hz, 4H, CH2N), 3.76 (s, 
6H, CH3O), 3.77 (s, 6H, CH3O), 3.85 (s, 4H, 4-CH2), 6.76-6.84 (m, 4H, 5-H + 6-
H), 6.90 (d, J = 1.5 Hz, 2H, 3-H). 
13
C NMR (100 MHz, CD3OD) δ 29.5, 38.7, 
39.6, 56.4, 56.6, 113.1, 114.3, 122.7, 131.0, 149.1, 150.3, 153.5, 166.1; HRMS 
(ESI+) m/z calc. for C26H35N4O8S2 [M+H]
+ 
595.1891, found: 595.1897; Anal. 
Calc. for C26H34N4O8S2: C, 52.51; H, 5.76; N, 9.42. Found: C, 52.54; H, 5.72; N, 
9.49. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(2-(hydroxyimino)-3-
(3-nitrophenyl)propanamide) (75n) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH
O2N
NO2
 
75n (170 mg, 30% from acid 74k) was prepared according to general procedure A 
above, and obtained as an amorphous white solid after purification by flash 
column chromatography  (gradient acetone/PE40-60, 3 : 7 to 4 : 6). Rf 0.35 (AcOEt 
: PE40-60, 4 : 6); IR (neat) 1655, 1625, 1520, 1425, 1346, 1208 cm
-1
; 
1
H NMR (400 
MHz, CD3OD) δ 2.82 (t, J = 6.8 Hz, 4H, CH2S), 3.52 (t, J = 6.8 Hz, 4H, CH2N), 
4.03 (s, 4H, 4-CH2), 7.48 (m, 2H, 6-H), 7.68 (m, 2H, 5-H), 8.04 (m, 2H, 1-H), 
8.16 (m, 2H, 3-H); 
13
C NMR (100 MHz, CD3OD) δ 29.8, 38.6, 39.6, 122.4, 124.9, 
130.5, 136.7, 140.6, 149.7, 152.1, 165.6; HRMS (ESI+) m/z calc. for 
C22H25N6O8S2 [M+H]
+ 
565.1170, found: 565.1198; Anal. Calc. for C22H24N6O8S2: 
C, 46.80; H, 4.28; N, 14.89. Found: C, 46.71; H, 4.23; N, 14.77. 
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(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-5-
nitrophenyl)-2-(hydroxyimino)propanamide) (75o) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH
Br
Br
O2N
NO2
 
75o (123 mg, 11% from acid 74l) was prepared according to general procedure A 
above, and obtained as an amorphous white solid after purification by flash 
column chromatography (gradient acetone : PE40-60, 3 : 7 to 4 : 6). Rf 0.25 
(acetone : PE40-60, 3 : 7); IR (neat) 1655, 1620, 1526, 1426, 1344, 1026, 988 cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 2.83 (t, J = 6.7 Hz, 4H, CH2S), 3.53 (t, J = 6.7 
Hz, 4H, CH2N), 4.02 (s, 4H, 4-CH2), 7.84-7.87 (m, 2H, 5-H), 8.12-8.15 (m, 2H, 3-
H), 8.20 (m, 2H, 1-H). 
13
C NMR (100 MHz, CD3OD - d
6
-DMSO) δ 29.8, 38.7, 
39.6, 123.3, 124.1, 125.5, 139.4, 142.8, 150.2, 151.7, 165.0; HRMS (ESI+) m/z 
calc. for C22H23Br2N6O8S2 [M+H]
+ 
720.9380, found: 720.9412; Anal. Calc. for 
C22H22Br2N6O8S2: C, 36.58; H, 3.07; N, 11.63. Found: C, 36.64; H, 3.01; N, 
11.68. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3,5-dibromo-4-
hydroxyphenyl)-2-(hydroxyimino)propanamide) (75p) 
N
H
N
O
S
N
N
H
O
S
HO
OH
Br
Br
HO
Br
OH
Br  
75p (270 mg, 22% from acid 74n) was prepared according to general procedure A 
above, and obtained as an amorphous light yellow solid after purification by flash 
column chromatography (gradient acetone : PE40-60, 35 : 65 to 50 : 50). Rf 0.3 
(acetone : PE40-60, 4 : 6); IR (neat) 1653, 1625, 1520, 1544, 1474, 1406, 1159 cm
-
1
; 
1
H NMR (400 MHz, CD3OD) δ 2.82 (t, J = 6.7 Hz, 4H, CH2S), 3.53 (t, J = 6.7 
Hz, 4H, CH2N), 3.79 (s, 4H, 4-CH2), 7.39 (s, 4H, Ar-H). 
13
C NMR (100 MHz, 
CD3OD) δ 28.5, 38.6, 39.6, 112.0, 132.3, 134.0, 150.7, 152.6, 165.7; HRMS 
(ESI+) m/z calc. for C22H23Br4N4O6S2 [M+H]
+ 
818.7787, found: 818.7811; Anal. 
Calc. for C22H22Br4N4O6S2: C, 32.14; H, 2.70; N, 6.81. Found: C, 32.08; H, 2.70; 
N, 6.74. 
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(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(2-(hydroxyimino)-3-
(3-methoxy-4-(methylthio)phenyl)propanamide) (75q) 
1
2
3
4
5
6
N
H
N
O
S
N
N
H
O
S
HO
OH
S
O
S
O  
75q (320 mg, 36% from acid 74o) was prepared according to general procedure A 
above, and obtained as an amorphous light yellow solid after purification by flash 
column chromatography (gradient acetone/PE40-60, 35 : 65 to 50 : 50). Rf 0.15 
(acetone/PE40-60, 3 : 7); IR (neat) 1655, 1624, 1525, 1484, 1408, 1248, 1031 cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 2.32 (s, 6H, CH3S), 2.79 (t, J = 6.7 Hz, 4H, 
CH2S), 3.49 (t, J = 6.7 Hz, 4H, CH2N), 3.80 (s, 6H CH3O), 3.88 (s, 4H, 4-CH2), 
6.85 (dd, J = 7.9, 1.6 Hz, 2H, 3-H), 6.86 (d, J = 1.6 Hz, 2H, 5-H), 7.03 (d, J = 7.9 
Hz, 2H, 2-H); 
13
C NMR (100 MHz, CD3OD/d
6
-DMSO) δ 14.7, 29.9, 38.6, 39.5, 
56.4, 112.6, 123.1, 126.0, 127.0, 136.3, 153.3, 157.5, 165.7; HRMS (ESI+) m/z 
calc. for C26H35N4O6S4 [M+H]
+ 
627.1434, found: 627.1439; Anal. Calc. for 
C26H34N4O6S4: C, 49.82; H, 5.47; N, 8.94. Found: C, 49.92; H, 5.56; N, 8.93. 
 
(E)-Ethyl 3-(3-bromo-4-hydroxyphenyl)acrylate (86) 
1
2
3
4
5
6
HO
Br
O
O  
To a solution of 3-bromo-4-hydroxybenzaldehyde 72a (1 g, 4.98 mmol, 1 eq.) in 
freshly distilled pyridine (2.5 mL) under an argon atmosphere were added 3-
ethoxy-3-oxopropanoic acid 83 (705 µL, 5.97 mmol, 1.2 eq.) and pyrrolidine (41 
µL, 0.498 mmol, 0.1 eq.). The resulting mixture was heated to 75°C. After 5 
hours, the solvent was evaporated. The residue was dissolved in AcOEt (20 mL), 
the organic phase was washed with 0.5 N aqueous HCl (4 mL). The aqueous 
phase was extracted with AcOEt (5 mL). The combined organic layers were dried 
(MgSO4) and concentrated. The product (1.21 g, 90%) was obtained after flash 
column chromatography (AcOEt/PE40-60 2 : 8) and recrystallization 
(CH2Cl2/hexane): m.p 103-106°C; Rf 0.55 (AcOEt/PE40-60 2 : 8). IR (neat) 3323, 
1682, 1632, 1599, 1200 cm
-1
;  
1
H NMR (400 MHz, CDCl3) δ 1.33 (t, J = 7.1 Hz, 
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3H, CH3), 4.25 (q, J = 7.1 Hz, 2H, CH2), 5.81 (s, 1H, OH), 6.30 (d, J = 16.0 Hz, 
1H, CHC(O)), 7.03 (d, J = 8.4 Hz, 1H, 2-H), 7.40 (dd, J = 8.4, 2.0 Hz, 1H, 3-H), 
7.55 (d, J = 16.0 Hz, 1H, 4-CH), 7.65 (d, J = 2.0 Hz, 1H, 5-H); 
13
C NMR (100 
MHz, CDCl3) δ 14.3, 60.5, 110.8, 116.4, 117.3, 128.8, 129.1, 131.7, 142.6, 153.9, 
166.9; HRMS (ESI+) m/z calc. for C11H12BrO3 [M+H]
+ 
270.9964 found: 
270.9959; Anal. Calc. for C11H11BrO3: C, 48.73; H, 4.09. Found: C, 48.85; H, 
4.05. 
 
Ethyl 3-(3-bromo-4-hydroxyphenyl)-2,3-dihydroxypropanoate (87) 
1
2
3
4
5
6
HO
7
8 CO2Et
OH
9
OH
10
Br
1
2
3
4
5
6
HO
7
8 CO2Et
OH
9
OH
10
Br
 
To a mixture of unsaturated ester (86) (400 mg, 1.48 mmol, 1 eq.) in a 2 : 1 
CH3CN/H2O mixture (12 mL) was added 4-methylmorpholine-N-oxide (NMO) 
(225 mg, 1.92 mmol, 1.3 eq.), at 0°C under an argon atmosphere. To this mixture 
was added a solution of osmium tetroxide (7.5 mg, 0.03 mmol, 0.02 eq.) in  t-
BuOH (1.5 mL). The resulting mixture was stirred at 0°C for 45 minutes, then at 
rt for 13 hours. Saturated aqueous Na2SO3 (1 mL) was added and CH3CN was 
evaporated under reduced pressure. The aqueous phase was extracted with AcOEt 
(4 x 15 mL). The combined organic phases were dried (MgSO4) and concentrated 
under reduced pressure. The product (405 mg, 90%) was obtained as a light 
yellow oil after purification by flash column chromatography (AcOEt/PE40-60 6 : 
4). Rf 0.4 (AcOEt/PE40-60 6 : 4);
 1
H NMR (400 MHz, d
6
-DMSO) δ 1.11 (t, J = 7.1 
Hz, 3H, CH3), 3.98-4-07 (m, 3H, CH2CH3 + 8-H), 4.65-4.72 (m, 1H, 7-H), 5.32 
(d, J = 7.2 Hz, 1H, OH), 5.44 (d, J = 5.7 Hz, 1H, OH), 6.86 (d, J = 8.3 Hz, 1H, 2-
H), 7.11 (dd, J = 8.3, 1.8 Hz, 1H, 3-H), 7.43 (d, J = 1.8 Hz, 1H, 5-H), 10.07 (s, 
1H, 1-OH); 
13
C NMR (100 MHz, d
6
-DMSO) δ 13.9, 59.9, 73.2, 75.4, 108.5, 
115.5, 126.9, 131.1, 134.1, 152.9, 172.0; HRMS (CI+) m/z calc. for C11H17BrNO5 
[M+NH4]
+ 
322.0285 found: 322.0291; Anal. Calc. for C11H13BrO5: C, 43.30; H, 
4.29. Found: C, 43.33; H, 4.15.  
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(E)-Ethyl 3-(3-bromo-4-hydroxyphenyl)-2-(hydroxyimino)propanoate (88) 
1
2
3
4
5
6
HO
CO2Et
NOH
Br
 
To a solution of diol 87 (215 mg, 0.705 mmol, 1 eq.) in anhydrous benzene (5.6 
mL) under an argon atmosphere was added p-toluenesulfonic acid monohydrate 
(13.4 mg, 0.0705 mmol, 0.1 eq.). The resulting mixture was heated at reflux for 3 
hours, then cooled to rt. The solvent was evaporated and the residue dissolved in 
anhydrous MeOH (1.6 mL), under an argon atmosphere. Hydroxylamine 
hydrochloride (49.0 mg, 0.705 mmol, 1 eq.) and sodium acetate (64 mg, 0.775 
mmol, 1.1 eq.) were successively added at 0°C. The resulting mixture was stirred 
for 6.5 hours. The white precipitate was removed by filtration and washed with 
MeOH. The filtrate was concentrated and the product (152 mg, 71%) was 
obtained after purification by flash column chromatography (AcOEt/CH2Cl2 1 : 
9). Ester 88 has been previously reported in the literature.
158,242
 
1
H NMR (400 
MHz, CDCl3) δ 1.34 (t, J = 7.1 Hz, 3H, CH3), 3.88 (s, 2H, 4-CH2), 4.30 (q, J = 7.1 
Hz, 1H, CH2CH3), 5.41 (br. s, 1H, 1-OH), 6.92 (d, J = 8.3 Hz, 1H, 2-H), 7.18 (dd, 
J = 8.3, 2.1 Hz, 1H, 3-H), 7.43 (d, J = 2.1 Hz, 1H, 5-H); 
13
C NMR (100 MHz, 
CDCl3) δ 14.1, 29.3, 62.1, 110.1, 116.0, 129.2, 130.2, 132.5, 151.1, 151.4, 163.1; 
HRMS (ESI+) m/z calc. for C11H13BrNO4 [M+H]
+ 
302.0022 found: 302.0034. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
hydroxyphenyl)-2-(hydroxyimino)propanamide) (28, PSAMMAPLIN A) 
HO
Br
H
N
O
N
HO
S
S
N
H
O
N
OH
Br
OH
 
To a solution of cystamine 53 (12.6 mg, 0.0828 mmol, 1 eq.) and ester 88 (50 mg, 
0.166 mmol, 2 eq.) in an anhydrous 1 : 1 CH2Cl2/CH3CN mixture (2.4 mL) , in a 
sealed tube and under an argon atmosphere, was added trimethylaluminium (2M 
in hexanes, 166 µL, 0.331 mmol, 4 eq.). Particular care was taken while handling 
the pyrophoric trimethylaluminium reagent. The resulting mixture was stirred at rt 
for 30 minutes, then at 60°C for 12h. 0.5M aqueous HCl was added dropwise and 
the solution was extracted several times with AcOEt over 20 minutes.  The 
Towards novel small molecule epigenetic inhibitors  Experimental 
176 
 
combined organic layers were dried (MgSO4) and concentrated under reduced 
pressure. Purification by flash column chromatography (acetone/PE40-60 1 : 1) 
afforded Psammaplin A (27 mg, 49%, 82% brsm). 
 
(E)-Methyl 3-(4-(dimethylamino)phenyl)acrylate (92) 
1
2
3
4
5
6
N
CO2Me  
Palladium (II) acetate (280 mg, 1.25 mmol, 0.05 eq.) was added to a mixture of 4-
bromo-N,N-dimethylbenzenamine 91 (5.0 g, 25.0 mmol, 1 eq.), methylacrylate 
(22.5 mL, 250 mmol, 10 eq.), triethylamine (10.4 mL, 75 mmol, 3 eq.) and tris(2-
methylphenyl)phosphine (760 mg, 2.5 mmol, 0.1 eq.) in anhydrous and degassed 
DMF (125 mL), at rt, under an inert atmosphere. The resulting mixture was stirred 
at 140 °C for 20h and monitored by TLC. The mixture was then poured into water 
(500 mL) and extracted with Et2O (2 x 400 mL) and CH2Cl2 (400 mL). The 
combined organic phases were washed with brine (300 mL), dried (MgSO4) and 
concentrated. The product (4.42 g, 86%) was purified by flash column 
chromatography (AcOEt/PE40-60 15 : 85). Light yellow crystals: m.p. 126-128°C 
(EtOH/water) (lit.
10
 132-135 °C); Rf 0.5 (AcOEt/PE40-60, 2 : 8); IR (neat) 1699, 
1601, 1524, 1441, 1365, 1328, 1163, 984 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 
3.02 (s, 6H, NMe2), 3.78 (s, 3H, OCH3), 6.22 (d, J = 15.8 Hz, 1H, 4-CHCH), 6.64-
6.70 (m, 2H, 2-H +6-H), 7.38-7.46 (m, 2H, 3-H + 5-H), 7.63 (d, J = 15.8 Hz, 1H, 
4-CH); 
13
C NMR (100 MHz, CDCl3) δ 40.1, 51.3, 111.8, 112.0, 122.1, 129.7, 
145.3, 151.7, 168.3; HRMS (ESI+) m/z calc. for C12H16NO2 [M+H]
+ 
206.1176, 
found: 206.1179; Anal. Calc. for C12H15NO2: C, 70.22; H, 7.37; N, 6.82. Found: 
C, 70.31; H, 7.43; N, 6.93. 
 
Methyl 3-(4-(dimethylamino)phenyl)-2,3-dihydroxypropanoate (93) 
1
2
3
4
5
6
N
7
8 CO2Me
OH
OH
1
2
3
4
5
6
N
7
8 CO2Me
OH
OH
 
To a mixture of unsaturated ester 23 (3.0 g, 14.6 mmol, 1 eq.) and NMO (3.77 g, 
32.1 mmol, 2.2 eq.) in a 2 : 1 CH3CN/H2O mixture (130 mL) was added a solution 
of osmium tetroxide (74 mg, 0.292 mmol, 0.02 eq.) in t-BuOH (15 mL). The 
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resulting mixture was stirred at rt under an inert atmosphere. The reaction was 
monitored by TLC. After 36h, saturated aqueous Na2SO3 was added and the 
mixture was extracted 3 times with AcOEt. The combined organic layers were 
washed 2 times with brine, dried (MgSO4) and concentrated under reduced 
pressure. Purification by flash column chromatography (AcOEt/CH2Cl2 6 : 4) 
afforded diol 93 (2.57 g, 73%). Colourless crystals: m.p. 69-71°C (Et2O); Rf 0.35 
(AcOEt/CH2Cl2, 6 : 4); IR (neat) 3456, 1743, 1613, 1519, 1437, 1202, 1119, 1061 
cm
-1
; 
1
H NMR (400 MHz, d
6
-DMSO) δ 2.85 (s, 6H, NMe2), 3.54 (s, 3H, OCH3), 
4.03 (dd, J = 7.3, 4.5 Hz, 1H, 8-H), 4.67 (m, 1H, 7-H), 5.23 (d, J = 5.6 Hz, 1H, 
OH), 5.28 (d, J = 7.3 Hz, 1H, OH), 6.62-6.68 (m, 2H, 2-H + 6-H), 7.10-7.17 (m, 
2H, 3-H + 5-H); 
13
C NMR (100 MHz, d
6
-DMSO) δ 40.2, 51.2, 73.8, 75.8, 111.7, 
127.3, 129.3, 149.6, 172.7; HRMS (ESI+) m/z calc. for C12H18NO4 [M+H]
+ 
240.1230, found: 240.1237; Anal. Calc. for C12H17NO4: C, 60.24; H, 7.16; N, 
5.85. Found: C, 60.42; H, 7.03; N, 5.94. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(4-
(dimethylamino)phenyl)-2-(hydroxyimino)propanamide) (89) 
1
2
3
4
5
6
N
H
N
O
N
HO
S
S
N
H
O
N
OH N
 
To a solution of diol 93 (1.20 g, 5.01 mmol, 1 eq.) in anhydrous benzene (40 mL) 
was added p-toluenesulfonic acid monohydrate (48 mg, 0.251 mmol, 0.05 eq.). 
The resulting mixture was stirred at reflux for 3.5h, and then quenched with a 
saturated aqueous NaHCO3 solution (20 mL). The two phases were separated, and 
the aqueous phase extracted with AcOEt (20 mL). The combined organic layers 
were dried (MgSO4) and concentrated to afford the crude arylpyruvate ester 
intermediate (1.11 g, quant.) which was used without further purification. To a 
solution of the crude arylpyruvic ester intermediate (800 mg, 3.62 mmol, 1.0 eq.) 
in anhydrous MeOH (8 mL) were added hydroxylamine hydrochloride (277 mg, 
3.98 mmol, 1.1 eq.) and sodium acetate (356 mg, 4.34 mmol, 1.2 eq.). The 
resulting mixture was stirred for 2h under an inert atmosphere and monitored by 
TLC. The solvent was then evaporated. The residue was dissolved in water and 
extracted 2 times with AcOEt. The combined organic phases were dried (MgSO4) 
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and concentrated, affording methyl 3-(4-(dimethylamino)phenyl)-2-
(hydroxyimino)propanoate 94 (835 mg, 98%) which was used without further 
purification. 
1
H NMR (400 MHz, d
6
-DMSO) δ 2.83 (s, 6H), 3.67-3.73 (m, 5H), 
6.58-6.66 (m, 2H), 6.97-7.05 (m, 2H), 12.32 (s, 1H); 
13
C NMR (100 MHz, d
6
-
DMSO) δ 28.9, 40.2, 52.0, 112.5, 123.6, 129.1, 149.0, 150.1, 164.2; HRMS 
(ESI+) m/z calc. for C12H17N2O3 [M+H]
+ 
237.1234, found: 237.1239. 
A solution of cystamine 53 (161 mg, 1.06 mmol, 1 eq.) and trimethylaluminium 
(2M in hexane, 1.06 mL, 2.12 mmol, 2 eq.) in anhydrous CH2Cl2 (20 mL) was 
stirred for 0.5h at rt, in a sealed tube and under an inert atmosphere. Particular 
care was taken while handling the pyrophoric trimethylaluminium reagent. Gas 
evolution could be observed and the pressure was released several times over 
0.5h. Ester 94 (500 mg, 2.12 mmol, 2 eq.) was then added in several portions and 
the resulting mixture was stirred at reflux for 8h. The formation of a yellow 
precipitate could be observed. The mixture was cooled to rt and quenched by 
addition of 0.5M aqueous HCl (pH ~ 3). The biphasic solution was stirred 
vigorously and the pH was maintained at 3 for 30 minutes. After stirring for 30 
minutes the pH was adjusted to 8-9 by addition of aqueous NaHCO3. The layers 
were separated and the aqueous layer was extracted 2 times with AcOEt. The 
combined organic phases were dried (MgSO4) and concentrated. The product was 
purified by flash column chromatography (gradient acetone/PE40-60, 3 : 7 to 4 : 6). 
After concentration of the fractions, CH2Cl2 was added to the resulting oily 
residue, allowing precipitation of the product as a white amorphous solid. 
Compound 89 (315 mg, 53% from 93, 76% brsm) was collected by filtration and 
dried under vacuum. White amorphous solid; Rf 0. 5 (acetone/PE40-60, 4 : 6); IR 
(neat) 3393, 3375, 3265 (br), 1653, 1624, 1518, 1439, 1423, 1342, 1221 cm
-1
; 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 2.77-2.84 (m, 16H, NMe2 + CH2S), 3.40 (m, 4H, 
CH2N), 3.68 (s, 4H, 4-CH2), 6.58-6.63 (m, 4H, 2-H + 6-H), 6.99-7.04 (m, 4H, 3-H 
+ 5-H), 7.99 (t, J = 5.8 Hz, 2H, NH), 11.69 (s, 2H, OH); 
13
C NMR (100 MHz, d
6
-
DMSO) δ 27.7, 36.9, 38.0, 40.2, 112.4, 124.1, 129.2, 148.9, 152.3, 163.3; HRMS 
(ESI+) m/z calc. for C26H37N6O4S2 [M+H]
+ 
561.2312, found: 561.2321; Anal. 
Calc. for C26H36N6O4S2: C, 55.69; H, 6.47; N, 14.99. Found: C, 55.80; H, 6.40; N, 
14.95. 
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Methyl 3-(3-bromo-4-(dimethylamino)phenyl)-2,3-dihydroxypropanoate (95) 
1
2
3
4
5
6
N
7
8
CO2Me
OH
OH
Br
 
N-bromosuccinimide (744 mg, 4.18 mmol, 1 eq.) was added to a solution of diol 
93 (1.0 g, 4.18 mmol, 1 eq.) in anhydrous DMF (35 mL) under an inert 
atmosphere. The resulting mixture was stirred at rt and monitored by TLC. After 
2h the mixture was poured into water (100mL) and extracted with AcOEt (2 x 100 
mL). The combined organic layers were washed 2 times with brine (100 mL), 
dried (MgSO4) and concentrated. Purification by flash column chromatography 
(AcOEt/CH2Cl2 4 : 6) afforded the brominated product 95 (1.20 g, 90%) as a 
brown viscous oil. Rf 0.5 (AcOEt/CH2Cl2, 4 : 6); IR (neat) 3427, 1735, 1602, 
1494, 1438, 1402, 1271, 1195, 1113, 1051, 1037, 945 cm
-1
; 
1
H NMR (400 MHz, 
d
6
-DMSO) δ 2.68 (s, 6H, NMe2), 3.61 (s, 3H, CH3), 4.14 (dd, J = 7.5, 3.5 Hz, 1H, 
8-H), 4.81 (dd, J = 5.9, 3.5 Hz, 1H, 7-H), 5.31 (d, J = 7.5 Hz, 1H, OH), 5.52 (d, J 
= 5.9 Hz, 1H, OH), 7.11 (d, J = 8.3 Hz, 1H, 2-H), 7.27 (dd, J = 8.3, 1.9 Hz, 1H, 3-
H), 7.56 (d, J = 1.9 Hz, 1H, 5-H); 
13
C NMR (100 MHz, d
6
-DMSO) δ 43.8, 51.4, 
72.9, 75.0, 117.8, 120.1, 126.6, 131.7, 138.1, 150.2, 172.5; HRMS (ESI+) m/z 
calc. for C12H17BrNO4 [M+H]
+ 
318.0335, found: 318.0344; Anal. Calc. for 
C12H16BrNO4: C, 45.30; H, 5.07; N, 4.40. Found: C, 45.26; H, 4.97; N, 4.34. 
 
Methyl 3-(3-bromo-4-(dimethylamino)phenyl)-2-(hydroxyimino)propanoate 
(96) 
1
2
3
4
5
6
N
CO2Me
N
HO
Br
 
To a solution of diol 95 (900 mg, 2.83 mmol, 1 eq.) in anhydrous benzene (23 
mL) was added p-toluenesulfonic acid monohydrate (108 mg, 0.564 mmol, 0.2 
eq.). The resulting mixture was stirred at reflux for 36h, and then quenched with a 
saturated aqueous NaHCO3 solution (23 mL). The two phases were separated, and 
the aqueous phase was extracted with AcOEt (1 x 23 mL). The combined organic 
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layers were dried (MgSO4) and concentrated to afford 795 mg of a solid 7 : 3 
mixture of the arylpyruvic ester intermediate and starting material respectively, 
which was used without further purification. 
To this crude solid (795 mg: 560 mg of dehydrated intermediate, 235 mg of 95) 
dissolved in anhydrous MeOH (5.6 mL) were added hydroxylamine hydrochloride 
(193 mg, 2.78 mmol) and sodium acetate (249 mg, 3.04 mmol, 1.2 eq.). The 
resulting mixture was stirred for 2h at rt under an inert atmosphere and monitored 
by TLC. The solvent was then evaporated. The residue was dissolved in water and 
extracted 2 times with AcOEt. The combined organic phases were dried (MgSO4) 
and concentrated. Purification by flash chromatography (AcOEt/PE40-60 3 : 7) 
afforded compound 96 (485 mg, 54% from 95, 75% brsm) as a yellow viscous oil. 
Rf 0.45 (AcOEt/PE40-60, 3 : 7); IR (neat) 3234, 1721, 1492, 1440, 1399, 1299, 
1202, 1114, 1002, 945 cm
-1
; 1H NMR (400 MHz, d
6
-DMSO) δ 2.66 (s, 6H, 
NMe2), 3.72 (s, 3H, CH3O), 3.76 (s, 2H, 4-CH2), 7.09 (d, J = 8.3 Hz, 1H, 2-H), 
7.14 (dd, J = 8.3, 1.9 Hz, 1H, 3-H), 7.37 (d, J = 1.9 Hz, 1H, 5-H), 12.53 (s, 1H, 
OH); 
13
C NMR (100 MHz, d
6
-DMSO) δ 28.8, 43.7, 52.2, 118.1, 120.8, 128.6, 
132.2, 133.3, 149.1, 149.8, 164.0; HRMS (ESI+) m/z calc. for C12H16BrN2O3 
[M+H]
+ 
315.0339, found: 315.0345; Anal. Calc. for C12H15BrN2O3: C, 45.73; H, 
4.80; N, 8.89. Found: C, 45.64; H, 4.93; N, 8.79. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
(dimethylamino)phenyl)-2-(hydroxyimino)propanamide) (90) 
1
2
3
4
5
6
N
Br
H
N
O
N
HO
S
S
N
H
O
N
OH
Br
N
 
A solution of cystamine 53 (97 mg, 0.634 mmol, 1 eq.) and trimethylaluminium 
(2M in hexane, 635 µL, 1.27 mmol, 2 eq.) in anhydrous CH2Cl2 (12 mL) was 
stirred for 1h at rt, in a sealed tube and under an inert atmosphere. Particular care 
was taken while handling the pyrophoric trimethylaluminium reagent. Gas 
evolution could be observed and the pressure was released several times over 
0.5h. Ester 96 (400 mg, 1.27 mmol, 2 eq.) in CH2Cl2 (2 mL) was then added 
dropwise and the resulting mixture was stirred at reflux for 8h. The mixture was 
cooled to rt and quenched by addition of 0.5M aqueous HCl (pH ~ 3). The 
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biphasic solution was stirred vigorously and the pH was maintained at 3 for 30 
minutes. After stirring for 30 minutes the pH was adjusted to 8-9 by addition of 
aqueous NaHCO3. The layers were separated and the aqueous layer was extracted 
2 times with AcOEt. The combined organic phases were dried (MgSO4) and 
concentrated. The product (175 mg, 34% from 90, 50% brsm) was purified by 
flash column chromatography (gradient acetone/PE40-60, 3 : 7 to 4 : 6) and 
obtained as a white amorphous solid. Rf 0. 5 (acetone/PE40-60, 4 : 6); IR (neat) 
3209 (br), 1655, 1625, 1523, 1490, 1452, 1432, 1204 cm
-1
; 
1
H NMR (400 MHz, 
d
6
-DMSO) δ 2.65 (s, 12H, NMe2), 2.81 (t, J = 6.8 Hz, 4H, CH2S), 3.41 (m, 4H, 
CH2N), 3.73 (s, 4H, 4-CH2), 7.06 (d, J = 8.3 Hz, 2H, 2-H), 7.15 (dd, J = 8.3, 1.8 
Hz, 2H, 3-H), 7.38 (d, J = 1.8 Hz, 2H, 5-H), 8.08 (t, J = 5.9 Hz, 2H, NH), 11.89 
(s, 2H, OH); 
13
C NMR (100 MHz, d
6
-DMSO) δ 27.8, 36.9, 38.1, 43.7, 118.0, 
120.7, 128.8, 132.6, 133.4, 149.6, 151.4, 163.1; HRMS (ESI+) m/z calc. for 
C26H35Br2N6O4S2 [M+H]
+ 
717.0522, found: 717.0531; Anal. Calc. for 
C26H34Br2N6O4S2: C, 43.46; H, 4.77; N, 11.70. Found: C, 43.58; H, 4.65; N, 
11.59. 
 
General procedure for the synthesis of ketoamide containing analogues:  
The appropriate crude acid (1 eq.) was added to a solution of the appropriate 
primary amine (1 eq. for 2-(methylthio)ethanamine, 0.5 eq. for cystamine, 
obtained from neutralization of cystamine dihydrochloride with sodium hydroxide 
in water and extraction with chloroform) and diisopropylethylamine (1.1 eq.) at 
0ºC in freshsly distilled THF (13 mL/mmol), followed by py-BOP (1.1 eq.). The 
resulting mixture was stirred overnight at rt. The day after the solvent was 
evaporated in vacuo and the product was purified by flash column 
chromatography without any prior work-up. 
 
 
3-(3-Bromo-4-hydroxyphenyl)-N-(2-(methylthio)ethyl)-2-oxopropanamide 
(97a) 
1
2
3
4
5
6
Br
HO
O
H
N
O
S
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Following the general procedure above, crude acid 51 was coupled with 2-
(methylthio)ethanamine 77 to afford product 97a (370 mg, 40%) as a white solid 
after purification by flash column chromatography (AcOEt : CH2Cl2, 1 : 9) and 
recrystallization from Et2O: m.p. 55-59ºC; Rf 0.6 (AcOEt : PE40-60, 1 : 1); IR 
3346, 1655, 1543, 1505, 1419 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 2.12 (s, 3H, 
CH3S), 2.66 (t, J = 6.5 Hz, 2H, CH2S), 3.52 (m, 2H, CH2N), 4.13 (s, 2H, 4-CH2), 
5.47 (br. s., 1H, OH), 6.98 (d, J = 8.3 Hz, 1H, 2-H), 7.11 (dd, J = 8.3, 2.0 Hz, 1H, 
3-H), 7.26 (br. t., 1H, NH), 7.37 (d, J = 2.0 Hz, 1H, 5-H). 
13
C NMR (100 MHz, 
CDCl3) δ 15.1, 33.4, 37.8, 41.8, 110.3, 116.2, 126.0, 130.7, 133.1, 151.5, 159.8, 
195.3; HRMS (ESI+) m/z calc. for C12H15BrNO3S [M+H]
+
 331.9951, found: 
331.9945; Anal. Calc. for C12H14BrNO3S: C, 43.38; H, 4.25; N, 4.22. Found: C, 
43.48; H, 4.16; N, 4.13. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
hydroxyphenyl)-2-oxopropanamide) (97b) 
1
2
3
4
5
6
Br
HO
O
H
N
O
S
Br
OH
O
N
H
O
S
 
Following the general procedure above, crude acid 51 was coupled with 
cystamine 53 to afford product  97b (117 mg, 24%) as an amorphous white solid 
after purification by flash column chromatography (AcOEt : CH2Cl2, 3 : 7). Rf 0.6 
(AcOEt : CH2Cl2, 4 : 6); IR 3354, 1668, 1495, 1418 cm
-1
; 
1
H NMR (400 MHz, 
CDCl3) δ 2.82 (t, J = 6.4 Hz, 4H, CH2S), 3.63 (m, 4H, CH2N), 4.12 (s, 4H, 4-
CH2), 5.49 (br. s, 2H, OH), 6.97 (d, J = 8.3 Hz, 2H, 2-H), 7.10 (dd, J = 8.3, 2.0 
Hz, 2H, 3-H), 7.30 (br. t., 2H, NH), 7.37 (d, J = 2.0 Hz, 2H, 5-H). 
13
C NMR (100 
MHz, CDCl3) δ 37.2, 38.4, 41.8, 110.3, 116.2, 125.9, 130.7, 133.1, 151.6, 160.0, 
195.3; HRMS (ESI+) m/z calc. for C22H23Br2N2O6S2 [M+H]
+ 
632.9359, found: 
632.9368; Anal. Calc. for C22H22Br2N2O6S2: C, 41.65; H, 3.50; N, 4.42. Found: C, 
41.54; H, 3.58; N, 4.37. 
 
3-(3-Bromo-4-methoxyphenyl)-N-(2-(methylthio)ethyl)-2-oxopropanamide 
(98a) 
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Following the general procedure above, crude acid 74a was coupled with 2-
(methylthio)ethanamine 77 to afford product 98a (481 mg, 63%) as a white solid 
after purification by flash column chromatography (AcOEt : PE40-60, 4 : 6) and 
recrystalization from Bu2O: m.p. 64-66ºC; Rf 0.65 (AcOEt : PE40-60, 1 : 1); IR 
1682, 1521, 1498, 1281, 1257, 1055 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 2.12 (s, 
3H, CH3S), 2.66 (t, J = 6.5 Hz, 2H, CH2S), 3.52 (m, 2H, CH2N), 3.88 (s, 3H, 
CH3O), 4.13 (s, 2H, 4-CH2), 6.86 (d, J = 8.4 Hz, 1H, 2-H), 7.17 (dd, J = 8.4, 2.1 
Hz, 1H, 3-H), 7.26 (br. t., 1H, NH), 7.44 (d, J = 2.1 Hz, 1H, 5-H). 
13
C NMR (100 
MHz, CDCl3) δ 15.1, 33.4, 37.8, 41.8, 56.2, 111.7, 112.0, 126.0, 130.0, 134.5, 
155.1, 159.8, 195.4; HRMS (ESI+) m/z calc. for C13H17BrNO3S [M+H]
+ 
346.0107, found: 346.0111; Anal. Calc. for C13H16BrNO3S: C, 45.10; H, 4.66; N, 
4.05. Found: C, 45.19; H, 4.60; N, 3.92. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
methoxyphenyl)-2-oxopropanamide) (98b) 
1
2
3
4
5
6
Br
O
O
H
N
O
S
Br
O
O
N
H
O
S
 
Following procedure A, crude acid 74a was coupled with cystamine 53 to afford 
product  98b (255 mg, 42%) as an amorphous white solid after purification by 
flash column chromatography (AcOEt : PE40-60, 6 : 4). Rf 0.4 (AcOEt : PE40-60, 1 : 
1); IR 1660, 1526, 1496, 1256 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 2.83 (t, J = 6.4 
Hz, 4H, CH2S), 3.63 (m, 4H, CH2N), 3.87 (s, 6H, CH3O), 4.13 (s, 4H, 4-CH2), 
6.85 (d, J = 8.5 Hz, 2H, 2-H), 7.16 (dd, J = 8.4, 2.2 Hz, 2H, 3-H), 7.31 (br. t., 2H, 
NH), 7.43 (d, J = 2.2 Hz, 2H, 5-H). 
13
C NMR (100 MHz, CDCl3) δ 37.2, 38.4, 
41.8, 56.2, 111.7, 112.0, 125.9, 130.0, 134.5, 155.1, 160.0, 195.3; HRMS (ESI+) 
m/z calc. for C24H27Br2N2O6S2 [M+H]
+ 
660.9672, found: 660.9692; Anal. Calc. 
for C24H26Br2N2O6S2: C, 43.52; H, 3.96; N, 4.23. Found: C, 43.62; H, 3.88; N, 
4.10. 
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General procedure for the synthesis of hydrazone containing analogues: 
To a solution of the appropriate ketoamide containing compound (1.1 eq.) in 
freshly distilled MeOH (10 mL/mmol) at rt was added hydrazine monohydrate 
(compounds 97a and 98a: 1.1 eq.; compounds 97b and 98b: 2.2 eq.). The 
resulting mixture was heated to reflux for 2.5 hours then cooled to rt. The solvent 
was then evaporated in vacuo and the product was purified by flash column 
chromatography. 
 
(E)-3-(3-Bromo-4-hydroxyphenyl)-2-hydrazono-N-(2-
(methylthio)ethyl)propanamide (111a) 
1
2
3
4
5
6
HO
Br
N
H2N
H
N
O
S
 
111a (220 mg, 58%) was prepared from 97a according general procedure above, 
and obtained as a white solid after purification by flash column chromatography 
(AcOEt/CH2Cl2 15 : 85) and recrystallization fromCH2Cl2: m.p. 103-104ºC 
(CH2Cl2); Rf 0.25 (AcOEt : CH2Cl2, 1 : 9);  IR 3414, 3359, 3116, 1633, 1620, 
1528, 1509, 1421 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 2.14 (s, 3H, CH3S), 2.69 (t, 
J = 6.5 Hz, 2H, CH2S), 3.56 (m, 2H, CH2N), 3.81 (s, 2H, 4-CH2), 5.59 (br. s, 1H, 
OH), 5.68 (br. s, 2H, NH2), 6.92 (d, J = 8.3 Hz, 1H, 2-H), 7.07 (dd, J = 8.3, 2.0 
Hz, 1H, 3-H), 7.31 (d, J = 2.0 Hz, 1H, 5-H), 7.32 (br. t, 1H, NH). 
13
C NMR (100 
MHz, CDCl3) δ 15.2, 27.6, 34.0, 37.9, 110.6, 116.4, 128.8, 129.2, 131.5, 141.6, 
151.2, 164.6; HRMS (ESI+) m/z calc. for C12H17BrN3O2S [M+H]
+
 346.0219, 
found: 346.0214; Anal. Calc. for C12H16BrN3O2S: C, 41.63; H, 4.66; N, 12.14. 
Found: C, 41.55; H, 4.60; N, 12.07. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
hydroxyphenyl)-2-hydrazonopropanamide) (111b) 
1
2
3
4
5
6
HO
Br
N
H2N
H
N
O
S
S
N
H
O
N
NH2 OH
Br  
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111b (182 mg, 74%) was prepared from 97b according to general procedure 
above, and obtained as an amorphous white solid after purification by flash 
column chromatography (MeOH/CH2Cl2 6 : 94). Rf 0.35 (MeOH: CH2Cl2, 6 : 94);  
IR 3359, 3312, 1626, 1530, 1503, 1193 cm
-1
; 
1
H NMR (400 MHz, d
6
-DMSO) δ 
2.82 (t, J = 6.8 Hz, 4H, CH2S), 3.42 (m, 4H, CH2N), 3.64 (s, 4H, 4-CH2), 6.81 (d, 
J = 8.3 Hz, 2H, 2-H), 7.01 (dd, J = 8.3, 1.9 Hz, 2H, 3-H), 7.21 (s, 4H, NH2), 7.31 
(d, J = 1.9 Hz, 2H, 5-H), 7.79 (t, J = 5.9 Hz, 2H, NH), 9.97 (s, 2H, OH). 
13
C NMR 
(100 MHz, d
6
-DMSO) 26.1, 37.3, 38.0, 108.8, 116.0, 128.7, 129.0, 132.4, 136.8, 
152.1, 165.0; HRMS (ESI+) m/z calc. for C22H27Br2N6O4S2 [M+H]
+
 660.9896, 
found: 660.9910; Anal. Calc. for C22H26Br2N6O4S2: C, 39.89; H, 3.96; N, 12.69. 
Found: C, 39.84; H, 3.88; N, 12.61. 
 
(E)-3-(3-Bromo-4-methoxyphenyl)-2-hydrazono-N-(2-
(methylthio)ethyl)propanamide (112a) 
1
2
3
4
5
6
O
Br
N
H2N
H
N
O
S
 
112a (273 mg, 69%) was prepared from 98a according general procedure above, 
and obtained as an amorphous white solid after purification by flash column 
chromatography (AcOEt/CH2Cl2 1 : 9). Rf 0.55 (AcOEt : CH2Cl2, 1 : 9);  IR 3376, 
3338, 1637, 1517, 1491, 1251, 1051 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 2.14 (s, 
3H, CH3S), 2.69 (t, J = 6.5 Hz, 2H, CH2S), 3.56 (m, 2H, CH2N), 3.82 (s, 2H, 4-
CH2), 3.86 (s, 3H, CH3O), 5.67 (br. s, 2H, NH2), 6.81 (d, J = 8.4 Hz, 1H, 2-H), 
7.13 (dd, J = 8.4, 2.1 Hz, 1H, 3-H), 7.31 (br. t, 1H, NH), 7.40 (d, J = 2.1 Hz, 1H, 
5-H). 
13
C NMR (100 MHz, CDCl3) δ 15.2, 27.6, 34.0, 37.9, 56.3, 112.1, 112.3, 
128.3, 128.8, 133.0, 141.7, 154.7, 164.5; HRMS (ESI+) m/z calc. for 
C13H19BrN3O2S [M+H]
+
 360.0376, found: 360.0372; Anal. Calc. for 
C13H18BrN3O2S: C, 43.34; H, 5.04; N, 11.66. Found: C, 43.26; H, 4.93; N, 11.56. 
 
(2E,2'E)-N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
methoxyphenyl)-2-hydrazonopropanamide) (112b) 
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112b (217 mg, 59%) was prepared from 98b according general procedure above, 
and obtained as an amorphous white solid after purification by flash column 
chromatography (MeOH/CH2Cl2 2 : 98).  Rf 0.3 (AcOEt : PE40-60, 3 : 7);  IR 3396, 
3316, 1637, 1516, 1493, 1253, 1053 cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 2.87 (t, 
J = 6.7 Hz, 4H, CH2S), 3.56 (t, J = 6.7 Hz, 4H, CH2N), 3.76 (s, 4H, 4-CH2), 3.81 
(s, 6H, CH3O), 6.90 (d, J = 8.4 Hz, 2H, 2-H), 7.16 (dd, J = 8.4, 2.0 Hz, 2H, 3-H), 
7.39 (d, J = 2.0 Hz, 2H, 5-H). 
13
C NMR (100 MHz, CD3OD) δ 27.7, 39.1, 39.6, 
56.8, 112.5, 113.4, 129.8, 131.3, 134.1, 139.2, 156.0, 167.8; HRMS (ESI+) m/z 
calc. for C24H31Br2N6O4S2 [M+H]
+
 689.0209, found: 689.0206; Anal. Calc. for 
C24H30Br2N6O4S2: C, 41.75; H, 4.38; N, 12.17. Found: C, 41.81; H, 4.30; N, 
12.12. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-(3-bromo-4-
hydroxyphenyl)propanamide) (115) 
1
2
3
4
5
6
H
N
O
S
Br
HO
S
N
H
O
OH
Br  
To a solution of cystamine 53 (43.5mg, 0.286 mmol, 1 eq.), triethylamine (239 
µL, 1.71 mmol, 6 eq.) and HOBt (92.6 mg, 0.685 mmol, 2.4 eq.) in CH2Cl2 (10 
mL), under an argon atmosphere, at rt, were added successively EDCI (131 mg, 
0.685 mmol, 2.4 eq.) and 3-(3-bromo-4-hydroxyphenyl)propanoic acid 114 (140 
mg, 0.571 mg, 2 eq.). The resulting mixture was stirred for 15h at rt before the 
solvent was evaporated. The residue was then dissolved in ethyl acetate (10 mL), 
washed with 1N aqueous HCl (5 mL), saturated aqueous NaHCO3 (5 mL) and 
brine (5 mL). The organic phase was dried (MgSO4) and concentrated. The 
product (83 mg, 48%) was obtained as a white solid after purification by flash 
column chromatography (AcOEt). Rf 0.2 (AcOEt). IR (neat) 3283, 1635, 1537, 
1506, 1495, 1419, 1221 cm
-1
; 
1
H NMR (400 MHz, CD3OD) δ 2.43 (t, J = 7.4 Hz 
4H, CH2C(O)), 2.70 (t, J = 6.7 Hz, 4H, CH2S), 2.81 (t, J = 7.4 Hz, 4H, 4-CH2), 
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3.42 (t, J = 6.7 Hz, 4H, CH2N), 6.79 (d, J = 8.3 Hz, 2H, 2-H), 6.99 (dd, J = 8.3, 
2.1 Hz, 2H, 3-H), 7.30 (d, J = 2.1 Hz, 2H, 5-H). 
13
C NMR (100 MHz, CD3OD) δ 
31.6, 38.5, 38.9, 39.5, 110.7, 117.2, 129.7, 133.9, 134.7, 153.7, 175.2; HRMS 
(ESI+) m/z calc. for C22H27Br2N2O4S2 [M+H]
+ 
604.9774 found: 604.9781; Anal. 
Calc. for C22H26Br2N2O4S2: C, 43.58; H, 4.32; N, 4.62. Found: C, 43.66; H, 4.38; 
N, 4.71. 
 
 
 
3-(1,3-Dioxoisoindolin-2-yl)-N-(tetrahydro-2H-pyran-2-yloxy)propanamide 
(123) 
N
O
O O
HN O
1
O
2
3
45
6
 
To a mixture of 3-(1,3-dioxoisoindolin-2-yl)propanoic acid 121
175
  (3.5 g, 16.0 
mmol, 1 eq.) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine
155
 54 (1.96 g, 16.8 
mmol, 1.05 eq.) in chloroform (135 mL) was added EDCI (3.37 g, 17.6 mmol, 1.1 
eq.), followed by DMAP (195 mg, 1.60 mmol, 0.1 eq.). The resulting mixture was 
stirred overnight at rt. The day after, the reaction mixture was concentrated, water 
(195 mL) was added and extracted with AcOEt (3 x 135 mL). The combined 
organic layers were washed with brine (195 mL), dried (Na2SO4) and 
concentrated in vacuo. The product (4.06 g, 80%) was obtained as a white solid 
after purification by flash column chromatography (gradient MeOH/CH2Cl2 2 : 98 
to 10:90). Rf 0.45 (AcOEt : CH2Cl2, 1 : 1); IR (neat) 1710, 1680, 1653, 1398, 
1113 cm
-1
; 
1
H NMR (400 MHz, d
6
-DMSO) δ 1.38-1.72 (m, 6H, 4-H2 + 5-H2 + 6-
H2), 2.36 (t, J = 7.0 Hz, 2H, CH2C(O)), 3.40 (m, 1H, 3-HA), 3.78 (t, J = 7.0 Hz, 
2H, NCH2), 3.83 (m, 1H, 3-HB), 4.74 (m, 1H, 1-H), 7.81-7.91 (m, 4H, Ar-H), 
11.08 (s, 1H, NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 18.3, 24.5, 27.6, 31.1, 34.0, 
61.3, 100.7, 122.9, 131.6, 134.2, 166.2, 167.5; HRMS (ESI+) m/z calc. for 
C16H18N2NaO5 [M+Na]
+ 
341.1108, found: 341.1109; Anal. Calc. for C16H18N2O5: 
C, 60.37; H, 5.70; N, 8.80. Found: C, 60.31; H, 5.62; N, 8.75. 
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4-(1,3-Dioxoisoindolin-2-yl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 
(124) 
N
H
O
O 1
2
3
4
5O
6
N
O
O
 
To a mixture of 4-(1,3-dioxoisoindolin-2-yl)butanoic acid 122
175
  (4.0 g, 17.2 
mmol, 1 eq.) and O-(tetrahydro-2H-pyran-2-yl)hydroxylamine
155
 54 (2.11 g, 18.0 
mmol, 1.05 eq.) in chloroform (145 mL) was added EDCI (3.62 g, 18.9 mmol, 1.1 
eq.), followed by DMAP (210 mg, 1.72 mmol, 0.1 eq.). The resulting mixture was 
stirred overnight at rt. The day after, the reaction mixture was concentrated, water 
(210 mL) was added and extracted with CHCl3 (3 x 140 mL). The combined 
organic layers were washed with brine (210 mL), dried (Na2SO4) and 
concentrated in vacuo. The product (5.35 g, 94%) was obtained as a white solid 
after purification by flash column chromatography (MeOH/CH2Cl2 5 : 95). Rf 
0.45 (AcOEt : CH2Cl2, 1 : 1); 
1
H NMR (400 MHz, d
6
-DMSO) δ 1.40-1.70 (m, 6H, 
2-H + 3-H + 4-H), 1.81 (app-quintuplet, J = 7.2 Hz, 2H, NCH2CH2), 2.03 (t, J = 
7.2 Hz, 2H, CH2C(O)), 3.47 (m, 1H, 5-HA), 3.57 (t, J = 6.9 Hz, 2H, CH2N), 3.88 
(m, 1H, 5-HB), 4.75 (m, 1H, 1-H), 7.78-7.92 (m, 4H, ArH), 10.92 (s, 1H, NH). 
13
C 
NMR (100 MHz, d
6
-DMSO) δ 18.2, 23.8, 24.6, 27.7, 29.6, 37.0, 61.2, 100.8, 
122.9, 131.6, 134.2, 167.8, 168.2. HRMS (ESI+) m/z calc. for C17H20N2NaO5 
[M+Na]
+ 
355.1264, found: 355.1266. Anal. Calc. for C17H20N2O5: C, 61.44; H, 
6.07; N, 8.43. Found: C, 61.51; H, 6.02; N, 8.36. 
 
3-Amino-N-(tetrahydro-2H-pyran-2-yloxy)propanamide (125) 
H2N N
H
O
O 1
2
3
4
5O
6
 
To a mixture of 3-(1,3-dioxoisoindolin-2-yl)-N-(tetrahydro-2H-pyran-2-
yloxy)propanamide 123 (3.23 g, 10.1 mmol, 1 eq.) in freshly distilled methanol 
(65 mL) was added hydrazine monohydrate (517 μL, 10.7 mmol, 1.05 eq.). The 
resulting mixture was heated to reflux for 2.5h, then cooled to rt. The white 
precipitate formed was filtered off and washed with a small amount of methanol. 
The methanolic phase was concentrated in vacuo and the product (805 mg, 42 %) 
was obtained as a white solid after purification by flash column chromatography 
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(CHCl3/MeOH/aq. NH3 80 : 18 : 2) without prior workup. Rf 0.2 
(CHCl3/MeOH/aq. NH3 80 : 18 : 2); IR (neat) 1659, 1573, 1361, 1112, 1073, 1031 
cm
-1
; 
1
H NMR (400 MHz, d
6
-DMSO) δ 1.42-1.74 (m, 6H, 2-H2 + 3-H2 + 4-H2), 
2.06 (t, J = 6.6 Hz, 2H, CH2(O)), 2.72 (t, J = 6.6 Hz, 2H, NCH2), 3.44-3.54 (m, 
1H, 5-HA), 3.85-3.96 (m, 1H, 5-HB), 4.52 (br. s, 2H, NH2), 4.81 (m, 1H, 1-H). 
13
C 
NMR (100 MHz, d
6
-DMSO) δ 18.2, 24.6, 27.7, 36.3, 38.1, 61.2, 100.7, 168.3; 
HRMS (ESI+) m/z calc. for C8H17N2O3 [M+H]
+ 
189.1234, found: 189.1232; Anal. 
Calc. for C8H16N2O3: C, 51.05; H, 8.57; N, 14.88. Found: C, 51.15; H, 8.65; N, 
14.94. 
 
4-Amino-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 126 
N
H
O
O 1
2
3
4
5O
6
H2N
 
To a mixture of 4-(1,3-dioxoisoindolin-2-yl)-N-(tetrahydro-2H-pyran-2-
yloxy)butanamide 124 (2.50 g, 7.52 mmol, 1 eq.) in freshly distilled methanol (50 
mL) was added hydrazine monohydrate (401 μL, 8.27 mmol, 1.1 eq.). The 
resulting mixture was stirred overnight at rt. The white precipitate formed was 
filtered off and washed with a small amount of methanol. The methanolic phase 
was concentrated in vacuo and the product (758 mg, 50 %) was obtained as a 
white solid after purification by flash column chromatography (CHCl3/MeOH/aq. 
NH3 80 : 18 : 2) without prior workup. Rf 0.2 (CHCl3/MeOH/aq. NH3 80 : 18 : 2); 
1
H NMR (400 MHz, d
6
-DMSO) δ 1.42-1.74 (m, 8H, 2-H2 + 3-H2 + 4-H2 + 
NCH2CH2), 2.00 (t, J = 7.3 Hz, 2H, CH2C(O)), 2.49 (t, J = 7.3 Hz, 2H, NCH2), 
3.44-3.54 (m, 1H, 5-HA), 3.85-3.96 (m, 1H, 5-HB), 4.56 (br. s, 2H, NH2), 4.79 (m, 
1H, 1-H). 
13
C NMR (100 MHz, d
6
-DMSO) δ 18.2, 24.6, 27.7, 29.0, 29.8, 41.0, 
61.2, 100.7, 169.1; HRMS (ESI+) m/z calc. for C9H19N2O3 [M+H]
+ 
203.1390, 
found: 203.1389; Anal. Calc. for C9H18N2O3: C, 53.45; H, 8.97; N, 13.85. Found: 
C, 53.53; H, 8.90; N, 13.81. 
 
(E)-3-(3-Bromo-4-hydroxyphenyl)-N-(3-(hydroxyamino)-3-oxopropyl)-2-
(hydroxyimino)propanamide (116) 
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To a solution of 3-(3-bromo-4-hydroxyphenyl)-2-hydroxyacrylic acid 51 (1 eq.) in 
freshly distilled pyridine (2 mL/mmol), under argon, was added O-(tetrahydro-
2H-pyran-2-yl)hydroxylamine 54 (1.5 eq.). The resulting mixture was stirred 
overnight at room temperature. Pyridine was then removed in vacuo, the residue 
was dissolved in 1N HCl (5.5 mL/mmol) and extracted three times with ethyl 
acetate (5.5 mL/mmol). The combined organic layers were dried (Na2SO4), 
filtrated and concentrated to afford the crude O-THP protected oxime 
intermediate, used for the next step without further purification. To a solution of 
the crude O-THP protected oxime intermediate (1 eq.) in dry dioxane (2.7 
mL/mmol) under argon were added EDCI (1.7 equiv.) and NHS (1.9 equiv.). The 
resulting mixture was stirred at room temperature for 3 hours. The solvent was 
then evaporated in vacuo. The residue was dissolved in EtOAc (12 mL/mmol), 
washed with saturated aqueous NaHCO3 (2 x 12 mL/mmol), 1N aqueous HCl (2 x 
12 mL/mmol) and brine (1 x 12 mL/mmol). The organic phase was then dried 
(Na2SO4), filtrated, and the solvent evaporated in vacuo. The residue was 
dissolved in dry dioxane (2.7 mL/mmol) under argon and a second solution of 3-
amino-N-(tetrahydro-2H-pyran-2-yloxy)propanamide 125 (1.0 eq.) and NEt3 (1.0 
eq.) in dry dioxane (2.7 mL/mmol) were added. The resulting mixture was then 
stirred overnight at rt. The day after the solvent was evaporated and the product 
was purified by flash collumn chromatography (1 : 1 AcOEt/PE40-60). The O-THP 
diprotected precursor was then dissolved in an anhydrous 0.5M solution of HCl in 
9:1 dioxane/iPrOH (21 mL / mmol). The resulting mixture was stirred at rt and the 
reaction monitored by TLC. After 20h the solvent was evaporated in vacuo and 
the product (81 mg, 13%) was obtained as a white solid after purification by flash 
column chromatography (1 : 9 MeOH/CH2Cl2). Rf 0.15 (MeOH : CH2Cl2, 1 : 9); 
IR (neat) 3202, 1626, 1532, 1492, 1418, 1211, 993 cm
-1
; 
1
H NMR (400 MHz, d
6
-
DMSO) δ 2.17 (t, J = 7.1 Hz, 2H, CH2C(O)), 3.32 (app-q, J = 7.0 Hz, 2H, N-
CH2), 3.67 (s, 2H, 4-CH2), 6.83 (d, J = 8.3 Hz, 1H, 2-H), 7.01 (dd, J = 8.3, 2.0 Hz, 
1H, 3-H), 7.29 (d, J = 2.0 Hz, 1H, 5-H), 7.93 (t, J = 5.8 Hz, 1H, NHCH2), 8.74 (s, 
1H, NHOH), 10.03 (s, 1H, 1-OH), 10.44 (s, 1H, NHOH), 11.87 (s, 1H, NOH). 
13
C 
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NMR (100 MHz, d
6
-DMSO) δ 27.5, 31.9, 35.4, 108.8, 116.1, 128.7, 129.0, 132.7, 
151.6, 152.3, 162.8, 167.3; HRMS (ESI+) m/z calc. for C12H15BrN3O5 [M+H]
+ 
360.0190, found: 360.0195; Anal. Calc. for C12H15BrN3O5: C, 40.02; H, 3.92; N, 
11.67. Found: C, 40.14; H, 3.83; N, 11.61. 
 
(E)-4-(3-(3-Bromo-4-hydroxyphenyl)-2-(hydroxyimino)propanamido)-N-
hydroxybutanamide 117 
1
2
3
4
5
6
Br
HO
N
HO
H
N
O
N
H
O
OH
 
To a solution of 3-(3-bromo-4-hydroxyphenyl)-2-hydroxyacrylic acid 51 (1 eq.) in 
freshly distilled pyridine (2 mL/mmol), under argon, was added O-(tetrahydro-
2H-pyran-2-yl)hydroxylamine 54 (1.5 eq.). The resulting mixture was stirred 
overnight at room temperature. Pyridine was then removed in vacuo, the residue 
was dissolved in 1N HCl (5.5 mL/mmol) and extracted three times with ethyl 
acetate (5.5 mL/mmol). The combined organic layers were dried (Na2SO4), 
filtrated and concentrated to afford the crude O-THP protected oxime 
intermediate, used for the next step without further purification. To a solution of 
the crude O-THP protected oxime intermediate (1 eq.) in dry dioxane (2.7 
mL/mmol) under argon were added EDCI (1.7 equiv.) and NHS (1.9 equiv.). The 
resulting mixture was stirred at room temperature for 3 hours. The solvent was 
then evaporated in vacuo. The residue was dissolved in EtOAc (12 mL/mmol), 
washed with saturated aqueous NaHCO3 (2 x 12 mL/mmol), 1N aqueous HCl (2 x 
12 mL/mmol) and brine (1 x 12 mL/mmol). The organic phase was then dried 
(Na2SO4), filtrated, and the solvent evaporated in vacuo. The residue was 
dissolved in dry dioxane (2.7 mL/mmol) under argon and a second solution of 4-
amino-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 126 (1.0 eq.) and NEt3 (1.0 
eq.) in dry dioxane (2.7 mL/mmol) were added. The resulting mixture was then 
stirred overnight at rt. The day after the solvent was evaporated and the product 
was purified by flash collumn chromatography (1 : 1 acetone/PE40-60). The O-THP 
diprotected precursor was then dissolved in a anhydrous 0.5M solution of HCl in 
9:1 dioxane/iPrOH (21 mL / mmol). The resulting mixture was stirred at rt and the 
reaction monitored by TLC. After 20h the solvent was evaporated in vacuo and 
the product (170 mg, 15%) was obtained as a white solid after purification by 
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flash column chromatography (1 : 9 MeOH/CH2Cl2). Rf 0.15 (MeOH : CH2Cl2, 1 : 
9); IR (neat) 3184, 1623, 1536, 1493, 1418, 1208, 993 cm
-
1; 1H NMR (400 MHz, 
d
6
-DMSO) δ 1.63 (quintet, J = 7.3 Hz, 2H, NCH2CH2), 1.92 (t, J = 7.3 Hz, 2H, 
CH2C(O)), 3.11 (m, 2H, NCH2), 3.68 (s, 2H, 4-CH2), 6.83 (d, J = 8.3 Hz, 1H, 2-
H), 7.01 (dd, J = 8.3, 2.0 Hz, 1H, 3-H), 7.29 (d, J = 2.0 Hz, 1H, 5-H), 8.00 (t, J = 
6.0 Hz, 1H, NHCH2), 8.67 (s, 1H, NHOH), 10.03 (s, 1H, 1-OH), 10.34 (s, 1H, 
NHOH), 11.77 (s, 1H, NOH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 25.2, 27.7, 29.8, 
38.3, 108.7, 116.0, 128.8, 129.0, 132.7, 151.9, 152.2, 163.1, 168.7; HRMS (ESI+) 
m/z calc. for C13H17BrN3O5 [M+H]
+ 
374.0346, found: 374.0359; Anal. Calc. for 
C13H16BrN3O5: C, 41.73; H, 4.31; N, 11.23. Found: C, 41.63; H, 4.23; N, 11.18. 
 
 
2-Acetylsulfanylethyl ammonium chloride (127)  
ClH.H2N
SAc
 
127 was prepared as previously reported.
176
 2-mercaptoethyl-ammonium chloride 
(2.0 g, 17.6 mmols, 1 eq.) was stirred under argon in acetyl chloride (10 mL) for a 
few minutes at room temperature, progressive HCl gas evolution was obsverved. 
The mixture was then stirred at 40°C for 2 hours to complete the reaction, then 
cooled to room temperature. The precipitate was filtered, washed with Et2O, 
recrystalized from EtOH, washed with Et2O and dried in vacuo to afford the pure 
product (1.89 g, 69%) as a white solid: m.p. 142 – 145 °C (EtOH) (lit.176146-147 
°C). Anal. Calc. For C4H10ClNOS: C, 30.87; H, 6.48; N, 9.00. Found: C, 30.76; 
H, 6.54; N, 8.96. 
 
(E)-(S)-2-(3-(3-Bromo-4-methoxyphenyl)-2-
(methoxyimino)propanamido)ethyl ethanethioate (128) 
1
2
3
4
5
6
Br
O
N
H
N
O
S
O
O
 
128 (216 mg, 30% from acid 74a) was prepared according to the general 
procedure described earlier for the symthesis of O-methyloxime containing 
analogues, and obtained as a yellowish oil after purification by flash column 
chromatography (AcOEt : CH2Cl2, 2 : 98). Rf 0.35 (AcOEt : CH2Cl2 2 : 98); IR 
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1674, 1520, 1495, 1044 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 2.33 (s, 3H, CH3C), 
3.04 (t, J = 6.6 Hz, 2H, CH2S), 3.48 (m, 2H, CH2N), 3.81 (s, 2H, 4-CH2), 3.84 (s, 
3H, CH3O-1), 4.01 (s, 3H, CH3O-N), 6.78 (d, J = 8.4 Hz, 1H, 2-H), 6.97 (br. t, 
1H, NH), 7.21 (dd, J = 8.4, 2.1 Hz, 1H, 3-H), 7.46 (d, J = 2.1 Hz, 1H, 5-H). 
13
C 
NMR (100 MHz, CDCl3) δ 28.4, 28.6, 30.6, 39.1, 56.2, 63.1, 111.4, 111.8, 129.4, 
129.8, 133.9, 151.4, 154.4, 162.6, 195.6; HRMS (ESI+) m/z calc. for 
C15H20BrN2O4S [M+H]
+
 403.0322, found: 403.0336; Anal. Calc. for 
C15H19BrN2O4S: C, 44.67; H, 4.75; N, 6.95. Found: C, 44.74; H, 4.78; N, 6.89. 
 
 
(E)-(S)-2-(3-(3-Bromo-4-methoxyphenyl)-2-
(hydroxyimino)propanamido)ethyl ethanethioate (129) 
1
2
3
4
5
6
Br
O
N
H
N
O
S
HO
O
 
To a solution of crude acid 74a (1 eq.) in freshly distilled pyridine (2 mL/mmol), 
under argon, was added hydroxylamine hydrochloride (1.5 eq.). The resulting 
mixture was stirred overnight at rt. Pyridine was then removed in vacuo, the 
residue was dissolved in 1N HCl (5.5 mL/mmol) and extracted three times with 
ethyl acetate (5.5 mL/mmol). The combined organic layers were dried (Na2SO4), 
filtered and concentrated to afford the relatively pure oxime intermediate, used for 
the next step without further purification. To a solution of this crude oxime 
derivative in dioxane (10 mL/mmol) under argon was added DCC (1 eq.) and N-
hydroxyphthalimide (1 eq.). After 2 hours of stirring at rt, 2-Acetylsulfanylethyl 
ammonium chloride 127 (1 eq.) and triethylamine (2.1 eq.) were added and the 
resulting mixture was stirred overnight at rt. The day after the solvent was 
evaporated and the product (50 mg, 19 % from acid 74a) was obtained as a white 
powder after purification by flash column chromatography (AcOEt : CH2Cl2 2 : 8) 
and trituration in warm AcOEt: m.p. 167-169 °C; Rf 0.6 (AcOEt : CH2Cl2, 2 : 8); 
1
H NMR (400 MHz, CD3OD) δ 2.29 (s, 3H, CH3C), 3.01 (t, J = 6.6 Hz, 2H, 
CH2S), 3.41 (m, 2H, CH2N), 3.82 (s, 2H, 4-CH2), 3.83 (s, 3H, CH3O), 6.91 (d, J = 
8.5 Hz, 1H, 2-H), 7.22 (dd, J = 8.5, 2.1 Hz, 1H, 3-H), 7.44 (d, J = 2.1 Hz, 1H, 5-
H);
 13
C NMR (100 MHz, CDCl3) δ 28.7, 29.4, 30.4, 39.9, 56.7, 112.1, 113.1, 
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130.5, 131.8, 134.7, 152.9, 155.9, 165.9, 197.1; HRMS (ESI+) m/z calc. for 
C14H18BrN2O4S [M+H]
+
 389.0165, found: 389.0164 (M+H)
+
; Anal. Calc. for 
C14H17BrN2O4S: C, 43.20; H, 4.40; N, 7.20. Found: C, 43.29; H, 4.32; N, 7.32. 
 
(S)-2-(3-(3-Bromo-4-methoxyphenyl)-2-oxopropanamido)ethyl ethanethioate 
(130) 
1
2
3
4
5
6
Br
O
O
H
N
O
S
O
 
To a solution of acid 74a under argon in dioxane (5.5 mL/mmol) was added DCC 
(1 eq,), N-hydroxyphtalimide (1 eq.). After 2 hours of stirrung at rt, 2-
Acetylsulfanylethyl ammonium chloride 127 (1 eq.) and triethylamine (2.1 eq.) 
were added and the resulting mixture was stirred overnight at rt. The day after the 
solvent was evaporated and the product (64 mg, 23 %) was purified by flash 
column chromatography (AcOEt : CH2Cl2 1 : 9) and trituration in Bu2O: m.p. 93-
95°C; Rf 0.65 (AcOEt : CH2Cl2, 1 : 9); IR 1685, 1523, 1498, 1106 cm
-1
; 
1
H NMR 
(400 MHz, CDCl3) δ 2.35 (s, 3H, CH3C), 3.05 (t, J = 6.4 Hz, 2H, CH2S), 3.50 (m, 
2H, CH2N), 3.88 (s, 3H, CH3O), 4.13 (s, 2H, CH2C(O)), 6.86 (d, J = 8.5 Hz, 1H, 
2-H), 7.16 (dd, J = 8.5, 2.1 Hz, 1H, 3-H), 7.21 (br. t, 1H, NH), 7.42 (d, J = 2.1 Hz, 
1H, 5-H). 
13
C NMR (100 MHz, CDCl3) δ 28.3, 30.6, 39.3, 41.7, 56.2, 111.7, 
112.0, 125.9, 130.0, 134.5, 155.1, 159.9, 195.2, 195.5; HRMS (ESI+) m/z calc. for 
C14H17BrNO4S 374.0056 [M+H]
+
, found: 374.0061; Anal. Calc. for 
C14H16BrNO4S: C, 44.93; H, 4.31; N, 3.74. Found: C, 45.04; H, 4.27; N, 3.81. 
 
(2E,2'E)-N,N'-(Hexane-1,6-diyl)bis(3-(3-bromo-4-hydroxyphenyl)-2-
(hydroxyimino) propanamide) (134) 
1
2
3
4
5
6
N
H
N
O N
N
H
O
HO
OH
HO
Br
OH
Br  
Following the general procedure described earlier for the synthesis of oxime 
containing analogues, 134 (44 mg) was obtained in 12% yield from the 
corresponding arylpyruvic acid 51 and hexane-1,6-diamine, after purification by 
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flash column chromatography (AcOEt : PE40-60). Amorphous white solid; 134 has 
been previously reported in the literature and our data matched reported ones. Rf 
0.1 (AcOEt : PE40-60, 1 : 1); 
1
H NMR (400 MHz, CD3OD) δ 1.22-1.32 (m, 4H, 
NCH2CH2), 1.42-1.52 (m, 4H, NCH2CH2), 3.20 (t, J = 7.0 Hz, 4H, NCH2), 3.79 
(s, 4H, 4-CH2), 6.76 (d, J = 8.3 Hz, 2H, 2-H), 7.06 (dd, J = 8.3, 2.1 Hz, 2H, 3-H), 
7.36 (d, J = 2.1 Hz, 2H, 5-H). 
13
C NMR (100 MHz, CD3OD) δ 27.5, 28.8, 30.4, 
40.2, 110.5, 117.1, 130.4, 130.7, 134.5, 153.6, 153.8, 165.8; HRMS (ESI+) m/z 
calc. for C24H29Br2N4O6 [M+H]
+ 
627.0448, found: 627.0470. 
 
(E)-3-(3-Bromo-4-hydroxyphenyl)-N-(3-(2-((E)-3-(3-bromo-4-
hydroxyphenyl)-2-(hydroxyimino)propanamido)ethylthio)propyl)-2-
(hydroxyimino)propanamide (135) 
1
2
3
4
5
6
7
N
H
N
O
8
9
S
10
11
12
13
14
15
16
N
N
H
O
17
18
19
HO
OH
HO
Br
OH
Br  
Following the general procedure described earlier for the synthesis of oxime 
containing analogues, 135 (53 mg) was obtained in 14% yield from the 
corresponding arylpyruvic acid and 3-(2-aminoethylthio)propan-1-amine 137,
243
 
after purification by flash column chromatography (AcOEt : PE40-60). Amorphous 
white solid; Rf 0.1 (AcOEt : PE40-60, 1 : 1); IR (neat) 3248, 1646, 1605, 1539, 
1495, 1420; 
1
H NMR (400 MHz, CD3OD) δ 1.74 (quintet, J = 7.2 Hz, 2H, 18-H2), 
2.50 (t, J = 7.2 Hz, 2H, 19-H2), 2.61 (t, J = 6.7 Hz, 2H, 9-H2), 3.30 (t, J = 7.2 Hz, 
2H, 17-H2), 3.39 (t, J = 6.7 Hz, 2H, 8-H2), 3.79 (s, 4H, 7-H2 + 16-H2), 6.76 (d, J = 
8.3 Hz, 2H, 2-H + 11-H), 7.06 (dd, J = 8.3, 2.1 Hz, 2H, 3-H + 12-H), 7.36 (d, J = 
2.1 Hz, 2H, 5-H + 14-H). 
13
C NMR (100 MHz, CD3OD) δ 28.7, 28.8, 29.9, 30.4, 
32.1, 39.4, 40.0, 110.5 (2C), 117.1 (2C), 130.4 (2C), 130.7 (2C), 134.5 (2C), 
153.2, 153.5, 153.8 (2C), 165.8, 166.0; HRMS (ESI+) m/z calc. for 
C23H27Br2N4O6S [M+H]
+ 
645.0013, found: 645.0045; Anal. Calc. for 
C23H26Br2N4O6S: C, 42.74; H, 4.05; N, 8.67. Found: C, 42.89; H, 3.98; N, 8.53. 
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2. Biological evaluation 
 
General procedure A for the in situ reduction of disulfides 
To the appropriate dimeric compound (neat, 1.0 eq.) was added solid TCEP (1.5 
eq.). Dilution with the adequate amount of a 9 : 1 DMSO/distilled water solution 
and agitation for 20-30 minutes (magnetic stirrer) at rt afforded the required stock 
solution of thiol. All thiols were used immediately after reduction. 
 
Example: preparation of a 50 mM stock solution of Psammaplin A. To pure 
Psammaplin A (5.0 mg, 1 eq.) was added solid TCEP (3.2 mg, 1.5 eq.). 301 μL of 
a 9 : 1 DMSO/water was added, and the resulting mixture was stirred for 20 
minutes at rt. The resulting stock solution was used immediately. Complete and 
clean reduction was observed by 
1
H NMR. HRMS allowed for the observation of 
[M-H]
-
, [M+HCOO]
-
 and [2M-H]
-
 ions. 
 
General procedure B for the in situ reduction of disulfides 
An 18.75 mM solution (S1) of TCEP in a 9:1 (v/v) mixture of DMSO/deionized 
water was prepared. To 40 μL of S1 were added 10 μL of a 50 mM solution (S2) 
of the appropriate dimeric compound. The resulting mixture was incubated for 20 
minutes at 25 °C in the dark, with occasional shaking. The resulting 20 mM stock 
solution of thiol was used immediately. 
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HDAC assay 
 
 DMSO, Pluronic, TCEP and Trypsin (bovine pancreas) were purchased 
from Sigma-Aldrich and Boc-Lys(Ac)-AMC from Bachem (Switzerland). The 
recombinant human histone deacetylases HDAC1 and HDAC6 were obtained 
from BPS Biosciense (US). All reactions were performed in black half area 96-
well microplates (Greiner bio-one, Germany) according to the general procedure 
described by Wegener et al.
177
 with some minor modifications. The reaction 
buffer contains 50 mM KH2PO4/K2HPO4 , 15 mM Tris/HCl, pH 8, 250 mM NaCl, 
0.001% (v / v) Pluronic, and 250 µM EDTA. The buffer components were 
purchased from Merck (Germany), Roth (Germany) and Sigma-Aldrich. 
 
 The fluorogenic HDAC assay consists of two steps: In the first step the 
Boc-Lys(Ac)-AMC  substrate is deacetylated by the corresponding HDAC. The 
deacetylated substrates, therefore containing a basic amino acid residue serves as 
substrate for trypsin in the subsequent second step. The second step generates the 
signal due to the release of fluorescent AMC, whose fluorescence serves as an 
indirect measure of HDAC enzyme activity. 50 mM stock solutions of test 
compounds were prepared in DMSO and diluted for testing using reaction buffer. 
 
 Thiols were obtained from their corresponding disulfides via general 
procedure A or B above. Varying the procedure did not show significant influence 
on the final calculated IC50. Test experiments have shown TCEP to have no 
influence on enzyme activity at concentrations up to 25 μM. 
  
 A serial dilution of test compounds was preincubated with 7.4 nM HDAC1 
or 2.8 nM HDAC6, respectively, for 20 min at 21±1 
0
C in the dark. The enzyme 
reaction was initiated by the addition of Boc-Lys(Ac)-AMC substrate. The 
reaction mixture was incubated at 30°C in the dark and stopped after 60 min by 
the addition of a mixture of 67 µM trypsin and 200 nM SAHA. The fluorescence 
of AMC serves as an indirect measure of HDAC enzyme activity. The kinetics of 
AMC release was measured on a fluorescence plate reader PolarStar (BMG) using 
an excitation wavelength of 340 nm and an emission wavelength of 460 nm. 
Complete cleavage of deacetylated Boc-Lys-AMC by trypsin was achieved after 
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about 10-15 min. The fluorescence intensity of the plateau was averaged over at 
least 5 min and normalized with respect to per cent of enzyme activity. Finally, 
the normalized fluorescence intensities were plotted versus the concentration of 
test compounds and fitted to a four-parameter logistic model
244
 to calculate the 
IC50 values. 
 
Protein expression and purification of Histone deacetylase-like 
amidohydrolase (HDAH) 
 
 The recombinant HDAH from Bordetella strain FB188 (DSM 11172) 
containing an N-terminal His6-affinity tag was prepared as previously reported.
178
 
Briefly, HDAH was expressed in E. coli strain BL21 and the cell lysate was 
applied to a His-Trap FF (Amersham Biosciences) column loaded with zinc ions. 
After removing non binding proteins, the pure enzyme was eluted with 500 mM 
Imidazol. The resulting pure enzyme was dialyzed against assay buffer and 
directly used to test compounds. The purity of HDAH (> 98%) was determined 
using polyacrylamide gel electrophoresis and Coumassie Brilliant Blue G-250 to 
stain protein. 
 
DNMT assay 
 
 All reactions were performed in 384 well microtitre plates (Greiner). End 
point detection reaction was carried out using the restriction endonuclease Gla1 
purchased from SybEnzyme (Novosibirsk, Russia). The break light hemi-
methylated oligonucleotide used was obtained from ATDBio Ltd. (Southampton, 
UK) (5‟-FAM-ATCTAGCG5ATCAGTTTTCTGATG5G5TAGAT-dab 3‟). The 
S-(5‟-adenosyl)-L-methionine chloride (SAM), methyl donor for the DNMT1 
reaction was obtained from Sigma (Gillingham, UK), SAH, S-(5‟-Adenosyl)-L-
homocysteine and all other reagents were also obtained from Sigma unless 
otherwise stated. Final fluorescent signal was read using a BMG-LabTech 
Pherastar (Aylesbury, UK) at 520nm (Em)/485nm (Ex) wavelengths. All single 
point data were analysed using Excel, dose response curves were analysed and 
IC50 calculated using XLFit 4.0 (IDBS, Guilford, UK). DNMT1 enzyme was 
produced in-house (CRT, London, UK) from an N-his tagged full length construct 
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expressed in Sf9 insect cells and protein was harvested after a 50 h infection.  The 
protein was purified and concentrated following nickel affinity and gel filtration 
chromatography, and glycerol was added to a final concentration of 50%.  
Approximately 3-5 mg/ml stock was obtained from 500 ml Sf9 cell pellet and this 
was stored at -20C. All assay reagents were added to the assay plates using a 
multidropCombi (ThermoScientific, Basingstoke, UK), all compound dilutions 
were performed using a BeckmanCoulter Biomek FX (High Wycombe, UK) for 
the serial dilutions and a PlateMate+ (thermoScientific-Matrix, Basingstoke, UK) 
for all plate to plate transfers dilutions and compound addition to assay plates. 
 
 All assays were carried out as follows, into the wells of a 384 plate was 
added 1μl of compound, (at appropriate concentration for testing, normally 30μM 
for single point screening), then a 5μl mix of SAM (10μM final concentration), 
and hemi-methylated oligo (125nM final concentration). The reaction was started 
by the addition of 5μl of DNTM1 enzyme, at 80nM final concentration in DNMT 
assay buffer (MOPS 100mM, 125mM NaCl, 2.5mM MgCl2, pH6.5, 0.05% Triton 
X-100 and 5mM DTT). Negative control wells were prepared as above but no 
SAM was added to mimic a complete inhibition of the DNMT1 reaction. For the 
positive control wells, no compounds were added. The reaction was incubated for 
1 hr at room temperature. The reaction was stopped and signal developed by the 
addition of a 40μl mix of a Gla1 0.00156U/μl and SAH, 125μM final 
concentration mix in Gla1 buffer (Tris-HCl 100mM, NaCl 400mM, MgCl2 
3.75mM, Triton X-100 (0.01%), 0.05%,DTT 5mM, pH8). This second enzymatic 
reaction was incubated for 7hr at room temperature prior to reading the 
fluorescence signal at 520nm. 
 Thiols were obtained from their respective disulfides according to general 
procedure A. 
 
 
MSssI in vitro DNA methylation assay 
 
 Enzyme reagents for the MSssI in vitro DNA methylation studies were 
obtained from New England Biolabs. One unit of MSssI  enzyme was incubated 
with 1 µg bacteriophage λ DNA in a 20 µl   reaction volume containing 50 mM 
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NaCl, 10 mM Tris-HCl (pH 7.9 at 25°C), 10 mM MgCl2, 1mM dithiothreitol 
(NEBuffer2) and 160 µM S-adenosylmethionine,  in the presence and absence 
inhbitors for two hours at 37°C.  Following DNA methylation, the MSssI enzyme 
was heat inactivated by incubation at 65°C for 20 minutes. The extent of DNA 
methylation was subsequently assessed by the addition of 30 µl of NEBuffer 2 
containing 10 units of BstUI restriction endonuclease and digestion for 1 hour at 
60°C. The digested DNA was analysed by gel electrophoresis  using a 1.5% 
agarose gel. 
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3. Deeper investigation of the role of the oxime unit in 
Psammaplin A and design of novel lead compounds 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))dibenzamide (140) 
1
2
3
4
5
6
H
N
O
S
S
N
H
O
 
To an iced cooled solution of benzoyl chloride 139 (0.6 mL, 5.16 mmol, 1 eq.) in 
freshly distilled CH2Cl2 (50 mL), under inert atmosphere, were added 
triethylamine (1.58 mL, 11.4 mmol, 2 eq.) and cystamine dihydrochloride (581 
mg, 2.58 mmol, 0.5 eq.). The resulting mixture was stirred for 2 hours at 0°C, then 
for 18 hours at rt. The organic phase was washed with 1N aqueous HCl (50 mL). 
The aqueous phase was extracted one more time with CH2Cl2 (50 mL). The 
combined organic layers were dried (MgSO4) and the product (885 mg, 95%) was 
obtained as colourless needles after purification by flash column chromatography 
(AcOEt/CH2Cl2 3 : 7) and recrystallisation (EtOH/H2O): m.p. 122-124°C; Rf 0.4 
(AcOEt/CH2Cl2 3 : 7). IR (neat) 3268, 1634, 1553, 1325, 1309, 1289; 
1
H NMR 
(400 MHz, CDCl3) δ 2.98 (t, J = 6.4 Hz, 4H, CH2S), 3.79 (m, 4H, CH2N), 7.07 
(br. t, 2H, NH), 7.36-7.45 (m, 4H, 2-H + 6-H), 7.46-7.53 (m, 2H, 1-H), 7.79-7.87 
(m, 4H, 3-H + 5-H). 
13
C NMR (100 MHz, CDCl3) δ 37.9, 39.1, 127.1, 128.5, 
131.6, 134.1, 167.8; HRMS (ESI+) m/z calc. for C18H21N2O2S2 [M+H]
+ 
361.1039 
found: 361.1041; Anal. Calc. for C18H20N2O2S2: C, 59.97; H, 5.59; N, 7.77. 
Found: C, 59.91; H, 5.48; N, 7.66. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(5-methylisoxazole-3-
carboxamide) (142) 
H
N
O
S
S
N
H
ONO
N O  
To a solution of 5-methylisoxazole-3-carboxylic acid 141 (300 mg, 2.36 mmol, 
1.0 eq.) in freshly distilled CH2Cl2 (25 mL), under inert atmosphere, were added 
HOBt (351 mg, 2.60 mmol, 1.1 eq.) and EDCI (498 mg, 2.60 mmol, 1.1 eq.) at rt. 
After stirring for 10 minutes at rt, cystamine dihydrochloride (266 mg, 1.18 mmol, 
0.5 eq.) and freshly distilled NEt3 (0.823 mL, 5.90 mmol, 2.5 eq.) were added. 
Towards novel small molecule epigenetic inhibitors  Experimental 
202 
 
The resulting mixture was stirred at rt and followed by TLC. After 24 h, the 
reaction was stopped. The reaction mixture was diluted with CH2Cl2 and the 
remaining insoluble material was dissolved after addition of small amounts of 
MeOH. The resulting mixture was washed with water (20 mL). The aqueous 
phase was back extracted with generous amounts of CH2Cl2. The combined 
organic layers were dried (MgSO4) and concentrated under reduced pressure. The 
product (250 mg, 62%) was obtained as a colourless solid after precipitation from 
MeOH; Rf 0.75 (MeOH/CH2Cl2 6 : 94); IR (neat) 3351, 3143, 1662, 1607, 1549, 
1466, 1446, 1281, 1220; 
1
H NMR (400 MHz, d
6
-DMSO) δ 2.45 (s, 6H, CH3), 
2.90 (t, J = 6.8 Hz, 4H, CH2S), 3.52 (m, 4H, CH2N), 6.52 (s, 2H, CH), 8.82 (t, J = 
5.6 Hz, 2H, NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 11.7, 36.6, 38.1, 101.2, 
158.7, 158.8, 171.1; HRMS (ESI+) m/z calc. for C14H19N4O4S2 [M+H]
+ 
371.0842, 
found: 371.0852; Anal. Calc. for C14H19N4O4S2: C, 45.39; H, 4.90; N, 15.12. 
Found: C, 45.29; H, 4.81; N, 14.96. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(1H-pyrazole-3-carboxamide) 
(144) 
H
N
O
S
S
N
H
ONHN
N NH  
To a solution of 1H-pyrazole-3-carboxylic acid 143 (400 mg, 3.57 mmol, 1.0 eq.) 
in freshly distilled CH2Cl2 (32 mL), under inert atmosphere, were added HOBt 
(530 mg, 3.93 mmol, 1.1 eq.) and EDCI (752 mg, 3.93 mmol, 1.1 eq.) at rt. After 
stirring for 10 minutes at rt, cystamine dihydrochloride (272 mg, 1.78 mmol, 0.5 
eq.) and freshly distilled NEt3 (1.05 mL, 7.49 mmol, 2.1 eq.) were added. The 
resulting mixture was stirred at rt and followed by TLC. After 36 h, the reaction 
was stopped. The organic layer was washed with water (32 mL), and the aqueous 
phase was back extracted with AcOEt (3 x 24 mL). The combined organic layers 
were dried (MgSO4) and the product (491 mg, 81%) was obtained as an 
amorphous white solid after flash column chromatography (MeOH/CH2Cl2 8 : 
92). Rf 0.4 (MeOH/CH2Cl2 1 : 9); IR (neat) 3187, 1631, 1547, 1461, 1434, 1351, 
1315, 1218, 1189; 
1
H NMR (400 MHz, d
6
-DMSO) δ 2.90 (t, J = 6.9 Hz, 4H, 
CH2S), 3.52 (m, 4H, CH2N), 6.65 (br. s, 2H, CCH), 7.79 (br. s, 2H, NHCH), 8.33 
(br. t, 2H, NH amide), 13.24 (br. s, 1H, NH pyrazole). 
13
C NMR (100 MHz, d
6
-
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DMSO) δ 37.1, 37.9, 104.9, 129.9, 146.4, 161.6; HRMS (ESI+) m/z calc. for 
C12H17N6O2S2 [M+H]
+ 
341.0849, found: 341.0856; Anal. Calc. for C12H16N6O2S2: 
C, 42.34; H, 4.74; N, 24.69. Found: C, 42.24; H, 4.65; N, 24.56. 2 tautomeric 
forms of the pyrazole ring in solution (Scheme 2) were observable by 
1
H NMR, 
what is a known phenomenon for 1H-pyrazole-3(5)-(N-tert-butyl)carboxamide in 
solution.
245
 Recording 
1
H NMR spectra at higher temperature did not show 
significant variation in the spectrum. The signals for the major tautomer are 
reported. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(1H-pyrrole-3-carboxamide) 
(146) 
1
H
N
O
S
S
N
H
O
2HN
3
4
NH  
To a solution of cystamine (164 mg, 1.08 mmol, 1.0 eq.) and ethyl 1H-pyrrole-3-
carboxylate
213
 145 (300 mg, 2.16 mmol, 2.0 eq.) in freshly distilled CH2Cl2 (7 
mL), in a sealed tube and under an inert atmosphere was added 
trimethylaluminium (2M in hexanes, 2.16 mL, 4.31 mmol, 4.0 eq.) dropwise at 
0°C. The reaction mixture was stirred for 5 minutes at 0°C, then at rt for 20 
minutes. Particular care was taken while handling the pyrophoric 
trimethylaluminium reagent. The pressure was released 4-5 times over 20 
minutes, then the resulting mixture was  refluxed for 24h. After a day, the reaction 
was cooled to rt, 1N HCl was added, and stirring was continued for 20 minutes. 
The reaction mixture was then extracted several times at pH = 0, 3, 5 and 7 with 
generous amounts of AcOEt. The combined organic layers were dried (MgSO4) 
and concentrated in vacuo. The product (100 mg, 27%, 69% brsm) was obtained 
as an amorphous white solid after purification by flash column chromatography 
(MeOH/CH2Cl2 12 : 88); Rf 0.3 (MeOH/CH2Cl2 12 : 88); IR (neat) 3236, 1607, 
1560, 1518, 1426, 1331, 1204; 
1
H NMR (400 MHz, d
6
-DMSO) δ 2.87 (t, J = 6.9 
Hz, 4H, CH2S), 3.46 (m, 4H, CH2N), 6.45 (m, 2H ), 6.73 (m, 2H), 7.30 (m, 2H), 
7.97 (t, J = 8.0 Hz, 2H), 11.12 (br. s, 2H). 
13
C NMR (100 MHz, d
6
-DMSO) δ 37.5, 
38.1, 107.1, 118.3, 119.4, 120.3, 164.1; HRMS (ESI+) m/z calc. for C14H19N4O2S2 
[M+H]
+ 
339.0944, found: 339.0954; Anal. Calc. for C14H18N4O2S2: C, 49.68; H, 
5.36; N, 16.55. Found: C, 49.54; H, 5.30; N, 16.46. 
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N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(1H-indole-3-carboxamide) 
(148) 
1
H
N
O
S
S
N
H
O
2HN
3
4
NH
5
6
7 8  
To a solution of 1H-indole-3-carboxylic acid 147 (300 mg, 1.86 mmol, 1.0 eq.) in 
dry DMF (6 mL), under inert atmosphere, were added HOBt (277 mg, 2.05 mmol, 
1.1 eq.) and EDCI (393 mg, 2.05 mmol, 1.1 eq.) at rt. After stirring for 10 minutes 
at rt, cystamine dihydrochloride (210 mg, 0.93 mmol, 0.5 eq.) and freshly distilled 
DIPEA (0.972 mL, 5.58 mmol, 3.0 eq.) were added. The resulting mixture was 
stirred at rt and followed by TLC. After 14 h, the reaction was stopped. The 
reaction mixture was diluted with AcOEt (50 mL), washed with water (2 x 25 
mL) and dried (MgSO4). The combined organic phases were concentrated and the 
product (35 mg, 9%) was obtained after precipitation from EtOH.  Rf 0.4 
(AcOEt); IR (neat) 3221, 1546, 1433, 1332, 1208; 
1
H NMR (400 MHz, d
6
-
DMSO) δ 2.95 (t, J = 6.5 Hz, 4H, CH2S), 3.57 (m, 4H, CH2N), 7.02-7.18 (m, 4H, 
6-H + 7-H), 7.42 (d, J = 7.8 Hz, 2H, 5-H), 8.01 (d, J = 2.5 Hz, 2H, 2-H), 8.08-
8.19 (m, 4H, NH amide + 8-H), 11.56 (br. s, 2H, NH indole). 
13
C NMR (100 
MHz, d
6
-DMSO) δ 37.6, 38.1, 110.3, 111.7, 120.2, 120.9, 121.7, 125.9, 127.7, 
136.0, 164.6; HRMS (ESI+) m/z calc. for C22H23N4O2S2 [M+H]
+ 
439.1257, found: 
439.1258; Anal. Calc. for C22H22N4O2S2: C, 60.25; H, 5.06; N, 12.78. Found: C, 
60.14; H, 4.95; N, 12.66. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))dinicotinamide (150) 
1
H
N
O
S
S
N
H
O
2N
3
4
5
6
N  
To a solution of nicotinic acid 149 (700 mg, 5.69 mmol, 1.0 eq.) in freshly 
distilled CH2Cl2 (60 mL), under inert atmosphere, were added HOBt (845 mg, 
6.25 mmol, 1.1 eq.) and EDCI (1.20 g, 6.25 mmol, 1.1 eq.) at rt. After stirring for 
10 minutes at rt, cystamine dihydrochloride (640 mg, 2.84 mmol, 0.5 eq.) and 
freshly distilled NEt3 (1.66 mL, 11.9 mmol, 2.1 eq.) were added. The resulting 
mixture was stirred at rt and followed by TLC. After 25 h, the reaction was 
stopped and the solvent was evaporated. The resulting residue was dissolved in 
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saturated aqueous NaHCO3 (60 mL) and extracted with AcOEt (3 x 60 mL). The 
combined organic layers were dried (MgSO4) and the product (663 mg, 64%) was 
obtained as an amorphous white solid after flash column chromatography 
(MeOH/CH2Cl2 1 : 9). Rf 0.45 (MeOH/CH2Cl2 1 : 9); IR (neat) 3316, 1641, 1591, 
1542, 1301, 1279, 1197, 1279; 
1
H NMR (400 MHz, d
6
-DMSO) 2.95 (t, J = 6.8 
Hz, 4H, CH2S), 3.58 (m, 4H, CH2N), 7.50 (ddd, J = 7.8, 4.8, 0.6 Hz, 2H, 5-H), 
8.17 (m, 2H, 6-H), 8.70 (dd, J = 4.8, 1.5 Hz, 2H, 4-H), 8.87 (t, J = 5.4 Hz, 2H, 
NH), 8.99 (d, J = 2.1 Hz, 2H, 2-H). 
13
C NMR (100 MHz, d
6
-DMSO) δ 36.9, 38.6, 
123.4, 129.6, 134.8, 148.3, 151.8, 164.8; HRMS (ESI+) m/z calc. for 
C16H19N4O2S2 [M+H]
+ 
363.0944, found: 363.0960; Anal. Calc. for C16H18N4O2S2: 
C, 53.02; H, 5.01; N, 15.46. Found: C, 52.97; H, 4.97; N, 15.34. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))difuran-3-carboxamide (152) 
1
H
N
O
S
S
N
H
O
2O
3
4
5
O  
To a solution of furan-3-carboxylic acid 151 (400 mg, 3.57 mmol, 1.0 eq.) in 
freshly distilled CH2Cl2 (38 mL), under inert atmosphere, were added HOBt (530 
mg, 3.93 mmol, 1.1 eq.) and EDCI (752 mg, 3.93 mmol, 1.1 eq.) at rt. After 
stirring for 10 minutes at rt, cystamine dihydrochloride (402 mg, 1.78 mmol, 0.5 
eq.) and freshly distilled NEt3 (1.05 mL, 7.49 mmol, 2.1 eq.) were added. The 
resulting mixture was stirred at rt and followed by TLC. After 40 h, the reaction 
was stopped. The organic phase was washed with 1N aqueous HCl (40 mL). The 
aqueous phase was extracted one more time with CH2Cl2 (40 mL). The combined 
organic layers were washed with saturated aqueous NaHCO3 (80 mL) and the 
aqueous layer was back extracted with CH2Cl2 (80 mL). The combined organic 
layers were dried (MgSO4) and the product (120 mg, 20%) was obtained as an 
amorphous white solid after flash column chromatography (MeOH/CH2Cl2 5 : 
95). Rf 0.4 (MeOH/CH2Cl2 6 : 94); IR (neat) 3270, 1618, 1568, 1545, 1529; 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 2.88 (t, J = 6.8 Hz, 4H, CH2S), 3.49 (m, 4H, 
CH2N), 6.83 (s, 2H, 5-H), 7.72 (s, 2H, 4-H), 8.16 (s, 2H, 2-H), 8.39 (t, J = 5.2 Hz, 
2H, NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 37.0, 38.1, 108.8, 122.6, 144.0, 
145.1, 161.6; HRMS (ESI+) m/z calc. for C14H17N2O4S2 [M+H]
+ 
341.0624, found: 
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341.0630; Anal. Calc. for C14H16N2O4S2: C, 49.40; H, 4.74; N, 8.23. Found: C, 
49.04; H, 4.68; N, 8.13. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))dithiophene-3-carboxamide (154) 
1
H
N
O
S
S
N
H
O
2S
3
4
5
S  
To a solution of thiophene-3-carboxylic acid 153 (300 mg, 2.34 mmol, 1.0 eq.) in 
freshly distilled CH2Cl2 (25 mL), under inert atmosphere, were added HOBt (348 
mg, 2.57 mmol, 1.1 eq.) and EDCI (493 mg, 2.57 mmol, 1.1 eq.) at rt. After 
stirring for 10 minutes at rt, cystamine dihydrochloride (263 mg, 1.17 mmol, 0.5 
eq.) and freshly distilled NEt3 (0.815 mL, 5.85 mmol, 2.1 eq.) were added. The 
resulting mixture was stirred at rt and followed by TLC. After 24 h, the reaction 
was stopped. The organic phase was washed with 1N aqueous HCl (25 mL). The 
aqueous phase was extracted one more time with generous amounts of CH2Cl2 
and AcOEt. The combined organic layers were washed with saturated aqueous 
NaHCO3 and the aqueous layer was back extracted with AcOEt. The combined 
organic layers were dried (MgSO4) and the product (340 mg, 78%) was obtained 
as an amorphous white solid after flash column chromatography (MeOH/CH2Cl2 
5 : 95). Rf 0.5 (MeOH/CH2Cl2 5 : 95); IR (neat) 3292, 1623, 1552, 1298, 1287 
1184; 
1
H NMR (400 MHz, d
6
-DMSO) δ 2.91 (t, J = 6.9 Hz, 4H, CH2S), 3.52 (m, 
4H, CH2N), 7.48 (dd, J = 5.0, 1.1 Hz, 2H, 5-H), 7.58 (dd, J = 5.0, 3.0 Hz, 2H, 4-
H), 8.11 (dd, J = 3.0, 1.1 Hz, 2H, 2-H), 8.51 (t, J = 5.5 Hz, 2H, NH). 
13
C NMR 
(100 MHz, d
6
-DMSO) δ 37.0, 38.4, 126.6, 126.7, 128.6, 137.5, 162.0; HRMS 
(ESI+) m/z calc. for C14H17N2O2S4 [M+H]
+ 
373.0167, found: 373.0184; Anal. 
Calc. for C14H16N2O2S4: C, 45.13; H, 4.33; N, 7.52. Found: C, 45.21; H, 4.39; N, 
7.54. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))dipicolinamide (156) 
1
2
3
4
N
5
6
H
N
O
S
S
N
H
O
N  
To a solution of picolinic acid 155 (700 mg, 5.69 mmol, 1 eq.) in freshly distilled 
CH2Cl2 (60 mL), under inert atmosphere, were added HOBt (845 mg, 6.25 mmol, 
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1.1 eq.) and EDCI (1.20 g, 6.25 mmol, 1.1 eq.) at rt. After stirring for 10 minutes 
at rt, cystamine dihydrochloride (640 mg, 2.84 mmol, 0.5 eq.) and triethylamine 
(1.66 mL, 11.9 mmol, 2.1 eq.) were added. The resulting mixture was stirred at rt 
and followed by TLC. After 25 h, the reaction was stopped. The solvent was 
evaporated. Sat. Aq. NaHCO3 (60 mL) was added and the mixture was extracted 
with AcOEt (3 x 60 mL). The combined organic layers were dried (MgSO4) and 
the product (825 mg, 80%) was obtained as colourless needles after flash column 
chromatography (AcOEt/CH2Cl2 9 : 1) and recrystallisation (Et2O): m.p. 74-76°C; 
Rf 0.6 (AcOEt). IR (neat) 3373, 1660, 1519, 1434, 1289; 
1
H NMR (400 MHz, 
CDCl3) δ 2.96 (t, J = 6.4 Hz, 4H, CH2S), 3.82 (m, 4H, CH2N), 7.38-7.47 (m, 2H, 
1-H), 7.79-7.89 (m, 2H, 2-H), 8.14-8.23 (m, 2H, 3-H), 8.40 (br. t, 2H, NH), 8.52-
8.59 (m, 2H, 6-H). 
13
C NMR (100 MHz, CDCl3) δ 37.9, 38.1, 122.2, 126.2, 137.3, 
148.1, 149.7, 164.5; HRMS (ESI+) m/z calc. for C16H19N4O2S2 [M+H]
+ 
363.0944 
found: 363.0966; Anal. Calc. for C16H18N4O2S2: C, 53.02; H, 5.01; N, 15.46. 
Found: C, 53.13; H, 4.94; N, 15.50. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))dipyrimidine-2-carboxamide 
(158) 
H
N
O
S
S
N
H
ON
N
N
N
 
To an ice cold solution of pyrimidine-2-carboxylate 157 (700 mg, 5.07 mmol, 1.0 
eq.) and cystamine (386 mg, 2.53 mmol, 0.5 eq.) in CHCl3 (20 mL), under inert 
atmosphere, was added dropwise trimethylaluminium (2M in hexanes, 5.07 mL, 
10.1 mmol, 2.0 eq.). The resulting mixture was stirred at reflux in a sealed tube. 
After 24 h, the reaction was stopped. 1N HCl was then added dropwise at 0°C and 
the resulting mixture was stirred for a few minutes at 0°C  then rt for 25 minutes. 
Particular care was taken while handling the pyrophoric trimethylaluminium 
reagent. The pH was then adjusted to 9 with saturated aqueous NaHCO3 and the 
biphasic mixture extracted with generous amounts of CHCl3. The combined 
organic layers were dried (MgSO4) and the product (288 mg, 31%) was obtained 
as a yellow solid after flash collumn chromatography (MeOH/CH2Cl2 7 : 93). Rf 
0.45 (MeOH/CH2Cl2 8 : 92); IR (neat) 3272, 1674, 1567, 1524, 1411; 
1
H NMR 
(400 MHz, CDCl3) δ 2.97 (t, J = 6.3 Hz, 4H, CH2S), 3.86 (m, 4H, CH2N), 7.43 (d, 
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J = 4.8 Hz, 2H, N=CHCH), 8.40 (br. t, 2H, NH), 8.87 (d, J = 4.8 Hz, 4H, N=CH). 
13
C NMR (100 MHz, CDCl3) δ 37.5, 38.4, 122.5, 157.5, 162.3; HRMS (ESI+) m/z 
calc. for C14H17N6O2S2 [M+H]
+ 
365.0849, found: 365.0839; Anal. Calc. for 
C14H16N6O2S2: C, 46.14; H, 4.43; N, 23.06. Found: C, 46.26; H, 4.44; N, 22.94. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(2-hydroxybenzamide) (160) 
1
2
3
4
5
6
H
N
O
S
S
N
H
O
OH
HO  
To a solution of 2-hydroxybenzoic acid 159 (500 mg, 3.62 mmol, 1 eq.) in freshly 
distilled CH2Cl2 (40 mL), under inert atmosphere, were added HOBt (538 mg, 
3.98 mmol, 1.1 eq.) and EDCI (763 mg, 3.98 mmol, 1.1 eq.) at rt. After stirring 
for 10 minutes at rt, cystamine dihydrochloride (408 mg, 1.81 mmol, 0.5 eq.) and 
triethylamine (1.06 mL, 7.60 mmol, 2.1 eq.) were added. The resulting mixture 
was stirred at rt and followed by TLC. After 20 h, the reaction was stopped. The 
organic phase was washed with 1N aqueous HCl (40 mL). The aqueous phase was 
extracted one more time with CH2Cl2 (40 mL). The combined organic layers were 
dried (MgSO4) and the product (420 mg, 59%) was obtained as an amorphous 
white solid after flash column chromatography and recrystalisation (EtOH/H2O). 
Rf 0.3 (AcOEt/CH2Cl2 3:7). IR 3323, 1605, 1545, 1495, 1456, 1370, 1309 cm
-1
; 
1
H NMR (400 MHz, d
6
-DMSO) δ 2.96 (t, J = 6.8 Hz, 4H, CH2S), 3.61 (m, 4H, 
CH2N), 6.85-6.93 (m, 4H, 2-H + 6-H), 7.35-7.44 (m, 2H, 1-H), 7.79-7.87 (m, 2H, 
3-H), 8.97 (br. t, 2H, NH), 12.44 (s, 2H, OH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 
36.7, 38.2, 115.1, 117.3, 118.5, 127.7, 133.7, 159.8, 168.9; HRMS (ESI+) m/z 
calc. for C18H21N2O4S2 [M+H]
+ 
393.0937 found: 393.0950; Anal. Calc. for 
C18H20N2O4S2: C, 55.08; H, 5.14; N, 7.14. Found: C, 55.15; H, 5.05; N, 7.07. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(2,6-dihydroxybenzamide) 
(162) 
1
2
3
4
5
6
H
N
O
S
S
N
H
O
OH
OH
OH
HO  
To a solution of cystamine 53 (345 mg, 2.27 mmol, 1 eq.) in freshly distilled 
CH2Cl2 (40 mL) and dioxane (10 mL), under inert atmosphere, were added HOBt 
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(736 mg, 5.45 mmol, 2.4 eq.), 2,6-dihydroxybenzoic acid 161 (700 mg, 4.54 
mmol, 2 eq.), and EDCI (958 mg, 5.00 mmol, 2.2 eq.) at rt. The resulting mixture 
was stirred at rt and followed by TLC. After 24 h, the reaction was stopped. The 
product (155 mg, 16%) was obtained as an amorphous off white solid after flash 
column chromatography (MeOH/CH2Cl2 5 : 95) and recrystalisation 
(acetone/hexane). Rf 0.3 (MeOH/CH2Cl2 5 : 95). IR (neat) 3270, 1593, 1553, 
1452, 1341, 1279, 1237; 
1
H NMR (400 MHz, d
6
-DMSO) δ 2.97 (t, J = 6.4 Hz, 
4H, CH2S), 3.67 (m, 4H, CH2N), 6.36 (d, J = 8.2 Hz, 4H, 2-H + 6-H), 7.16 (d, J = 
8.2 Hz, 2H, 1-H), 9.14 (br. t, 2H, NH), 12.56 (br. s, 4H, OH). 
13
C NMR (100 
MHz, d
6
-DMSO) δ 36.7, 37.6, 102.3, 107.1, 133.4, 160.2, 170.0; HRMS (ESI+) 
m/z calc. for C18H21N2O6S2 [M+H]
+ 
425.0836 found: 425.0839; Anal. Calc. for 
C18H20N2O6S2: C, 50.93; H, 4.75; N, 6.60. Found: C, 50.83; H, 4.70; N, 6.50. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-hydroxypicolinamide) (164) 
H
N
O
S
S
N
H
ON
1
2
3
NOH
OH
 
To a solution of 3-hydroxypicolinic acid 163 (300 mg, 2.16 mmol, 1.0 eq.) in 
freshly distilled CH2Cl2 (25 mL), under inert atmosphere, were added HOBt (321 
mg, 2.37 mmol, 1.1 eq.) and EDCI (455 mg, 2.37 mmol, 1.1 eq.) at rt. After 
stirring for 10 minutes at rt, cystamine dihydrochloride (164 mg, 1.08 mmol, 0.5 
eq.) and freshly distilled NEt3 (631 μL, 4.53 mmol, 2.1 eq.) were added. The 
resulting mixture was stirred at rt and followed by TLC. After 48 h, the reaction 
was stopped. The organic phase was washed with water (25 mL). The aqueous 
phase was extracted one more time with AcOEt (3 x 25 mL). The combined 
organic layers were dried (MgSO4) and the product (225 mg, 53%) was obtained 
as a white solid after flash column chromatography (MeOH/AcOH/CH2Cl2 4 : 1 : 
96). Rf 0.8 (MeOH/AcOH/CH2Cl2 4 : 1 : 96); IR (neat) 3381, 3347, 1646, 1575, 
1529, 1442, 1440, 1289; 
1
H NMR (400 MHz, CDCl3) δ 2.97 (t, J = 6.4 Hz, 4H, 
CH2S), 3.82 (m, 4H, CH2N), 7.31 (dd, J = 8.6, 1.5 Hz, 2H, 3-H), 7.35 (dd, J = 8.6, 
4.1 Hz, 2H, 2-H), 8.07 (dd, J = 4.1, 1.5 Hz, 2H, 1-H), 8.42 (br. t, 2H, NH), 12.03 
(s, 2H, OH). 
13
C NMR (100 MHz, CDCl3) δ 37.7, 37.8, 126.2, 128.7, 131.2, 
139.5, 157.8, 168.9; HRMS (ESI+) m/z calc. for C16H19N4O4S2 [M+H]
+ 
395.0842, 
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found: 395.0847; Anal. Calc. for C16H18N4O4S2: C, 48.72; H, 4.60; N, 14.20. 
Found: C, 48.85; H, 4.66; N, 14.04. 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-methylpicolinamide) (181) 
1
2
N
3
4
5
6
O
H
N
S
S
N
H
O
N
 
Compound 181 (334 mg, 67%) was obtained as a white solid, according to the 
general produre described above. Rf 0.4 (AcOEt/PE40-60 8 : 2); IR (neat) 3291, 
1660, 1518, 1440, 1409; 
1
H NMR (400 MHz, CDCl3) δ 2.73 (s, 6H, CH3Ar), 2.96 
(t, J = 6.5 Hz, 4H, CH2S), 3.78 (m, 4H, CH2N), 7.30 (dd, J = 7.8, 4.5 Hz, 2H, 1-
H), 7.58 (dd, J = 7.8, 0.9 Hz, 2H, 6-H), 8.38 (dd, J = 4.5, 0.9 Hz, 2H, 2-H), 8.50 
(br. t, 2H, NH). 
13
C NMR (100 MHz, CDCl3) δ 20.5, 38.0, 38.1, 125.7, 135.5, 
141.0, 145.3, 146.9, 165.9; HRMS (ESI+) m/z calc. for C18H23N4O2S2 [M+H]
+
 
391.1257, found: 391.1252; Anal. Calc. for C18H22N4O2S2: C, 55.36; H, 5.68; N, 
14.35. Found: C, 55.30; H, 5.58; N, 14.23 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(3-methoxypicolinamide) (184) 
1
2
N
3
4
5
6
O
H
N
S
S
N
H
O
N
O
O
 
Compound 184 (182 mg, 80%) was obtained as a white solid, according to the 
general produre described above. Rf 0.5 (MeOH/CH2Cl2 1 : 9); IR (neat) 3296, 
1655, 1509, 1464, 1426, 1279, 1248, 1211; 
1
H NMR (400 MHz, CDCl3) δ 2.94 (t, 
J = 6.4 Hz, 4H, CH2S), 3.77 (m, 4H, CH2N), 3.93 (s, 6H, CH3O), 7.34 (dd, J = 
8.5, 1.5 Hz, 2H, 6-H), 7.38 (dd, J = 8.5, 4.1 Hz, 2H, 1-H), 8.12 (br. t, 2H, NH), 
8.18 (dd, J = 4.1, 1.5 Hz, 2H, 2-H). 
13
C NMR (100 MHz, CDCl3) δ 37.7, 38.0, 
56.0, 120.4, 127.0, 138.6, 140.1, 155.8, 164.3; HRMS (ESI+) m/z calc. for 
C18H23N4O4S2 [M+H]
+
 423.1155, found: 423.1162; Anal. Calc. for C18H22N4O4S2: 
C, 51.17; H, 5.25; N, 13.26. Found: C, 51.08; H, 5.36; N, 13.16. 
 
General procedure for amide bond formation between cystamine 53 and 
chloropyridine carboxylic acids 165-167: 
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To a solution of the appropriate carboxylic acid (1.0 eq.) in freshly distilled 
CH2Cl2 (11 mL/mmol) at rt was added HOBt (1.1 eq.) and EDCI (1.1 eq.). The 
resulting mixture was stirred at rt for 10-15 minutes, then cystamine 
dihydrochloride (0.5 eq.) and freshly distilled triethylamine (2.5 eq.) were added. 
After 24 hours at rt, the organic phase was washed with sat. aq. NaHCO3 (11 
mL/mmol). The aquoue phase was back extracted two times with CHCl3 (11 
mL/mmol). The combined organic layers were dried (MgSO4) and concentrated 
under reduced pressure. The product was purified by by flash collumn 
chromatography. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(6-chloropicolinamide) (168) 
1
2 N
3
4
5
6
O
H
N
S
S
N
H
O
N
Cl7
Cl
 
Compound 168 (910 mg, 66%) was obtained as a white solid, according to the 
general produre described above. Rf 0.45 (AcOEt/CH2Cl2 3 : 7); IR (neat) 3324, 
1653, 1558, 1535, 1433, 1402, 1308; 
1
H NMR (400 MHz, CDCl3) δ 2.98 (t, J = 
6.5 Hz, 4H, CH2S), 3.82 (m, 4H, CH2N), 7.46 (dd, J = 7.8, 0.8 Hz, 2H, 1-H), 7.82 
(app-t, J = 7.8 Hz, 2H, 6-H), 8.13 (dd, J = 7.8, 0.8 Hz, 2H, 5-H), 8.18 (br. t, 2H, 
NH). 
13
C NMR (100 MHz, CDCl3) δ 37.6, 38.5, 121.0, 127.1, 140.0, 150.1, 150.2, 
163.1; HRMS (ESI+) m/z calc. for C16H17Cl2N4O2S2 [M+H]
+
 431.0164, found: 
431.0173; Anal. Calc. for C16H16Cl2N4O2S2: C, 44.55; H, 3.74; N, 12.99. Found: 
C, 44.55; H, 3.66; N, 12.90. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(5-chloropicolinamide) (169) 
1
2
N
3
4
5
6
O
H
N
S
S
N
H
O
N
Cl
Cl  
Compound 169 (947 mg, 69%) was obtained as a white solid, according to the 
general produre described above. Rf 0.45 (AcOEt/CH2Cl2 3 : 7); IR (neat) 3352, 
1655, 1525, 1464, 1442, 1302; 
1
H NMR (400 MHz, CDCl3) δ 2.96 (t, J = 6.4 Hz, 
4H, CH2S), 3.81 (m, 4H, CH2N), 7.81 (dd, J = 8.3, 2.3 Hz, 2H, 6-H), 8.14 (d, J = 
8.3 Hz, 2H, 2-H), 8.25 (br. t, 2H, NH), 8.50 (d, J = 2.3 Hz, 2H, 5-H). 
13
C NMR 
(100 MHz, CDCl3) δ 37.8, 38.2, 123.2, 135.1, 137.1, 147.2, 147.8, 163.6; HRMS 
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(ESI+) m/z calc. for C16H17Cl2N4O2S2 [M+H]
+
 431.0164, found: 431.0162; Anal. 
Calc. for C16H16Cl2N4O2S2: C, 44.55; H, 3.74; N, 12.99. Found: C, 44.63; H, 3.62; 
N, 12.91. 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(4-chloropicolinamide) (170) 
1
2
N
3
4
5
6
O
H
N
S
S
N
H
O
N
Cl
Cl  
Compound 170 (460mg, 42%) was obtained as a white solid, according to the 
general produre described above. Rf 0.65 (AcOEt/CH2Cl2 3 : 7); IR (neat) 3355, 
1669, 1558, 1516; 
1
H NMR (400 MHz, CDCl3) δ 2.96 (t, J = 6.4 Hz, 4H, CH2S), 
3.82 (m, 4H, CH2N), 7.43 (dd, J = 5.2, 2.0 Hz, 2H, 1-H), 8.19 (d, J = 2.0 Hz, 2H, 
5-H), 8.32 (br. t, 2H, NH), 8.45 (d, J = 5.2 Hz, 2H, 2-H). 
13
C NMR (100 MHz, 
CDCl3) δ 37.7, 38.3, 123.0, 126.4, 146.0, 149.0, 151.1, 163.3; HRMS (ESI+) m/z 
calc. for C16H17Cl2N4O2S2 [M+H]
+
 431.0164, found: 431.0159; Anal. Calc. for 
C16H16Cl2N4O2S2: C, 44.55; H, 3.74; N, 12.99. Found: C, 44.56; H, 3.65; N, 
12.89. 
 
Chlorine displacement, general procedure : 
To a solution of the appropriate chlorinated derivative in THF (11 mL/mmol) was 
added a solution of the appropriate amine (40% w/w in water, 11 mL/mmol). The 
resulting mixture was heated at 160°C under microwave irradiation and the 
progress of the reaction was monitored by TLC. The reaction mixture was then 
concentrated and the product was purified by flash collumn chromatography. 
 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(6-
(dimethylamino)picolinamide) (171) 
1
2 N
3
4
5
6
O
H
N
S
S
N
H
O
N
N
N
 
Compound 171 (153 mg, 74%) was obtained as a white solid, according to the 
general produre described above. Rf 0.2 (MeOH/CH2Cl2 2 : 98); IR (neat) 3338, 
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1657, 1520, 1520, 1499, 1428, 1378; 
1
H NMR (400 MHz, CDCl3) δ 2.96 (t, J = 
6.4 Hz, 4H, CH2S), 3.11 (s, 12H, NMe2), 3.79 (m, 4H, CH2N), 6.66 (d, J = 8.3 Hz, 
2H, 1-H), 7.44 (d, J = 7.0 Hz, 2H, 5-H), 7.57 (dd, J = 8.3, 7.0 Hz, 2H, 6-H), 8.39 
(br. t, 2H, NH). 
13
C NMR (100 MHz, CDCl3) δ 38.0, 38.1 (2C), 109.1, 110.0, 
138.2, 147.4, 157.7, 165.2; HRMS (ESI+) m/z calc. for C20H29N6O2S2 [M+H]
+
 
449.1788, found: 449.1772; Anal. Calc. for C20H28N6O2S2: C, 53.55; H, 6.29; N, 
18.73. Found: C, 53.46; H, 6.39; N, 18.78. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(4-
(dimethylamino)picolinamide) (173) 
1
2
N
3
4
5
6
O
H
N
S
S
N
H
O
N
N
N  
Compound 173 (143 mg, 92%) was obtained as a white solid, according to the 
general produre described above. Rf 0.5 (MeOH/CH2Cl2 5 : 95); IR (neat) 3347, 
1665, 1603, 1513, 1437 1378 1286, 1222; 
1
H NMR (400 MHz, CDCl3) δ 2.94 (t, J 
= 6.5 Hz, 4H, CH2S), 3.05 (s, 12H, NMe2), 3.78 (m, 4H, NCH2), 6.54 (dd, J = 5.9, 
2.8 Hz, 2H, 1-H), 7.45 (d, J = 2.8 Hz, 2H, 5-H), 8.14 (d, J = 5.9 Hz, 2H, 2-H), 
8.50 (br. t, 2H, NH). 
13
C NMR (100 MHz, CDCl3) δ 37.9, 38.2, 39.2, 105.2, 
108.0, 148.1, 149.7, 155.2, 165.3; HRMS (ESI+) m/z calc. for C20H29N6O2S2 
[M+H]
+
 449.1788, found: 449.1781; Anal. Calc. for C20H28N6O2S2: C, 53.55; H, 
6.29; N, 18.73. Found: C, 53.46; H, 6.32; N, 18.78. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(6-
(methylamino)picolinamide) (174) 
1
2 N
3
4
5
6
O
H
N
S
S
N
H
O
N
N
H
H
N
 
Compound 174 (25 mg, 13%) was obtained as a white solid, according to the 
general produre described above. Rf 0.2 (MeOH/CH2Cl2 4 : 96); IR (neat) 3341, 
1660, 1601, 1525, 1506, 1466, 1419; 
1
H NMR (400 MHz, CDCl3) δ 2.95 (m, 10H, 
CH3N + CH2S), 3.79 (m, 4H, CH2N), 4.71 (br. q, 2H, CH3NH), 6.52 (d, J = 8.3 
Hz, 2H, 1-H), 7.46 (d, J = 7.3 Hz, 2H, 5-H), 7.55 (m, 2H, 6-H), 8.36 (br. t, 2H, 
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NH amide). 
13
C NMR (100 MHz, CDCl3) δ 28.9, 38.0, 38.1, 109.8, 111.3, 138.3, 
147.8, 158.1, 165.1; HRMS (ESI+) m/z calc. for C18H25N6O2S2 [M+H]
+
 421.1475, 
found: 421.1464; Anal. Calc. for C18H24N6O2S2: C, 51.41; H, 5.75; N, 19.98. 
Found: C, 51.45; H, 5.85; N, 19.88. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(4-
(methylamino)picolinamide) (176) 
1
2
N
3
4
5
6
O
H
N
S
S
N
H
O
N
NH
HN  
Compound 176 (85 mg, 44%) was obtained as a white solid, according to the 
general produre described above. Rf 0.2 (MeOH/CH2Cl2 5 : 95); IR (neat) 3350, 
1662, 1615, 1537, 1513, 1357; 
1
H NMR (400 MHz, d
6
-DMSO) δ 2.73 (d, J = 4.9 
Hz, 6H, CH3), 2.93 (t, J = 6.6 Hz, 4H, CH2S), 3.56 (m, 4H, CH2N), 6.57 (dd, J = 
5.7, 2.4 Hz, 2H, 1-H), 6.85 (q, J = 4.7 Hz, 2H, CH3NH), 7.17 (d, J = 2.4 Hz, 2H, 
5-H), 8.07 (d, J = 5.7 Hz, 2H, 2-H), 8.75 (t, J = 6.0 Hz, 2H, NH amide). 
13
C NMR 
(100 MHz, CDCl3) δ 28.5, 37.0, 37.9, 105.1, 108.0, 148.2, 149.8, 155.4, 164.5; 
HRMS (ESI+) m/z calc. for C18H25N6O2S2 [M+H]
+
 421.1475, found: 421.1476; 
Anal. Calc. for C18H24N6O2S2: C, 51.41; H, 5.75; N, 19.98. Found: C, 51.30; H, 
5.89; N, 19.89. 
 
N,N'-(2,2'-Disulfanediylbis(ethane-2,1-diyl))bis(5-
(dimethylamino)picolinamide) (179) 
1
2
N
3
4
5
6
O
H
N
S
S
N
H
O
N
N
N
 
To a solution of acid 178
215
 (50 mg, 0.30 mmol, 1.0 eq.) in freshly distilled 
CH2Cl2 (3.4 mL) were added HOBt (45 mg, 0.33 mmol, 1.1 eq.) and EDC (63 mg, 
0.33 mmol, 1.1 eq.) at rt. The resulting mixture was stirred at rt for 15 minutes. 
Cystamine dihydrochloride (34 mg, 0.15 mmol, 0.5 eq.) and Et3N (105 μL, 0.752 
mmol, 2.5 eq.) were added, and the resulting mixture was stirred at rt for 24 hours. 
The solvent was evaporated under reduced pressure, and the product (17 mg, 
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25%) was purified by flash column chromatography (MeOH/CH2Cl2 3 : 97). Rf 
0.2 (MeOH/CH2Cl2 3 : 97); 
1
H NMR (400 MHz, CDCl3) δ 2.95 (t, J = 6.4 Hz, 2H, 
CH2S), 3.05 (s, 6H, NMe2), 3.79 (m, 2H, CH2N), 6.98 (dd, J = 8.8, 3.0 Hz, 6-H), 
7.96-8.04 (m, 2H, 2-H + 5-H), 8.13 (br. t, 1H, NH). HRMS (ESI+) m/z calc. for 
C20H29N6O2S2 [M+H]
+
 449.1788, found: 449.1778. 
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4. Towards photoswitchable HDAC inhibitors 
 
(E)-1-(4-Iodophenyl)-2-phenyldiazene (197) 
1
2
3
4
5
6
N
N 7
8
9
10
11
12
I
 
Compound 197 has been previously reported by Trauner and coworkers
219d
 and 
has been prepared according to the same procedure. Briefly, a solution of 
nitrosobenzene (2.5 g, 23.3 mmol, 1.0 eq.) and 4-iodobenzenamine (4.24g, 19.4 
mmol, 0.83 eq.) in glacial acetic acid (160 mL) was stirred at 40°C for 12h. The 
resulting mixture was then diluted with water (625 mL) and extracted with 
CH2Cl2 (625 mL). The organic phase was washed with brine (2 x 625 mL), dried 
(MgSO4) and concentrated. The product (5.65 g, 94%) was purified by flash 
column chromatography (AcOEt/PE40-60 3 : 7). NMR data matched perfectly with 
reported ones. 
1
H NMR (400 MHz, CDCl3) δ 7.51 (m, 3H, 1-H + 2-H + 6-H), 7.66 
(m, 2H, 8-H + 12-H), 7.87 (m, 2H, 9-H + 11-H), 7.92 (m, 2H, 3-H + 5-H). 
13
C 
NMR (100 MHz, CDCl3) δ 97.6, 122.9, 124.5, 129.1, 131.3, 138.3, 151.9, 152.4; 
HRMS (ESI+) m/z calc. for C12H10IN2 [M+H]
+ 
308.9883, found: 308.9890. 
 
(E)-1-(3-Iodophenyl)-2-phenyldiazene (196) 
1
2
3
4
5
6
N
N 7
8
9
10
11
12
I
 
196 was prepared according to the same procedure. 
1
H NMR (400 MHz, CDCl3) δ 
7.27 (t, J = 7.9 Hz, 1H, 9-H), 7.45-7.57 (m, 3H, 1-H + 2-H + 6-H), 7.79 (m, 1H, 
10-H), 7.88-7.97 (m, 3H, 3-H + 5-H + 8-H), 8.26 (t, J = 1.7 Hz, 1H, 12-H). 
13
C 
NMR (100 MHz, CDCl3) δ 94.6, 123.0, 123.5, 129.1, 130.5, 130.6, 131.5, 139.5, 
152.3, 153.3; HRMS (ESI+) m/z calc. for C12H10IN2 [M+H]
+ 
308.9883, found: 
308.9877.  
 
N-(Tetrahydro-2H-pyran-2-yloxy)acrylamide (198) 
H
N
O
O O
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To an ice cold solution of O-(tetrahydro-2H-pyran-2-yl)hydroxylamine 54 
155
 (5.0 
g, 42.7 mmol, 1 eq.) and NEt3 (6.55 mL, 47.0 mmol, 1.1 eq.) in freshly distilled 
CH2Cl2 (375 mL) was added a second solution of acryloyl chloride 203 (3.64 mL, 
44.8 mmol, 1.05 eq.) in CH2Cl2 (50 mL) over 1 hour. The resulting was then 
stirred at rt for 24h. The organic phase was then washed with water (250 mL). The 
organic phase was extracted one more time with CH2Cl2 (250 mL). The combines 
organic layers were dried (MgSO4) and concentrated. The product (4.41 g, 60%) 
was purified by flash column chromatography (gradient AcOEt/PE40-60 3 : 7 to 7 : 
3) and obtained as a white solid. Rf 0.35 (AcOEt : PE40-60, 7 : 3); 
1
H NMR (400 
MHz, d
6
-DMSO) δ 1.20-1.70 (m, 6H), 3.52 (m, 1H), 3.94 (m, 1H), 4.87 (m, 1H), 
5.65 (dd, J = 9.0, 3.1 Hz, 1H), 6.04-6.24 (m, 2H), 11.24 (s, 1H). 
13
C NMR (100 
MHz, d
6
-DMSO) δ 18.2, 24.6, 27.7, 61.3, 100.9, 126.1, 128.4, 161.8; HRMS 
(ESI+) m/z calc. for C8H13NO3Na [M+Na]
+ 
194.0788, found: 194.0788; Anal. 
Calc. for C8H13NO3: C, 56.13; H, 7.65; N, 8.18. Found: C, 56.15; H, 7.76; N, 
8.08. 
 
(E)-3-(3-((E)-Phenyldiazenyl)phenyl)-N-(tetrahydro-2H-pyran-2-
yloxy)acrylamide (199) 
1
2
3
4
5
6
N
N 7
8
9
10
11
12 13
14
N
H
O
O 15
16
17
18
19O
20
 
A mixture of compound 196 (1.80 g, 5.84 mmol, 1 eq.), compound 198 (1.50 g, 
8.76, 1.5 eq.), NEt3 (2.44 mL, 17.5 mmol, 3 eq.), tri o-tolylphosphine (178 mg, 
0.584 mmol, 0.1 eq.), palladium acetate (66 mg, 0.292 mmol, 0.05 eq.) in 
anhydrous DMF (25 mL) was heated at 100°C for 24h under inert atmosphere. 
The reaction mixture was then diluted with water (120 mL), extracted with 
CH2Cl2 (2 x 90 mL). The combined organic layers were washed with brine (90 
mL), dried (MgSO4) and concentrated under vacuum. The product (1.69 g, 82%) 
was obtained as an orange solid after flash column chromatography (AcOEt/PE40-
60 1 :1). Rf 0.6 (AcOEt : PE40-60 7 : 3); IR (neat) 3177, 1662, 1628, 1206, 1116; 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 1.45-1.85 (m, 6H, 16-H2 + 17-H2 + 18-H2), 3.55 
(m, 1H, 19-HA), 3.97 (m, 1H, 19-HB), 4.94 (m, 1H, 15-H), 6.67 (d, J = 15.8 Hz, 
1H, 14-H), 7.54-7.70 (m, 5H, 1-H + 2-H + 6-H + 9-H + 13-H), 7.78 (d, J = 7.4 
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Hz, 1H, 10-H), 7.91 (m, 3H, 3-H + 5-H + 8-H), 8.07 (s, 1H, 12-H), 11.30 (s, 1H, 
NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 18.2, 24.6, 27.7, 61.3, 101, 120.1, 120.8, 
122.5, 123.5, 129.4, 130.0, 130.5, 131.7, 136.0, 138.4, 151.8, 152.2, 162.1; 
HRMS (ESI+) m/z calc. for C20H22N3O3 [M+H]
+ 
352.1656, found: 352.1660; 
Anal. Calc. for C20H21N3O3: C, 68.36; H, 6.02; N, 11.96. Found: C, 68.49; H, 
6.10; N, 11.89. 
 
(E)-3-(4-((E)-Phenyldiazenyl)phenyl)-N-(tetrahydro-2H-pyran-2-
yloxy)acrylamide (200) 
1
2
3
4
5
6
N
N 7
8
9
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13
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N
O
O
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A mixture of compound 200 (1.80 g, 5.84 mmol, 1 eq.), compound 198 (1.50 g, 
8.76, 1.5 eq.), NEt3 (2.44 mL, 17.5 mmol, 3 eq.), tri o-tolylphosphine (178 mg, 
0.584 mmol, 0.1 eq.), palladium acetate (66 mg, 0.292 mmol, 0.05 eq.) in 
anhydrous DMF (25 mL) was heated at 100°C for 24h under inert atmosphere. 
The reaction mixture was then diluted with water (120 mL), extracted with 
CH2Cl2 (2 x 90 mL). The combined organic layers were washed with brine (90 
mL), dried (MgSO4) and concentrated under vacuum. The product (1.63 g, 80%) 
was obtained as an orange solid after flash column chromatography (AcOEt/PE40-
60 1 :1). Rf 0.6 (AcOEt : PE40-60, 7 : 3); IR (neat) 3194, 1658, 1622, 1206, 1116; 
1
H NMR (400 MHz, d
6
-DMSO) δ 1.45-1.85 (m, 6H, 18-H2 + 19-H2 + 20-H2), 
3.55 (m, 1H, 17-HA), 3.98 (m, 1H, 17-HB), 4.94 (m, 1H, 15-H), 6.65 (d, J = 15.8 
Hz, 1H, 14-H), 7.59 (m, 4H, 1-H + 2-H + 6-H + 13-H), 7.81 (m, 2H, 9-H + 11-H), 
7.92 (m, 4H, 3-H + 5-H + 8-H + 12-H), 11.34 (s, 1H, NH). 
13
C NMR (100 MHz, 
d
6
-DMSO) δ 18.2, 24.6, 27.7, 61.3, 101.0, 120.5, 122.6, 123.1, 128.7, 129.4, 
131.7, 137.5, 138.3, 151.9, 152.1, 162.1; HRMS (ESI+) m/z calc. for C20H22N3O3 
[M+H]
+ 
352.1656, found: 352.1656; Anal. Calc. for C20H21N3O3: C, 68.36; H, 
6.02; N, 11.96. Found: C, 68.29; H, 6.00; N, 11.86. 
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(E)-N-Hydroxy-3-(4-((E)-phenyldiazenyl)phenyl)acrylamide (201) 
1
2
3
4
5
6
N
N 7
8
9
10
11
12
13
14 H
N
O
OH
 
A solution of compound 199 (500 mg, 1.42 mmol, 1 eq.) and pyridinium 
paratoluenesulfonate (36 mg, 0.142 mmol, 0.1 eq.) in a 1 :1 mixture of THF and i-
PrOH (30 mL) was heated at 50°C for 8h under inert atmosphere. The solvent was 
then evaporated under vacuum and the product (288 mg, 76%) was obtained as an 
amorphous dark orange solid after purification by flash column chromatography 
(MeOH/CH2Cl2/AcOH 8 : 92 : 0.5) and attempted recrystalization (AcOH/EtOH, 
filtration and washings with cold Et2O). Rf 0.3 (MeOH : CH2Cl2 8 : 92); IR (neat) 
3244, 1662, 1567, 1353; 
1
H NMR (400 MHz, d
6
-DMSO) δ 6.59 (d, J = 15.7 Hz, 
1H, 14-H), 7.48-7.68 (m, 4H, 1-H + 2-H + 6-H + 13-H), 7.80 (m, 2H, 9-H + 11-
H), 7.92 (m, 4H, 8-H + 12-H + 3-H + 5-H), 9.15 (br. s, 1H, OH), 10.86 (br. s, 1H, 
NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 120.9, 122.6, 123.1, 128.6, 129.5 131.7, 
137.1, 137.8, 151.9, 152.0, 162.3; HRMS (ESI-) m/z calc. for C15H12N3O2 [M-H]
- 
266.0935, found: 266.0919; Anal. Calc. for C15H13N3O2: C, 67.40; H, 4.90; N, 
15.72. Found: C, 67.52; H, 4.77; N, 15.63. 
 
(E)-N-Hydroxy-3-(3-((E)-phenyldiazenyl)phenyl)acrylamide (202) 
1
2
3
4
5
6
N
N 7
8
9
10
11
12 13
14
N
H
O
OH
 
A solution of compound 200 (500 mg, 1.42 mmol, 1 eq.) and pyridinium 
paratoluenesulfonate (36 mg, 0.142 mmol, 0.1 eq.) in a 1 :1 mixture of THF and i-
PrOH (30 mL) was heated at 50°C for 8h under inert atmosphere. The solvent was 
then evaporated under vacuum and the product (302 mg, 79%) was obtained as an 
amorphous dark orange solid after purification by flash column chromatography 
(MeOH/CH2Cl2/AcOH 8 : 92 : 0.5) and attempted recrystalization (AcOH/EtOH, 
filtration and washings with cold Et2O). Rf 0.3 (MeOH : CH2Cl2 8 : 92); IR (neat) 
3210, 1611, 1535, 1362; 
1
H NMR (400 MHz, d
6
-DMSO) δ 6.62 (d, J = 15.2 Hz, 
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1H, 14-H), 7.50-7.70 (m, 5H, 1-H + 2-H + 6-H + 9-H + 13-H), 7.77 (m, 1H, 10-
H), 7.84-7.98 (m, 3H, 3-H + 5-H + 8-H), 8.06 (s, 1H, 12-H), 9.14 (br. s, 1H, OH), 
10.83 (br. s, 1H, NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 120.5, 120.9, 122.6, 
123.1, 129.5, 130.1, 130.5, 131.7, 136.1, 137.3, 151.8, 152.2, 162.3; HRMS (ESI-
) m/z calc. for C15H12N3O2 [M-H]
- 
266.0935, found: 266.0921; Anal. Calc. for 
C15H13N3O2: C, 67.40; H, 4.90; N, 15.72. Found: C, 67.30; H, 4.97; N, 15.85. 
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5. Development of new probes for a Fluorescence Resonance 
Energy Transfer (FRET) based inhibitor assay for Histone 
Deacetylases 
 
General procedure for the synthesis of 3-(5-(dimethylamino)naphthalene-1-
sulfonamido)alkanoic acids: 
To a solution of the appropriate amino-acid (1.63 mmol, 1.1 eq.) in 1N aqueous 
sodium hydroxide (2 mL) was added a second solution of dansyl chloride (400 
mg, 1.48 mmol, 1 eq.) in THF (13 mL), at rt. The resulting mixture was stirred at 
rt for 1.5 hour before THF was evaporated under reduced pressure. The resulting 
aqueous phase was acidified with concentrated aqueous HCl (10%) and extracted 
several times (AcOEt) from pH 4.5-5 to pH 2.5-3. The combined organic layers 
were dried (MgSO4) and concentrated under reduced pressure. The products were 
obtained as sticky green oil after purification by flash column chromatography 
(MeOH/CH2Cl2). 
 
 
3-(5-(Dimethylamino)naphthalene-1-sulfonamido)propanoic acid (213) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O
COOH  
213 was prepared according to the general procedure above. 282 mg, 59%. 
1
H 
NMR (400 MHz, CDCl3) δ 2.53 (t, J = 5.7 Hz, 2H, CH2COOH), 2.89 (s, 6H, 
NMe2), 3.13-3.22 (m, 2H, CH2N), 5.62 (br. s, 1H, NH), 7.19 (d, J = 7.5 Hz, 1H, 2-
H), 7.48-7.61 (m, 2H, 1-H + 8-H), 8.21-8.30 (m, 2H, 6-H + 7-H), 8.55 (d, J = 8.4 
Hz, 1H, 9-H). 
13
C NMR (100 MHz, CDCl3) δ 34.1, 38.5, 45.4, 115.3, 118.7, 
123.2, 128.5, 129.4, 129.5, 129.9, 130.6, 134.6, 151.9, 176.6; HRMS (ESI+) m/z 
calc. for C15H19N2O4S [M+H]
+ 
323.1060 found: 323.1054. 
 
4-(5-(Dimethylamino)naphthalene-1-sulfonamido)butanoic acid (214) 
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12
3
4 5
6
7
8 9
10
N
S NH
O
O
COOH  
214 was prepared according to the general procedure above.314mg, 63%. 
1
H 
NMR (400 MHz, CDCl3) δ 1.68-1.80 (m, 2H, NCH2CH2), 2.32 (t, J = 7.0 Hz, 2H, 
CH2COOH), 2.89 (s, 6H, NMe2), 2.92-3.00 (m, 2H, CH2N), 4.83 (br. s, 1H, NH), 
7.19 (d, J = 7.6 Hz, 1H, 2-H), 7.47-7.60 (m, 2H, 1-H + 8-H), 8.20-8.30 (m, 2H, 6-
H + 7-H), 8.54 (d, J = 8.5 Hz, 1H, 9-H). 
13
C NMR (100 MHz, CDCl3) δ 24.5, 
30.7, 42.4, 45.4, 115.3, 118.7, 123.2, 128.4, 129.5, 129.6, 129.9, 130.5, 134.5, 
151.9, 178.2; HRMS (ESI+) m/z calc. for C16H21N2O4S [M+H]
+ 
337.1217 found: 
337.1213. 
 
5-(5-(Dimethylamino)naphthalene-1-sulfonamido)pentanoic acid (215) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O
COOH  
215 was prepared according to the general procedure above. 345 mg, 67%. 
1
H 
NMR (400 MHz, CDCl3) δ 1.40-1.60 (m, 4H, NCH2CH2CH2), 2.22 (t, J = 7.0 Hz, 
2H, CH2COOH), 2.82-2.95 (m, 8H, CH2N + NMe2), 4.74 (br. s, 1H, NH), 7.19 (d, 
J = 7.3 Hz, 1H, 2-H), 7.49-7.60 (m, 2H, 1-H + 8-H), 8.24 (d, J = 7.3 Hz, 1H, 7-
H), 8.27 (d, J = 8.6 Hz, 1H, 6-H), 8.54 (d, J = 8.6 Hz, 1H, 9-H). 
13
C NMR (100 
MHz, CDCl3) δ 21.5, 28.9, 33.3, 42.7, 45.4, 115.2, 118.7, 123.1, 128.3, 129.5, 
129.6, 129.8, 130.3, 134.7, 151.9, 178.0; HRMS (ESI+) m/z calc. for 
C17H23N2O4S [M+H]
+ 
351.1373 found: 351.1374. 
 
6-(5-(Dimethylamino)naphthalene-1-sulfonamido)hexanoic acid (216) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O 11
12
13
14
15
COOH
 
216 was prepared according to the general procedure above. 314 mg, 58%. 
1
H 
NMR (400 MHz, CDCl3) δ 1.14-1.27 (m, 2H, 13-H2), 1.33-1.50 (m, 4H, 12-H2 + 
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14-H2), 2.19 (t, J = 7.3 Hz, 2H, 15-H2), 2.83-2.95 (m, 8H, CH2N + NMe2), 4.68 
(br. s, 1H, NH), 7.19 (d, J = 7.5 Hz, 1H, 2-H), 7.48-7.60 (m, 2H, 1H + 8-H), 8.24 
(d, J = 7.3 Hz, 1H, 7-H), 8.28 (d, J = 8.7 Hz, 1H, 6-H), 8.54 (d, J = 8.6 Hz, 1H, 9-
H). 
13
C NMR (100 MHz, CDCl3) δ 23.8, 25.7, 29.1, 33.6, 42.9, 45.4, 115.2, 118.7, 
123.2, 128.3, 129.6 (2C), 129.8, 130.4, 134.7, 151.9, 179.1; HRMS (ESI+) m/z 
calc. for C18H25N2O4S [M+H]
+ 
365.1530 found: 365.1526. 
 
7-(5-(Dimethylamino)naphthalene-1-sulfonamido)heptanoic acid (217) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O 11
12
13
14
15
16
COOH  
217 was prepared according to the general procedure above.457 mg, 81%. 
1
H 
NMR (400 MHz, CDCl3) δ 1.10-1.21 (m, 4H, 13-H2 + 14-H2), 1.32-1.42 (m, 2H, 
15-H2), 1.42-1.52 (m, 2H, 12-H2), 2.23 (t, J = 7.5 Hz, 2H, CH2COOH), 2.84-2.93 
(m, 8H, 11-H2), 4.66 (t, J = 6.1 Hz, 1H, NH), 7.19 (d, J = 7.3 Hz, 1H, 2-H), 7.48-
7.60 (m, 2H, 1-H + 8-H), 8.25 (d, J = 7.3 Hz, 1H, 7-H), 8.28 (d, J = 8.7 Hz, 1H, 6-
H), 8.54 (d, J = 8.5 Hz, 1H, 9H). 
13
C NMR (100 MHz, CDCl3) δ 24.3, 25.9, 28.3, 
29.2, 33.7, 43.1, 45.4, 115.2, 118.7, 123.2, 128.3, 129.6 (2C), 129.9, 130.4, 134.7, 
152.0, 179.1; HRMS (ESI+) m/z calc. for C19H27N2O4S [M+H]
+ 
379.1686 found: 
379.1684. 
 
8-(5-(Dimethylamino)naphthalene-1-sulfonamido)octanoic acid (218) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O 11
12
13
14
15
16
17
COOH
 
218 was prepared according to the general procedure above. 493 mg, 85%. 
1
H 
NMR (400 MHz, CDCl3) δ 1.04-1.20 (m, 6H, 13-H2 + 14-H2 + 15-H2), 1.28-1.39 
(m, 2H, 16-H2), 1.45-1.56 (m, 2H, 12-H2), 2.28 (t, J = 7.4 Hz, 2H, 17-H2), 2.84-
2.93 (m, 8H, NMe2 + 11-H2), 4.64 (t, J = 6.0 Hz, 1H, NH), 7.19 (d, J = 7.5 Hz, 
1H, 2-H), 7.48-7.60 (m, 2H, 1-H + 8-H), 8.25 (d, J = 7.3 Hz, 1H, 7-H), 8.29 (d, J 
= 8.7 Hz, 1H, 6-H), 8.54 (d, J = 8.5 Hz, 1H, 9-H). 
13
C NMR (100 MHz, CDCl3) δ 
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24.4, 26.1, 28.5, 28.7, 29.3, 33.8, 43.2, 45.4, 115.2, 118.7, 123.2, 128.3, 129.6 
(2C), 129.8, 130.4, 134.8, 151.9, 179.3; HRMS (ESI+) m/z calc. for C20H29N2O4S 
[M+H]
+ 
393.1843 found: 393.1843. 
 
Coupling with benzylhydroxylamine, general procedure: 
To a solution of the appropriate acid (1eq.) in freshly distilled CH2Cl2 (17 
mL/mmol), at rt and under an inert atmosphere (argon) were added successively 
HOBt (1.1 eq.) and EDCI (1 eq.). After 30 minutes stirring, benzylhydroxylamine 
hydrochloride (1.1 eq.) and diisopropylethylamine (1.1 eq.) were added, and the 
reaction was followed by TLC (PE40-60/acetone). After 24h, the organic phase was 
washed with water (17 mL/mmol). The aqueous phase was extracted with CH2Cl2 
(1 x 17 mL/mmol). The combined organic layers were dried (MgSO4) and 
concentrated. The coupling product was purified by flash column chromatography 
(PE40-60/acetone) and obtained as a light green sticky oil. 
 
 
N-(Benzyloxy)-3-(5-(dimethylamino)naphthalene-1-
sulfonamido)propanamide (219) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O
NH
O
O
13
14
15
16
1718
19
 
219 was prepared according to the general procedure above. 73mg, 85%. 
1
H NMR 
(400 MHz, d
6
-DMSO) δ 2.12 (t, J = 7.3 Hz, 2H, CH2C(O)), 2.82 (s, 6H, NMe2), 
2.91-3.02 (m, 2H, CH2N), 4.68 (s, 2H, OCH2), 7.25 (d, J = 7.4 Hz, 1H, 2-H), 
7.28-7.40 (m, 5H, OCH2ArH), 7.54-7.68 (m, 2H, 1-H + 8-H), 8.01 (t, J = 5.5 Hz, 
1H, SNH), 8.11 (d, J = 7.3 Hz, 1H, 7-H), 8.27 (d, J = 8.7 Hz, 1H, 6-H), 8.47 (d, J 
= 8.5 Hz, 1H, 9-H), 11.01 (s, 1H-C(O)NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 
32.8, 39.0, 45.0, 76.7, 115.1, 119.0, 123.5, 127.8, 128.1, 128.2 (2C), 128.7, 129.0 
(2C), 129.4, 135.6, 135.8, 151.3, 166.7. HRMS (ESI+) m/z calc. for C22H26N3O4S 
[M+H]
+ 
428.1639 found: 428.1642. 
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N-(Benzyloxy)-4-(5-(dimethylamino)naphthalene-1-sulfonamido)butanamide 
(220) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O
O
HN O
 
220 was prepared according to the general procedure above. 70 mg, 48%. 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 1.45-1.64 (m, 2H, NCH2CH2), 1.91 (t, J = 7.3 Hz, 
2H, CH2C(O)), 2.70-2.78 (m, 2H, CH2N), 2.82 (s, 6H, NMe2), 4.70 (s, 2H, 
CH2O), 7.26 (d, J = 7.5 Hz, 1H, 2-H), 7.28-7.39 (m, 5H, OCH2ArH), 7.55-7.66 
(m, 2H, 1-H + 8-H), 7.91 (t, J = 5.8 Hz, 1H, SNH), 8.08 (d, J = 7.3 Hz, 1H, 7-H), 
8.29 (d, J = 8.7 Hz, 1H, 6-H), 8.45 (d, J = 8.5 Hz, 1H, 9-H), 10.88 (s, 1H, 
C(O)NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 25.2, 29.3, 41.9, 45.0, 76.6, 115.0, 
119.0, 123.5, 127.7, 128.1 (2C), 128.2, 128.7, 129.0 (2C), 129.3, 135.8, 135.9, 
151.3, 168.7. HRMS (ESI+) m/z calc. for C23H28N3O4S [M+H]
+ 
442.1795 found: 
442.1807. 
 
N-(Benzyloxy)-5-(5-(dimethylamino)naphthalene-1-
sulfonamido)pentanamide (221) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O
NH
O
O
 
221 was prepared according to the general procedure above. 140 mg, 72%. 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 1.25-1.46 (m, 4H, NCH2CH2CH2), 1.83 (t, J = 7.3 
Hz, 2H, CH2C(O)), 2.70-2.79 (m, 2H, CH2N), 2.82 (s, 6H, NMe2), 4.73 (s, 2H, 
CH2O), 7.25 (d, J = 7.5 Hz, 1H, 2-H), 7.29-7.39 (m, 5H, OCH2ArH), 7.55-7.64 
(m, 2H, 1-H + 8-H), 7.87 (t, J = 5.8 Hz, 1H, SNH), 8.08 (d, J = 7.3 Hz, 1H, 7-H), 
8.29 (d, J = 8.7 Hz, 1H, 6-H), 8.45 (d, J = 8.5 Hz, 1H, 9-H), 10.87 (s, 1H, 
C(O)NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 21.9, 28.6, 31.5, 42.0, 45.0, 76.6, 
115.0, 119.0, 123.5, 127.7, 128.0, 128.1, 128.2, 128.6, 129.0 (2C), 129.2, 135.9, 
136.0, 151.2, 168.9. HRMS (ESI+) m/z calc. for C24H30N3O4S [M+H]
+ 
456.1952 
found: 456.1972. 
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N-(Benzyloxy)-6-(5-(dimethylamino)naphthalene-1-sulfonamido)hexanamide 
(222) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O 11
12
13
14
15
O
HN O
 
222 was prepared according to the general procedure above. 178 mg, 92%. 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 1.02-1.12 (m, 2H, 13-H2), 1.22-1.35 (m, 4H, 12-H2 
+ 14-H2), 1.80 (t, J = 7.4 Hz, 2H, 15-H2), 2.70-2.77 (m, 2H, 11-H2), 2.82 (s, 6H, 
NMe2), 4.74 (s, 2H, CH2O), 7.25 (d, J = 7.4 Hz, 1H, 2-H), 7.28-7.39 (m, 5H, 
OCH2ArH), 7.55-7.64 (m, 2H, 1-H + 8-H), 7.85 (t, J = 5.7 Hz, 1H, SNH), 8.09 (d, 
J = 7.3 Hz, 1H, 7-H), 8.30 (d, J = 8.7 Hz, 1H, 6-H), 8.45 (d, J = 8.5 Hz, 1H, 9-H), 
10.86 (s, 1H, C(O)NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 24.3, 25.3, 28.7, 31.9, 
42.2, 45.0, 76.6, 115.0, 119.1, 123.5, 127.6, 128.1 (3C), 128.6, 129.0 (2C), 129.2, 
136.0, 136.1, 151.2, 169.1. HRMS (ESI+) m/z calc. for C25H32N3O4S [M+H]
+ 
470.2108 found: 470.2118 
 
N-(Benzyloxy)-7-(5-(dimethylamino)naphthalene-1-
sulfonamido)heptanamide (223) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O 11
12
13
14
15
16
NH
O
O
 
223 was prepared according to the general procedure above. 158 mg, 82%. 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 0.90-1.10 (m, 4H, 13-H2 + 14-H2), 1.18-1.35 (m, 
4H, 12-H2 + 15-H2), 1.82 (t, J = 7.3 Hz, 2H, 16-H2), 2.70-2.79 (m, 2H, 11-H2), 
2.82 (s, 6H, NMe2), 4.74 (s, 2H, CH2O), 7.25 (d, J = 7.6 Hz, 1H, 2-H), 7.28-7.39 
(m, 5H, OCH2ArH), 7.55-7.64 (m, 2H, 1-H + 8-H), 7.87 (t, J = 5.6 Hz, 1H, SNH), 
8.09 (d, J = 7.3 Hz, 1H, 7-H), 8.30 (d, J = 8.7 Hz, 1H, 6-H), 8.45 (d, J = 8.5 Hz, 
1H, 9-H), 10.88 (s, 1H, C(O)NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 24.6, 25.5, 
27.8, 28.8, 32.0, 42.2, 45.0, 76.6, 115.0, 119.1, 123.5, 127.7, 128.1 (2C), 128.2, 
128.7, 129.0 (2C), 129.2, 136.0, 136.1, 151.3, 169.2. HRMS (ESI+) m/z calc. for 
C26H34N3O4S [M+H]
+ 
484.2265 found: 484.2272. 
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N-(Benzyloxy)-8-(5-(dimethylamino)naphthalene-1-sulfonamido)octanamide 
(224) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O 11
12
13
14
15
16
17
O
HN O
 
224 was prepared according to the general procedure above. 148 mg, 78%. 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 0.92-1.10 (m, 6H, 13-H2 + 14-H2 +15H2), 1.19-
1.29 (m, 2H, 16-H2), 1.29-1.39 (m, 2H, 12-H2), 1.86 (t, J = 7.3 Hz, 2H, 17-H2), 
2.72-2.80 (m, 2H, CH2N), 2.82 (s, 6H, NMe2), 4.76 (s, 2H, CH2O), 7.25 (d, J = 
7.6 Hz, 1H, 2-H), 7.30-7.39 (m, 5H, OCH2ArH), 7.55-7.64 (m, 2H, 1-H + 8-H), 
7.84 (t, J = 5.6 Hz, 1H, SNH), 8.09 (d, J = 7.3 Hz, 1H, 7-H), 8.30 (d, J = 8.7 Hz, 
1H, 6-H), 8.45 (d, J = 8.5 Hz, 1H, 9-H), 10.88 (s, 1H, C(O)NH). 
13
C NMR (100 
MHz, d
6
-DMSO) δ 24.6, 25.6, 28.0, 28.1, 28.9, 32.0, 42.2, 45.0, 76.6, 115.0, 
119.1, 123.5, 127.6, 128.1 (2C), 128.2, 128.6, 129.0 (2C), 129.2, 136.0, 136.1, 
151.2, 169.2. HRMS (ESI+) m/z calc. for C27H36N3O4S [M+H]
+ 
498.2421 found: 
498.2431. 
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Benzyl deprotection, general procedure: 
To a solution of the appropriate O-benzyl protected hydroxamic acid (1 eq.) under 
an inert atmosphere (argon) were successively added 10% palladium on charcoal 
(0.1 eq.) and anhydrous methanol (25 mL/mmol) at rt. The solution was saturated 
with hydrogen by bubbleling for a few minutes while stirring. The system was 
then closed and kept under H2. The resulting mixture was stirred at rt and 
followed by TLC (CH2Cl2/MeOH). After 3h, the reaction mixture was filtered 
through a pad of celite. The latter was washed several times with MeOH. The 
filtrate was concentrated and the product was purified by flash column 
chromatography (CH2Cl2/MeOH) and obtained as a brown solid. 
 
 
3-(5-(Dimethylamino)naphthalene-1-sulfonamido)-N-hydroxypropanamide 
(225) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O
NH
O OH  
225 was prepared according to the general procedure above. 41 mg, 83%. 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 2.11 (t, J = 7.4 Hz, 2H, CH2C(O)), 2.83 (s, 6H, 
NMe2), 2.90-3.02 (m, 2H, CH2N), 7.26 (d, J = 7.5 Hz, 1H, 2-H), 7.52-7.70 (m, 
2H, 1-H + 8-H), 7.96 (t, J = 5.8 Hz, 1H, SNH), 8.10 (d, J = 7.2 Hz, 1H, 7-H), 8.27 
(d, J = 8.6 Hz, 1H, 6-H), 8.47 (d, J = 8.5 Hz, 1H, 9-H), 8.71 (br. s, 1H, OH), 10.40 
(br. s, 1H, C(O)NH). 
13
C NMR (100 MHz, d
6
-DMSO) δ 32.8, 39.0, 45.0, 115.1, 
119.0, 123.5, 127.8, 128.2, 128.9, 129.0, 129.3, 135.6, 151.3, 166.4. HRMS 
(ESI+) m/z calc. for C15H20N3O4S [M+H]
+ 
338.1169 found: 338.1173. 
 
4-(5-(Dimethylamino)naphthalene-1-sulfonamido)-N-hydroxybutanamide 
(226) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O
O
HN OH
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226 was prepared according to the general procedure above. 32 mg, 67%. 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 1.50-1.62 (m, 2H, NCH2CH2), 1.89 (t, J = 7.3 Hz, 
2H, CH2C(O)), 2.70-2.80 (m, 2H, CH2N), 2.83 (s, 6H, NMe2), 7.26 (d, J = 7.5 Hz, 
1H, 2-H), 7.54-7.66 (m, 2H, 1-H + 8-H), 7.92 (br. s, 1H, SNH), 8.08 (d, J = 7.3 
Hz, 1H, 7-H), 8.28 (d, J = 8.6 Hz, 1H, 6-H), 8.46 (d, J = 8.5 Hz, 1H, 9-H), 8.65 
(br. s, 1H, OH), 10.28 (br. s, 1H, C(O)NH). 
13
C NMR (100 MHz, CDCl3) δ 25.0, 
29.6, 42.4, 45.4, 115.3, 118.5, 123.2, 128.6, 129.5, 129.6, 129.9, 130.7, 134.3, 
152.1, 170.7. HRMS (ESI+) m/z calc. for C16H22N3O4S [M+H]
+ 
352.1326 found: 
352.1333. 
 
5-(5-(Dimethylamino)naphthalene-1-sulfonamido)-N-hydroxypentanamide 
(227) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O
NH
O OH  
227 was prepared according to the general procedure above. 66 mg, 69%. 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 1.20-1.48 (m, 4H, NCH2CH2CH2), 1.83 (t, J = 7.2 
Hz, 2H, CH2C(O)), 2.70-2.80 (m, 2H, CH2N). 2.83 (s, 6H, NMe2), 7.25 (d, J = 7.5 
Hz, 1H, 2-H), 7.52-7.68 (m, 2H, 1-H + 8-H), 7.88 (br. s, 1H, SNH), 8.08 (d, J = 
7.0 Hz, 1H, 7-H), 8.29 (d, J = 8.7 Hz, 1H, 6-H), 8.45 (d, J = 8.5 Hz, 1H, 9-H), 
8.64 (br. s, 1H, OH), 10.28 (br. s, 1H, C(O)NH).
 13
C NMR (100 MHz, CDCl3) δ 
22.0, 28.7, 31.9, 42.6, 45.4, 115.3, 118.8, 123.2, 128.4, 129.5, 129.6, 129.9, 130.4, 
134.6, 151.9, 171.2. HRMS (ESI+) m/z calc. for C17H24N3O4S [M+H]
+ 
366.1482 
found: 366.1494. 
 
6-(5-(Dimethylamino)naphthalene-1-sulfonamido)-N-hydroxyhexanamide 
(228) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O 11
12
13
14
15
O
HN OH
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228 was prepared according to the general procedure above. 73 mg, 60%. 
1
H 
NMR (400 MHz, d
6
-DMSO) δ 1-1.18 (m, 2H, 13-H2), 1.20-1.40 (m, 4H, 12-H2 + 
14-H2), 1.79 (t, J = 7.3 Hz, 2H, 15-H2), 2.68-2.94 (m, 8H, NMe2 + 11-H2), 7.25 
(d, J = 7.5 Hz, 1H, 2-H), 7.52-7.70 (m, 2H, 1-H + 8-H), 7.86 (t, J = 5.6 Hz, 1H, 
SNH), 8.09 (d, J = 7.1 Hz, 1H, 7-H), 8.29 (d, J = 8.6 Hz, 1H, 6-H), 8.45 (d, J = 
8.4 Hz, 1H, 9-H), 8.61 (br. s, 1H, OH), 10.27 (br. s, 1H, C(O)NH).
 13
C NMR (100 
MHz, CDCl3) δ 24.0, 25.3, 28.7, 32.2, 42.6, 45.5, 115.3, 118.9, 123.3, 128.5, 
129.6, 129.7, 129.8, 130.4, 134.7, 151.8, 170.8. HRMS (ESI+) m/z calc. for 
C18H26N3O4S [M+H]
+ 
380.1639 found: 380.1644. 
 
7-(5-(Dimethylamino)naphthalene-1-sulfonamido)-N-hydroxyheptanamide 
(229) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O 11
12
13
14
15
16
NH
O OH  
229 was prepared according to the general procedure above. 97 mg, 85%. (400 
MHz, d
6
-DMSO) δ 0.92-1.14 (m, 4H, 13-H2 + 14-H2), 1.18-1.36 (m, 4H, 12-H2 + 
15-H2), 1.82 (t, J = 7.3 Hz, 2H, 16-H2), 2.69-2.80 (m, 2H, 11-H2), 2.83 (m, 6H, 
NMe2), 7.25 (d, J = 7.5 Hz, 1H, 2-H), 7.53-7.67 (m, 2H, 1-H + 8-H), 7.85 (t, J = 
5.5 Hz, 1H, SNH), 8.09 (d, J = 6.7 Hz, 1H, 7-H), 8.30 (d, J = 8.6 Hz, 1H, 6-H), 
8.45 (d, J = 8.5 Hz, 1H, 9-H), 8.61 (br. s, 1H, OH), 10.26 (br. s, 1H, C(O)NH). 
13
C NMR (100 MHz, CDCl3) δ 24.8, 25.5, 28.0, 29.0, 32.4, 43.0, 45.4, 115.2, 
118.9, 123.2, 128.4, 129.4, 129.6, 129.8, 130.3, 134.9, 151.8, 171.6. HRMS 
(ESI+) m/z calc. for C19H28N3O4S [M+H]
+ 
394.1795 found: 394.1801. 
 
8-(5-(Dimethylamino)naphthalene-1-sulfonamido)-N-hydroxyoctanamide 
(230) 
12
3
4 5
6
7
8 9
10
N
S NH
O
O 11
12
13
14
15
16
17
O
HN OH
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230 was prepared according to the general procedure above. 60 mg, 57%. 
1
H 
NMR (400 MHz, d
6
-DMSO) 0.92-1.11 (m, 6H, 13-H2 + 14-H2 + 15-H2), 1.17-
1.44 (m, 4H, 12-H2 + 16-H2), 1.85 (t, J = 7.3 Hz, 2H, 17-H2), 2.70-2.90 (m, 8H, 
NMe2 + 11-H2), 7.25 (d, J = 7.5 Hz, 1H, 2-H), 7.53-7.68 (m, 2H, 1-H + 8-H), 7.85 
(t, J = 5.7 Hz, 1H, SNH),  8.09 (d, J = 7.3 Hz, 1H, 7-H), 8.30 (d, J = 8.6 Hz, 1H, 
6-H), 8.45 (d, J = 8.4 Hz, 1H, 9-H), 8.63 (br. s, 1H, OH), 10.28 (br. s, 1H, 
C(O)NH). δ 13C NMR (100 MHz, CDCl3) δ 24.8, 25.7, 28.0, 28.4, 29.1, 32.6, 
43.0, 45.4, 115.2, 118.9, 123.3, 128.4, 129.6, 129.7, 129.8, 130.3, 134.8, 151.8, 
171.1. HRMS (ESI+) m/z calc. for C20H30N3O4S [M+H]
+ 
408.1952 found: 
408.1961. 
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6. Chemoproteomics of HDAC8 
 
Tert-butyl 2-(4-(hydroxymethyl)phenoxy)ethylcarbamate (236) 
BocHN
O 1
2
3
4
5
6
OH
 
To a cooled (-20°C) solution of methyl 4-(2-(tert-
butoxycarbonylamino)ethoxy)benzoate 235
240
 (7.0g, 23.7 mmol, 1 eq.) in freshly 
distilled THF (350 mL) was added dropwise over 10 minutes LiAlH4 (2M in THF, 
13.6 mL, 27.3 mmol, 1.15 eq.). The resulting solution was then stirred at 0°C for 2 
hours. The reaction was then cooled to -10°C and were addded dropwise water 
(1.05 mL), 10% NaOH (2.1 mL) and water (3.15 mL). After stirring for another 
10 minutes at 0°C, the precipitate was removed by filtration. The filtrate was then 
concentrated and the product (6.02 g, 95%) was obtained after flash collumn 
chromatography (AcOEt/PE40-60 1 : 1). Rf 0.5 (AcOEt/PE40-60 1 : 1); IR (neat) 
3393, 1669 1695, 1518,1251; 
1
H NMR (400 MHz, CDCl3) δ 1.45 (s, 9H, 
C(CH3)3), 1.87 (br. s, 1H, OH), 3.51 (m, 2H, CH2N), 4.00 (t, J = 5.1 Hz, 2H, 
CH2O), 4.61 (s, 2H, ArCH2), 5.02 (br. s, 1H, NH), 6.87 (m, 2H, 2-H + 6-H), 7.28 
(m, 2H, 3-H + 5-H). 
13
C NMR (100 MHz, CDCl3) δ 28.4, 40.1, 64.9, 67.2, 79.5, 
114.5, 128.6, 133.6, 155.9, 158.1; HRMS (CI+) m/z calc. for C14H22NO4 [M+H]
+
 
268.1543, found: 268.1544; Anal. Calc. for C14H21NO4: C, 62.90; H, 7.92; N, 
5.24. Found: C, 63.00; H, 7.85; N, 5.15. 
 
Tert-butyl 2-(4-(bromomethyl)phenoxy)ethylcarbamate (237) 
BocHN
O 1
2
3
4
5
6
Br
 
To a solution of alcohol 236 (3.0g, 11.2 mmol, 1 eq.) and CBr4 (4.84g, 14.6 
mmol, 1.3 eq.) in freshly distilled CH2Cl2 (85 mL) was added triphenylphosphine 
(3.83g, 14.6 mmol, 1.3 eq.) by portions at 0°C. The resulting mixture was then 
stirred at rt and the progress of the reaction was followed by TLC. After complete 
conversion, the solvent was evaporated under reduced pressure and the product 
(3.08g, 83%) was obtained after flash collumn chromatography (AcOEt/PE40-60 
2 : 8). Rf 0.7 (AcOEt/PE40-60 3 : 7); IR (neat) 3364, 1679, 1513; 
1
H NMR (400 
MHz, CDCl3) δ 1.45 (s, 9H, C(CH3)3), 3.52 (app-q, J = 5.1 Hz, 2H, CH2N), 4.01 
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(t, J = 5.1 Hz, 2H, CH2O), 4.49 (s, 2H, ArCH2), 5.00 (br. s, 1H, NH), 6.85 (m, 2H, 
2-H + 6-H), 7.31 (m, 2H, 3-H + 5-H). 
13
C NMR (100 MHz, CDCl3) δ 28.3, 33.7, 
40.0, 67.2, 79.5, 114.7, 130.3, 130.4, 155.8, 158.6; HRMS (CI+) m/z calc. for 
C14H21BrNO3 [M+H]
+ 
330.0699, found: 330.0707; Anal. Calc. for C14H20BrNO3: 
C, 50.92; H, 6.10; N, 4.24. Found: C, 50.83; H, 6.05; N, 4.18. 
 
Methyl 1-(4-(2-(tert-butoxycarbonylamino)ethoxy)benzyl)-1H-indole-6-
carboxylate (239) 
BocHN
O 1
2
3
4
5
6
N
7
8
9
1011
12 13
14
15
CO2Me  
To a solution of commercial methyl 1H-indole-6-carboxylate 238 (1.40g, 7.98 
mmol, 1 eq.) in anhydrous DMF (40 mL) was added NaH (60% dispersion in 
mineral oil, 351 mg, 8.78 mmol, 1.1 eq.) at 0°C. After stirring at 0°C for 20 
minutes, bromide 237 (2.90g, 8.78 mmol ,1.1 eq.) was added in one portion. The 
resulting mixture was stirred at 0°C for 30 minutes, then at rt for 5 hours. The 
reaction mixture was then cooled to 0°C and water (2 mL) was added dropwise, 
followed by sat. aq. NH4Cl (2mL). The reaction was diluted with AcOEt (400 
mL), washed with a 1 : 1 water/brine solution (2 x 200 mL), dried (MgSO4) and 
concentrated. The product (2.70g, 80%) was obtained after purification by flash 
collumn chromatography (AcOEt/PE40-60 2 : 8). Rf 0.6 (AcOEt/PE40-60 35 : 65); IR 
(neat) 3373, 1702, 1511, 1274, 1231, 1166; 
1
H NMR (400 MHz, CDCl3) δ 1.44 (s, 
9H, C(CH3)3), 3.50 (m, 2H, CH2NBoc), 3.92 (s, 3H, CH3O), 3.97 (t, J = 5.1 Hz, 
2H, CH2O), 4.98 (br. s, 1H, NH), 5.30 (s, 2H, ArCH2), 6.57 (d, J = 3.0 Hz, 1H, 
10-H), 6.82 (m, 2H, 2-H + 6-H), 7.06 (m, 2H, 3-H + 5-H), 7.24 (d, J = 3.0 Hz, 1H, 
11-H), 7.65 (d, J = 8.3 Hz, 1H, 15-H), 7.80 (dd, J = 8.3, 1.4 Hz, 1H, 14-H), 8.10 
(d, J = 1.4 Hz, 1H, 12-H). 
13
C NMR (100 MHz, CDCl3) δ 28.3, 40.0, 49.5, 51.9, 
67.1, 79.5, 102.0, 111.9, 114.7, 120.5, 120.6, 123.3, 128.3, 129.3, 131.2, 132.3, 
135.6, 155.8, 158.2, 168.1; HRMS (ESI+) m/z calc. for C24H28N2NaO5 [M+Na]
+ 
447.1890, found: 447.1874; Anal. Calc. for C24H28N2O5: C, 67.91; H, 6.65; N, 
6.60. Found: C, 68.03; H, 6.76; N, 6.60. 
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Tert-butyl 2-(4-((6-(hydroxycarbamoyl)-1H-indol-1-yl)methyl)phenoxy) 
ethylcarbamate 
BocHN
O 1
2
3
4
5
6
N
7
8
9
1011
12 13
14
15
NH
O
OH  
To a solution of ester 239 (2.2g, 5.18 mmol, 1 eq.) in a 1 : 1 THF/MeOH mixture 
(25 mL) was added aqueous hydroxylamine (50% w/w, 30 mL) and sodium 
hydroxide (828 mg, 20.7 mmol, 4 eq.) at rt. After stirring for 8 hours at rt, the 
reaction mixture was diluted with water (30 mL). The volatiles were removed 
under reduced pressure. The pH was then adjusted to 6-7 using 1N HCl. The 
precipitated product that formed was isolated by filtration, washed 3 times with 
cold acidic (pH 5-6) water, and dried under vacuum. The crude product (2.35g) 
was used for the next step without further purification. 
1
H NMR (400 MHz, d
6
-
DMSO) δ 1.35 (s, 9H, C(CH3)3), 3.23 (m, 2H, CH2NBoc), 3.89 (t, J = 5.6 Hz, 2H, 
CH2O), 5.36 (s, 2H, ArCH2), 6.49 (d, J = 2.9 Hz, 1H, 10-H), 6.86 (m, 2H, 2-H + 
6-H), 6.98 (br. t, J = 5.1 Hz, 1H, NH), 7.15 (m, 2H, 3-H + 5-H), 7.44 (d, J = 8.3 
Hz, 1H, 14-H), 7.53 (d, J = 8.3 Hz, 1H, 15-H), 7.59 (d, J = 2.9 Hz, 1H, 12-H), 
7.92 (s, 1H). 
13
C NMR (100 MHz, d
6
-DMSO) δ 28.1, 40.0, 48.5, 66.2, 77.7, 
100.9, 108.9, 114.4, 117.7, 119.7, 126.6, 128.3, 129.8, 130.1, 130.9, 135.0, 155.6, 
157.7, 164.9; HRMS (ESI+) m/z calc. for C23H26N3O5 [M+H]
+ 
426.2023, found: 
426.2028. 
 
2-(4-((6-(Hydroxycarbamoyl)-1H-indol-1-yl)methyl)phenoxy)ethanaminium 
formate (232) 
H3N
O 1
2
3
4
5
6
N
7
8
9
1011
12 13
14
15
NH
O
OH
HCOO
 
Crude boc protected compound 239 (600mg) was stirred at rt in 4N HCl/dioxane 
for 3 hours. The Solvent was then evaporated under reduced pressure and the 
product (270 mg, 55% over 2 steps) was purified by preparative reverse phase 
LC/MS (HCOOH). 
1
H NMR (400 MHz, d
6
-DMSO) δ 3.00 (t, J = 5.4 Hz, 2H, 
NCH2CH2), 3.99 (t, J = 5.4 Hz, 2H, CH2O), 5.38 (s, 2H, ArCH2), 6.52 (d, J = 3.1 
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Hz, 1H, 10-H), 6.89 (m, 2H, 2-H + 6-H), 7.18 (m, 2H, 3-H + 5-H), 7.43 (dd, J = 
8.2, 1.3 Hz, 1H, 14-H), 7.57 (d, J = 8.2 Hz, 1H, 15-H), 7.63 (d, J = 3.1 Hz, 1H, 
11-H), 7.93 (d, J = 1.3 Hz, 1H, 12-H), 8.33 (s, 1H, HCOO). 
13
C NMR (100 MHz, 
d
6
-DMSO) δ 39, 48.5, 66.2, 101.0, 109.3, 114.6, 117.7, 120.0, 125.5, 128.4, 
130.3, 131.4, 134.9, 157.4, 165.0, 165.3; HRMS (ESI+) m/z calc. for C18H20N3O3 
[free amine +H]
+ 
326.1499, found: 326.1508. 
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APPENDICES 
 
Appendix 1: Crystallographic data for compound 111a. 
 
 
 
Table 1. Crystal data and structure refinement for 111a. 
 
Identification code MF0904 
Empirical formula C12 H16 Br N3 O2 S 
Formula weight 346.25 
Temperature 173(2) K 
Diffractometer, wavelength OD Xcalibur 3, 0.71073 Å 
Crystal system, space group Monoclinic, P2(1)/c 
Unit cell dimensions a = 10.18411(14) Å  = 90° 
 b = 14.96067(18) Å  = 
99.2862(14)° 
 c = 9.13052(13) Å  = 90° 
Volume, Z 1372.91(3) Å3, 4 
Density (calculated) 1.675 Mg/m3 
Absorption coefficient 3.148 mm-1 
F(000) 704 
Crystal colour / morphology Colourless platy needles 
Crystal size 0.48 x 0.27 x 0.04 mm3 
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 range for data collection 3.10 to 32.71° 
Index ranges -14<=h<=15, -22<=k<=21, -
13<=l<=13 
Reflns collected / unique 15014 / 4603 [R(int) = 0.0222] 
Reflns observed [F>4(F)] 3319 
Absorption correction Analytical 
Max. and min. transmission 0.866 and 0.395 
Refinement method Full-matrix least-squares on 
F2 
Data / restraints / parameters 4603 / 4 / 188 
Goodness-of-fit on F2 0.927 
Final R indices [F>4(F)] R1 = 0.0240, wR2 = 0.0518 
R indices (all data) R1 = 0.0401, wR2 = 0.0532 
Largest diff. peak, hole 0.651, -0.783 eÅ-3 
Mean and maximum shift/error 0.000 and 0.001 
 
 
 
Table 2. Bond lengths [Å] and angles [°] for 111a. 
 
C(1)-C(6) 1.3865(18) 
C(1)-C(2) 1.3949(18) 
C(1)-Br(7) 1.8876(13) 
C(2)-O(8) 1.3626(15) 
C(2)-C(3) 1.3909(18) 
C(3)-C(4) 1.3901(18) 
C(4)-C(5) 1.3884(18) 
C(5)-C(6) 1.3938(18) 
C(5)-C(9) 1.5185(17) 
C(9)-C(10) 1.4960(18) 
C(10)-N(17) 1.2897(17) 
C(10)-C(11) 1.4993(18) 
C(11)-O(11) 1.2453(16) 
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C(11)-N(12) 1.3310(16) 
N(12)-C(13) 1.4574(17) 
C(13)-C(14) 1.5166(19) 
C(14)-S(15) 1.8110(15) 
S(15)-C(16) 1.7977(16) 
N(17)-N(18) 1.3522(17) 
 
C(6)-C(1)-C(2) 120.91(12) 
C(6)-C(1)-Br(7) 119.49(10) 
C(2)-C(1)-Br(7) 119.59(10) 
O(8)-C(2)-C(3) 123.36(12) 
O(8)-C(2)-C(1) 118.64(12) 
C(3)-C(2)-C(1) 118.00(12) 
C(4)-C(3)-C(2) 120.95(12) 
C(5)-C(4)-C(3) 121.08(12) 
C(4)-C(5)-C(6) 117.99(12) 
C(4)-C(5)-C(9) 124.48(12) 
C(6)-C(5)-C(9) 117.52(11) 
C(1)-C(6)-C(5) 121.06(12) 
C(10)-C(9)-C(5) 116.57(11) 
N(17)-C(10)-C(9) 125.50(12) 
N(17)-C(10)-C(11) 115.04(12) 
C(9)-C(10)-C(11) 119.29(11) 
O(11)-C(11)-N(12) 123.40(12) 
O(11)-C(11)-C(10) 120.60(12) 
N(12)-C(11)-C(10) 115.99(11) 
C(11)-N(12)-C(13) 125.16(12) 
N(12)-C(13)-C(14) 112.18(11) 
C(13)-C(14)-S(15) 115.40(10) 
C(16)-S(15)-C(14) 103.22(7) 
C(10)-N(17)-N(18) 119.25(12) 
 
 
